

Values Live new UPL



We are all about

with people, in

a human way -

showing respect,

demonstrating trust,

celebrating diversity.

For us, technology is

an enabler, not the

endgame. We see

connectivity and how it creates new

opportunities for

everyone. With this,

comes our promise

to protect people's safety in every way we

can.

the value in human

connecting



Nothing's

impossible



We serve a cause bigger than ourselves sustainability of global food systems. We win when we create sustainable solutions based on responsible choices, when everyone we serve and partner with grows too, and when together we achieve sustainable growth for society as a whole - the biggest win of all.

Work new UPL







world.

No one is faster or more efficient. We thrive on targets and challenges that, while possibly daunting at first glance, only excite and energise us. Wherever we operate, speed and agility are in our DNA. The world needs our urgency.



Food systems are highly complex and present huge challenges. We cut through this by keeping it simple. People value simplicity, customers especially. And everyone likes fun, so let's have some, doing what we love to do.

Forward-looking statement

This document contains statements about expected future events and financial and operating results of UPL, which are forward-looking. By their nature, forward-looking statements require the Company to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the assumptions, predictions and other forward-looking statements will not prove to be accurate. Readers are cautioned not to place undue reliance on forward-looking statements as a number of factors could cause assumptions, actual future results and events to differ materially from those expressed in the forward-looking statements. Accordingly, this document is subject to the disclaimer and qualified in its entirety by the assumptions, qualifications and risk factors referred to in the management's discussion and analysis of the UPL Annual Report 2018-19.

UPL in numbers

22,077

Revenues in FY2019 (₹ in crore)

1,447

Net Profit in FY2019 (₹ in crore)

1,023

Patents granted

>138

Countries of presence

10,300+

Number of employees

4,111

EBITDA in FY2019 (₹ in crore)

48

Manufacturing Facility locations

>12,400

Registrations

5th

Rank among global crop protection product players (trailing twelve months basis)

75

Number of countries, workforce representation

Contents

- 02 OpenAg
- 06 Eight things you need to know about UPL Limited
- 08 Milestones
- 10 Our attractive performance across the years
- 12 Chairman's communiqué
- 16 Message from the Global CEO
- 20 Message from the Global COO
- 22 Today's UPL
- 24 Competence drivers
- 31 The world will need more food
- 32 Sectoral context

- 33 UPL's contrarian approach
- 34 UPL's focus areas
- 35 UPL. First among equals
- 36 UPL's strategy
- 40 Our geography-wise performance review
- 46 Management discussion and analysis
- 54 Risk management process at UPL
- 57 Corporate information
- 58 Notice
- 67 Directors' report
- 136 Standalone financial statements
- 209 Consolidated financial statements

'OpenAg' A new UPL

An open agriculture network for the world that feeds sustainable growth for all.

No limits, no borders.

Modern agriculture faces multiple challenges

Population

The challenge of feeding a growing global population in the midst of growing resource scarcity.

Resilient

The challenge of making agriculture climatesmart and farming more resilient to global warming.

Affordability

The challenge of making new agro technologies affordable for every single farmer, strengthening profitability while reducing environment impact.

Productivity

The challenge of enhancing farmer productivity with relevant inputs; minimizing risks associated with traditional farming practices.

Model

Addressing challenges with a new model that converges different players across the valuechain.

Purpose

Connecting farmers to food processors to supermarkets to consumers around a new purpose.

Vision | Our vision is to be an icon for growth, technology and innovation. We only have one vision and it is not highlighted by the year.

Change the game

- to make every
single food product single food product more sustainable.

How OpenAg is equipped to address

The only way the challenge of growing more food for the world in a declining quantum of land area can be met is through a new model - one that brings together different stakeholders together across the food value chain.

From farmers to food processors to supermarkets to consumers – around a new purpose.

A purpose we call 'OpenAg'.

A purpose where we play a new role by creating a network that changes the way the food system thinks and works - exposing it to new ideas, new possibilities and new solutions.

OpenAg will change the game

At UPL Limited, OpenAg, will change the game by creating a society where agriculture is valued, outputs are sustainable and farmers are able to prosper.

The acquisition of Arysta LifeScience, has helped by the foundation for 'OpenAg'.





Eight things you need to know about UPL Limited.

The world's fifth largest post-patent crop protection products company.

And the world's fastest growing in this space.

01 Pedigree

UPL Limited is a global crop protection company of Indian origin. Founded in 1969 by Mr. R. D. Shroff (Chairman), the Company is backed by a team of motivated and experienced industry professionals. The Company is listed on the National Stock Exchange and Bombay Stock Exchange in India. The Company's market capitalisation as on 31st March 2019 stood at ₹48,693 crore.

02 Leading

UPL acquired Arysta LifeScience, a global provider of innovative crop protection solutions, in early 2019. The acquisition will enhance UPL's position as a global leader in agricultural solutions with close to US\$ 5 billion in combined sales and EBITDA of ~US\$ 1 billion as well as a portfolio of more than 12,400 product registrations. UPL has a strong presence in India, the Americas and Western Europe while Arysta has a relatively stronger presence in Africa, Russia and Eastern Europe.

03 Solutions-oriented

UPL has transformed from a crop protection products provider to a complete crop solutions partner, enhancing food security across the world. The Company has diversified its portfolio across seeds, seed treatment solutions, postharvest solutions and industrial chemicals. UPL's large basket of crop protection products safeguard crops against pest infestations. It has also created a retail chain in select geographies to provide onestop solution to farmers.

04 Global presence

UPL's products are marketed in more than 138 countries, strengthening its global positioning and de-risking the business from an excessive dependence on any single region. The Company accounts for around 14% share of India's organised crop protection products sector. The Company has or direct global presence in major markets with a direct access to distribution and with sales forces deployed across more than 40 nations.

05 All-encompassing

UPL's product portfolio comprises fungicides, herbicides, insecticides, plant growth regulators, rodenticides, specialty chemicals, nutri-feeds, seeds and seed treatment products. With Arysta under its wing, UPL will bolster its portfolio of BioSolutions and Seed Treatment products. It has also ventured into providing value-added services in select markets.

06 Innovative

UPL's investments in research and innovation have helped the Company generate 1,023 patents and more than 12,400 product registrations worldwide.

07 Comprehensive

UPL has expanded across the sectoral value-chain, from R&D and registrations to manufacturing, packaging and marketing, making it possible to emerge as one of the most comprehensive crop protection product companies in the world.

08 Awards and achievements

2012: 'Agriculture Leadership' award for Mr. Rajju Shroff and Mr. Vikram Shroff

2013: Ernst & Young 'Entrepreneur of the Year' award

2015: 'Lifetime Achievement' award by AGROW for Mr. Rajju Shroff

2016: First position in the agrochemical sector for UPL (Dun & Bradstreet's 'Top-500 Companies in 2016')

2017: IIRIM – India Green Manufacturing Challenge 2016 -'Silver and Special' awards (Unit#2)

2018: Frost & Sullivan - TERI Sustainability 4.0 Awards 2018 - 1st Runner-up, Challengers category

Frost & Sullivan and TERI Sustainability 4.0 Awards 2018 -Challengers Award - Large Business, **Process Sector**

Gold Award 'Brands for Environment' for year 2018 - Top 10 Environment Friendly Factories in the country

Gold Award 'Friendly Green Factory' for Year 2018 - 'TOP 20 Clean and Green Factory' in Country

Gold Award 'Sustainable development' for Year 2018 -'Top 20 Factory for sustainable development, innovation and Systems' in the country

Outstanding business award, India Manufacturing Excellence Award (IMEA) 2018 by Frost & Sullivan -Gold Certificate of Merit

India Green Manufacturing Challenge (IGMC) by Frost & Sullivan - Silver Award

National Awards for Manufacturing Competitiveness, (NAMC 2017-2018) - Gold medal.



Started manufacturing red phosphorus



- Entered the crop protection products sector
- Started exporting products



Began production of yellow phosphorus at Ankleshwar



- Acquired the UK-based MTM Agrochemical to gain access to the European herbicides market
- Commenced operations at the Jhagadia plant, UPL's largest manufacturing site, with a cumulative capacity of 240,000 metric tonnes per annum

Milestones



- Acquired Cerexagri for boosting revenues significantly through its global distribution network
- Successfully completed a QIP issue of equity shares



- Acquired RiceCo for leveraging the global sales and marketing network for the rice segment
- Acquired Manzate brand, strengthening its fungicide portfolio



 Acquired DVA Agro and SIB for gaining entry into Brazil



- Crossed ₹100 billion in revenues
- Introduced Unizeb Gold







- Acquired Devrinol for gaining entry and distribution access into the American, Japanese and Rest of World markets
- Set-up a caustic chlorine plant



- Acquired SWAL to enhance scale and distribution in India with a parallel distribution network
- Registered first EMR (SAAF)



- Acquired Reposo for gaining entry into Argentina
- Acquired Advanta, thereby making an entry into the seeds business

Performance highlights,

Revenues (₹ in crore)

EBITDA (₹ in crore)

18.8

EBITDA margin (%)







- Crossed US\$ 2 billion in revenues
- Surpassed 5,000 registrations
- Merged Advanta into UPL



• US\$ 500 million Bonds issued by overseas subsidiary UPL Corporation, under Rule 144A and Regulation S with an investment grade rating from Moody's, S&P and Fitch



- US\$ 300 million Bonds issued by overseas subsidiary UPL Corporation, under Regulation S with an investment grade rating from S&P and Fitch
- Crossed US\$ 2.7 billion in revenues
- Crossed 6,000 registrations
- Announced the acquisition of Arysta LifeScience and completed it within six months

Net profit (₹ in crore)

Net profit margin (%)

Earnings per share (₹)

(Only UPL figures considered, as RoCE computation is for UPL consolidated financials. Arysta financial statements are for a period of two months and have not been considered as we await the Asset Valuation report for the Arysta group of companies to determine the RoCE for the combined business)



Our attractive performance across the years



Revenues

(₹ in crore)

Definition

Revenues (including Other Income). FY2019 figure includes Arysta LifeScience revenues for two months (February and March 2019).

Why is this measured?

To measure the Company's ability in comprehending global demand trends and launching appropriate products.

Performance, FY2019

Revenues Grew 23.2% to ₹22,077 crore during FY2019, following increased demand and realisations.

Value impact

Improved product offtake strengthened the Company's marketplace reputation.



EBITDA

(₹ in crore)

Definition

Earnings before deduction of interest, depreciation and amortization extraordinary items and tax. FY2019 figure includes Arysta LifeScience EBITDA for two months (February and March 2019).

Why is this measured?

It is an index that showcases the Company's ability to optimise operating costs despite inflationary pressures and can be compared with sectoral peers.

Performance, FY2019

The Company's EBITDA grew 16.9%.

Value impact

A rising EBITDA highlights the Company's operational efficiency and attractive earnings.



Net profit

(₹ in crore)

Definition

Profit earned during the year after deducting all expenses and provisions

Why is this measured?

It highlights the strength of the business model in generating value for its shareholders.

Performance, FY2019

The Net Profit for the year was ₹2,340 crore and after considering exceptional costs and Purchase Price Allocation Adjustments related to the Arysta Life Science acquisition, the Net Profit for the year was ₹1,447 crore.

Value impact

A healthy Net Profit protects the interests of all stakeholders.



RoCE

Definition

It is a financial ratio that measures a company's profitability and the efficiency with which its capital is put to use in the business

Why is this measured?

RoCE is a useful metric in comparing profitability across companies based on the amount of capital they use - especially in capitalintensive sectors.

Performance, FY2019

The RoCE of the Company was 21.3% compared to the previous year. After considering debt for acquisition of Arysta LifeScience, the RoCE was

Value impact

Enhanced RoCE can drive valuations and visibility.

^{** (}Only UPL figures considered)



Definition

EBITDA margin is a profitability ratio used to measure a company's financial efficiency

Why is this measured?

The EBITDA margin gives an idea of how much a company earns (before accounting for depreciation, amortisation, interest and taxes) on each rupee of sales.

Performance, FY2019

The Company EBIDTA margin was 20.8%. Following the acquisition of Arysta LifeScience, acquired inventories were valued at a Fair Market Value, as required under Ind AS accounting standards, resulting in margin of 18.8%.

Value impact

Provides a better picture of profit growth trends and business health



Interest cover

Definition

This is derived by the dividing of EBITDA by interest outflow

Why is this measured?


Interest cover indicates the Company's ability in servicing interest - the higher the better.

Performance, FY2019

The Company's interest cover was 6.57. Postacquisition of Arysta LifeScience, the interest cover was at 5.33 on account of a drop in EBITDA (refer above) and increase in debt.

Value impact

A healthy interest cover indicates the Company's liquidity and ability to address debt servicing and repayment obligations.



80

Gearing

Definition

This is the ratio of net debt to net worth (less revaluation reserves)

Why is this measured?


This is one of the defining measures of a company's financial health, indicating solvency (the lower the gearing the better).

Performance, FY2019

The Company's debtequity ratio was 0.30. Post acquisition of Arysta LifeSciences, the Company's debt-equity ratio was 1.80.

Value impact

A low debt-equity ratio suggests adequate borrowing room to sustain growth.



Dear There lorder,

The year under review was one of the most memorable in UPL Limited's history.

The Company acquired Arysta LifeScience in an all-cash US\$ 4.2 billion deal, which was completed within a record six months.

This helped the combined entity emerge as the fifthlargest crop protection products company in the world with combined sales of US\$ 4.7 billion in FY2019 (trailing twelve months basis).

Explaining the acquisition

Over the last few years, the global crop protection products industry has undergone consolidation, warranting a greater need for scale across serious players.

Scale enhances economies of scale, ability to attract fresh talent, ability to launch differentiated products and a stronger registration pipeline.

UPL, over the last 25 years, has made 40+ acquisitions and been successful in accelerating growth in a profitable manner.

The Arysta LifeScience acquisition represents the largest in our existence and possibly the most important. Arysta LifeScience (formed in 2001) is present in the proprietary post-patent space, a segment growing faster than the mainstream

As the pace of discovery of new active ingredients has declined and an increasing number of products are going off-patent, Arysta LifeScience possesses one of the world's best supply chain systems as well as a broad products portfolio comprising herbicides, fungicides, insecticides, bio-solutions and seed treatment targeted at specialty crops and applications.

UPL's landmark acquisition bodes well for a number of reasons.

One, UPL has a strong manufacturing presence with plants in 34 global locations (26 for active ingredients / formulations and eight for seeds). On the other hand, Arysta's asset-light model outsources most manufacturing operations (with formulation plants in 14 locations), electing to focus largely on marketing. The coming together of the companies will empower UPL to provide strong manufacturing support to Arysta on the one hand and leverage the latter's deep distribution capability on the other - a win-win.

(US\$/billion) Combined sales of the Company (trailing twelve months basis)

Global manufacturing locations of the Company

from global markets

registrations post acquisition

Two, Arysta possesses a proven expertise in the realm of certain proprietary molecules. Following the acquisition, UPL will gain access to these proprietary molecules.

Three, the two companies possess complementary portfolios: UPL's crop protection products are goto products for row crops, while Arysta's products are preferred for the cultivation of specialty crops like horticulture. The complementary product portfolios of the two entities have helped create a company with a larger and relatively de-risked application presence. This was evident in the unconditional approval from 40+ anti-trust regulators, without requiring any portfolio divestments.

Four, the two companies also enjoy a presence in complementary markets. Arysta enjoys a strong presence in Eastern Europe and CIS countries; UPL possesses a similar presence in Western Europe and Latin America. Arysta enjoys a relatively large presence in Africa, Russia and Ukraine, where UPL is less conspicuous. Following the acquisition, UPL will be able to tap deeper into these territories.

Five, following the acquisition, UPL's product registrations more than doubled - from ~6,150 to more than

12,400. Considering that it takes between two to five years to get a product registered, this acquisition has strengthened the Company's longterm prospects.

Six, both companies complement each other in managing risks and financial resources. One of the primary reasons for UPL's success in Latin America has been its ability to manage market volatility, which holds true for Arysta's performance in sub-Saharan Africa, where the Company dealt with currency and political risks. The coming together of UPL and Arysta provides a neat complement that will disproportionately strengthen the overall complement.

I am optimistic that this acquisition will broaden UPL's positioning as a global company of Indian origin. More than 83% of UPL revenues are derived from global markets. UPL has recruited globally and locally, strengthening its terrain familiarity and the ability to take decisions closer to the ground. The result is that the Company reported sustainable and profitable growth despite monetary, political, climatic, regulatory and economic challenges.

Need for specialised solutions

Falling crop commodity prices over the past few years impacted the demand for crop protection products, resulting in industry consolidation and relevant counter-strategies. Urbanisation and climatic vagaries affected sectoral growth. Changing climatic conditions are increasing pest disturbance, increasing their population and enhancing their appetite, threatening global food security. The need of the hour is to provide specialised solutions that protect yields and minimize preand post-harvest losses.

Scientists have found that globally, pathogens and pests have affected crop yields by 10 to 40% for major food crops like wheat, rice, maize, soybean and potato.

(Source: University of California's Division of Agriculture and Natural Resources / International Society for Plant Pathology).

OpenAg

Our purpose is to create...

An open network for agriculture, activating connections across the world's agriculture system.

Powering new levels of sustainable growth – for farmers, for producers, for customers and partners, for societies everywhere.

Ours is a world of no borders and no limits. Not a hard-wired linear value chain, but an agile, fluid network of relationships and interplays that leapfrog traditional boundaries and jump to new opportunities. Where connections are more personal and solutions more personalised.

From crop protection, to biosolutions, to innovative hybrid platforms and beyond... We create more choice, faster access, greater value and sustainability.

We open possibilities and shape the future in an interactive and synergistic way. Agriculture with no borders, growth for all. OpenAg.

Besides, the global population of 7.6 billion is expected to grow to 8.6 billion by 2030 and 9.8 billion by 2050, making it imperative for companies like UPL to come up with specialised crop protection products with greater speed than ever.

This priority is also evident in India, one of the largest agricultural markets of the world. Around 70% of India's rural households depend primarily on agriculture; around 86% of India's farmers are categorised as 'small and marginal' and own less than 2 hectares, which is the equivalent of two football fields. A number of measures were undertaken by the Government of India, including enhanced minimum support prices for a number of crops. The Central Government also aims to double farmers' income by 2022 through measures like Pradhan Mantri Krishi

Sinchayee Yojana, Pradhan Mantri Fasal Bima Yojana and National Food Security Mission, among others.

At UPL, we believe that crop protection products addressing pre- and postharvest losses play a pivotal role. The Indian Council of Agricultural Research estimated that around 30%-35% of the annual crop yield in India is lost to pests. India's pesticide consumption is one of the lowest in the world; the average hectare in India consumes just 0.6 kilograms of pesticide compared to 5-7 kilograms per hectare in the US and 11-12 kilograms per hectare in Japan, a large headroom. We believe that the sector has an important role to play at a time when the country is engaged in strengthening farmers' income.

Overview

Following the acquisition of Arysta LifeScience, UPL has evolved from being just a product-based company to a solution-oriented organisation covering all major crops.

The new UPL is attractively positioned to address the existing and emerging needs of farmers across a wider global footprint with a larger basket of products.

We believe that the new UPL will enhance value for its stakeholders. I thank our large family of stakeholders for their trust and assure that we will continue to enhance value for our Company in the foreseeable future.

RD Shroff, Chairman

UPL's acquisition of Arysta is value-accretive

Parameters	UPL	Arysta	Combined entity	
Market positioning	Seventh-largest agricultural solutions player with a focus on post-patent products	Tenth-largest agricultural solutions player with a focus on specialty and niche markets	Fifth-largest agricultural solutions player with a healthy mix of product offerings for row crops and specialty crops	
Key geographies	India, Western Europe, the US and Latin America	Eastern Europe, Russia, the Middle East, Africa and Latin America	Stronger presence in Latin America, Europe and the rest of the world	
Product registrations	>6,500	>5,800	>12,400	
Manufacturing strategy	Low-cost manufacturing of complex active ingredients and formulations	Asset-light model with an emphasis on outsourcing	Blend of in-house manufacturing and outsourcing capabilities	
Manufacturing Facility locations	34	14	48	
Product portfolio	Seeds to post-harvest	BioSolutions, seed treatment and late-stage R&D-led pipeline of differentiated products	Comprehensive product portfolio addressing a wide range of crops	
Crop focus	Corn, soybean, cotton, rice, fruits, vegetables and sugar cane	Fruits, vegetables, cotton, sugarcane, sunflower, cacao and cereals	Wider basket of crops across all major agricultural regions across the world	
Product development Focus on innovative formulations, combinations, mixtures and label extensions		Late-stage product development capabilities and strong ties with innovators of active ingredients	Late-stage product development capabilities combined with innovative formulations, mixtures and combinations, marketed strategically	



Message from the Global CEO of UPL Limited

Dear shareholders,

Past 50 years

At our recent Flag Day celebration, where UPL marked 100 days since the successful acquisition of Arysta LifeScience, my family and I had the opportunity to reflect on UPL's incredible journey over the past 50 years. In 1969, we began producing red phosphorus – a bold move at a time when nobody thought it possible to do so in India.

With hard work, perseverance and a dedication to doing things better, the UPL team has grown from a small operation in Vapi, into the leading agri-inputs company in India and a globally respected player.

I attribute our success to never losing sight of our customers–growers, small and large, whose daily efforts bring us the food we so often take for granted. This lies at the heart of our commitment to OpenAg – our philosophy for the future of UPL.

OpenAccess

UPL has always believed in supporting local farms and communities – no matter how big or small or what crops they grow – by giving them access to the best products available. This is a part of our commitment to ensure food security for all, irrespective of which corner of the world people reside in. We find ourselves equally at home in emerging economies serving a small cocoa farmer in Africa to citrus cooperatives in Brazil to large corn farmers in the American Mid-West.

OpenSolutions

We can serve all these farmers because of the range of technologies UPL can bring to bear on the challenges they face. We help farmers get their crops established, ensuring the germination and nurturing of their precious seed stock. We help farmers deal with the challenges of climate change, to reduce irrigation needs and plant abiotic stresses. Sometimes this means we help with the effective management of weeds, diseases and other pests that have become resistant to old solutions. At other times, we help with crop finishing and post-harvest solutions, to maximise quality and yield while minimising waste in the supply chain. Growers look to UPL to help them do their job, and we relish the challenge of finding better ways to assist them, whether by providing time-tested advice on how to improve farm productivity to using precision AG technology to give them the best data on what they need to do in their fields.

OpenManufacturing

We believe in connecting UPL with diverse communities and interests worldwide and that these connections create extraordinary value.

We now operate globally with almost 50 active ingredient manufacturing and formulation facilities spread around the world and provide supply reliability through our multisource strategy. We continue to maintain stringent safety standards and improve the sustainability of our operations, reducing our carbon emissions, water consumption, waste water discharge and solid waste to minimise our environmental footprint.

OpenInnovation

We are engaged in innovation, conducting research and development across more than 25 R&D facilities in four continents and collaborating with leading commercial partners, scientific institutions and universities to continuously understand and meet our customers' future needs. We are proud to have become a market leader in bringing new biological solutions to the market – helping growers make great strides in biocontrol as well as biostimulation to improve yield and input efficiency – all of which is key for providing even more sustainable options to farmers facing different challenges.

We are engaged in innovation, conducting research and development across more than 25 R&D facilities in four continents and collaborating with leading commercial partners, scientific institutions and universities to continuously understand and meet our customers' future needs

OpenHearts

We also see our mission as contributing to social progress, and actively work to advance the well-being of people everywhere. I am particularly proud of the work we have done in supporting malaria eradication efforts in Africa, supporting rural education projects in India, and our work to eliminate all forms of child labour in seed supplier farms.

UPL's lifelong vision and commitments to ensure food security for all, supporting local farmers and communities in the process. It is as relevant today as it has ever been.

FY2019 performance

In FY2019, we delivered revenues of ₹22,077 crore, EBITDA of ₹4,111 crore and a Net Profit of ₹1,447 crore. For the sake of clarity, this includes Arysta figures for two months, as the acquisition was completed on February 1, 2019. If the Arysta figures are not considered, UPL posted strong growth of 14% (in revenues), growth in EBITDA of 18% and growth of 10% in net profit. I am enthused that UPL continues to deliver on its promise of sustainable and profitable growth. In the coming years, we will continue to focus on the revenue and cost synergies that we have targeted to achieve, ensuring that the combined Company will be an outperformer in the global agri-inputs space.

Looking to the next 50 years

Even as we reinvent our business for a new phase of growth - and firmly establish UPL as a global leader in sustainable agriculture and food systems – we take time to think deeply about our Company, our culture and the values that guide our behaviour.

We have got to where we are today because we were guided by a good value system. Similarly, our future success will be routed in us remaining committed to our values, while also being a leader in doing things better and differently. We have therefore codified our values, to ensure that we measure ourselves by how we live up to them each day. These



Always human



One team, one focus



Nothing's impossible



Agile



Win-Win-Win



Keep it simple, make it fun

Our vision is for UPL to be an icon for growth, technology, and innovation. We will only achieve this by living our values and meeting a standard of behaviour that is truly worldclass.

UPL has never compromised on quality. We started as young and idealistic, and remain so. We are always willing to try new things and to see if we can do things better. With the help of our customers, our employees, and our shareholders, we will continue to do so.

The fire of my father and mother's bold decision 50 years ago still burns bright within us all. It motivates us to continue to be bold in our ambitions for what is possible, and how UPL can continue to change the world.

I would like to thank all shareholders, other stakeholders and employees for their support over the past 50 years to make this possible.

Thank you

Jai Shroff

Global Chief Executive Officer

Message from the Global COO



Dear shareholders,

The year 2018-19 a strategically decisive one in UPL's existence.

In July 2018, the Company announced the acquisition of Arysta LifeScience. Global regulatory approvals were obtained in just six months, with the acquisition closing on February 1, 2019. Following the transaction, UPL's combined sales (on a trailing twelve-month basis) grew from US\$ 2.7 billion to US\$ 4.7 billion.

With the combination of UPL and Arysta we have created a formidable global player in agriinputs, a tier-one company with the scale to win in a consolidating industry landscape.

Both businesses are geographically complementary: UPL enjoys a strong presence in India, the Americas and Western Europe, while Arysta is a market leader in Latin America, South and Eastern Europe, Africa and Japan. The new UPL is a global player with a particularly strong position in the emerging markets. Up to 80% of the increase in agricultural

production in the next 30 years is expected to come from the emerging markets.

UPL's strengths lie in manufacturing and differentiated post-patent products, while Arysta focused on specialty products, deep marketing and R&D capabilities. Since closing, UPL has one of the broadest product portfolios in the industry, comprising 12,400+ product registrations globally. We can now provide complete solutions from seed to post-harvest in most key crops and key markets, retaining our leading position in the rapidly growing biosolutions segment. To cement our role as a solution provider for sustainable farming, UPL is building competences to expand the use of digital services and processes. Investments in artificial intelligence tools to predict customer needs with higher accuracy, and using robotic sensors to access realtime, on-field farmer data, are some examples of this effort.

Looking forward, we plan to take advantage of the numerous synergies in revenues and costs. Through cross-selling and an increased customer presence we expect to generate more than \$300m in top-line synergies in three years. Cost savings in raw materials, personnel and fixed manufacturing expenses are projected to reach more than \$200m in two years. We plan to focus deeper on operational efficiency, both in manufacturing, working capital management and R&D, where we strive to be the industry benchmark.

From the beginning, we knew that the most important decision we would take was building the right team that would take UPL to the next level. Soon after closing, we announced the new leadership team. The best leaders from both legacy companies were selected and empowered to drive the integration. In the initial stage, the team spent a great time listening to employees, customers and partners. We examined the underlying strengths of both organisations to identify the core values of the New UPL. Agility, a 'nothing is impossible' mindset, team work, a human approach to leadership, special emphasis on winwin-win partnerships and a strong growth-orientation, were among the principles we highlighted.

Farmers around the world are seeking solutions to offset the impact of climate change; consumers are asking for

healthier food products and societies are expecting a drastic reduction in the environmental impact of farming. What is our role in society? What motivates us to give our best every day? Where is our industry heading?

Reflecting on these fundamental questions gave birth to our new purpose: OpenAg.

OpenAg is an open agriculture network for the world, feeding sustainable growth for all. Through OpenAg, we aim to power new levels of sustainable growth for the benefit of the entire eco-system comprising farmers, food processors, customers, partners and society at large.

No limits, no borders. With this new purpose, the new UPL emerges as a key contributor to solutions for some of society's most important challenges.

Exciting times lie ahead.

Diego Lopez Casanello Global Chief Operating Officer

UPL-Present across the value chain

Seeds: High-yielding seeds enhance food security.

Crop protection products: Fight pests, protecting harvests.

Soil enhancement technologies: Innovative soil enhancement technologies offset inconsistent water supply effects during crop cycles.


Post-harvest solutions: Post-harvest solutions prevent grain and fruit damage during transportation and storage.

Farmer engagement initiatives: Farmer engagement comprises value-added services to educate farmers and help them address everyday challenges.

Today's UPL.
A convergence of synergies across geographies, crops and products


UPI

- Stronger presence in India, Americas and Western Europe
- Industry-leading manufacturing capabilities
- Diversified portfolio across the value
- Strong registration and product development capabilities
- Robust Balance Sheet and track record of more than 40 successful mergers and acquisitions
- ** UPL mix as of March 31, 2018; Arysta mix as of December 31, 2017




Arysta

- Stronger presence in Africa, Russia and Eastern Europe
- Unique asset-light model, underscoring high capital utilisation efficiency
- Specialisation in fast-growing market segments and specialty crops
- Proven R&D capabilities



'New' UPL


- · A global leader in the field of agricultural solutions
- R&D-focused and verticallyintegrated organisation
- · Healthy mix of high-value crops and high-growth geographies
- Well-positioned to achieve sustainable growth
- Convergence of synergistic traits
- >12,400 registrations
- Ability to come up with innovative products in a customer-oriented manner
- ** UPL and Arysta adjusted as of March 31, 2018



UPL's best-in-class manufacturing capabilities

Over the past five decades, UPL has established a growing global presence on the back of manufacturing facilities in 48 locations (national and international) engaged in the production of active ingredients and formulations.

The Company invested extensively in backward integration, resulting in a significant cost advantage over international peers, strengthening quality management and reducing its dependence on just a few vendors.



Backward integration

UPL's ability to identify products with high-growth potential and investing in backward integration has strengthened its competitiveness. UPL's track record in scaling capacities at costs and timelines lower than prevailing sectoral benchmarks has been derived from its rich understanding of plant designs, best-in-class equipment procurement through strategic partnerships, offsite construction flexibility, 3D design capabilities

and relatively shorter commissioning timelines.

Lower asset costs

UPL chose to set up a greater portion of its active ingredient manufacturing plants in India on account of locational and fundamental advantages. For instance, the Company's MR205 and glufosinate plants were commissioned in half the time taken by peers, resulting in significant savings that generated a faster realization of revenues and profits.

Arysta's manufacturing competence

Arysta focused on the commissioning of localised 'close-to-customer' formulation manufacturing facilities, while outsourcing active ingredient requirements to third party vendors, an effective assetlight approach. The acquisition will empower UPL to integrate its 'building block' products with Arysta's outsourcing skill and contacts, widening the value chain. The acquisition represents a coming together of UPL's manufacturing units across 34 locations with Arysta's 14 formulation facilities, creating effective global scale and synergy.

Consistent service capability

Owing to a tightening local environment regulations, there was a disruption in material supplies from China. As a proactive measure, UPL invested in additional capacities, strengthening resource security. This boosted the Company's manufacturing credibility and value chain. The result: even as competing supply lines were affected, UPL continued to service farmer needs in an uninterrupted manner.



Competence driver 4PL. Deepening its presence in complementary markets

The acquisition of Arysta is expected to enhance overall value for UPL across the foreseeable future.

Arysta will deepen UPL's presence in Europe and the US, which are challenging markets to enter on account of strict regulatory frameworks (Europe) and consolidated distribution channels (US). Besides, Arysta enjoys a meaningful presence in Africa, Eastern Europe and Japan, while UPL is the market leader in India. These complementary markets will widen the Company's geographic footprint globally and significantly enhance revenues.

In overlapping markets like Latin America (contributing 30%+ of sales for both too) there is a complementarity at work. The two entities focus on different crops (UPL on row crops and Arysta on specialty crops), leveraging different distribution channels (co-operatives / small dealers for Arysta and large growers / dealers for UPL).

The result is that the acquisition of Arysta will empower UPL to deepen its presence in new segments. The minimal overlap was validated by 42 countries green-flagging the acquisition from an anti-trust standpoint in just six months. The result is that UPL more than doubled product registrations from \sim 6,150+ to \sim 12,400, widening its crop-cum-product portfolio and deepening its presence in sub-scale and existing geographies.

Strengthening ties with Brazilian farmers

The three principal distribution channels in Brazil comprise agricultural co-operatives, distributors of inputs (or dealers) and direct sale to large farm operations. Following consolidation in the mid-2000s, dealers represent ~60% of the sales of agricultural inputs, while the remainder is sold through co-operatives and direct sale to large farmers. In addition to traditional channels, UPL strengthened its Brazil presence through direct sales to large growers. On the other hand, Arysta strengthened its presence through cooperatives.

UPL and Arysta enjoy complementary crop specialisations. While UPL's products are preferred by cotton and soybean farmers, Arysta is respected for corn applications. UPL and Arysta balance each other when it comes to fruits and vegetables in Latin America: while UPL's strength lies in citrus, Arysta's lies in sugarcane.

By acquiring Arysta, which offers specialty applications as well as cost-effective products, UPL will now be empowered to forge enduring engagements with customers, resulting in a superior value proposition.

Growing stronger together in North **America**

UPL's objective to reinforce its North America footprint will now be catalysed by Arysta's strong presence in North American presence (especially in the Midwest where corn is a key crop and in Canada's wheat belt). In both regions, Arysta enjoys a larger sales team than UPL. Supplementing Arysta's dominance in wheat, UPL is the go-to brand for rice farmers (through subsidiary RiceCo) as well as fruit and vegetables (predominantly potato), creating an effective complement.

In the last few years, UPL has sought to grow its presence in the American Midwest, a region where row crops (corn and soybean) are predominant. The Company positioned itself to address opportunities in the resistance management space with a portfolio of herbicides and fungicides. It has recently launched two brands of the herbicide Glufosinate for soybean and corn to pluq these gaps. Glufosinate is the potential alternative to Glyphosate (~US\$ 5 billion market globally) as Glyphosateresistant weeds are increasing.

UPL's cost-competitive business model, coupled with Arysta's deep marketing capabilities, should generate sustainable growth in revenues, market share and margins.

Extending into Europe, Africa and CIS countries

Arysta enjoys a strong presence in Eastern Europe, Africa and CIS. Deep agricultural fundamentals enabled the region to emerge as a leading producer and exporter of wheat, barley, corn, sunflower, winter oilseed rape, sugar beet and vegetables.

UPL enjoys a longstanding competence in crops like vines, sugar beet and potato; Arysta's portfolio is geared towards cereals, the largest crop in Europe, rapeseed oil and some specialty fruit crops.

In Africa, Arysta is a market leader in South Africa, Ivory Coast, Burkina Faso and Mozambique, now a competitive advantage for UPL. Arysta's strong presence in the Central and Eastern Europe (Poland and Hungary) allows UPL to venture into this untapped geography.

By acquiring Arysta, which offers specialty applications as well as cost-effective products, UPL will now be empowered to forge enduring engagements with customers resulting in a superior value proposition.

UPL. Offering farmer solutions through an integrated portfolio

UPL's product portfolio comprises several post-patent active ingredients. The growth of the Company in these segments has been driven by formulations, mixtures and combination products manufactured at its manufacturing facilities at competitive costs.

Arysta's portfolio comprises proprietary post-patent and generic molecules. The Company's strategy is to focus on niche active ingredients and develop R&D-driven formulations and combinations, which address emerging issues faced by agriculturalists. It partnered research-focused companies in Japan, entering into in-licensing arrangements for innovative molecules. Arysta develops proprietary combinations using these molecules in addition to acquisitions strengthening its product pipeline.

The differentiated product portfolio of both companies indicates a minimal molecule overlap. Arysta enjoys a strong bio-solutions product portfolio, where UPL dose not posses an adequate presence. The acquisition helped plug gaps and create an integrated portfolio of crop protection products.

UPL's portfolio has been reinforced with Arysta's strong presence in the BioSolutions segment. BioSolutions provide novel solutions through a range of biological stimulants,

soil health and foliar nutrition products to help farmers access a better quality output. These unique technologies provide a bio-stimulation effect and improved nutrition, resulting in healthy plant growth, better yield, quality and tolerance to biotic and abiotic stresses. They help in and Integrated Pest Management (IPM) approach with a wide range of innovative solutions to make farming more sustainable and profitable.

UPL+Arysta's integrated portfolio of crop protection products will target key crops like soybean, corn, fruits and vegetables and cereals

UPL's crop exposure	Arysta's crop exposure	Combined entity	Key geographies
Corn	Corn	Corn	The US and Brazil
Soybean	Soybean	Soybean	The US and Brazil
Fruits and vegetables	Fruit and vegetables	Fruit and vegetables	Europe, Brazil and the US
Cotton	Cereals	Cereals and cotton	Europe and Brazil
Rice	Cocoa	Rice and cocoa	Asia and Brazil
Sugar beet	Sugarcane	Sugar beet and sugar cane	Europe, Asia and Brazil
Tree nuts and aquatics	Sunflower	Tree nuts, aquatics and Sunflower	North America

UPL. Leverages focused innovation to reinforce status as a global leader

Over the years, UPL has consistently invested in research and innovation.

The result is that the Company has evolved from being a generic player into a branded post-patent player with an extensive presence across the valuechain.

The Company progressively diversified to emerge as a holistic solutions provider. Consider this: UPL launched 544 products in five years and revenues from these products accounted for a 24% share of the Company's revenues in 2018-19.

Arysta's portfolio of Bio-Solutions includes more than 700 bio-stimulants, innovative nutrition and bio-control

products. Its portfolio of Bio-Solutions and seed treatment products is complementary to UPL. Arysta is ranked fifth globally when it comes to seed treatment products and is the fifth largest in biocontrol. In Bio-stimulants, it ranks second. Arysta possess significant R&D capabilities in biocontrol as it requires lower capex than agrochemical active ingredient discovery. It is also associated with a lower rate of

discovery failure since most of the ingredients are naturallyoccurring.

This differentiated portfolio enhances value for UPL, strengthening its commitment to invest in cutting-edge technologies and solutions for farmers, and to help them fight adversities.

Arvsta's portfolio enhances UPL value

	UPL	Arysta	Combined entity
Product development and registration	 Greater focus on innovative formulations, combinations, mixtures and label extensions Expertise in securing product registrations, across geographies 	 Late-stage development capabilities and access to J-makers Strong relationships with innovators of active ingredients 	 Access to active ingredients and J-makers Late-stage product development of innovative formulations, mixtures and combinations

The acquisition. Uniting two entities with credible pedigree


UPL was a strong global player with a team size of 7,100+ employees prior to the acquisition. Arysta's team strength was 3,200+ across the markets of its presence.

The acquisition resulted in a joint synergy related to values and demonstrated performance.

Following the acquisition, UPL segregated its global presence into seven regions; four of which are headed by managers from Arysta. This ensured leadership participation from both organisations and wider responsibility-sharing.

Following the acquisition announcement, senior team members from both companies chalked out a cultural

integration plan. This catalysed regulatory approvals from 42 countries and accelerated operations as a cohesive unit, eliminating gestation.





Vicente Gongora

Region Head - North

Marcel Dreyer Region Head - AMEANZ



Hildo Brilleman Region Head - Europe



Rico Christensen Chief Marketing Officer



Sameer Tandon Region Head - India



Fabio Torretta Region Head - Brazil



Hisaya Kobayashi Region Head - Asia

The world will need more food...

More mouths to feed

Global population in 2019 (billion)



Global population in 2050 (billion)

Growing urbanisation

Percentage of global urban population, 2018



Percentage of global urban population, 2050

Growing animal protein consumption

Global meat production excluding eggs, 2013 (million



Global meat production excluding eggs and seafood, 2050 (million MT)

Arable land (developing countries)

Per person, 2000, (sq m)



Per person, 2050, (sq m)

Increased productivity emphasis

Agricultural productivity growth %, 2017



Required annual agricultural growth % till 2050

Arable land (industrialised countries)

Per person, 2000 (sq m)



Per person, 2050 (sq m)

Water scarcity

% of world population to suffer water scarcity, 2050

Global economic growth

% global GDP growth, 2016 to 2050

UPL's proposition

OpenAq

An open agriculture network that ensures sustainable growth for all. No limits, no borders

Two limits, no borders.				
People	Customer- centricity			Technology partnerships and mergers and acquisitions
Prudent financial management				

Sectoral context



Population growth

Population has a direct correlation with food requirement. According to the UN, the current world population of 7.1 billion is expected to reach 9 billion by 2050.



Food security

The number of undernourished people in the world has been on the rise since 2014. In 2017, the number of undernourished people is estimated to have increased to 821 million - ~one in every nine people.



Shrinking farmlands

Arable land availability in industrialised countries is expected to decline by around 20% by 2050.



Reducing yields

Agricultural productivity growth in 2017 was 1.66% and needs to increase to 1.75% to address additional demand by 2050.



Post-harvest damage

As much as 30% of crop output gets wasted once it is taken out of the ground.



Changing preferences

People are consuming more poultry and dairy-based food. Global meat production, excluding eggs and seafood, in 2050 is expected to increase 50% to 455 million tonnes, warranting greater feed and cattle food.



Crop losses

Pest attack at various stages of a crop's lifecycle results in lower yield. Reduction in crop loss could increase productivity and farmers' incomes.

UPL's contrarian approach

Most sectoral players chose to be regional

UPL increased its footprint through a presence in more than 138 countries

Most sectoral players chose to source raw materials from third parties UPL focused on backward integration comprising key raw material manufacturing and power generation

Most sectoral players focused on producing pesticides

UPL invested in business diversification to emerge as a one-stop crop solution Company

Most sectoral players sought short-term business gains

UPL focused on a long-term business sustainability by strengthening its fundamentals

Most sectoral players were engaged in bottomline enhancement

UPL focused on enhancing value for all stakeholders

Most sectoral players prioritised existing products

UPL focused on continuous R&D investment in to introduce innovative products

Most sectoral players were product-centric

UPL chose to be farmer-centric

Most sectoral players were reactive in the face of stiffening environmental regulations

UPL proactively undertook environmental conservation initiatives

Most sectoral players neglected the importance of workplace safety

UPL invested in guaranteeing workplace safety and reported TRFR of 0.38, well below the global TRFR standard

UPL's focus areas



Farmers

The vast majority of farmers across the world are small holders, with just a hectare or two. Farming accounts for a major source of income for many across the world. UPL has focused on improving farm prosperity by introducing products that could help resist pest attacks and enhance productivity.



Environment

UPL has focused intensively on reducing the environmental impact of agriculture through new technologies and simple measures such as helping small farmers in growing the right crop in the right place. UPL's drought mitigation technology (Zeba) provides significant savings for farmers, reducing water consumption, and storing water in the ground to keep crops hydrated during drought. Since 2015-16, CO2 emissions per tonne of production reduced by 13%, waste disposal per tonne of production reduced by 22%, water consumption per tonne of production reduced by 3% and waste water discharge per tonne of production reduced by 11%. We mitigated the product mix change impact and reduced our environment footprint in our global operations.



R&D

Agriculture needs to adapt and change to the pace of our evolving world to fulfill its promise to humankind. UPL's research and development aims to provide comprehensive solutions for the unique needs of modern customers. The Company has invested ₹1,580 crore in R&D over the past four years, which has yielded gains in terms of market share and farmer prosperity. It filed over 500 patents globally for products and processes.



The Company's pool of knowledgeable sectoral experts across areas (chemical engineering, project management, operations, farmer engagement, supply chain management, quality control, marketing, strategic direction and financial management) has enabled it to stay ahead of the curve.



Innovation


The Company has established a reputation for being a pioneer in the industry. It was the first to manufacture groundbreaking products like Glufosinate, Pendimethalin and Zeba among others.




Technology

UPL embraced cutting-edge technologies to enhance operating efficiency. The Company was among the first in the industry to optimised output quality and minimize leakage.

UPL. First among equals





UPL's strategy

Strategic focus	Innovate and excel	Cost advantage
Key enablers	Nurturing a culture of process innovation and product excellence, reflected in the number of patents and registrations.	Continuous procedural improvement and backward integration helped streamline processes and enhanced cost-competitiveness.
Material issues addressed	Used cutting- edge technology to manufacture differentiated products	Automated processes, shrunk carbon footprint and reduced costs
Capital impacted	Manufactured, Intellectual and Financial	Financial and Social

Supp	olier of choice	Robust people practices	Responsible citizenship	Focus on value creation
of cho back c driven positic stop p	ged as a supplier ice on the of our quality- approach and oned as a one- provider of crop ction solutions.	Facilitated personal and professional development by creating a meritocracy. The Company strives to achieve the highest levels of engagement, aided by numerous initiatives.	Engaged in community- strengthening initiatives in the realms of education, health and social welfare.	Graduated from the manufacturer of products to providing holistic solutions to agriculturalists. UPL has become a greater force in the industry by acquiring Arysta LifeScience in FY2019.
reach	ed last-mile by strengthening oution channels	Improved employee engagement and transparency	Fostered community development and enhanced prosperity	Addressed customer needs effectively
Intelle Manut Social	ctual, factured and	Intellectual and Human	Social and Natural	Intellectual, Manufactured and Social

UPL's performance

UPL's performance has been the result of a convergence of various forward-looking intentions, initiatives and investments.



Revenue growth

UPL's revenues have grown at a CAGR of 15% over the last five years leading to ₹22,077 crore in FY2019.



Global footprint

UPL widened its footprint to more than 138 countries in FY2019.



Corporate governance

UPL's Board comprised 10 members with diverse industry experiences, strengthening the Company's managerial bandwidth.



People management

UPL reported a high people retention rate, not only on an overall basis but also at the senior managerial level



Manufacturing facilities

The Company's manufacturing capacity grew by 25% from FY2015 to FY2019.



Product registrations

UPL's product registrations grew by 2,546 over the past five years.



Operational consolidation

UPL consolidated its strengths with 25+ acquisitions over the past decade.



Vertical integration

UPL vertically integrated its business by manufacturing key raw materials reducing thirdparty dependence.

Value created

Financial capital

Revenues (₹ in crore)

Earnings per share (₹)

RoCE (%)

Manufacturing capital

Manufacturing locations

UPL's value-accretive resources



Financial capital

The financial resources that we seek are based on funds we mobilise from investors, promoters, banks and financial institutions in the form of net worth, internal accruals or debt.



Manufactured capital

The Company's manufacturing infrastructure, technologies and equipment constitute its manufactured capital. The proximity of the Company's plants to key raw materials is integral to its competence.



Human capital

The Company's management, employees and contractual workers form an integral part of its workforce, with their cumulative experience and competence, enhancing value.



Intellectual capital

The Company's focus on cost optimisation and operational excellence, as well as its repository of proprietary knowledge account for its intellectual resources.



Social and relationship capital

The Company's relationships with communities and partners (vendors and customers) influence its role as a responsible corporate citizen.

Influencers of business fundamentals

Corporate governance

Code of conduct

Human capital

Number of employees

Employee cost during FY2019 (₹ in crore)

Natural capital


13

Reduction in carbon footprint from baseline 2015-16 (%)

Reduction in water consumption per tonne of production (%)

Our geography-wise performance review

India



** Proforma revenues i.e. not including Arysta

Market overview

Production, of crop protection products in India grew at a CAGR of 4.3% between FY2014 and FY2018. During FY2019, production rose by

2.9%. To feed a rising population, food production needs to increase, warranting the need for more agriinputs for better quality and higher crop yield.

Although food grain production has grown at a CAGR of 1.8% between FY2014 and FY2018, India loses agricultural produce worth more than US\$ 11 billion annually to weeds. At US\$ 4.42 billion, the actual economic losses due to weeds were found to be the highest in rice, followed by wheat (US\$ 3.376 billion) and soybean (US\$ 1.56 billion). However, the average yield loss was the lowest for rice – 14% for transplanted rice and 21% for direct-seeded rice.

UPL is the market leader in India, the country accounting for over 17% of the Company's overall revenues. The Company has reported 7% growth in revenues derived from India over the previous year (based on proforma revenues i.e. not including Arysta). India houses 16 manufacturing facilities of UPL. During the last year, the Company launched 75 products in the country.

Key brands

Insecticides

Herbicides

Fungicides

Crop nutrition/ fumigants and storage

Key developments, FY2019

- Grew revenues by 7% despite excess inventory in the market place
- Introduced 22 herbicides, 17 fungicides, 23 insecticides, 3 seed treatment and 10 adjacent technology products

Optimism

· Government initiatives are aimed at enhancing farmers' income and driving productivity

- Increasing MSPs of key crops
- Increased weed resistance, enhancing the use of innovative herbicides

Outlook


Rising per capita income is driving food demand in India, diet preferences shifting from carbohydrates to meat products and organic / diet foods. Rapid urbanisation, growth of nuclear families, dual-income households coupled with a young population and

increasing media penetration, have led to a surge in the demand for packaged foods, alcoholic and non-alcoholic beverages, snacks and savouries, among others.

With a low per hectare consumption of crop protection products, the sector is expected to report considerable growth. Following the acquisition of Arysta, UPL is expected to drive growth in this market through the introduction of innovative crop protection solutions.

Our geography-wise performance review

Latin America



** Proforma revenues i.e. not including Arysta

across the region over the coming decade by 11% on average, with the most important changes expected in the cereal and oilseeds sectors. The remainder of the expansion of crop production will be due to an expansion in harvested area.

Total agricultural land use in the region could expand by ~11 million hectares. Soybean cultivation could account for the vast majority (~62%) motivated by domestic demand for protein meal in Brazil and rising global demand for soybeans. While ~46% of the region's soybean production will be exported, mostly to China, ~54% of total soybean output could be processed in the region into meal and

Brazil is the largest exporter of coffee, soybeans, crop-based ethanol, cotton, corn, rice and sugarcane to the world and could continue to play a pivotal role as a key supplier of crops across the globe, with Russia, India, China, Western Europe and the United States.

UPL enjoys a strong presence in Latin America, and accounts for a 36% share of total revenues. The key countries in the region include Brazil, Argentina, Colombia and Mexico.

Market overview

Latin America accounts for ~16% of agricultural exports despite accounting for ~7% of the global GDP. The region is one of the few parts of the world with a significant unexploited agricultural land bank, suggesting that the region could play a pivotal role in global food production and exports.

Latin America accounts for 60% of global soybean exports, 33% of corn exports, 45% of coffee exports and ~75% of bananas exports. Additionally, a large proportion of fruits and vegetables consumed around the world have also originated in Latin America. Total crop production in the region is projected to grow by 1.8% every year till 2027. ~60% of this growth will be due to yield improvements, which could rise

Key brands



Herbicides Clorim

Fungicides

Key developments, FY2019

- Grew revenues by 25%
- Introduced 72 herbicides, 63 fungicides, 75 insecticides, six seed treatment products and 10 adjacent technology products
- Contributed 36% to UPL's overall revenues, (% are on Proforma revenues i.e. not including Arysta).

Optimism

- Access to sugarcane co-operative channel due to Arysta offering a complete portfolio for the crop
- Access to new AI's which enhance the portfolio of key crops like soybean and corn

- Promoting Pronutiva concept across regions and crops
- Access to distribution channels in countries where the legacy UPL had a sub-scale presence

Outlook

The region is expected to remain an important global supplier of various food commodities, accounting for 56-59% of global trade of soybeans and sugar and 30% of the global meat trade by 2027.


Current trade policies in Argentina, such as the removal of export taxes on maize and wheat, should encourage export-oriented production of those crops. With the US classifying cane

ethanol as an advanced renewable fuel, encouraging imports from Brazil, the region's position as a net exporter of ethanol could strengthen with the value of net trade expanding 11% per annum.

Latin America has pioneered the adoption of agri-business technologies like the direct sowing practice to reduce soil erosion. The result: 81% of Argentina's land is arable compared to 23% in the US and 10% in Europe. By joining hands with Bayer, UPL expects to widen its customer base in this region.

Our geography-wise performance review

urope



** Proforma revenues i.e. not including Arysta

Market overview

Europe is an important region for the global agricultural industry, both in terms of land bank as well as production, owing to the variety of natural resources and climatic conditions. Furthermore, the latest technological developments in the contitent sharply increased yields.

Organic farming is gaining popularity, with Spain and Italy accounting for ~1.97 million hectares of organic agricultural land and more than 52,000 organic producers.

Cereals, oilseeds and sugar cultivation areas in the EU-28 are expected to decline during FY2020 to around 70.7 million hectares. A dry autumn hampered sowing, but mild winter

conditions brightened prospects in Europe. On the basis of historical trend of yields, European cereals harvest could reach 308 million tonnes. Oilseeds area is expected to decline by 6% due to lowered rapeseed sowings during FY2020. Oilseed output is fairly stable compared to the previous season's figure of ~33 million tonnes. Adverse weather conditions lowered sugar production by 17% y-o-y during 2018-19 (~17.6 million tonnes), resulting in a deficit of 5%.

UPL posted a strong growth of 16% in terms of revenues derived from Europe. Over a period of time, UPL has extended its footprint across the region to reduce its dependence on a specific country. The Company also diversified its presence across crops sugar beet, oilseeds, fruit (grape and others) and vegetables.

Key brands

Herbicides

Fungicides Cuprofix, Microthial

Key developments, FY2019

- Grew revenues by 16%
- Introduced 89 herbicides, 68 fungicides, 44 insecticides and six adjacent technology products
- Contributed 14% to UPL's overall revenues. (% are on Proforma revenues i.e. not including Arysta).

Outlook


Share of total


Sugar beet production for 2019-20 is forecast at 123

million tonnes (an increase of 9% over 2018-19) and sugar production could reach 18.3 million tonnes (an increase of 4% over 2018-19). Cereal production is expected to grow to 341 million tonnes by 2030, driven by feed offtake, brightened export prospects (particularly for wheat) and increasing demand for cereals. However, growth could be restricted due to the limited potential for farmland expansion and decelerated yield growth in the region.

Our geography-wise performance review


North America





FY16 FY17 FY18 FY19

Growth over last



** Proforma revenues i.e. not including Arysta

Market overview

Across North America, agriculture has become mechanised and dependent on an integrated system of supporting agri-businesses. Total US food and agricultural exports to Canada and Mexico more than quadrupled between 1993 and 2016, growing from US\$ 11 billion to US\$ 43 billion, accounting for 25% of all US agriculture exports. The US has the most abundant, varied and productive agricultural system in the world today and is a key driver of economic growth, providing US\$ 2 trillion in annual revenues, employment for 19 million people and US\$ 130 billion in profit for more than 2.6 million businesses.

UPL offers a range of products for key crops like rice, tree nuts, aquatics, turfs and ornamentals, fruits and vegetables in North America. The Company gained a foothold in the niche segment of aquatics (crop protection products used to counter weeds in fresh water lakes), horticultural and post-harvest crop protection products.

Key brands

Insecticide

Herbicides

Fungicides

Crop nutrition/ fumigants and storage

Key developments, FY2019


- Grew revenues by 13%
- Introduced 27 herbicides, eight fungicides, eight insecticides, six seed treatment products and one adjacent technology product
- Contributed 18% to UPL's overall revenues (% based on proforma revenues i.e. not including Arysta).

Optimism

- Access to cereal segment with proprietary AIs and bundling the same with the legacy UPL range to offer a complete portfolio for cereal crops
- Increasing the wallet share of key customers
- Resistance to key weeds giving an opportunity for key value-added mixtures
- Specialty product portfolio for exotic vegetables

Our geography-wise performance review

Rest of the World



** Proforma revenues i.e. not including Arysta

The Australian agriculture market accounted for 58% of Australian land use (385 million hectares, excluding timber production) and 14% of goods and services exports in 2016-17. Australia is the 12th largest exporter of agriculture products in the world and is expected to increase its agricultural output to AUD100 billion by 2030.

China emerged as the largest consumer of soybean in the world while the overall production of grains remained relatively stable at 600

million tonnes per year. Nearly 112.2 million hectares were sown in 2017, down by 0.81 million hectares when compared with the previous year. Wheat, rice, corn and oil-bearing crops remained the primary agricultural commodities in China. China's focus is on improving the quality of production by adjusting acreage and production to balance the skewed supply-demand

In Japan, among the top 10 crops produced, sugar cane saw the most significant increase in 2016, growing by 24.9% over the volume in 2015. Sugar cane was also the fastestgrowing crop between 2012 and 2016, clocking a CAGR of 9.2%.

Turkey is among the top 10 agro economies in the world, with half the country comprising agricultural lands and ~25% of the population employed in agriculture. Turkey is a major producer of wheat, sugar beet, milk, poultry, cotton, tomatoes and other fruits and vegetables. It is also the top producer of apricots and hazelnuts in the world. Turkey imports oilseeds, including soybeans and meals, as well as grain products.

UPL has a strong presence in Australia, Turkey, Japan, Indonesia and China. UPL reported a strong performance in these countries, growing revenues on the back of a strong distribution network. The Company's products are used for a variety of crops across these geographies - rice (Indonesia, Bangladesh and Vietnam), cotton, wheat and sugar cane (Turkey and Pakistan) and pulses (Nigeria, Morocco and Egypt).

Key brands



Key developments, FY2019

- Grew revenues by 6%
- Introduced 72 herbicides, 34 fungicides, 71 insecticides, one seed treatment product and six adjacent technology products
- Contributed 17% to UPL's overall revenues (% on proforma revenues i.e. not including Arysta).

Optimism

- Presence in Africa market where legacy Arysta has been strong
- In-sourcing and leveraging UPL's manufacturing strength for key AIs where legacy Arysta was buying from a third party.
- Probable band of non-selective herbicides in key Asian geographies, creating an opportunity for legacy UPL brands like Tarang, Lifeline and Fanate

Outlook

The Vietnamese agro-industry is expected to benefit from economic and financial integration in South East Asia (the ASEAN Economic Community) with investments in the agricultural supply chain. Vietnam concluded a free trade agreement with EU, which is likely to boost trade in coffee, rice and seafood. China's demand for agricultural products is projected to grow in the near future. Although soybean is likely to remain the dominant import commodity, overseas purchases of corn and higher-valued commodities are also anticipated to expand. The global suppliers on international rice markets are expected to remain the same, principally being Thailand, India and Vietnam, while Cambodia and Myanmar are projected to expand exports over the next decade and capture a greater share of the global export market.



Management discussion and analysis

Global economic overview

The global economy grew by 3.6% in 2018 compared with 3.8% in 2017, against a backdrop of the failure of Brexit negotiations, tightened financial conditions, geopolitical tensions and higher crude oil prices. Global growth is estimated at 3.3% in 2019.

(Source: World Economic Outlook).

Global economic growth over six years

Year	2015	2016	2017(E)	2018(E)	2019 (P)
Real GDP growth (%)	3.2	3.1	3.8	3.6	3.3

(Source: World Economic Outlook, January 2019) E: Estimated; P: Projected

Indian economic overview

After growing at 7.2% in 2017-18, the Indian economy slowed down to 6.8% in 2018-19 (as per the May 2019 estimate of CSO). The principal developments during the year comprised 8.6% increase in per capita income, decline in the national inflation, steady interest rates, and weaker consumer sentiment in the second half of the financial year following a large non-banking financial institution announcing its inability to meet dues. India is now the sixth largest economy (eleventh largest in 2013-14) that reported an FDI of US\$ 239 billion in the last five years. The country also reported a 23-notch jump to a record 77th position in the World Bank's report on the Ease of Doing Business that captured the performance of 190 countries reporting an improvement in six of 10 parameters. India's globalrank for 'getting credit' as per World Bank's Ease of Doing Business Index improved from 44 in 2016 to 22 in 2018

Relevant government initiatives

Increasing MSP: The Government fixed MSPs of 22 mandated kharif and rabi crops and FRP for sugarcane. The Central government committed to provide farmers with a 50% return over the cost of production for all mandated crops, strengthening the rural economy.

Pradhan Mantri Kisan Samman Nidhi: A scheme announced by the Central Government promising an annual assured income of ₹6,000 (US\$ 84.5) for any farmer who owns ≤2 hectares of farmland. However, the newly elected government has removed cap on landholding size. The revised Scheme is now expected to

cover around 2 crore more farmers. increasing the coverage of PM-KISAN to around 14.5 crore beneficiaries, with an estimated expenditure by the Central Government of ₹87,217.50 crore for the year 2019-20.

Direct Benefit Transfer: The Direct Benefit Transfer initiative reengineered the cash disbursement process in welfare schemes through simpler and faster flow of information/ funds to ensure accurate targeting of beneficiaries, removing duplication and reducing fraud. In 2018-19 alone, this scheme is estimated to have transferred more than ₹314,465 crore and the gains to have accrued since scheme implementation is estimated at more than ₹120,000 crore.

PM- AASHA: The price deficiency scheme for farmers (PM- AASHA) was pared down to ₹1,400 crore for FY2019 and ₹1,500 crore for FY2020. A new ₹3,000 per month pension scheme for unorganised workers with a monthly income ≤₹15,000 has a modest outlay of more than ₹500 crore.

The fiscal deficit for FY2019 is revised to 3.4% of the GDP against 3.3% budgeted earlier. For FY2020 too, the deficit will remain at the same level in relation to the GDP as in FY2019 while the 3% FRMB goal is now left to be achieved in FY2021.

Targeted income support scheme:

A targeted income support scheme (an approximation of the universal basic scheme flagged by many) is, however, being seen as more efficacious in addressing the distress in the farming sector and rural India, than the farm loan waivers being implemented by various State Governments.

Other schemes and sops: The sops for the farm sector do not end at the basic minimum income. In a move to provide supplementary income, the Central Government also focused on allied agricultural activities by extending credit provisions and giving more credence to the animal husbandry and the fisheries sectors. In addition to announcing an outlay of ₹750 crore and setting up of Rashtriya Kamdhenu Aayog to enhance the production and productivity of cows, it also extended interest subvention to farmers pursuing animal husbandry and fisheries through Kisan Credit Card scheme, with an additional 3% for timely repayment. With over 40 million accounts, an extension of KCC is expected to provide further access to formal finance. Moreover, by raising the duration of interest subvention of 2% for farmers hit by natural calamities from one year to the entire period of loan duration and also raising the subvention limit to 5%, it has shown that it can be farmerfriendly.

(Source: Financial Express, Live Mint, Economic Times, Reuters, PIB, Union Budget, World Bank, Times Now, dbtbharat.gov.in)

Outlook

Assuming no major global and domestic political shocks, India's markets are expected to perform better in 2019.

(Source: CSO, Fitch, Economic Times, Business Standard, IBEF, Business Today, India Today)


Indian agricultural sector overview

Agriculture is the primary source of livelihood for ~58% of India's population. Gross value added by agriculture, forestry and fishing is estimated at ₹1,842,873 trillion in FY2018-19. The agriculture sector's contribution to the Indian economy was higher (14.39%) than the global average (6.4%). India is the largest producer of spices, pulses, milk, tea, cashew and jute as well as the secondlargest producer of wheat, rice, fruits and vegetables, sugarcane, cotton and oilseeds. India has the tenthlargest arable land resources in the world. It is also the largest producer, consumer and exporter of spices and spice products. With 20 agro-climatic regions, all 15 major climates in the world exist in India. The country also possesses 46 of the 60 soil types in the world.


In 2018-19, food grain production in India was estimated at 283.37 million tonnes compared to 277.49 million tonnes in the previous fiscal. Overall agri and processed food exports rose to ₹1.28 lakh crore in the financial year 2018-19 from ₹1.20 lakh crore in the 2017-18 fiscal. Agriculture storage capacity in India increased at 4% CAGR between 2014-17 to reach 131.8 million metric tonnes.

(Source: PR Newswire, IBEF, Statistics Times)

Kharif area sown, 2018-19



Rabi area sown, 2018-19



(Source: IBEF)

Key numbers

- ~70% of rural households depend primarily on agriculture and ~86% of India's farmers are categorised as 'small and marginal', meaning they own less than 2 hectares - the size of two football fields.
- The average monthly surplus available to a rural Indian home, whether a farm or non-farm household, was ₹1,413.
- The growth in the agriculture, forestry and fishing sector's GVA - a measure of income before produce is sold - was estimated at 3.8% in 2018-19, compared to 3.4% in 2017-18, according to the Central Government's first advance estimate on national income for 2018-19. But the share of this sector in GVA declined 1.8 bps to 16.4% over five years to 2017-18 (first advance estimates).
- Since April 2017, eight states have announced farm loan waivers worth

- ₹190,000 crore and the Central Government has increased the procurement price for kharif and rabi crops.
- Over 45 years to 2015-16, the number of farms in India more than doubled from 71 million in 1970-71 to 145 million in 2015-16, while the average farm size more than halved from 2.28 hectares to 1.08 hectares.
- An indication of the distress is an almost eight-fold rise in 'agrarian riots' between 2014 and 2016, which included conflict over land and water.
- India's food grain requirement for 2025 should be 300 million tonnes.
- Despite these high levels of production, agricultural yield in India is lower than many other countries. India is the second-largest producer of paddy in the world after China, but, even though India's paddy yield increased 2.5x over 56 years to 2017,

- its yield (3.8 tonnes per hectare) was ~18% lower than China's in 2017. Brazil (6.2 tonnes per hectare) and the US (8.4 tonnes per hectare) too had higher yields.
- Between 2014 and 2016, gross farm revenue reduced 6% despite subsidies for fertiliser, power and irrigation, which somewhat offset the price-depressing effect of market interventions.

(Source: Agriculture Census 2015-16, India Spend, Oxfam, Economic Survey 2017-18, Live Mint National Crime Records Bureau, PRS Legislative Research, Organisation for Economic Cooperation and Development, Indian Council for Research on International Economic Relations)

Budget, 2019-20

- All 22 crops were put under Minimum Support Price. The various pro-farmer policies led to the production of agricultural commodities in record quantities
- However, the income of farmer families reduced

- There has been a need to provide structured income support to the poor farmer families to buy fertilizers and seeds among others
- The support is aimed to help farmers reduce their indebtedness and enable them to live a respectable
- To provide assured income to small and marginal farmers, the Government introduced a historic yojana Pradhan Mantri Kisan Samman

Nidhi (KISAN). Under the yojana, the eligible farmers, will get direct income support of ₹6000 per year.

 The income support will be transferred directly to the account of the beneficiary farmer in three equal installments of ₹2000 each. It would be fully funded by the Government of India. The scheme is expected to benefit 12 crore farmer families. Around ₹75,000 crore will be borne by the Centre every year. The first

installment will be issued soon after preparing a list. ₹20,000 crore will be spent this financial year.

- PM Kisan will provide assured supplementary income to vulnerable farmer families.
- Besides this, farmers affected by natural calamities will be given 3% interest subvention on crop loans.

(Source: Ministry of Finance, Union Budget 2018-19,

How India compares with the world

- In 2017, 18% of Chinese were employed in agriculture compared to 43% of Indians, according to World Bank data. Over 26 years till 2017, the proportion fell 37 bps in China, while in India it fell 21 bps, keeping India above the world average of 26.4% of people employed in agriculture.
- India's spending on agriculture research (as a percentage of agriculture GDP) is 0.3%. China, the US, Brazil and South Africa spent 2x, 4x, 6x and 10x more than India, respectively.

(Source: Hindu Business Line)

Food demand drivers

Food processing: The Indian food processing industry accounts for 32% of the country's total food market and contributes ~ 8.4% of gross value added in agriculture.

Grocery market: The Indian food and grocery market is the world's sixthlargest, with retail contributing 70% of the sales. India's food retail market is expected to touch US\$ 827 billion by 2023, up from US\$ 487 billion in 2017, growing at a compound annual growth rate (CAGR) of 9.23%,

Growing population: 1.5 million people are added every year to India's population and it is estimated that India will become the most populous country by 2022.

Rising incomes: India's per capita income will grow by more than 2x by 2027. Estimated per capita income growth in India stood at 11.1% during FY2018-19. Rising income levels have resulted in more disposable incomes, driving consumption.

Export revenues: The Central Government planned to increase export revenues from US\$ 37 billion currently to US\$ 60 billion by 2022, playing a pivotal role in terms of doubling of farmers' incomes.

(Source: Live Mint, Business Today, PIB)

Outlook

The Indian agricultural market is expected to reach ₹89,380 billion by 2023, exhibiting a five-year CAGR of 12.2%. India is expected to achieve the ambitious goal of doubling farm incomes - from US\$ 1,505.27 in 2015-16 to US\$ 3,420.21 by 2022. The agriculture sector in India is expected to gain momentum in the coming years due to increased investments in agricultural infrastructure. India is expected to become self-sufficient in pulses in the coming few years due to the concerted efforts of scientists to get early-maturing varieties of pulses and the Central Government's decision to increase minimum support prices.

Global crop protection products market overview

The market for crop protection products was pegged at US\$ 57.5 billion in 2018, and is expected to reach US\$ 66.7 billion by 2023, registering a CAGR of 3.1%. Currently, the herbicide segment constitutes the largest market share (42.7%). This segment is expected to retain its higher position, due to the large-scale adoption of herbicide-resistant crops in North and South America.

(Source: Phillips McDougall))

The crop protection products industry has been transforming over the years, with changing crop mix trends and environmental regulations. Growing population, decline in arable land and food security are the primary focus areas for all countries, these factors driving the demand for higher agricultural output, global augmenting the growth of the crop protection products industry. Synthetic pesticides form the largest category within the market for crop protection products, with bio-pesticides accounting for a comparatively smaller share.

(Source: Mordor Intelligence)

Emerging trends

Increasing food demand and diminishing land area: Global population is increasing exponentially. It has increased nearly fourfold in the past 100 years, and is projected to reach 9.2 billion by 2050. Supplying food to this growing population has become a global concern. By 2030, the per capita farmland is expected to decrease to 1,800 square meters from 2,200 square meters in 2005. Various crop pests contribute to yield loss, causing global crop loss of 10-16%, annually. Although new technologies are continuously being developed to fight pest attacks, they are also leading to the development of new strains of pests that are difficult to kill. The amount of loss in major crops, due to fungi alone, is enough to feed ~9% of the global population.

Increasing use of herbicides and weed control: The increasing use of herbicides is anticipated to drive the global crop protection products market because of the investments made for development of new varieties of herbicides, which are more effective and eco-friendly. The increased use of herbicides is a result of the shift in preference of consumers toward

fruits and green vegetables owing to increasing awareness of health and fitness

(Source: Mordor Intelligence)

Indian crop protection products market overview

India is the fourth-largest global producer of crop protection products, with an estimated market size of ~₹197 billion in 2018, after the US, Japan and China. India has also emerged as the thirteenth-largest exporter of crop protection products globally. With more mouths to feed, shrinking arable area, loss of yield due to increased pest attacks, the crop protection products industry in the country is on the rise.

Production of crop protection products grew at a CAGR of 4.3% between 2013-14 and 2017-18, and in 2018-19 it rose by 2.9%. The production capacity of crop protection players in India was pegged at ~292,000 million tonnes in 2018-19.

Paddy accounts for the maximum share of crop protection products consumption (26%-28%), followed by cotton (18% -20%). Andhra Pradesh, Maharashtra, Punjab, Madhya

Pradesh, Chhattisgarh, Gujarat, Tamil Nadu and Haryana account for >70% of the crop protection products used in India. Andhra Pradesh is the leading consumer of crop protection products with a market share of 24%.

Crop protection product exports increased at a CAGR of 12.8% between 2013-14 and 2017-18. In 2018-19, crop protection products exports increased by 11% whereas imports increased by 4.4%, compared to the corresponding period in the previous financial year. Latin America, North America, Europe and Asia have emerged as important markets for the Indian crop protection products industry. Fungicide and herbicide exports grew at CAGRs of 25.5% and 27.5%, respectively, between 2013-14 and 2017-18. In 2018-19, exports of insecticides, fungicides and herbicides increased by 10.2%, 17.2% and 1.8%, respectively. Fungicide and herbicide imports grew at a CAGR of 15.5% and 28.4%, respectively, between 2013-14 and 2017-18. Insecticide imports fell by 3.7% during the same period.

The crop protection products industry is expected to grow at a CAGR of 8.1% to reach ₹316 billion by 2024.

SWOT analysis

Strengths

- Low-cost manufacturing
- Availability of cutting-edge technologies
- Ample capacity

Weaknesses

- High expenditure required in R&D
- Dependence on monsoons
- Consumption imbalance
- Capital-intensive processes
- Restrictive norms
- Health hazards

Opportunities

- Focus on innovative farming solutions
- Patent expiry
- Export potential
- Scope for increase in usage
- Rural infrastructure and IT
- Availability of credit facilities
- Increase in MSPs
- Rising labour costs

Threats

- Genetically-modified
- Spurious crop protection products

Growth drivers

Increasing demand: The total food grain production in India was estimated at 281.37 million tonnes during 2018-19 compared to 277.49 million tonnes in 2017-18. An increasing population and the need for achieving food grain self-sufficiency, are expected to drive growth.

Farmland availability: Rapid urbanisation has had a detrimental impact on land availability. The pressure is to increase yield per hectare, which can be achieved

through increased usage of productivity-enhancing inputs like crop protection products.

Climatic conditions: Farms need an array of inputs to protect crops from the effects of erratic climatic conditions. Irregular monsoons, coupled with a lack of irrigation (60% of cultivable land in India is nonirrigated), results in low agricultural yields.

Off-patent molecules: The share of off-patent molecules compared to patented molecules and

proprietary off-patent molecules has been increasing over the years. Agrochemicals worth US\$ 4.1 billion are expected to go off-patent by 2020. This provides significant export opportunities for Indian companies. who possess an expertise in the offpatent segment.

Per capita consumption: India has one of the lowest pesticides consumption in the world. India's per hectare consumption of just 0.6 Kg compared to US (5-7 Kg/ha) and Japan (11-12 Kg/ha).

Types of key agrochemicals and their primary use

Insecticides

Controls insect pests, which reduce crop yield and quality

Fungicides


Prevents and cures fungal plant diseases

Herbicides

Prevents or reduces weeds, which hamper crop growth and harvest


(Source: CARE)

Domestic market segmentation by type of pesticides




(Source: FICCI, CARE)

Region-wise share of exports of India



Exports of key agrochemicals (000' tonnes)



Agrochemical markets: 2018/2017 (Distributor level, \$M.)

Sales (\$m.)	2018	2017	Change % 2018/2017
Conventional crop protection	57,561	54,319	+6.0
Non-crop agrochemical market	7,538	7,311	+3.1
Total agrochemicals	65,099	61,630	+5.6

Source: Phillips McDougall

Global market by region and product sector 2018 (\$M)

	Herbicides	Insecticides	Fungicides	Others	Total CCP
APAC	6,375	5,784	4,685	645	17,489
LATAM	5,653	3,574	4,434	520	14,181
Europe	5,340	1,710	4,485	466	12,001
NAFTA	6,341	2,566	2,310	406	11,623
MEA	899	915	405	48	2,267
World	24,608	14,549	16,319	2,085	57,561

Source: Phillips McDougall

Financial analysis

The financial statements of the Company were prepared in accordance with Ind-AS. The financial statements comply with the accounting standards laid down under the Companies (Accounting Standards) Rules, 2006, as amended, and the relevant provisions of the Companies Act, 2013. The financial

statements were prepared under the historical cost convention on an accrual basis. The accounting policies were consistent with those used in the previous years.

Balance sheet

• Net worth increased to ₹14,645 crore as on 31st March 2019 compared to ₹9,169 crore as on 31st March 2018.

- Borrowings as on 31st March 2019 stood at ₹29,142 crore compared to ₹6,665 crore as on 31st March 2018.
- Total non-current assets as on 31st March 2019 stood at ₹36,056 crore compared to ₹8,019 crore as on 31st March 2018.

Profit and loss statement

- Revenues increased by 23.2% from ₹17,920 crore in FY2018 to ₹22,077 crore in FY2019.
- EBITDA increased to ₹4,111 crore in FY2019 compared to ₹3,517 crore in FY2018.
- Net profit was ₹2,022 crore in FY2018 and ₹1,447 crore in FY2019.
- Gross profit margin decreased by 360 bps from 53.7% in FY2018 to 50.1% in FY2019.
- Total expenses for FY2019 stood at ₹19,957 crore compared to ₹15,459 crore in FY2018.

 Depreciation and amortisation stood at ₹969 crore in FY2019 compared to ₹675 crore in FY2018.

Working capital management

- Current assets as on 31st March 2019 stood at ₹26,966 crore compared to ₹15,004 crore as on 31st March 2018.
- Current ratio as on 31st March 2019 was 1.73 compared to 1.96 as on 31st March 2018.
- Inventories increased from ₹4,538 crore as on 31st March 2018 to ₹9,270 crore as on 31st March 2019.

- Short-term loans and advances reduced to ₹51 crore as on 31st March 2019 compared to ₹147 crore as on 31st March 2018.
- Current liabilities stood at ₹15,564 crore as on 31st March 2019 compared to ₹7,642 crore as on 31st March 2018.
- Cash and bank balances stood at ₹2,826 crore as on 31st March 2019 compared to ₹2,859 crore as on 31st March 2018.

Key ratios

Particulars	FY2018-19	FY2017-18
EBITDA/Revenue (%)	18.8	20.1
EBITDA/Net interest (%)	5.33	8.23
Debt-equity ratio	199%	72.7%
Return on equity (%)	10.4	22.1
Book value per share (₹)	287	180
Earnings per share (₹)	28.42	39.79

Human resources

UPL's prudent HR practices has helped reinforce its market leadership across more than 40 countries. UPL employs professionals from 75 countries around the world and invests in formal and informal training as well as on-the-job learning. UPL transferred key executives across geographies to enrich its international leadership pool. UPL reinforced engagements with employees across levels by providing an enriched workplace, challenging job profile and maintaining ongoing dialogue. UPL enjoys one of the highest employee retention rates in the industry.

Risk management at UPL

UPL has put in place a proactive and structured risk and opportunity management framework across organisational levels. The breadth of the Company's operations provides increased resilience to risks and greater ability to capture opportunities.

UPL uses organisation-wide procedures for identifying and managing risks and opportunities. Guided by the procedures, the risk team supports the management by examining and analysing critical business transactions.

Each business function conducts risk and opportunity assessments and identifies measures for managing risks. The proposals are then processed by the risk management team, which issues a recommendation based on specific cases and the risks and opportunities associated with them. The final decision is made by the Board.

Risk management process at UPL



Risk **Impact** Mitigation Result



Competition risk

Increased competition might affect the Company's prospects.

- The Company's wide product portfolio enhances its ability to address the multiple needs of customers across the global competitive crop protection products market.
- Access to cutting-edge technology increases UPL's productivity and reduces operational costs.
- The Company's strong product registration team across the globe ensures that the pipeline of new product registrations remains plentiful.

UPL has >12,400 product registrations across the globe.



Geographical

Slowdown in product offtake in a particular geography, impacting the Company's profitability.

- UPL is present in 138 countries across the globe and is supported by state-ofthe-art manufacturing units across 48 locations globally.
- The Company has a strong presence in key agricultural markets across Asia, Africa, Latin America, Europe and North America.

83% of the Company's revenues came from international markets.

Risk Mitigation Result **Impact**



Industrial risk

Demand slowdown in downstream industries could slow the growth and lead to inventory pile-up.

- The Company is present across all key geographies and multiple crop segments, enabling it to de-risk itself from any regional or crop-specific slowdown. With food demand rising across the globe, reducing crop loss is the need of the hour.
- The Company offers solutions across the value chain starting from seeds to seed treatment products to pre - and post-harvest solutions. It introduced valueadded solutions like Adarsh Farm Services and Adarsh Kisan Centre, among others, to emerge as one-stop solution provider for farmers around the world.

During periods when most peers reported lower growth or contraction, UPL consistently increased its revenues



Liquidity risk

Lack of adequate capital could impact the daily operations of the Company.

- UPL's cash profit reduced from ₹2,980 crore during FY2018 to ₹2,653 crore during FY2019.
- The Company's working capital cycle stood at 95 days of turnover equivalent during FY2019 (84 days in FY2018).

The Company's current ratio and quick ratio stood at 1.73 and 1.14, respectively, during FY2019.



R&D risk

Inability to introduce products regularly could impact business sustainability.

- The Company's 500+ strong R&D team works relentlessly on launching innovative formulations, mixtures and combinations; resulting in a steady stream of post-patent products, which offer greater efficacy than those offered by peers.
- The Company received 1,023 patents.

The Company's Innovation Rate in FY2019 was 17%



Marketing risk

Inability to market products successfully could decelerate growth.

- To be closer to customers, UPL set up formulation facilities near key markets, backed by strong distribution channels, ensuring that the Company's products are well-recognised all over the world.
- UPL analyses grassroots realities to strengthen demand forecasting.
- UPL has strengthened its branding and marketing competence to enhance user confidence

The Company invested judiciously to promote brands FY2019.

Risk Mitigation Result **Impact**



Margins risk

A decline in profitability could adversely impact the long-term prospects of the Company.

- The Company's unflagging commitment to profit optimization ensured that the Company was able to maintain margins even in difficult times
- The Company embarked on cost optimisation initiatives, which helped maintain profits.
- Bulk volume purchase and better negotiation with suppliers helped the Company reduce raw material costs and improve the bottomline.
- The Company's backward integration initiatives allowed it to surge ahead of sectoral peers.
- The Company's decision to set up active ingredient manufacturing facilities in India allowed it to leverage the benefits resulting from lower capex and labour costs.

The Company's EBITDA margin and net margin reduced by 126 and 474 bps, respectively, during FY2019

The reduction was primarily on account of the Arysta acquisition-related adjustments.



Price risk

The Company's product might be outpriced in a competitive marketplace, resulting in the loss of market share.

UPL capitalised on the cost-effective availability of labour in India and sizeable production capacities that allows it to make most of the advantages stemming from superior economies of scale.

During FY2019, UPL optimised its manufacturing costs on the back of strategic improvements to its manufacturing processes.



Forex risk

Currency fluctuations could significantly dent the Company's bottomline.

- UPL takes adequate forward covers for open exposures.
- The Company's huge export volumes act as a natural hedge.
- UPL transacts in several major currencies such as the US dollar, Euro, Japanese yen and British pound.
- The Company uses a plain forward cover to hedge forex volatility.

The Company succeeded in protecting its margins.

Internal control systems and their adequacy

The Company believes that corporate efficiency, managerial effectiveness and asset safeguarding can be guaranteed by exercising adequate internal controls and ensuring procedural standardisation. At UPL, internal control is implemented through the following initiatives:

- Accurate and timely recording of transactions by utilising a multi-layered system of checks and balances
- Implementation of ERP enabling real-time access to mission-critical
- Application of accounting policies in line with prescribed standards
- Periodic reviews of long-term plans and annual budgets
- Implementation of business intelligence to assess consumer preferences
- Constant monitoring of processes via routine audits

Cautionary statement

The statements in the management discussion and analysis section with regard to projections, estimates and expectations have been made in good faith. The achievement of results is subject to risks, uncertainties and even less than accurate assumptions. Market data and information are gathered from various published and unpublished reports. Their accuracy, reliability and completeness cannot be assured.

Corporate information

Board of Directors

Mr. R. D. Shroff - Chairman & Managing Director

Mrs. S. R. Shroff - Vice Chairman

Mr. J. R. Shroff - Global CEO of the Group

Mr. V. R. Shroff - Executive Director

Mr. A. C. Ashar - Director - Finance

Mr. K. Banerjee - Whole - Time Director (Resigned w.e.f. 1st August, 2018)

Mr. Pradeep Goyal

Dr. Reena Ramachandran

Mr. Vinod Sethi

Mr. Hardeep Singh

Mr. Vasant P. Gandhi

Chief Financial Officer

Mr. Anand Vora

Company Secretary

Mr. M. B. Trivedi

Auditors

BSR&Co.LLP

Chartered Accountants

Administrative Office

UPL House, 610 B/2, Bandra Village, Off Western Express Highway, Bandra (East)

Mumbai - 400 051

Phone: 91 22 7152 8000, Fax: 91 22 7152 8886

Registered Office

3-11, G.I.D.C., Vapi,

Dist.: Valsad, Gujarat-396 195.

Tel.: 0260-2400717, Fax: 0260-2401823

Bankers

Dena Bank

Bank of Baroda

State Bank of India

Canara Bank

IDBI Bank Ltd.

The Karur Vysya Bank Ltd.

Axis Bank Ltd.

Andhra Bank

ICICI Bank Ltd.

Kotak Mahindra Bank Ltd.

Secretarial Department

Uniphos House, C.D. Marg, Khar (West)

Mumbai - 400 052

Phone: 91 22 2646 8000, Fax: 91 22 2604 1010

Debenture Trustees

IDBI Trusteeship Services Limited

Asian Building, Ground Floor

17. R. Kamani Marq Ballard Estate

Mumbai - 400 001



UPL LIMITED

(CIN: L24219GJ1985PLC025132)

Notice

NOTICE is hereby given that 35th ANNUAL GENERAL MEETING of the Members of UPL LIMITED will be held on Wednesday, 28th August, 2019 at 11.00 a.m. at Hotel Green View Hall, National Highway No. 8, G.I.D.C., Vapi - 396 195, to transact the following business:

ORDINARY BUSINESS:

- 1. To consider and adopt:
 - a) The audited standalone financial statement of the Company for the financial year ended on 31st March, 2019 and the Reports of the Board of Directors and Auditors thereon.
 - b) The audited consolidated financial statements of the Company for the financial year ended on 31st March, 2019 and the Report of the Auditors thereon.
- 2. To declare dividend on equity shares.
- 3. To appoint a Director in place of Mr. Jaidev Rajnikant Shroff (DIN: 00191050), Non-Executive Director, who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

4. To approve the remuneration of the Cost Auditors for the financial year ending March 31, 2020

To consider and if thought fit, to pass, the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or reenactment thereof, for the time being in force), M/s. RA & Co., (Firm Registration No. 000242), Cost Accountants appointed as Cost Auditors by the Board of Directors of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2020, be paid remuneration amounting to ₹8,00,000/-(Rupees Eight Lakhs Only) plus Goods and Service Tax, as applicable, and out of pocket expenses if any."

5. Private placement of Non-Convertible Debentures

To consider and if thought fit, to pass, the following resolution as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 42, 71 and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made there under, as amended from time to time, consent of the Company be and is hereby accorded to the Board of Directors (hereinafter referred to as the "Board", which term shall be deemed to include any Committee of the Board constituted to exercise its powers, including the powers conferred by this Resolution) for making offer(s) or invitation(s) to subscribe to Non-Convertible Debentures on private placement basis, in one or more tranches, such that the total amount does not exceed ₹3,000 crores (Three Thousand Crores only) during a period of one year from the date of passing of this Resolution and that the said borrowing is within the overall borrowing limits of the Company.

RESOLVED FURTHER that the Board be and is hereby authorized to take all such steps as may be necessary, proper and expedient to give effect to this Resolution."

To re-appoint Mr. Pradeep Vedprakash Goyal (DIN: 00008370) as an Independent Director of the Company

To consider and if thought fit to pass with or without modification(s) the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 ("Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or reenactment thereof for the time being in force) read with Schedule IV to the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Pradeep Vedprakash Goyal (DIN: 00008370), and who has submitted a declaration that he meets the criteria of independence as provided in Section 149(6) of the Act and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and who is eligible for re-appointment, and in respect of whom the Company has received a notice in writing from a Member under Section 160(1) of the Act proposing his candidature for the office of Director of the Company be and is hereby re-appointed as an Independent Director of the Company to hold office for a second term of 5 (five) years commencing from August 28, 2019 and whose office shall not be liable to retire by rotation."

7. To re-appoint Dr. Reena Ramachandran (DIN: 00212371) as an Independent Director of the Company

To consider and if thought fit to pass with or without modification(s) the following resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 ("Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or reenactment thereof for the time being in force) read with Schedule IV to the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Reena Ramachandran (DIN: 00212371), and who has submitted a declaration that she meets the criteria of independence as provided in Section 149(6) of the Act and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and who is eligible for re-appointment, and in respect of whom the Company has received a notice in writing from a Member under Section 160(1) of the Act proposing her candidature for the office of Director of the Company be and is hereby re-appointed as an Independent Director of the Company to hold office for a second term of 5 (five) years commencing from August 28, 2019 and whose office shall not be liable to retire by rotation.

RESOLVED FURTHER THAT pursuant to Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, other applicable provisions, if any, of the Companies Act, 2013 and the applicable Rules made thereunder, including any amendment(s), statutory modification(s) and/or re-enactment thereof for the time being in force, approval of the Members of the Company be and is hereby granted to Dr. Reena Ramachandran (DIN 00212371), who has attained the age of seventy five (75) years, to continue to be a Non-Executive Independent Woman Director of the Company to hold office for a second term of 5 (five) years commencing from August 28, 2019.

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE A MEMBER. The instrument appointing proxy in order to be effective should be duly stamped, completed and signed and should be deposited at the Registered Office of the Company not later than 48 hours before the time fixed for the meeting.

A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.

- 2. All documents referred to in the accompanying Notice are open for inspection at the Registered Office of the Company on all working days except Saturdays between 11.00 a.m. and 1.00 p.m. up to the date of 35th Annual General Meeting.
- 3. Corporate members intending to send their authorized representatives to attend the Meeting are requested to send to the Company a certified true copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting.
- 4. Members/Proxies should bring the Attendance Slip duly filled in for attending the meeting.
- 5. The Members are requested to kindly send all their correspondence relating to the change of address, transmission/ transposition requests of shares, etc. directly to the Company's Registrar & Transfer Agents - Link Intime India Pvt. Ltd., Unit: UPL Limited, C 101, 247 Park, L B S. Marg, Vikhroli (West), Mumbai 400 083, quoting their Folio Number and in case their shares are held in dematerialized form, the intimation of change of address should be passed on to their respective Depository Participants.
- 6. Payment of dividend as recommended by the Directors, if declared at the Meeting, will be made on or after 2nd September, 2019 to the Members whose names stand in the Company's Register of Members on 29th May, 2019 being the RECORD DATE and to the Beneficiary Holders as per the Beneficiary List provided for the purpose by the National Securities Depository Limited and Central Depository Services (India) Limited.
- 7. Members seeking any information with regard to Accounts are requested to write to the Company at an early date so as to enable the management to keep the information ready.
- 8. Pursuant to the provisions of Section 205A of the Companies Act, 1956, unclaimed dividend for the

- financial year 1994-95 has been transferred to the General Revenue Account of the Central Government as required by the Companies Unpaid Dividend (Transfer to General Revenue Account of the Central Government) Rules, 1978. Members who have not encashed the Dividend Warrants pertaining to the said period may make their claims to the Registrar of Companies, Gujarat, Ahmedabad by submitting an application in prescribed form.
- 9. Pursuant to the provisions of Section 205A(5) of the Companies Act, 1956/ Section 124(5) of the Companies Act, 2013, as amended-
 - (a) Dividend for the year 1996-97 and from 2003-04 to 2010-11 and Interim Dividend for the year 2011-12 which remained unclaimed for a period of seven years from the date of transfer of same to the unpaid dividend account of the Company have been transferred to the Investor Education and Protection Fund established by the Central Government pursuant to Section 205C of the Companies Act, 1956/ Section 125(1) of the Companies Act, 2013.
 - (b) Dividend for the years 2011-12 to 2017-18 which remain unclaimed for a period of seven years from the date of transfer of same to the unpaid dividend account of the Company will be transferred to the Investor Education and Protection Fund established by the Central Government pursuant to Section 125(1) of the Companies Act, 2013.

Pursuant to the provisions of Investor Education and Protection Fund (Uploading of information regarding unpaid and unclaimed amounts lying with companies) Rules, 2012, the Company has uploaded the details of unpaid and unclaimed amounts lying with the Company as on 23rd August, 2018, on the website of the Company i.e. www.upl-ltd.com and also on the website of the Ministry of Corporate Affairs.

10. (a) Adhering to the various requirements set out in the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended, the Company has, during financial year 2018-19, transferred to the IEPF Authority all shares in respect of which dividend had remained unpaid or unclaimed for seven consecutive years or more as on the due date of transfer, i.e. 30th September, 2018. Details of shares transferred to the IEPF Authority are available on the website of the Company and the same can be accessed through the link https://www.upl-ltd.com/ pdf/policies/IEPF_News.pdf . The said details have also been uploaded on the website of the IEPF Authority and the same can be accessed through the link www.iepf.gov.in

- (b) Members may note that shares as well as unclaimed dividends transferred to IEPF Authority can be claimed back from them. Concerned members/ investors are advised to visit the web link http://iepf. gov.in/IEPFA/refund.html or contact Link Intime India Pvt. Ltd. for lodging claim for refund of shares and / or dividend from the IEPF Authority.
- 11. Members who have not registered their e-mail addresses so far, are requested to register their e-mail address for receiving all communication including Annual Report, Notices, Circulars, etc. from the Company electronically.
- 12. The Company is providing facility of one-way live webcast of the proceedings of the AGM from 11 am (IST) till the conclusion of the AGM. Members can use their remote e-voting login and password to view the proceedings of the AGM by accessing NSDL website where the EVEN number of the Compnay will be displayed.

13. Voting Options

(1) Voting through Electronic Means:

Pursuant to provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 (SS-2) on "General Meetings" issued by the Institutes of Company Secretaries of India, the Company is pleased to provide members facility to exercise their right to vote at the General Meeting by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the General Meeting ("remote e-voting") will be provided by National Securities Depository Limited (NSDL).

The Company has approached NSDL for providing remote e-voting services through e-voting platform. In this regard, your Demat Account/Folio Number has been enrolled by the Company for your participation in remote e-voting on resolutions placed by the Company on remote e-Voting system.

The Notice of the 35th Annual General Meeting of the Company inter alia indicating the process and manner of remote e-Voting process along with printed Attendance Slip and Proxy Form can be downloaded from the link https://www.evoting.nsdl.com or link https://www.uplltd.com

The remote e-voting period commences on August 25, 2019 (9:00 am) and ends on August 27, 2019 (5:00 pm). During this period, shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 21st August, 2019, may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the shareholder, the shareholder shall not be allowed to change it subsequently.

The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date i.e. August 21, 2019.

Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e. 28th August, 2019.

The process and manner for remote e-voting are as under:

- A. In case a Member receives an email from NSDL [for members whose email IDs are registered with the Company/Depository Participants(s)]:
 - (i) Open email and open PDF file viz; "UPL remote e-voting.pdf" with your Client ID or Folio No. as password. The said PDF file contains your user ID and password/PIN for remote e-voting. Please note that the password is an initial password.
 - (ii) Launch internet browser by typing the following URL: https://www.evoting.nsdl.com/
 - (iii) Click on Shareholder Login
 - (iv) Enter user ID and password as initial password/ PIN noted in step (i) above. Click Login.
 - (v) Password change menu appears. Change the password/PIN with new password of your choice with minimum 8 digits/characters or combination thereof. Note new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
 - (vi) Home page of remote e-voting opens. Click on remote e-voting: Active Voting Cycles.
 - (vii) Select "EVEN" of "UPL Limited".
 - (viii) Now you are ready for remote e-voting as Cast Vote page opens.
 - (ix) Cast your vote by selecting appropriate option and click on "Submit" and also "Confirm" when prompted.
 - (x) Upon confirmation, the message "Vote cast successfully" will be displayed.
 - (xi) Once you have voted on the resolution, you will not be allowed to modify your vote.
 - (xii) Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized

to vote, to the Scrutinizer through e-mail to upl. scrutinizer@gmail.com with a copy marked to evoting@nsdl.co.in

- B. In case a Member receives physical copy of the Notice of Annual General Meeting [for members whose email IDs are not registered with the Company/Depository Participant(s) or requesting physical copy]
 - (i) Initial password is provided as below/at the bottom of the Attendance Slip for the Annual General Meeting.
 - EVEN (Remote e-voting Event Number) USER ID PASSWORD/PIN
 - (ii) Please follow all steps from Sl. No. (ii) to (xii) above, to cast vote.

(2) Voting at AGM:

The Chairman shall, at the 35th Annual General Meeting, at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of ballot paper for all those members who are present at the General Meeting but have not cast their votes by availing the remote e-voting facility.

Please note the following:

A member may participate in the 35th Annual General Meeting even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the General Meeting.

A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the **cut-off date** i.e. August 21, 2019 only shall be entitled to avail the facility of remote e-voting as well as voting at the General Meeting through ballot paper.

The Board of Directors have appointed Mr. Jawahar Thacker, Chartered Accountant (Membership No. FCA 030646), as the Scrutinizer to scrutinize the voting and remote e-voting process in a fair and transparent manner.

The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than 48 hours of the conclusion of the General Meeting, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the

Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.

The results of voting will be declared and the same along with the Scrutinizers Report will be published on the website of the Company (www.upl-ltd.com) and the website of NSDL (www.nsdl.com) immediately after the declaration of result by the Chairman and the same will also be communicated to BSE Limited and the National Stock Exchange of India Limited within 48 hours from the conclusion of the Annual General Meeting.

Other information:

- o Login to remote e-voting website will be disabled upon five unsuccessful attempts to key-in the correct password. In such an event, you will need to go through 'Forgot Password' option available on the site to reset the same.
- o Your login id and password can be used by you exclusively for remote e-voting on the resolutions placed by the companies in which you are the shareholder.
- o It is strongly recommended not to share your password with any other person and take utmost care to keep it confidential.
- o Any person, who acquires shares of the Company and becomes member of the Company after dispatch of the notice and holding shares as on the cut-off date i.e. August 21, 2019, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or contact Company's Registrar & Transfer Agent.

However, If you are already registered with NSDL for remote e-voting then you can use your existing user ID and password/PIN for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/Password" option available on www.evoting.nsdl.com or contact NSDL at the toll free no.: 1800-222-990.

o You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).

In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for members and remote e-voting user manual for members available at the Downloads sections of https://www.evoting.nsdl.com or contact NSDL at the toll free no.: 1800-222-990.

Mumbai: 17th May, 2019

Registered Office: 3-11, G.I.D.C., Vapi, Dist. Valsad, Gujarat, Pin - 396 195.

CIN: L24219GJ1985PLC025132

Rajnikant Devidas Shroff Chairman and Managing Director (DIN: 00180810)

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013.

The Explanatory Statement for Item Nos. 4 to 7 of the accompanying Notice set out hereinabove is as under:

Item No. 4:

The Board, on the recommendation of the Audit Committee, has approved the appointment and remuneration of M/S. RA & Co., Cost Auditors to conduct the audit of the cost records of the Company for the financial year ending March 31, 2020.

In accordance with the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors has to be ratified by the shareholders of the Company.

Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out at Item No. 4 of the Notice for ratification of the remuneration payable to the Cost Auditors for the financial year ending March 31, 2020.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 4 of the Notice.

The Board commends the Ordinary Resolution set out at Item No. 4 of the accompanying Notice for approval by the Members of the Company.

Item No.5:

As per Sections 42 and 71 of the Act, read with the Rules framed thereunder, a company offering or making an invitation to subscribe to Non-Convertible Debentures (NCDs) on a private placement basis, is required to obtain the prior approval of the Members by way of a Special Resolution. Such an approval can be obtained once a year for all the offers and invitations made for such NCDs during the year.

NCDs, issued on private placement basis, is a significant source of borrowings for the Company. The approval of the Members is being sought by way of a Special Resolution under Sections 42 and 71 of the Act read with the Rules made thereunder, to enable the Company to offer or invite subscriptions of NCDs on a private placement basis, in one or more tranches for an amount not exceeding ₹3,000 crores (Rupees Three Thousand Crores Only) during the period of one year from the date of passing of the Resolution at Item No.5, within the overall borrowing limits of the Company, as approved by the Members from time to time.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 of the Notice

The Board commends the Special Resolution at Item No.5 of the accompanying Notice for approval by the Members of the Company.

Item Nos. 6 and 7

The Members of the Company had appointed Mr. Pradeep Vedpraksh Goyal (DIN: 00008370) and Dr. Reena Ramachandran (DIN: 00212371), as Independent Directors of the Company for 5 (five) consecutive years for a term up to the conclusion of the 35th Annual General Meeting of the Company in the calendar year 2019. The Members may note that pursuant to Section 149(10) of the Companies Act, 2013 ("the Act") an Independent Director shall hold office for a term of up to 5 (five) consecutive years on the Board of a company but shall be eligible for re-appointment for a further term of up to 5 (five) consecutive years on passing of a special resolution by the Company.

The Nomination and Remuneration Committee of the Board of the Company had unanimously recommended to the Board, the re-appointment of Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran as Independent Directors for another term not exceeding five (5) consecutive years commencing from 28th August, 2019.

The Nomination and Remuneration Committee, while recommending the re-appointment of Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran, had considered various factors, such as, the number of meetings of Board of Directors, Committees of the Board and General Meetings attended by them, time devoted and their participation at the meetings; their knowledge; skill; expertise; etc., their contributions in attaining Company's objectives; their independent judgment in the opinion of the entire Board.

Based on the recommendation made by the Nomination and Remuneration Committee as above, the Board of Directors, at its meeting held on 17th May 2019, has unanimously decided to re-appoint Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran, not liable to retire by rotation, for another term not exceeding 5 (five) consecutive years with effect from 28th August, 2019.

Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran have given their consent to be re-appointed as such and also the confirmation that they are not disqualified to act as Director in terms of Section 164 of the Act. Further, they have also provided confirmation under Section 149(7) of the Act that they meet the criteria of independence as prescribed, both, under Section 149(6) of the Act read with relevant Rules and under Regulation 16 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and they are independent of the management.

In the opinion of the Board, Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran, fulfil the conditions specified in Sections 149, 152 and other applicable provisions of the Act and the Rules made thereunder read with Schedule IV to the Act and of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company has received notice in writing under the provisions of Section 160 of the Act from Members proposing the candidature of Mr. Pradeep Vedpraksh Goyal and Dr. Reena Ramachandran for reappointment as Independent Directors of the Company.

Further, as per the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 notified on 9th May 2018 with effect from 1st April 2019, consent of Shareholders by way of Special Resolution shall also be required for continuation of directorship of the Non-Executive Directors of the Company who have attained the age of 75 years. As Dr. Reena Ramachandran, Independent Non- Executive Director has attained the prescribed age limit, special resolution at Resolution No. 7 is proposed for approval by the Shareholders of the Company.

Copy of the draft letters for respective appointments of Mr. Pradeep Vedprakash Goyal and Dr. Reena Ramachandran as Independent Directors setting out the terms and conditions are available for inspection by members at the Registered Office of the Company.

Brief Profile of Mr Pradeep Vedprakash Goyal:

Mr. Pradeep Vedprakash Goyal is a qualified Engineer with a B.Tech in Metallurgical Engineering at IIT Kanpur in 1978, graduating with the first rank. He has completed Masters in Materials Science & Engineering at Massachusetts Institute of Technology, USA in 1980, with a full scholarship. He has an outstanding management ability in running the business successfully with significant performance as a Team Leader.

In 2006, Mr. Goyal has Established a state-of-the-art research center 'Industrial Microwave Research Center' (IMRC) in Mumbai, which is dedicated to develop microwave based environment friendly technologies for saving energy and to give something better to the society. IMRC is recognized as an "In-house R&D unit" by Govt. of India, Ministry of Science and Technology, Department of Scientific & Industrial Research. Research was initiated in varied fields with an aim to reduce energy consumption and develop clean

Mr. Pradeep Vedpraksh Goyal is an active member of the Board, the Audit Committee and other committees of the Board. The Board is of the view that his continued association will be immensely valuable and beneficial to the Company and it is desirable to continue to avail services of Mr. Pradeep Vedpraksh Goyal as an Independent Director.

Brief Profile of Dr. Reena Ramachandran:

She is former Chairman and Managing Director, Hindustan Organic Chemicals Limited. She has served as member, Task Force, Performance management Division, Cabinet secretariat; Member, Board of Governors, IIT (Kanpur); Senior Scientific officer, Ministry of Science and Technology; Member- Governing Board, Council of Scientific and Industrial Research (CSIR); Expert Member, Technical Advisory Committee on HR, Reserve Bank of India; Member of the expert committee of HRD Ministry for devising Policy perspective for Management Education; Member, Film Censor Board,. She has over 40 years of experience across petroleum, Petrochemicals and cement industry. She was General Manager, ONGC and Ex. Director PCRA/ GGM, Cement Research Institute, Ballabhgarh. She has over a decade of experience in Management education.

She was awarded Life Time Achievement Award by the ministry of Petroleum and Natural Gas for outstanding contribution to Oil and gas industry during 'Urja Sangam-

She was also awarded as 'Mahila Shiromani' by Vice President of India, 1989. She has also been awarded 'Best Communicator' by Press Council, 1989, 'Manager of the Year' by ONGC,1987, 'Energy Man of the year' by IBPL Urja Research Foundation, 1997, Elected Fellow of Indian National Academy of Engineering (INAE) & All India Management Association(AIMA), Dewang Mehta Life Time Achievement Award,2009, Exemplary Leader Award-2010 by CMO Asia, Singapore, Life Time Achievement Award in Higher Education by Higher Education Forum in 2011, and Distinguished Alumni award by Allahabad University Alumni association in 2015.

She is the Founder President of the Forum of Women in Public Sector (WIPS). She is also associated with Women Leadership initiative in All India Management association (AIMA) for over 25 years.

Dr. Reena Ramachandran is an active member of the Board and Nomination and Remuneration Committee of the Board. The Board is of the view that her continued association will be immensely valuable and beneficial to the Company and it is desirable to continue to avail services of Dr. Reena Ramachandran as an Independent Director.

The disclosures as required pursuant to Regulation 36 of the Listing Regulations and as per Secretarial Standards issued by the Institute of Company Secretaries of India are stated in the table annexed hereto.

Mr. Pradeep Vedprakash Goyal and Dr. Reena Ramachandran are interested in the resolutions set out respectively at Item Nos. 6 and 7 of the Notice with regard to their respective re-appointments.

The relatives of Mr. Pradeep Vedprakash Goyal and Dr. Reena Ramachandran may be deemed to be interested in the resolutions set out respectively at Item Nos. 6 and 7 of the Notice, to the extent of their shareholding interest, if any, in the Company.

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in these resolutions.

The Board commends the Special Resolutions set out at Item Nos. 6 and 7 of the Notice for approval by the shareholders.

Mumbai: 17th May, 2019

Registered Office: 3-11, G.I.D.C., Vapi, Dist. Valsad, Gujarat, Pin - 396 195.

CIN: L24219GJ1985PLC025132

By Order of the Board of Directors For UPL LIMITED

Rajnikant Devidas Shroff Chairman and Managing Director (DIN: 00180810)

ANNEXURE

ADDITIONAL INFORMATION OF THE ABOVE DIRECTORS PURSUANT TO REGULATION 36 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND CLAUSE 1.2.5 OF SECRETARIAL STANDARDS ON GENERAL MEETINGS (INFORMATION AS ON THE DATE OF THIS NOTICE)

Name of the Director	Mr. Jaidev Rajnikant Shroff (DIN: 00191050)	Mr. Pradeep Vedprakash Goyal (DIN: 00008370)	Dr. Reena Ramachandran (DIN: 00212371)
Date of Birth	4th October, 1965	22nd November, 1955	26th September, 1941
Qualification(s)	Science Graduate	Metallurgy Engineer from IIT and Master Graduate from MIT, USA.	Double doctorate in Chemistry from Allahabad University & France
Date of First Appointment (appointment as an additional director on the Board)	1st October, 1992	31st January, 2002	21st October, 2003
Date of Last Re- appointment	8th July, 2017	22nd August, 2014	22nd August, 2014
Expertise in specific functional areas	He is well-recognized global leader in the chemical and agri-inputes industry with over 30 years of experience in India and internationally.	Metallurgy and Engineering Industry	Chemical industry and education field.
Shares held in the Company as on the date of the Notice	5400109 Equity Shares	Nil	Nil
Directorships held in other listed companies* excluding foreign companies	Uniphos Enterprises Limited Nivi Trading Limited	 Pradeep Metals Limited Uniphos Enterprises Limited 	None
*Only equity listed companies are considered (Based on disclosures received from the Director)	3. Ventura Guaranty Limited	3. Hind Rectifiers Ltd.	
Memberships of Committees in other listed companies* (*Only Audit Committee and Stakeholders' Relationship	None	Uniphos Enerprises Ltd., Chairman – Audit Committee and Stakeholders Relationship Committee	None
Committee memberships in equity listed companies have been considered)		2. Hind Rectifiers Ltd., Member – Audit Committee and Stakeholders Relationship Committee	
Remuneration last drawn for the financial year ended 31st March, 2019 (including sitting fees)	Nil	14,00,000 (Being commission and sitting fees)	12,75,000 (Being commission and sitting fees
Terms and conditions of appointment	Non-Executive Director liable to retire by rotation.	Re-appointment as Non- Executive Independent Director of the Company to hold office for a second term of 5 (five) years commencing from August 28, 2019 and whose office shall not be liable to retire by rotation. He is entitled to sitting fees and commission, if any.	Re-appointment as Non- Executive Independent Woman Director of the Company to hold office for a second term of 5 (five) years commencing from August 28, 2019 and whose office shall not be liable to retire by rotation. She is entitled to sitting fees and commission, if any.

Directors Report

The members of **UPL** Limited

Your Directors have pleasure in presenting their report and audited accounts for the year ended on 31st March 2019.

FINANCIAL RESULTS

(₹ in crore)

	Consolidated		Standalone	
	Current Year	Previous Year	Current Year	Previous Year
Total Revenue	22,077	17,920	9,220	7,809
Earnings before interest, tax, depreciation,	4053	3919	1,398	1,384
amortisation, exceptionals, prior period adjustments				
and minority interest				
Depreciation/amortization	969	675	724	666
Finance Cost	963	783	185	135
Exceptional items	451	63	4	7
Profit/(Loss) from Associates	14	(93)		
Profit before tax	1,684	2,305	486	576
Provision for taxation				
Current tax	442	311	83	180
Adjustments of tax relating to earlier years	(4)	(79)	(3)	(83)
Deferred tax	(273	43	1	(69)
Profit after tax				
Minority interest	1,519	2,030	404	548
	72	8		
Net profit for the year	1,447	2,022	404	548

OPERATIONAL PERFORMANCE

a) The Company ended the year with growth in revenues of 14%. This growth comprised of 7% growth in volumes, 4% growth in price and favorable exchange impact of 3%. Performance highlights by region are as follows:-

In India the growth in sale of crop protection products was 4%. Rainfall in India during last year was below average (91% of long term average) and less than the forecast made. The country experienced fifth straight year of less than normal rains.

Apart from deficit in rainfall the problems for farm sector were aggravated on account of erratic rains. In some parts of the country there were heavy floods resulting in loss of life, crops and property. The affected states were mainly Madhya Pradesh, Uttar Pradesh, Bihar and Jharkhand.

With less rains, the rabi season was also not very encouraging. In spite of such difficult situation in the country, the Company has achieved revenue growth of 4%. The growth was observed in key insecticides and herbicides.

The Company launched a few non-selective herbicides during the year. The Company's initiative of Adarsh Kisan Centre expanded to more areas and the farming community appreciated the same.

In Latin America, the Company's revenue grew by 25%, while the crop protection industry grew by 11% in CY2018. This is a significant achievement, considering that Brazil and some of the other Latin American countries faced political and economic uncertainties. The growth was across all key product segments, notably Sperto and Unizeb line of products of the Company. These products are very well accepted in these countries.

In North America the herbicide portfolio recorded good growth and has been successful in addressing the issue of weed-resistance. The market sentiment was adversely impacted due to trade war between China and USA. The Company's efforts to improve sales is now bearing fruit after good rains returned last year in USA.

As indicated in the last Annual Report the European market

has begun improving. Southern Europe witnessed wet weather resulting in growth in sale of fungicides. Also, the sugar beet season has been good, and this has driven sales of herbicides and fungicides.

As regards rest of the world, the revenue growth has been 6%. Africa and South East Asia countries have been the growth drivers in this region. The herbicide sales are improving in these markets. However, in Australia the extended drought impacted sales.

ACQUISITION OF ARYSTA LIFESCIENCE

During the year the Company through its subsidiary, UPL Corporation Limited in Mauritius, acquired Arysta LifeScience. Arysta had a turnover close to US\$ 2 billion. It too is a global provider of innovative crop protection solutions, including bio-solutions and seed treatment. Further, there is minimal overlap in the product portfolios of UPL and Arysta. The product portfolios of both companies are complementary, leading to significant cross-selling opportunities. In terms of regional presence, Arysta's stronger presence in Africa and Eastern Europe means that the combined entity will be able to offer a wide basket of solutions for various raw crops and specialty crops across a broad swathe of countries. This will comprise of crop protection products, bio-solutions and seed treatment products. This will encompass all aspects of crop life cycle, starting from seed up to post harvest. This acquisition will result in enhanced R&D capabilities for the

The acquisition was made for US\$ 4.2 billion. This was funded through a combination of fresh equity and debt at UPL Corporation level. The debt of US\$ 3 billion was provided by a syndicate of banks. The Company obtained all the regulatory approvals necessary to complete the acquisition in a period of six months.

With this acquisition the Company will be among top five global crop protection product companies.

FUTURE OUTLOOK

We expect the global crop protection industry to generate higher volumes in 2019, supported by improvement in prices. UPL is ideally positioned to take advantage of these upsides. The acquisition of Arysta LifeScience is opportune in that sense. Arysta brings with it a vast marketing network, multiple distribution channels, access to newer markets, a much wider and complementary product portfolio, making the future of the combined Company very bright. Arysta's strong presence in fast growing segments like bio-solutions and seed treatment will ensure that the Company is future ready. The Company has established its brand image in the market as a trusted supplier, which guarantees quality products at competitive prices. The Company devises its marketing strategies in a manner that ensures a win-win scenario for all stakeholders at all times. Overall a very bright and promising future is expected for the Company.

Your Directors have recommended dividend of 400% i.e. ₹8 per Equity Share of ₹2 each for the financial year ended 31st March, 2019, which if approved at the forthcoming Annual General Meeting, will be paid to all those Equity Shareholders of the Company whose names appear in the Register of Members as on 29th May, 2019 and whose names appear as beneficial owners as per the beneficiary list furnished for the purpose by National Securities Depository Limited and Central Depository Services (India) Limited.

DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR") the Company has formulated its Dividend Distribution Policy and the same is uploaded on the website of the Company which can be accessed at https://www.upl-ltd.com/policiescompliances-announcements.

BONUS SHARES

To mark the golden jubilee of the Company, your Directors have announced issue of Bonus Shares in the ratio of one bonus share for every two shares held by the member. The same will be subject to the approval of the members and for this a separate Extra Ordinary General Meeting will be held. On approval by the members, the Bonus Shares will be issued to those members whose names appear in the register of members as on the record date which will be announced after the said Extra Ordinary General Meeting and to those members whose names appear as beneficial owners as per the beneficiary list furnished for the purpose by National Securities Depository Limited and Central Depositary Services (India) Limited.

FINANCE

(a) Fixed Deposits

The Company has not accepted fixed deposits during the year. There are no fixed deposits outstanding as at 31st March, 2019.

(b) Particulars of Loans, Guarantees or Investments The details of Loans, Guarantees or Investments are given in the notes to the Financial Statements.

(c) Changes in Paid-up Share Capital

During the year the Company has issued and allotted the following shares:

(i) 9,589 equity shares of ₹2 each to Employees under Employee Stock Option Plan of the Company.

CREDIT RATING

The Company has a good reputation for prudent financial management and ability to meet its financial commitments. The Company's credit facilities in India have been rated by CARE as CARE AA+(Negative) for long term facilities and CARE A1+ for short term facilities and by CRISIL as CRISIL AA+(Negative) for long term facilities and CRISIL A1+ for short term facilities. Company's commercial paper are rated by CARE as CARE A1+ and by CRISIL as CRISIL A1+. Company's non-convertible debentures are rated by CARE as CARE AA+ (Negative) and by Brickwork Ratings as BWR AA+(Stable).

The international bonds issued by UPL Corporation Ltd, a subsidiary of the Company, have been rated by S&P as BBB-(Stable), Moody's Baa3 (Positive) & Fitch BBB-(Negative). It has issued 5 year US\$ 500 mn US\$ denominated Senior Notes under 144A/Reg S in October 2016 and a 10 year US\$ 300 mn US\$ denominated Senior Notes under Reg S in February/March 2018.

ESOP

The details as required to be disclosed under the SEBI (Share Based Employee Benefits) Regulation, 2014 are put on the Company's website at the link https://www.upl-ltd. com/policies-compliances-announcements

SAFETY AND ENVIRONMENT

Safety and well-being of each and every one working for and on behalf of the Company remains to be of top priority for the Company. Your company has taken some significant steps in order to enhance its overall safety performance as part of business continuity process, to take it to the next level eventually to meet its vision of being best in class and installed a unique engagement initiative "Safety First" for making safety a way of life.

Initiatives like Zero Leak Programme, Mistake proofing thuman ough Poka-yoke, Safety Abnormality reporting, 5S have helped sustain our safety performance. Capability Building through level 0, 1 & 2 training and employee engagement initiatives are continuously being strengthened. Level 0, 1 & 2 trainings are training for safety and functional capability building, an employee can take charge only after he/she has successfully passed the assessment. Your company has a system of internal & external safety audit and average compliances of 2nd and 3rd party audit have been a significant 95+%.

"Safety First" is a unique engagement Initiative to bring about interdependent culture, which focuses on enhanced safety Leadership through communication, engagement, horizontally deploying best practices and corrective/ preventive actions management, enhancing effectiveness of plant safety representatives and leadership involvement. Our company engaged services of overseas reputed consultants for imparting training on Safety Leadership on doing things differently making the same initiatives more impactful.

For the current year, our company had a LTIFR: 0.117 per 200 thousand hours worked. Company strongly focuses on the reporting of Safety Abnormalities, Man Machine and Man-Chemical interfaces and closure of the same through mistake proofing. 8 plants of the Company globally worked without any recordable incidents. Company made substantial improvement in execution of Green Field projects.

The Company has initiated a process of Activity based risk assessment and developing health and fire index as an additional measure for well being of the people employed as well as asset protection.

The motto remains: Everyone working for and on behalf of UPL - "Doing Safer is Doing Better".

Environment

At the Company, sustainability is driven by smarter innovation and profitable growth. We believe that a business can be profitable by adopting sustainable practices ensuring harmony with the society and environment. We are constantly working to reduce our environmental footprint and find innovative product solutions that benefit the society. Our commitment to environmental protection extends beyond the scope of legal requirements. We are committed to the chemical industry's Responsible Care™ initiative and have set out the basic principles of this commitment in our Global Environmental Footprint Reduction Plan. Certified HSEQ management systems control its operational implementation.

This year company has released its second Sustainability Report as per GRI standards in accordance with comprehensive option. The Company's Sustainable Development Plan is fully aligned with UN Sustainable Development Goals.

Reducing Environmental Impact

Our target is to reduce 30% environmental footprint in our manufacturing plants by 2020 compared to 2015-16.

Water Consumption	Carbon Emissions	Waste Disposal	Wastewater Discharge
Target	Target	Target	Target
water consumption in our manufacturing plants by	30% reduction in specific CO2 emissions in our manufacturing plants by 2020 from baseline 2015-16.	waste disposal in our manufacturing plants by	wastewater discharge in our manufacturing plants by
Performance	Performance	Performance	Performance
consumption per tonne of production in the Company's manufacturing plants	In 2018-19, CO2 emissions per tonne of production in the Company's manufacturing plants reduced by 13% compared to 2015-16. *	per tonne of production in the Company's manufacturing plants	discharge per tonne of production in the Company's manufacturing plants

Note: *we mitigated the product mix change impact & manage to reduce our environment footprint in our operation globally.

We have taken following initiatives this year to make our operating plant sustainable:

Specific Water Reduction Initiatives

Sustainable industrial water management plays a vital role in achieving future water security in a world where water stress will increase. The optimum utilization of all natural resources is an integral part of the Company's commitment to sustainable development. Aiming to decrease water demand in our operating plants, following initiatives has been taken this year:

- Reduced 3 % water as compared to our baseline 2015-16 after mitigating product mix change impact
- Recycling of 140 KLD STP treated water in DVACl plant's Cooling Tower at Unit-0
- Saved 2KLD water through evaporative condenser in IKI plant at Unit-1`
- Installed full fledge rain water harvesting system at Unit-4 Halol
- Increased efficiency of steam condensate recovery system.
- Installed latest technology in Unit -1 & Unit-5 to recycle & reuse treated wastewater into cooling tower to decrease water demand.

Specific Carbon Emissions Reduction Initiatives

Greenhouse gases trap heat and make the planet warmer. Human activities are responsible for almost all of the increase in greenhouse gases in the atmosphere. Climate change due to greenhouse gas emissions will have a growing impact on our business. Aiming to decrease carbon emissions in our operating plants, following initiatives has been taken this year:

- Reduced 13 % CO2 emissions as compared to our baseline 2015-16 after mitigating product mix change impact.
- Signed & executed green power purchase agreement for Unit-1 and Unit-5
- Installed Waste heat recovery system in fume incinerator of Unit-2
- Improved chiller performance by Increasing capacity of evaporator and replacement shell and tube type condenser with evaporative condenser at Unit-1
- Power generation from back pressure turbine at Unit-2 and Unit-5
- Installed Waste Heat recovery to condensate to preheat power plant boiler feed water leading to reduce coal consumption by 1620 MT/annum

Specific Waste Reduction Initiatives

We have taken special care to reduce, recycle and eliminate hazardous as well as non-hazardous solid waste. Aiming to decrease waste disposal from our operating plants, following initiatives has been taken this year:

- Reduced 22 % specific waste disposal as compared to baseline 2015-16 from our operating plants after mitigating product mix change impact.
- Reduced incinerable liquid waste by yield improvement at Unit-0 and Unit-1.
- Successful commissioning of Lime bulker handling facility in ammonia plant at Unit-1 to reduce lime dusting waste.
- Improved loss on drying (LOD) of ETP waste at Unit-5 and Unit-10 to reduce moisture content in waste quantity by installing Volute.

Specific Wastewater Reduction Initiatives

Aiming to decrease wastewater discharge from our operating plants, following initiatives has been taken this year:

- Reduced 11% specific wastewater discharge from 2015-16 baseline by operational excellence after mitigating product mix change impact.
- Achieved Zero Liquid discharge (ZLD) at Unit-10 Tarapur plant.
- Enhanced overall 61% wastewater treatment capacity.
- Installation of new system in cooling towers to avoid frequent blow down in Unit-3
- Dedicated technology group worked to achieve the environmental excellence and management standards thereby resulting in reduction of environmental footprint.

International Sustainability Rating

Global risk and opportunities from natural resource scarcity to changing governance standards, from global workforce management to continuous evolving regulatory landscape, Environment Social and Governance (ESG) factors holds the potential to impact short term or long-term risk of an organisation. ESG risks and opportunities assessment assist company's management to integrate these factors into the business portfolio and management evaluation process to mitigate the impact and embrace upon the arising opportunities.

The Company believes in continuous improvement for growth and transparently communicating the performance to our investors and other stakeholders at large. This year we participated in rating indices like FTSE Russell and DJSI which undertakes a comprehensive exercise of evaluating various ESG parameters of the Company.

Dow Jones Sustainability Index

S&P Dow Jones Indices partners with RobecoSAM, a specialist in sustainability investing, to provide investors with objective benchmarks for managing their sustainability investment portfolios. The DJSI allow the creation of portfolios of companies that fulfil certain sustainability criteria better than most of their peers within a given industry. It aims to represent the top 10% of the largest 800 companies in 20 emerging markets based on long-term economic, environmental and social criteria and the Company was selected in the top 10% companies which were invited to participate in the DJSI Emerging market index.

Our DJSI score in 2018 has improved 57% from 2017 score.

FTSE Russell index Series:

FTSE Russell is a British provider of stock market indices and associated data services, wholly owned by the London Stock Exchange (LSE). FTSE Russell has been at the forefront of innovating ESG indexing for nearly two decades. The FTSE4Good Index Series is a market-leading tool for investors seeking to invest in companies that demonstrate good sustainability practices.

Our FTSE score in 2018 has improved 70% from 2017 score. Therefore, the Company was awarded and listed in FTSE 4 Good Index for strong environmental, social and governance practices which were measured against globally recognised standards.

To understand more depth details about our sustainability practices. We have launched specific website for sustainability along with our corporate website on following link http://sustainability.upl-ltd.com/

RESEARCH AND DEVELOPMENT

Company's Research and Development Centres located across the Globe play vital role in accomplishing company's mission of manufacturing and supplying crop protection and specialty products worldwide.

Highly equipped Research and Development Centres have best facilities and high qualified scientific staff. Products and processes are designed and developed at these Centres so that technical products are produced in a cost-effective way. At the same time care is taken that products and processes are environmentally friendly.

Company's commitment to safe practices and products leads to designing of products and processes which are safe to use. Principles of Green Chemistry are followed by these scientists for the research and development work.

Company's Research and Development Centres are developing innovative combinations for effective pest management across the Globe. The developed products are tested for chemical properties, toxicity, impurity profile, bio-efficacy, residue and packaging and so on. The required data is generated at Research and Development Centres and then get the products tested at GLP laboratory to generate the data for submission to the regulatory authority of the country.

Company respects Intellectual Property of others and creates its own Intellectual property for the products and processes developed by the Research and Development Centres. Patents are obtained in the countries of interest and appropriate measures are taken to safeguard the IP.

CORPORATE SOCIAL RESPONSIBILITY

The Company's work for economic and social growth of

community started almost 50 years back because it believes that humankind is one community, where each member is responsible for the wellbeing of the other.

The Company's manufacturing plants are in 4 states of India – Gujarat, Maharashtra, J&K and West Bengal. Many of its development interventions are focused in these states, but the Company has taken many initiatives of national importance beyond neighbouring communities too.

The Company believes in holistic and sustainable growth of society. Its commitment and interventions cater all the segment of the society and have been classified in 4 focus areas. They are:

- 1. Institutions of Excellence
- 2. Sustainable Livelihood
- 3. Nature Conservation
- 4. Local and National Need

The Company has built institutions of excellence to RAISE RESPONSIBLE AND SKILLED HUMAN CAPITAL in the region through Academic excellence, Holistic growth and Vocational & life skills. It has built and is managing

- 1. Sandra Shroff Gnyan Dham School, Vapi 1,600 students /year
- Gnyan Dham Eklavya Model Residential School, Ahwa - 350 students /year
- Sandra Shroff ROFEL College of Nursing, Vapi 55 students / year
- Shroff S Rotary Institute of Chemical Technology (SRICT), Vataria, Ankleshwar - 330 students / year
- **UPL Center for Agriculture Excellence** 15,181 farmers trained.

This has resulted in continuous learning and development of around 2,500 students every year and more than 15,000 farmers trained till date.

Its **Agriculture development** initiative in CSR has empowered the farming community to experience a BETTER QUALITY OF LIFE through Enhanced profitability, Better nutrition and Capacity building. The Company has 9 initiative in 81 villages covering 3,111 farmer families.

The Skill development and entrepreneurship empowers youth and women to increase their INCOME EARNING CAPACITIES through 1) Developing and strengthening skills, 2) Improving resource accessibility and 3) Providing institutional support. It has 4 initiatives and Around 3,700 youth and women from 50 villages were trained/skilled.

The Company is working to empower rural women through formation and strengthening of Self Help Groups (SHG) and promoting entrepreneurial culture among the groups. This initiative not only empowers women financially, but also leads to their social and cultural growth. The Company is working with 1364 Women Members of 113 SHGs from 36 Villages.

The Company is working with various stakeholders to IMPROVE THE NATURAL HABITAT in the region through Information dissemination, Increased awareness and Focused efforts to preserve and protect the environment. The highlights are

- **85 Eco Clubs** in community school with 3,396 members.
- Work on Sarus conservation project which has reached to 36 villages with 83 RSPG (Rural Sarus Protection Group) members
- 84,633 saplings and 1,20,000 Mangroves planted under social forestry.
- 6 group wells constructed, and 5 ponds deepened under water conservation.
- Conducted Green Ganesha workshop in 77 schools covering 8,590 students
- This year partnered to support Deer & Ungulate breeding project.

The Company works with individuals and organizations to ensure that GROWTH AND DEVELOPMENT NEEDS OF THE NATION ARE MET through 1) Proactive interventions in the interest of the nation, 2) Support to Trusts and Institutions and 3) Relief and Rehabilitation efforts. To achieve the above, many initiatives are taken with active support and involvement of all stakeholders.

- Worked on building capacity of NGOs/CBOs in Mumbai by empowering 6 organisation in 1st phase and will be starting 2nd phase with new set of organisations.
- Made 47 sanitation blocks, mostly in community schools. 9,225 students and 3,000 commuters/ day are using said facility.
- A total of 37,415 participants have been trained (on women and highway safety).
- Working with 436 farmer families from 2 villages under Vandri cluster development.
- Supporting Global Parli project, which is a successful example of how India's villages can be transformed through revival and empowerment. Progressive, economically viable and prosperous villages can be a reality through right interventions.
- Supported Farmer Producer Company (FPC) in Motihari, Bihar - 3 FPCs in Motihari were provided with Cattle Feed Pallet Manufacturing plant each, 3 FPCs were provided with a Turmeric Processing Plant each and 4 FPCs have been given a financial aid to establish Jaggery Manufacturing units to enhance the farmers income levels.
- Partnership with Save the Children India (SCI) to support Special Care Centre which is a school for hearing impaired and intellectually disabled children that provides holistic education, nutrition and transportation, in a healthy nurturing and learning

- environment. SCI is working towards betterment, empowerment and rights of special children.
- Supported Prayas Society for implementing the **project** "Asptal - Sansad Mobile Swasthya (SMS) Seva" at Hamirpur, Himachal Pradesh.
- Supported 6 Cerebral Palsy Athletes and staff to participate in the World CP Games in Sant Cugat, Spain from Aug 6-12, 2018. The Company is proud that one participant from India bagged 2 gold medals at the

A study done by International Labour Organization (ILO) found that India has one of the highest numbers of working children worldwide, with more than 5 million working in agriculture alone. A large number of Indian farmers are small and marginal, and they frequently resort to child labor to manage their fields. Child labour deprives children of their childhood and is harmful to their physical and mental development. United Against Child Labour (Project UACL) is Company's proactive initiative to eliminate all forms of child labour in seed supplier farms and to ensure education for all children. The Company has adopted a multi-pronged strategy towards this objective which includes advocacy, engagement, awareness and legal contract.

VIA70 – Company's citizen centric application for Mumbai is a part of an honest, non-political and non-profitable attempt to create a model for integrating urban citizens of India with the governance of their locality. The Company is trying to create a model for improved urban governance in the form of a citizen centric application. This application aims to bring transparency to the citizens about their rights and the public workers available for them to approach.

The Company is working on fostering the spirit of community development amongst the employees through employee volunteering known as We Are United (WAU). WAU is a well-structured **employee volunteering** program through which employees get an opportunity to use their talents and passion for the benefit of the community. Most of the activities undertaken by the WAU volunteers are around Company's manufacturing locations and corporate office. In year 2018-2019 a total of 147 employee volunteers from India have spent 4,863 hrs for community work.

UPL Company is working in 6 countries with more than 70 development programs and benefitting around 60 communities.

UPL Brazil works on a complimentary education program empowering the local youth to lead meaningful lives. UCPL Colombia is responding to surrounding communities "whole life cycle" need by promoting the social and economic development through education, entrepreneurship and the conservation of the environment. UPL Argentina has established Social Security office at plant for every neighbor community (in the past they need to travel 46 km to have access to social security office). UPL Mexico has been collecting and distributing winter clothing to the poorest of the poor since 2015.

VIGIL MECHANISM / WHISTLEBLOWER POLICY

The Company has in place whistleblower policy to deal with any fraud, irregularity, or mismanagement in the Company. The Company has posted this policy on its website and the link is https://www.upl-ltd.com/policies-compliancesannouncements.

The Chairman of the Audit Committee oversees this policy. As per the policy, any employee or director can directly communicate with the Chairman of the Audit Committee to report any actual/suspected fraud or non-compliance.

In the past, the Company has taken all efforts to create awareness among the employees about the Policy. The Company also made all efforts to create awareness about the policy among the employees, who have joined during the year. The policy ensures complete protection and no victimization or discrimination to the whistleblower. Total confidentiality of the proceedings of the policy is maintained.

PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE

The Company takes the safety and mental health of the employees very seriously. The Company has implemented a strict policy as required under the Sexual Harassment at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed the reunder. As the Company moves into a modern era, the Company has implemented this policy for not just women employees but have made it gender neutral. Currently, under this policy, all the employees- permanent, temporary and contractual are protected from any form of Sexual Harassment. All employees are mandated to attend a classroom training and confirm their adherence to the rules as mentioned on Company's website. In Financial Year 2018-19, a total of 389 employees were trained on POSH workshop conducted by Company's external partners and 3500 employees acknowledged to comply with the POSH policy. A knowledgeable and experienced internal committee comprising mainly of women and an unbiased party is currently functional to attend and redress complaints that arise under this policy. Further, there are sub committees at unit locations to ensure strict adherence of this policy and make a workplace free from biases and prejudices.

INTERNAL CONTROL SYSTEMS AND THEIR **ADEQUACY**

The Company has robust systems for internal audit, risk assessment and mitigation with well-established processes both at the business and corporate levels. The Company has an inhouse independent Internal Audit Department with a team of qualified professionals, headed by Global Head - Internal Audit.

The scope and authority of the internal audit department is derived from the annual audit plan approved by the audit committee at the beginning of year. Reviews are conducted on an on-going basis, based on a comprehensive risk-based audit plan. Every quarter, the audit committee is presented with key internal controls issues/audit observations and

action taken update on the internal control issues/audit observations highlighted in the previous Audit Committee presentations.

Internal Audit function plays a key role in providing to both the management and to the audit committee of the board, an objective view and re-assurance of the overall internal control systems and effectiveness of the risk management processes and the status of compliances with operating systems, internal policies and regulatory requirements across the Company including its subsidiaries. Internal audit also assesses opportunities for improvement in business processes, systems and controls and provides recommendations designed to add value to the operations.

The Company has adequate internal controls in place across various business units and functions, which improves the efficiency, management effectiveness and safeguards assets of the organisation. The internal control is implemented through following initiatives:

- Accurate and timely recording of transactions with multi-layered system of checks and balances
- Implementation of ERP enabling real time data access
- Implementation of accounting policies in line with prescribed standards
- Periodic reviews of long-term plans and annual budgets
- Constant monitoring of processes and routine audits

Internal Controls over Financial Reporting:

The Company has developed and implemented a Risk & Control Framework to ensure internal controls over financial reporting. This framework includes testing & monitoring over entity level controls, process level controls & IT general controls. The entity level controls includes testing & monitoring compliance to policies like code of conduct, conflict of interest, whistle blower policy, Organization structure, Insider trading policy, HR policy & IT security policy. The process level controls includes risk control matrix for monitoring key business processes (like order to cash, procure to pay, financial closure process, treasury management, hire to retire, taxation, etc.)

On a periodic basis testing of entity level, process level controls & IT general controls is carried out and status of testing of controls is presented to the Audit Committee. During the year, all the controls were tested and no key reportable weaknesses in design and effectiveness was observed. The Company strives to ensure robust internal controls over financial reporting.

RISK MANAGEMENT FRAMEWORK

The Company has robust governance structure and risk management framework to identify and manage business risks in a proactive manner and at the same time enables the management to take advantage of any business opportunity arising.

Pursuant to Regulation 21 of the SEBI (Listing Obligation

and Disclosure Requirements) Regulation 2015, a Risk Management Committee is appointed consisting of three Executive / Promoter Directors of the Company. The Committee gets regular inputs from Senior Executives engaged in different functions and thereafter various risks are identified and mitigating plans are developed to resolve the same. If any identified risk is likely to have significant impact on the Company's operations, the Committee provides for support to the relevant executives and develops a detailed mitigation plan to overcome adverse effects of such risk. There is continuous monitoring by the Committee to ensure that the mitigation plans are effectively met in case such risks arises.

Some of the key Business Risks and their mitigation plans were discussed in the Board reports of earlier years. They are:-

- Industry Risks
- ii) R&D Risks
- iii) Currency Fluctuation Risks
- iv) Liquidity Risks
- v) HR Risks
- vi) Reputation Risks

Some of the other significant business risks identified and their mitigation plans are as under:-

- Input Availability Risks Of late China which is a key supplier of some of the essential inputs for the Company curtailed production and supply of the same in the international market due to environment concerns. This affected the production plan of the Company for some of its products. Efficient running of the plants require timely availability of various inputs. The Company however saw this as a great business opportunity and set up its own manufacturing plants to ensure regular supply of all inputs and thereby earning higher margins for its products. The Company has now achieved higher level of backward integration for its operations and is less dependent on outside supply. To further mitigate this risk the Company also identified and developed more than one alternative reliable sources of supply for such inputs. The Company does not expect this risk to be a major concern for its smooth operations.
- ii) Acquisition Risk Recently the Company has acquired, through its Mauritius subsidiary, Arysta LifeScience. The cost of acquisition of the same was US\$ 4.2 billion. The Company has borrowed US\$ 3 billion from a syndicate of banks and this has resulted into high gearing. Apart from the finance related risks, integration of two cultures and the working systems of staff of both the companies need to be aligned, otherwise this may lead to chaos and mis-management and loss of business and reputation. However, the Company considers this acquisition to be a great opportunity and a quantum leap of its business. Restructuring of the two entities will substantially reduce the administrative costs and the manpower cost. The combined turnover will increase

- manifold with improved margins. The Company has negotiated the terms of the borrowings such that it does not have to face any liquidity problem and enough cash generation will be available at the time of repayment of loan. To mitigate the risk of two different cultures and working systems of employees, the Company has set up a special integration team. In the past the Company has made many international acquisitions very successfully and the acquired companies have blended very well in the main stream. The CEO of the Group is personally involved to keep track of the integration activities. The Company does not expect this risk to be serious. in fact, with this acquisition the Company will be in the top five global crop protection product companies in the world.
- iii) Cyber Security Risks In today's world there is more and more reliance on IT systems. The Company's operations are spread out across the globe and are well connected with widespread use of internet. All communication equipment's such as mobiles, laptops, tablets etc. are widely used in all functions of the Company. Due to this, there are constant security threats to the data and possibility of misuse. Such cyber-attacks will result in loss of confidential data and also result in loss of business as well as reputation of the Company. To counter these risks, it is important to take suitable preventive measures to ensure data security at all times. The Company's IT systems are fully geared to meet the threat of any such attacks. Adequate control measures are also taken to ensure data security by continuous monitoring of data, security systems, limiting access to only necessary persons, event monitoring etc. Strong firewalls are in place and disaster recovery systems are established along with layers of security controls across locations in the system.

The Government has also responded to such threats by introducing legislation relating to cyber security. The Directors are made responsible for ensuring data security of the Company and taking adequate steps to ensure cyber security. The Company has also been vigilant against possible cyber-attacks and has taken preventive remedial measures to counter such attacks. The Risk Management Committee of the Board is appraised of steps taken to mitigate cyber security risks. Even though there have been many cyber threats all over the world such as Ransomware and other hacking threats, the Company is not impacted by the same because of strong data security measures taken.

SUBSIDIARY COMPANIES / ASSOCIATE COMPANIES

The Company has a large number of subsidiary companies and associates, spread all across the globe.

Crop protection product companies need registrations to enable them to sell their products in different countries in the world. These registrations are granted by local government body of each country to a local entity established in that country. For example, in India, Central Insecticide Board gives such registration to Indian Companies. In each country there are similar government authorities granting registration to the local companies for sale of agrochemicals. Further such registrations are mandatorily required for sale of each agrochemical for each pack size and technical content. Thus for same agrochemicals, multiple registrations will be required for different technical content and difference pack size.

The Company has a very large portfolio of various agrochemicals. To expand its market reach and explore various geographies beyond the national frontiers, it has established a large number of subsidiary companies in different countries of the world. This will enable the Company to supply and market its products to such countries. Till last year the Company had approximately 80 overseas subsidiary and associate companies, apart from a few Indian subsidiaries. With the acquisition of Arysta LifeScience the number has gone up to more than 200 overseas subsidiary and associate companies. Some of these subsidiaries may not be relevant and the Company has undertaken restructuring exercise to wind up companies that are dormant or where there are more than adequate number of subsidiary companies in a country. This restructuring exercise when completed will result in significant cost reduction, apart from having better administrative and financial control and avoidance of duplication of efforts and at the same time catering to larger number of customers with more inclusive crop protection solutions.

The details of essential parameters of each such subsidiary / associate company like share capital, assets, liabilities, turnover, profits before and after tax are given separately in the report and members can refer to the same.

Most of these overseas subsidiaries and associate companies are marketing arms and their main activity is confined to marketing by servicing their local market with greater efficiency and ensuring timely availability of different products of the Company. Some other entities are holding companies which hold investments in other group entities.

There are a few companies whose activities are not confined to marketing / investment. Some of the companies are engaged in manufacturing or formulation or seeds or other products. They are:-

- 1. United Phosphorus (India) LLP ,India
- 2. Optima Farm Solutions Limited ,India
- 3. UPL Europe Limited ,U.K.
- 4. Cerexagri B.V., Netherlands
- 5. Cerexagri S.A.S., France
- 6. United Phosphorus Inc., USA
- 7. Upl do Brasil Industria e Comércio de Insumos Agropecuários S.A., Brazil
- 8. UPL Argentina S A, Argentina
- 9. UPL Colombia SAS, Colombia
- 10. UPL Vietnam Co. Limited ,Vietnam
- 11. Arysta LifeScience India Limited ,India

- 12. Arysta LifeScience South Africa (Pty) Ltd ,South Africa
- 13. Arysta LifeScience S.A.S., France
- 14. Arysta LifeScience Ougrée Production Sprl ,Belgium
- 15. Wyjolab S.A. ,France
- 16. Natural Plant Protection S.A.S., France
- 17. Laboratoires Goëmar SAS, France
- 18. Arysta LifeScience Korea Ltd., Korea
- 19. Arysta LifeScience Vietnam Co., Ltd., Vietnam
- 20. Callivoire SGFD S.A., COTE D'IVOIRE
- 21. UPL Agricultural Solutions Italy Srl ,Italy
- 22. Arysta LifeScience do Brasil Indústria Química e Agropecuária SA ,Brazil
- 23. Grupo Bioquimico Mexicano, S.A. de C.V., Mexico
- 24. Arysta LifeScience Colombia S.A.S ,Colombia
- 25. Arysta LifeScience Mexico, S.A. de C.V., Mexico

During the year Arysta LifeScience was acquired by the Company at its Mauritius subsidiary level. Apart from this, some of the companies which became or ceased to be subsidiaries are as under:

a) New Subsidiaries:

Decco Gida Tanm ve Zirai Urunler San. Tic A.S.

- b) Cessations of Subsidiaries
 - a. Blue Star B V (merged)
 - b. DVA Technology Argentina SA(Liquidated).

MATERIAL SUBSIDIARY

The Company has one unlisted material subsidiary as per the parameters laid down by the Companies Act, 2013, namely, UPL Corporation Limited in Mauritius.

The said subsidiary does trading business and also holds investments for the group. The Turnover is ₹1,692 Cr and the Profit before tax is ₹393 Cr. The said subsidiary has not sold, disposed off or leased assets of more than 20% of its assets during the current year.

Pursuant to Regulation 24(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mr. Hardeep Singh, an Independent Director of the Company has been appointed as a Director on the Board of UPL Corporation Limited.

RELATED PARTY TRANSACTIONS

All Related Party Transactions entered into during the year were on arm's length basis and were in the ordinary course of business. There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

All Related Party Transactions are approved by the Audit Committee. Prior omnibus approval is obtained from the Audit Committee in respect of the transactions which are repetitive in nature. The transactions entered into pursuant to the omnibus approval so granted are reviewed on a quarterly basis by the audit committee.

The policy on Related Party Transactions as approved by the Board is uploaded on the Company's website. The same can be accessed on https://www.upl-ltd.com/ policiescompliances-announcements.

INSURANCE

All the properties and operations of the Company have been adequately insured.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

There are no significant and material order passed by the Regulators or Courts.

AUDITORS:

a) Statutory Auditors

At the 33rd Annual General Meeting of the Company held on 8th July, 2017, the Members of the Company have approved the appointment of B S R & Co. LLP, Chartered Accountants (ICAI Firm Registration Number 101248W/W-100022) as the Statutory Auditors of the Company pursuant to Section 139 of the Companies Act, 2013 for a term of 5 (five) years from the Company's financial year 2017-18, to hold office from the conclusion of 33rd Annual General Meeting of the Company.

The report of the Statutory Auditors along with the Notes to Schedules forms part of the Annual Report and contains an Unmodified Opinion without any qualification, reservation or adverse remark.

b) Cost Auditors

Pursuant to Section 148 of the Companies Act, 2013 read with The Companies (Cost Records and Audit) Amendment Rules, 2014, the cost account records maintained by the Company are required to be audited. Your Directors had, on the recommendation of the Audit Committee, appointed Messrs RA & Co., Cost Accountants to audit the cost accounts of the Company for the financial year 2019-20 on a remuneration of ₹8.00 lakhs. The Cost Auditors have submitted a certificate of their eligibility for such appointment. As required under the Companies Act, 2013, the remuneration payable to the cost auditor is required to be placed before the Members in a general meeting for their ratification. Accordingly, a Resolution seeking Member's ratification for the remuneration payable to Messrs RA & Co., Cost Auditors is included at Item No. 4 of the Notice convening the Annual General Meeting.

For the year 2018-19, the due date for filing the Cost Audit Report is 27th September, 2019 and the same will be filed in due course. The Cost Audit Report for the year 2017-18 was filed on 24th August, 2018.

c) Secretarial Auditors

Pursuant to the provisions of Section 204 of the

Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed Messrs N.L. Bhatia & Associates, a firm of Company Secretaries in Practice to undertake the Secretarial Audit of the Company. The Report of the Secretarial Audit Report is annexed herewith as "Annexure 3".

REPORTING OF FRAUD:

The Auditors of the Company have not reported any fraud as specified under section 143 (12) of the Companies Act,

DEPOSITORY SYSTEM

99.03% of the total paid-up equity shares of the Company are dematerialised as on 31st March, 2019.

DIRECTORS

In accordance with the provisions of section 152 of the Companies Act, 2013, and Articles of Association of the Company, Mr. Jaidev Rajnikant Shroff (DIN: 00191050) Director of the Company, retires by rotation at the forthcoming Annual General Meeting of the Company and being eligible, offer himself for re-appointment.

The earlier appointments of Mr. Pradeep Goyal (DIN: 00008370) and Dr. Reena Ramachandran (DIN: 00212371), the Independent Directors of the Company expire on the conclusion of forthcoming 35th Annual General Meeting of the members of the Company to be held on Wednesday, 28th August, 2019. The Board of Directors has re-appointed Mr. Pradeep Goyal (DIN: 00008370) and Dr. Reena Ramachandran (DIN: 00212371), Independent Directors for further period of 5 (five) years, with effect from 28th August, 2019, subject to the approval of the Members by Special Resolution and upon the terms and conditions as set out in the notice convening the 35th Annual General Meeting of the Company.

The Company has received notices in writing from members along with the deposit of requisite amount under Section 160 of the Companies Act, 203 proposing the candidature of these Directors for the office of Directors of the Company.

The special resolutions seeking approval of the Members of the Company for the re-appointment of Mr. Pradeep Goyal (DIN: 00008370) and Dr. Reena Ramachandran (DIN: 00212371) have been incorporated in the notice of the 35th Annual General Meeting of the Company along with brief details about them.

The information of Directors seeking re-appointment as required pursuant to Regulation 36(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is provided in the notice convening the 35th Annual General Meeting of the Company.

All the independent directors have given declaration that they meet the criteria of independence laid down under section 149 (6) of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

During the year Mr. Kalyan Mohan Banerjee has resigned from the Board of Directors of the Company with effect from 1st August, 2018.

The earlier appointment of Mr. Vinod Rajindranath Sethi (DIN: 00106598), the Independent Director of the Company expires on the conclusion of forthcoming 35th Annual General Meeting of the members of the Company to be held on Wednesday, 28th August, 2019. Mr. Sethi has expressed his unwillingness to seek fresh re-appointment for further period.

The Board takes this opportunity to place on record its deep sense of appreciation for the support and invaluable contribution made by Mr. Kalyan Mohan Banerjee and Mr. Vinod Rajindranath Sethi during their tenure as Directors of the Company.

EVALUATION OF THE BOARD'S PERFORMANCE:

Pursuant to the provisions of the Companies Act 2013 and Regulations 17(10) and 25(4)(a) of the Listing Regulations, the evaluation process for performance of the Board, various Committees and Directors was carried out. Structured questionnaire was prepared after taking into consideration inputs received from the Directors covering various aspects of the Board functioning, Board culture, duties, responsibilities and performance by Individual Directors, their adherence to the Code of Conduct, reliability and timeliness of flow of information, independence of judgement etc.

Evaluation of Independent Directors was carried out by taking into account various parameters such as Directors contribution, attendance, expertise, knowledge of the subject, decision making capability and other related factors.

The meeting of Independent Directors was held on 31st January 2019 and at the said meeting the performance of evaluation of all the Directors of the Company including the Chairman was reviewed. The Independent Directors were fully satisfied with the performance of the Board, various committees, other Directors and Senior Management of the Company for running it in a highly professional manner. They also appreciated the knowledge and expertise of the Chairman and his exemplary leadership qualities which demonstrate positive attributes in following the highest standards of Corporate values and culture of the Company.

REMUNERATION POLICY:

The Remuneration Policy has been disseminated on the Company's website at the link https://www.upl-ltd.com/ policies-compliances-announcements

FAMILIARIZATION PROGRAMME FOR THE **INDEPENDENT DIRECTORS:**

Pursuant to the SEBI Regulations, the familiarization program for the Independent Directors is worked out, with respect to their roles and responsibilities, nature of the industry in which the Company operates, its business model, risks and opportunities of the Company, etc. The

Program is aligned with the requirements under the Act and other related regulations.

Under this familiarization program the Independent Directors are informed about the business plans and operations, the corporate philosophy and the vision and mission of the Company. They are taken through various financial parameters, control mechanism, budgeting system, adherence to compliances and other important matters. At the time of the appointment of Independent Directors the formal letter of appointment is issued to each of them giving details of their duties and responsibilities in the Company. During their tenure as Independent Directors, they are appraised of various policies of the Company such as CSR, Plant Safety, HR, Succession Policy for Directors and Senior Management. As the Company has worldwide operations, they are also updated with various strategic initiatives in the matters of operations of the Company. Factory visits of various plants in India and abroad are arranged and the safety measures taken by the Company at various plants to protect the personnel, property and environment are informed in detail to them. To update their knowledge in line with the latest changes in legislation and business practices, eminent faculty members are invited by the Company to address them.

Details of familiarization program of Independent Directors with the Company are available on the website of the Company https://www.upl-ltd.com/policies-compliancesannouncements.

HUMAN RESOURCES:

As on 31st March, 2019, the Company has 4,703 employees in India, and 11,411 employees globally.

The Company continuously strives to be the best globally. The Company believes that the core foundation of this vision is the people. The HR strategy is committed to creating an engaging workforce and an inspirational leadership that continuously powers this vision. With a welcome addition of 3,400 new associates, the Company has undertaken a comprehensive exercise to reinvent its HR systems to respond to this complexity with greater strength.

Powering the New Organisation with a New Purpose

With the Arysta acquisition, the Company became globally the number one organisation in the post-patent space. It has a stronger portfolio, wider geographical reach and an employee base that went up more than 50%. A stronger organisation evolved a new purpose that energises all its associates around a new identity.

OpenAg- No limits, No Borders.

The concept enabled the Company as an open organisation which is committed to sustainable agriculture globally. It is anchored around openness - Open Hearts, Open Collaboration, Open Intelligence, Open Access and Open Innovation. The concept of openness to new ideas, new concepts, looking beyond the horizons, openness to diversity and inclusion of new associates rallied the Company's associates around this purpose. It played a key role in realigning their identity in the transformed Company.

The work on defining the new values, corresponding behaviors and the new culture has already progressed well. This comprises of:

a) Building the Post-Acquisition Organisation Structure The Company has built a newer organisation structure for a \$5 billion enterprise staffed with the right level of competent professionals. Timely planning and good stakeholder involvement were key to the success of this organisational change.

b) Creating a Consistent Employee Experience: Launching my UPL

An employee's way of life is defined by the organizational processes and systems. These are then translated into workflows. The Company is known for consistently improving the quality of employee experience through out his service span. This takes place through the HR ERP systems. The Company is going ahead with the implementation of "myUPL"- a one stop employee selfservice and transaction portal on the Success Factors platform. This is a great initiative in connecting employees across borders. The consistency in employee experience will make the integration process much more effective.

c) Creating a High Performance Work System

The integrated organization has made newer and bolder commitments to all stakeholders. To fulfill the same goal setting modules are rolled out on myUPL. It focuses on key goals and completely does away with routine activities. All employees are expected to focus on the high-impact goals. To support the same, the goal library of Success Factors and the goal cascade functionality is deployed.

d) Harnessing People Synergy in the new Organization As part of building the new integrated organisation, all role overlaps, and role redundancies were identified. This ensures exploring opportunities to deploy new talent in newly devised roles.

Way Forward

a) Cascading new values and behaviors

The Company's integration plans revolve around how the Company merges two different cultures effectively. The Company formulated the best values and purpose to come up with a new brand for Company's integrated organization. For this the Company has scheduled top team effectiveness programs to contextualize the values and behaviors of various business functions.

b) Cultural baselining

The Company understands the complexity of the cultural differences and the challenges that it might pose during integration. Towards this, the Company has operationalised concepts that will make the transition easier powered by a dynamic strategy that anchors on culture, and integration. The Company's efforts will help bring the people together and make them feel more integrated in the Company so that they move in a positive direction. The Company will provide the people trainings and career guidance that they may need.

c) Building internal talent for leadership succession As the HR processes for managing transition fall in place, there would be a focus on refining the competency framework for the new organisation. That would provide a starting point for initiating talent assessment and using that as an input, to build succession pipeline for key leadership roles.

PARTICULARS OF EMPLOYEES

The information required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) and 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given in the Annexures 4 and 5 hereunder and forms part of this Report.

ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars relating to energy conservation, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under sections 134(3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 are provided in Annexure 6 to this

DIRECTORS RESPONSIBILITY STATEMENT

To the best of their knowledge and belief and according to the information and explanations obtained by them, the directors make the following statements in terms of Section 134(3)(c) of the Companies Act, 2013:

- a) That in the preparation of the annual financial statements for the year ended 31st March, 2019, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any.
- b) That such accounting policies as mentioned in Note 2.1 of the Notes to the Financial Statements have been selected and applied consistently and judgement and estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2019 and of the profit of the Company for the year ended on that date.
- c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- d) That the annual financial statements have been prepared on a going concern basis.
- e) That proper internal financial controls were in place

- and that the financial controls were adequate and were operating effectively.
- f) That systems to ensure compliance with the provisions of all applicable laws were in place and were adequate and operating effectively.

CORPORATE GOVERNANCE

Your Company and its Board has been complying with Corporate Governance practices as set out in a separate report, in pursuance of requirement of para C of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Management Discussions and Analysis Report forms part of this Report. Auditor's certificate confirming compliance of the Corporate Governance as stipulated under the said Regulations is also attached to this Report.

Dealing with securities which have remained unclaimed

Members are hereby informed that as per Regulation 39(4) read with Schedule VI of the SEBI Regulations, the Company is in the process of sending reminders to those Members whose share certificates have remained unclaimed, to contact the Company immediately in the matter. The Registrar and Transfer Agent M/s Link Intime India Pvt. Ltd. is in the process of compiling the data for unclaimed shares. The Company, now after following the prescribed procedure will dematerialize unclaimed shares which are retained with the Company. These shares would be held by the Company on behalf of the holders of such shares in an "Unclaimed Suspense Account" to be opened with a depository. At the end of seven years, hereof, these shares shall be transferred by the Company to the IEPF. Dividends remaining unclaimed in respect of such shares shall also be held in a separate suspense account and would likewise be transferred to IEPF at the end of seven years.

Members may note that the lawful claimant in respect of these shares / dividend will be able to claim such shares dividend from the Company till such time they remain in the unclaimed suspense account as aforesaid.

COMPLIANCE WITH SECRETARIAL STANDARDS

The Board of Directors affirms that the Company has complied with the applicable Secretarial Standards issued by the Institute of Companies Secretaries of India relating to the meetings of the Board and General Meetings.

BUSINESS RESPONSIBILITY REPORTING

A separate section of Business Responsibility forms part of this Annual Report as required under Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Financial statements are prepared for the year 2018-19 in compliance with the provisions of the Companies Act, applicable Accounting Standards and as prescribed under the SEBI regulations. The consolidated statements are prepared on the basis of audited financial statements of the Company, its subsidiaries, associates and joint ventures. These consolidated financial statements along with the Auditors Report thereon form part of the Company's Annual Report. They are also put up on the website of the Company https://www.upl-ltd.com/ policiescompliances-announcements.

COPY OF THE ANNUAL RETURN

Pursuant to the Section 92(3) of the Companies Act, 2013 a copy of Annual Return has been placed on the website of the Company and the web link of such Annual Return is https:// www.upl-ltd.com/ policies-compliances-announcements

LISTING OF THE COMPANY'S EQUITY SHARES

The equity shares of the Company are listed on the BSE Ltd. and National Stock Exchange of India Ltd. There is no default in paying annual listing fees.

ACKNOWLEDGEMENT:

The Directors are thankful to all the stakeholders and various government agencies and ministries for their continued support.

CAUTIONARY STATEMENT:

Statements in the Director's Report and the Management Discussion and Analysis describing the Company's objectives, expectations or predictions, may be forward looking within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Company's operations include: global and domestic demand and supply conditions, availability of critical materials and their cost, changes in government policies and tax laws, economic development of the country, and other factors which are material to the business operations of the Company.

Mumbai 17th May 2019 On behalf of the Board of Directors

Registered Office:

3-11, G.I.D.C., Vapi Dist. Valsad, Gujarat Pin: 396195

Rajnikant Devidas Shroff Chairman & Managing Director (DIN: 00180810)

ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES

2SR policy and projects or programs.

1. A brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the

CSR Policy is stated herein below.

Weblink: http://www.upl-ltd.com/csrpolicy.pdf

2. The Composition of the CSR Committee.

Mr. Pradeep Goyal (Independent Director) Mrs. Sandra R. Shroff (Chairman)

Mr. Vikram R. Shroff (Director)

Average Net Profit: ₹239.81 Crores

3. Average net profit of the Company for last three financial years

4. Prescribed CSR Expenditure (two per cent. of the amount as in item 3 above) The Company is required to spend ₹4.80 crores towards CSR

5. Details of CSR spent during the financial year.

(a) Total amount spent for the financial year;

₹18.08 Crores

(b) Amount unspent, if any;

(c) Manner in which the amount spent during the financial year is detailed below.

8	Amount spent Direct or through implementing agency*		GNYAN	DHAM VAPI	CHARITABLE	TRUST			GNYAN	DHAM VAPI	CHARITABLE	TRUST
7	Cumulative spend upto the reporting period		20,00,000						50,00,000			
	ent on the	2.0ver heads	1						1			
9	Amount spent on the programme/project	1. Direct Expenses	50,00,000						50,00,000			
5	Amount outlay (budget) project/ programme wise		20,00,000						50,00,000			
	ogrammes	2.Specify the state/district	District	- Valsad,	Gujarat				District	- Dangs,	Gujarat	
4	Projects/Programmes	1.Local areas/others	AT & P - Vapi	396195					At & P - Ahwa District			
3	Sector in which the project is covered	Discription	Promotion of Education						Promotion of Education			
	Sector in wh	Schedule	Category (ii)						Category (ii)			
2	CSR project/activity identified		Smt. Sandraben Shroff Gnyan Dham	School (SSSGDS), a Co-educational	school establiched in year 1972,	affiliated to CBSE syllabus for	community in industrial town of Vapi.	https://www.srsgnyandham.org/	Eklavya Model Residential Schools	(EMRS) under PPP to provide quality	education to meritorious tribal	children.
_	No.		-	J 1	01	0		_	2			

<u></u>	2		ĸ	7	4	2	9		7	∞
Sr No.	CSR project/activity identified	Sector in wh	Sector in which the project is covered	Projects/Pr	Projects/Programmes	Amount outlay (budget) project/ programme wise	Amount spent on the programme/project	nt on the	Cumulative spend upto the reporting	Amount spent Direct or through implementing agency*
		Schedule	Discription	1.Local areas/others	2.Specify the state/district		1. Direct Expenses	2.0ver heads		
m	Shroff S. R. Rotary Institute of Chemical Technology (SRICT) an institution specializing in chemical technology to provide the specific needs of the Chemical Industry in Gujarat.	Category (ii)	Promotion of Education	At & P – Vataria 393135 Tal – Valia	District – Bharuch, Gujarat	4,00,00,000	4,93,60,538	1	4,93,60,538	Ankleshwar Rotary Education Society
4	Sandra Shroff Rofel College of Nursing stands with the desire to nurture up the minds of their students that can be a reason for a smile on the millions they had and will come in contact with in their academics, clinical and community area.	Category (ii)	Promotion of Education	AT & P - Vapi 396195	District - Valsad, Gujarat	4,00,00,000	7,00,00,000	1	7,00,00,000	GNYAN DHAM VAPI CHARITABLE TRUST
2	UPL Pragati to create sustainable livelihood with a sharper focus on farming community, unskilled youth and women to improve the quality of life in the long term. The Strategy envisaged for operationalizing under UPL Pragati for the sustainable livelihood has three pillars, viz Skill, Entrepreneurship and Agriculture	Category (i), (ii), (iii), (vi), (vii), (x)	(i) eradicating extreme hunger and poverty; (ii) promotion of education; (iii) promoting gender equality and empowering women; (vi) ensuring environmental sustainability; (vii) employment enhancing vocational skills; (X) Rural Development /	AT & P - Vapi AT & P - Ankelshwar & Jhagadia Villages in Dang	District - Valsad District - Bharuch, Gujarat District - Dangs, Gujarat	5,10,91,486	1,40,00,000	ı	1,40,00,000	S. R. Shroff Aajivika Trust (SRSAT)

—	2		က	4		2	9		7	000
Sr No.	CSR project/activity identified	Sector in whi	Sector in which the project is covered	Projects/Programmes	ogrammes	Amount outlay (budget) project/ programme wise	Amount spent on the programme/project	ent on the	Cumulative spend upto the reporting period	Amount spent Direct or through implementing agency*
		Schedule	Discription	1.Local areas/others	2.Specify the state/district		1. Direct Expenses	2.Over heads		
ý.	UPL Vasudha: Environment conservation and responsible actions towards nature go a long way in making nature an alternate source of livelihood for the local population, who have close economic and cultural links with nature. The UPL Vasudha aims at improving the quality of life of the natural habitat in the region through information dissemination, increased awareness and focused efforts to preserve and protect the same. The intitiatives under UPL Vasudha are 1) UPL Social Forestry & Mangrove Plantation 3) UPL Social Forestry & Mangrove Plantation 3) UPL Green Ganesha	Category (ii), (vii)	(ii) promotion of education;	"AT & P - Vapi AT & P - Ankelshwar & Jhagadia AT & P - Dahej Villages Kheda & Vadodara Dist"	"District - Valsad District - Bharuch, Gujarat District - Dangs, Gujarat"					S. R. Shroff Aajiwika Trust (SRSAT)
_	LOCAL AREA NEED - Development Support to community around UPL location. Focused initiatives are 1) UPL Suraksha 2) UPL School Sanitation 3) UPL Unnati 4) VIA70 and support like School bag and book provisioning, Infrastructure support, Medical Support etc to surrounding community."	Category (i), (ii), (iii), (vi), (vii), (x)	(i) eradicating extreme hunger and poverty; (ii) promotion of education; (iii) promoting gender equality and empowering women; (x) Rural Development / Slum Development	AT & P - Vapi AT & P - Ankelshwar & Jhagadia AT & P - Mumbai	District - Valsad District - Bharuch, Gujarat	3,00,000,000	1,17,38,829	1	1,17,38,829	"Direct by Company Also with local NGO's working in area as mentioned in column 2"

_	2		c	4		2	9		7	∞
Sr No.	CSR project/activity identified	Sector in wh	Sector in which the project is covered	Projects/Programmes	ogrammes	Amount outlay (budget) project/ programme wise	Amount spent on the programme/project	nt on the	Cumulative spend upto the reporting period	Amount spent Direct or through implementing agency*
		Schedule	Discription	1.Local areas/others	2.Specify the state/district		1. Direct Expenses	2.Over heads		
∞i	NATIONAL NEED - Development Support for National cause and	Category (i), (ii), (iii), (vi),	(i) eradicating extreme hunger and poverty;			6,14,50,000	2,56,51,000	1	2,56,51,000	2,56,51,000 Through NGO's mentioned in
	to organisation like	(vii), (x)	(ii) promotion of education;							column 2
	• Global Parli Project		(iii) promoting gender							
	 Friends of Tribal Society 		women;							
	 Veermata Jijabai Technological Institute 		(vi) ensuring environmental sustainability;							
	• Save the Children India		(vii) employment enhancing vocational skills;							
	 Kamaraj Children Education Trust 		(x) Rural Development / Slum Development							
	 Rohini Education Society 									
	• Mahatma Gandhi Vidyalay, MANCHAR									
	 Prayas Society 									
	 Swami Vivekanand Education Trust 									

CSR Policy

We, UPL Limited and our subsidiaries (together constituting the UPL Group), take initiative to contribute to harmonious and sustainable development of the society through all our business activities that we carry out in various countries across the globe. We recognize that business enterprises are economic organs of society that draw on various societal resources for its functioning and growth, It is our core belief therefore that a company's performance must be measured not only by its bottom line but also with respect to the social contributions made by the Company while achieving its financial goals.

A. CSR Vision

To be a catalyst for a more equitable and inclusive society by supporting long term sustainable transformation and social integration.

B. CSR Mission

We will achieve our vision by

- Implementing need based projects through participatory
- Focusing on building capacity to make community Self-Reliance
- Developing partnership.
- Transferring knowledge

C. CSR Values

The values that will govern to achiev our vision are

- Care
- Excellence and
- Sustainability

D. CSR focus areas

Our CSR initiative is called as UPL Pragati which means PROGRESS and is in line with our stated Vision. Our CSR activities will focus not just around our Factory and offices, but also in other geographies based on the needs of the communities. The Six CSR focus areas for community to progress are:

1. Education and Empowerment

Education is a basic human right pivotal to personal and societal development and so is an integral part of our CSR work. Under education we will work and support promotion of education, including primary education, higher education and employment oriented course especially among women, elderly, and the differently abled.

2. Employability and Entrepreneurship

A major factor contributing to rural youth underemployment is skills mismatch with huge skills deficit in limited job growth and expansion. We will work on enhancing vocation skills especially among youths, women, and the differently abled. We will also work on livelihood enhancement projects through Self Help Group and Entrepreneurship development Programme with women and economically backward groups.

3. Agriculture Development

Agriculture in India is both, a source of livelihood and food security for a vast majority of vulnerable sections of society. A higher priority to agriculture will be given under livelihood enhancement rural development projects so as to achieve the goals of reducing poverty and malnutrition as well as of inclusive growth. We will adopt a framework of UPL KhedutPragati Programme for our Agriculture development intervention and will work on farmers Capacity building, Lab to land and Technology intervention.

Under Nature conservation we will work on UPL Vasudha Project by nurturing and strengthening Eco and Environment club in schools, Tree Plantation, Species conservation, Soil & Water Conservation etc. Our Environment and Nature conservation activities will lead to environmental sustainability, ecological balance, protection of flora and fauna, animal welfare, agroforestry, conservation of natural resources and maintaining quality of soil, air and water;

4. Health and Sanitation

We will work on providing better healthcare facilities by partially funding and running hospital, health projects, public health programmes, Health awareness programmes, health check-up programme, Blood donation programme, provision of medicine & treatment facilities, program for preventing diseases and building immunity etc

We will also work on aspects of water, sanitation and hygiene because of which the health and financial burden on poor people is high. We will work on awareness programme, construction of toilet in schools and construction of toilet for general needy community.

5. National / Local area need

We will work on specific local area needs around our Factory locations.

We will respond to national need, which also include relief or rebuild which can arise from natural calamities.

E. CSR Implementation

In accordance with sub-section (1) of section 135 of the Companies Act 2013, UPL has set up a CSR committee to advise on the Company's CSR policy, and monitor the CSR activities of UPL Limited. All projects are identified as per needs of community.

F. CSR Resource contribution

Minimum 2% of the average of net profit made by the Company during immediately preceding three financial years as per Companies Act 2013.

ANNEXURE 2 TO DIRECTOR'S REPORT

SECRETARIAL AUDIT REPORT

FORM NO. MR-3

FOR THE FINANCIAL YEAR ENDED MARCH 31, 2019

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To, The Members **UPI** Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by UPL Limited (hereinafter called the company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the company has, during the audit period covering the financial year ended on March 31, 2019 complied with the statutory provisions listed hereunder and also that the Company has proper Boardprocesses and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2019 according to the provisions of:

- (1) The Companies Act, 2013 (the Act) and the Rules made thereunder;
- (2) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder:
- (3) The Depositories Act, 1996 and the Regulations and bye-laws framed thereunder;
- (4) Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment;
- (5) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
 - a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b) The Securities and Exchange Board of India

- (Prohibition of Insider Trading) Regulations, 2015;
- c) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008,
- d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
- e) The Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- 6) Other Laws applicable to the Company;
 - a) Narcotic Drugs and Psychotropic Substances Act,
 - b) The Insecticides Act, 1968
 - c) Factories Act, 1948 and Rules made thereunder
 - d) Explosives Act, 1889 Gas Cylinder Rules, 1981
 - e) Petroleum Act, 1934, Rules, 1976
 - Industrial Employment (Standing Orders)Act, 1946 & Rules 1957
 - g) Payment of Bonus Act 1965, & Rules, 1965
 - h) Maternity Benefit Act 1961 & Rules
 - Employees Compensation Act, 1923 & Rules.
 - Minimum Wages Act, 1948, M.W(C) Rules, 1950
 - Child Labour (P&R) Act 1986 & Rules.
 - Air(Prevention and Control of Pollution) Act 1981
 - m) Water(Prevention and Control of Pollution) Act 1974
 - n) The Noise (Regulation and Control) Rules 2000
 - o) Ozone Depleting Substances (Regulation & Control) Rules 2000
 - p) The Chemical Accidents (Emergency Planning, Preparedness and Response) Rules 1996
 - q) Payment of Wages Act 1936
 - Employees State Insurance Act 1948 and Rules and Regulations

- s) Employees PF & Miscellaneous Provisions Act 1952 &Employees Pension Scheme 1952
- Employees PF & Miscellaneous Provisions Act 1952 & Employees Provident Fund Scheme 1952
- u) Contract Labour (Regulation & Abolition) Act 1970
- v) Legal Metrology Act, 2009
- w) Industrial Disputes Act, 1947 and Rules made thereunder
- x) Indian Contract Act, 1872
- y) Environment Protection Act, 1986 and other environmental laws
- z) Payment of Gratuity Act, 1972
- aa) Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
- bb) The States Shops and Establishments Act.
- cc) Apprentice Act 1961 and Rules made thereunder
- dd) The Employees Deposit Linked Insurance Scheme 1976.
- ee) The Employment Exchange (Compulsory Notification of Vacancies) Act, 1959 and Rules made thereunder
- ff) The Equal Remuneration Act 1976 and Rules made thereunder
- gg) The Food Safety and Standard Act, 2006 & The Food Safety and Standard Rules, 2011
- hh) The prevention of Food Adulteration Act, 1954 and the Rules made thereunder
- The Bio-Medical Waste Management & The Handling rules, 1998
- ii) The Bureau of Indian Standards Act, 1986 and the Rules and Regulations made thereunder
- kk) The Chemical weapon convention Act 2000, and the Rules made thereunder
- The Explosive Act 1884 and the Static and Mobile Pressure Vessels (Unfired) Rules 1981
- mm) The Indian Standard code of Practice for selection, Installation and Maintenance of Portable First Aid Fire Extinguishers

- nn) The Electricity Act 2003 and the Indian Electricity Rules 1956
- oo) The Indian Boilers Act, 1923 & The Indian Boilers Regulations 1950

We have also examined compliance with the applicable clauses of the following:

a) Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes. All the decisions have been taken unanimously and no dissent recorded.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Date: 17th May, 2019

Place: Mumbai

For M/s N L Bhatia & Associates Practicing Company Secretaries UIN: P1996MH055800

> N. L. Bhatia Managing Partner FCS: 1176 CP. No. 422

To, The Members **UPL Limited**

Our report of even date is to be read along with this letter.

- (1) Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- (2) We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- (3) We have not verified the correctness and appropriate of financial records and Books of Accounts of the Company.
- (4) Wherever required we have obtained the Management representation about the compliance of Laws, Rules and Regulations and happening of events etc.
- (5) The compliance of the provisions of Corporate and Other Applicable Laws, Rules, Regulations, Standards is the responsibility of Management. Our examination was limited to the verification of procedures on test basis.
- (6) The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the Management has conducted the affairs of the Company.

For N. L. Bhatia & Associates Practising Company Secretaries UIN: P1996MH055800

> N. L. Bhatia Managing Partner FCS: 1176 CP. No. 422

Date: 17th May, 2019 Place: Mumbai

ANNEXURE 3 TO DIRECTOR'S REPORT

Disclosure required under Section 197(12) of the Companies Act, 2013 read with rule 5(1) of the Companies

(Appoinment and Remuneration of Manegerial Personnel) rules, 2014.

Forming part of the Directors' Report for the year ended 31st March, 2019.

1	The ratio of the remuneration of each director to the median remuneration	1020953 R D Shorff	181x
	of the employees of the Company for the financial year	1020957 Arun Ashar	46x
2	The percentage increase in remuneration of each director, Chief Financial	1020953 R. D. Shroff	13%
		1020957 Arun Ashar	10%
	the financial year	1000007 M. B. Trivedi	5%
		1203524 Anand Vora	10%
3	The percentage increase in the median remuneration of employees in the financial year		8%
4	The number of permanent employees on the rolls of company		4703
5	Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration	increased in salaries other than Key Managerial	2%
		Percentile increase in the Managerial remuneration	3%
6	The ratio of the remuneration of the highest paid director to that of the employee who are not directors but receive remuneration in excess of the highest paid director during the year		N/A
7	Affirmation that the remuneration is as per the remuneration policy of the Company		Yes

ANNEXURE 4 TO DIRECTOR'S REPORT

Statement pursuant to section 197(12) of the companies act, 2013 read with the companies

(Appoinment and remuneration of manegerial personnel) rules, 2014 and forming part of the Directors' Report for the year ended 31st March, 2019.

۲	Name	Designation	Remineration	Remineration Oualification D	Date of Ioining	АПР	Last Employement
Ž	ע ב	Pesignation:	אפוומוסוו	(daiiitaato)	ر المراج الم	א א	rast ringloyallialit
\propto	R D Shroff	Chairman & Managing Director	130809859	B.Sc.	29/05/1969	85	ΙΞ̈́Ζ
\leq	Ajit Premnath	COO & Global Business Head - Crop Protection	35183764	M.Sc., MBA (Marketing)	01/08/2015	61	UPL Europ Ltd.
ш	Farokh N Hilloo	Global Sales Director	28530819	B.A, Diploma in Import Export Management	08/07/1991	57	Indian Commercial Company Ltd.
>	Vidya Sagar Kaushik	President - Corporate Affairs and Industry Relations	29694574	B.Sc., PGDM	01/04/2011	99	Bayer Ag.
\leq	K R Srivastava	CEO - Specialty Chemicals	32082720	B.Chem., PGDBMA (IIM), DSM	20/07/1999	61	Pharmaceutical Products of India Ltd.
\triangleleft	Anand Kantilal Vora	Chief Financial Officer	37573161	B. Com, CA	05/08/2013	54	Bunge India
\triangleleft	Ashutosh Kumar Awasthi	Chief Executive Officer	17934680	B.Tech., MBA	11/06/2008	20	Piramal Glass Ltd.
\triangleleft	Arun Ashar	Director - Finance	31424564	B.Com., ACA	01/07/1994	70	Excel Industries Ltd.
\propto	Rohit Kumar	Director - Legal	23550618	LLB	01/07/2010	40	Freehills
\leq	Kishore Gurbux	Director - Global Institutional	18960560	B.Sc, MMM	01/04/2014	52	Gharda Chemicals Limited
\cup	Chandiramani	Business					
<u> </u>	Janakiraman Rajaraman	Director - Global Procurement	17622212	BE, MBA	01/07/2014	52	Heinz India
Š	Sameer Tandon	Regional Director - India	21351900	BE.	01/12/2016	49	Orient Electric limited
Z	Nitin Achyut Kolhatkar	Vice President - Finance	20589398	M.Com, ICWA	11/10/2011	22	Arshiya Ind. Ltd.
<u>~</u>	Raj Kumar Tiwari	Global Director - Supply Chain & Manufacturing	20501855	B.Tech., PGDM	06/09/2011	48	CEAT Tyres
\triangleleft	A Balaji	Chief Information Officer	14999816	B.Com, A.C.A	25/03/2015	51	Piramal Enterprise Ltd
S	Swapnil Onkar Ganvir	Executive Pilot	12447328	B. Com	15/06/2012	4	Air India Express
△	Prashant B Belgamwar	Business Director - South Asia, Advanta	14579459	B.Sc. M.Sc.	09/09/2016	54	Syngenta India Limited
2	Mahesh Vijay Wataney	Director - Industrial Chemical Business	11212569	BE. MMS	04/03/2013	20	Kansai Newtac
S	Sunil Raghunath Potale*	Vice President - Specialty Chemicals	14174612		11/02/1999	29	

					-		
Sr.	Sr. Name	Designation	Remuneration Qualification	Qualification	Date of Joining	Age	Last Employement
8							
20	P.Suresh Reddy *	Business Head	14311741	B.Sc. M.Sc. Agriculture	15/07/2003	53	Fmc India Pvt. Ltd
21	Sandeep Chowdhury *	Senior General Manager - Legal	10963670	MBA / B.Tech / Diploma	01/04/2017	44	ADVANTA SEEDS DMCC
22	M B Trivedi	Company Secretary	10279288	CA, CS	17/07/1978	99	S. V. Ghatalia & Co.
23	Rahul R Jadhav	Sr. General Manager - Accounts	10747668	M.COM	01/09/1992	20	Bayer Inida Ltd
24	S Balasubramanian	Director - Environment Business	20562770	M.SC	01/12/1994	54	M/S.Jeena & Co
25	Amul M Desai	Director - Manufacturing	10221514		20/03/1990	59	
26	K M Banerjee	Executive Director	10992555	B.Tech	01/07/1977	9/	
27	Ashish Dobhal	Senior General Manager - Global Sales Operations	10355836	M.Sc	04/03/2003	43	
28	Shyam Sunder Periwal	Vice President - Internal Audit	10321194	CS	08/03/2004	51	Otis Elavator Co (I)
29	D Melwyn Moses	Director - Manufacturing	10012349	BE Mechanical Engineering	15/10/2004	47	Merisant I.P.Ltd
30	Subhat Kumar Jindal	Senior General Manager - Manufacturing	11865788	BE Chemical Engineering	02/06/2015	21	Lanxess India Pvt/ Ltd
31	Shrenik Mehta	Global Portfolio Lead - Fungicides	11310907	Post Graduation Finance	18/04/2016	43	DCM Shriram
32	Mritunjay Chaubey	Vice President - Environment	10253602	BE/Ph.D.	01/07/2016	47	Unilever
33	Parasu Veera Uppara	Head - Technology & Business Development, Specialty Chemicals	10433916	BTECH / MTECH / PHD	22/08/2016	46	Reliance Industries Ltd.
34	Vishal Sodha	Global Head - IPR	11438535	BSC / MSC / PHD / LLB	09/09/2016	42	Apotex Pharmachem India Pvt. Ltd.
35	Maneesh Bhalla	Head - Projects	13204887	BE / MFM	17/11/2016	51	Reliance Industries Limited
36	Sanjay Singh	Global Chief Human Resource Officer	11017171	MBA	05/09/2018	50	CG POWER AND INDUSTRIAL SOLUTIONS LIMITED

- Gross remuneration shown above is subject to tax and comprises salary, allowances, commission, incentives, monetary value of perquisites, company's contribution to provident fund and superannuation fund.
- None of the above employee, along with the spouse and dependant children hold more than 2% of the equity shares of the Company. In addtion to the above, employees are also entitled to gratuity, medical benefits etc. in accordance with Company's rules.
 - Mr. R. D. Shroff is a relative of the Directors of the Company namely, Mrs. S. R. Shroff, Mr. J. R. Shroff and Mr. V. R. Shroff 3 3
- All emploees are permanent employees of the Company
- * Employed for the part of the year. 9 5

ANNEXURE 5 TO DIRECTOR'S REPORT

Conservation of Energy, Technology Absorption, Adaptation and Foreign Exchange Earnings and Outgo

Section 134(3)(m) of the Companies act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014

A. Conservation of Energy 2018-19

i. The following Energy conservation measures were taken during the year 2018-19.

The Company has dedicated 'Energy Cell' which is continuously working for achieving Energy excellence, by identifying and implementing new and innovative measures across The Company's plants. The Team closely monitors specific energy consumption pattern across all manufacturing sites. It also conducts Periodic Internal & external energy audits. This has resulted in reduction of energy and CO2 footprint. Energy Cell is also involved in building internal capability by imparting Trainings and demonstration of new technologies.

Key Focus area has been on heat integration in processes and waste heat recovery.

Major Energy saving initiatives are mentioned below;

- 1. Reduced utility cost of product by utility changeover from chilled water to cooling water in process.
- 2. Increment in mean time between cleaning and power reduction by Installation of VFD for ID blower.
- 3. Purchasing steam from community boiler.
- 4. Smart sensor for motor condition monitoring through cloud.
- 5. Excess steam sale to neighbor plants.
- 6. Power Purchase from Renewable sources. (5.7 MW from Wind)
- 7. Waste heat recovery from boiler flue gases by installing condensing economizer.
- 8. Reduced downtime & improved power generation capacity of power plant by installing surface condenser inline ball cleaning system.
- 9. 4 Effect MEE plant in place of single stage evaporation.
- 10. Roof top solar photo voltaic power generation of 760 KW.
- 11. Installed Back Pressure Turbine at multilocation to utilize kinetic energy, in place of steam PRV station.

- 12. We have installed Rain Water Harvesting system across The Company's units. This will not only harvest rain water but also save pumping power.
- ii. Steps taken by the Company to utilize alternate source & reduce energy consumption.
 - 1. To purchase additional Renewable Wind power purchase and achieve total 10 MWe.
 - 2. To purchase Renewable Solar Photo voltaic power @ 10 MWe.
 - 3. To recover **Kinetic energy** of PRV station and generate power using Back pressure Turbine. We have installed 4 such Turbines and 5 more are under process. Total power generation potential is @ 32 MW.
 - 4. To implement horizontal deployment of innovative measures, like process pinch, Heat integration, achieving higher overall efficiency, Closed loop condensate & Flash recovery system, Evaporative condenser etc.
 - 5. To achieve ISO 50001, Energy management system for PL01.
- iii. Capital Investment on energy conservation equipment's:
 - 1. A total of 24 Crores was invested into installation of energy efficient equipment. All future projects are being evaluated and approved based on the lowest energy and carbon foot print.
 - 2. The Company's units have been recipients of multiple awards as a recognition of our energy conservation measures and Sustainability.

B. Technology Absorption, Adaptation and Innovation

- Following initiatives were taken by the Company towards the technology absorption, adaptation and innovation:
 - 1. A second plant for an important herbicide was commissioned. The plant operates on a process which is designed to be cost effective by way of reduction in number of steps, raw materials cost and operational cost.
 - 2. The production of an herbicide active ingredient was started on commercial scale

- for manufacture and commercialization of a combination formulation meant mainly for corn crop.
- 3. A process for producing an intermediate of a previously commercialised herbicide, was commercialized after successful development with desired yield and quality. The intermediate is now produced in-house
- 4. Production of three specialty chemicals on a commercial scale was started and products with desired quality and yield are being produced.
- 5. The manufacturing process for an herbicide safener was improved to make it more cost effective and improved production yield.
- 6. Many new pesticide formulations were commercialized for launch both in the domestic and international markets.
- 7. Processes for several active ingredients were developed successfully at Research and Development Centres for future commercialization.
- 8. A large number of formulations of various active ingredients were successfully developed in the Research and Development Centres for future introduction
- 9. Processes were developed for the intermediates of at least three technical as an initiative to be self-dependent
- 10. The quality of many actives and formulation products were improved and the process implemented in the plant
- 11. Collaborative work with external agencies like Universities, Research Institutes and scientists in their individual capacity has resulted into innovations and new technology implementation at product and process stages and has been useful in upgradation of the existing technologies

ii. Benefits derived by the Company:

i. A second plant for an herbicide production was commissioned to increase in-house production of the technical active. This will result in sustained quality of the product and make the Company less dependent on vendors

- ii. An herbicide active ingredient to be used in a combination formulation was produced inhouse. This will result in cost-reduction and assured quality of the formulation
- iii. New products introduced globally, resulting in business expansion
- iv. Accomplishment of process development for several active ingredients will be helpful in the future implementation in the plants at commercial scale
- v. Industrial process development and execution will result in expansion in revenue
- vi. Production of Industrial chemicals and Specialty Chemicals will result in more revenue generation
- vii. Process development of active ingredients with backward integration will result in costeffectiveness and quality products
- viii. Several pre-mix formulations are developed which will result into market launches in future
- the existing technical products, improvement in quality and/or increase in yield have been worked out
- x. The marketed formulations have been worked upon for improved quality and cost effectiveness
- xi. Patent protection for the products and processes will help in reduced competition
- xii. There have been increasing number of regulatory approvals in many countries for many products which will help in faster product launches

iii. Expenditure incurred on R & D

Capital	1158.93 Lacs
Recurring	20371.44 Lacs
Total	21530.37 Lacs
Total R & D expenditure - 2.54	% (as a percentage

of turnover)

C. Foreign Exchange Earnings and Outgo:

1.	Total Foreign Exchange earned	₹519,521 Lacs
2.	Total Foreign Exchange outgo	₹340,978 Lacs

Report on Corporate Governance

1. Company's Philosophy on Code of Corporate Governance

The Company's philosophy on Corporate Governance relates to providing maximum service to all its stakeholders. It intends to enhance shareholder value by undertaking the best possible Corporate Governance practices. A high standard of Corporate Governance is maintained by being transparent, accountable and being in continuous interaction with shareholders, employees, lending institutions, banks, governmental agencies and all the dealers.

The Company's products are marketed not only in India

but also across the globe. The Company is, therefore, conscious of the fact that the management and the employees need to work ethically to achieve success.

2. Board of Directors

The Board of Directors consists of 10 Directors as on 31st March, 2019.

Five Board Meetings were held during the year, in accordance with the minimum requirement of four meetings. The dates on which the meetings were held are as follows: 27th April, 2018, 20th July, 2018, 31st July, 2018, 26th October, 2018 and 31st January, 2019.

Composition and category of directors, other Directorships and Committee memberships as on 31st March, 2019:

Name of the Director	Category	Attendand Particular			directorships ar mber/Chairmar		No. of Shares and Convertible
		Board Meeting	Last AGM	Other Directorships	Committee Memberships	Committee Chairmanships	Instruments held By non-executive directors
Mr. Rajnikant Devidas Shroff @ DIN: 00180810	Promoter and Executive Chairman and Managing Director	5	Present	8	1	-	N. A
Mrs. Sandra Rajnikant Shroff @ DIN: 00189012	Promoter and Non-Executive Vice Chairman	3	Present	7	-	-	Nil
Mr. Jaidev Rajnikant Shroff @ DIN: 00191050	Promoter and Non- Executive Director	4	Present	3	-	-	54,00,109 Equity Shares .
Mr. Vikram Rajnikant Shroff @ DIN: 00191472	Promoter and Non- Executive Director	5	Absent	4	-	-	45,02,883 Equity Shares.
Mr. Arun Chandrasen Ashar DIN: 00192088	Non-Promoter and Executive Director	5	Present	7	4	1	N.A
Mr. Kalyan Mohan Benerjee # DIN: 00276866	Non-Promoter and Executive Director	1	N.A.	1	-	-	N.A
Mr.Pradeep Vedprakash Goyal DIN: 00008370	Independent and Non-Executive Director	5	Absent	3	2	2	Nil
Dr. Reena Ramachandran DIN: 00212371	Independent and Non-Executive Director	5	Present	1	1	-	Nil
Mr. Pradip Pranjivan Madhavji # DIN: 00549826	Independent and Non-Executive Director	1	N.A.	2	2	1	Nil
Mr. Vinod Rajindranath Sethi DIN: 00106598	Independent and Non-Executive Director	5	Absent	2	1	-	Nil
Mr. Hardeep Singh DIN: 00088096	Independent and Non-Executive Director	5	Present	3	2	1	32,538 Equity Shares.
Mr. Vasant Prakash Gandhi DIN: 00863653	Independent and Non-Executive Director	5	Present	1	1	1	Nil

Notes:* Excludes Directorship in private limited companies, foreign companies and companies under Section 8 of the Companies Act,

@ Mr. Rajnikant Devidas Shroff and Mrs. Sandra Rajnikant Shroff are spouse of each other and father and mother respectively of Mr. Jaidev Rajnikant Shroff and Mr. Vikram Rajnikant Shroff. Mr. Jaidev Rajnikant Shroff and Mr. Vikram Rajnikant Shroff are sons of Mr. Rajnikant Devidas Shroff and Mrs. Sandra Rajnikant Shroff and brothers of each other.

Resigned during the year.

The details of familiarization programmes imparted to Independent Directors have been disclosed on the Company's website www.upl-ltd. com

3. Audit Committee

Terms of reference:

The terms of reference of Audit Committee are as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Companies Act, 2013. The broad terms of reference of Audit Committee as adopted by the Board are as under:

- 1. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- 2. Recommendation for appointment, remuneration and terms of appointment of auditors of the Company;
- 3. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- 4. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - a. Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of subsection 3 of section 134 of the Companies Act,
 - b. Changes, if any, in accounting policies and practices and reasons for the same;
 - c. Major accounting entries involving estimates based on the exercise of judgment by the management;
 - d. Significant adjustments made in the financial statements arising out of audit findings;
 - e. Compliance with listing and other legal requirements relating to financial statements;
 - Disclosure of any related party transactions;
 - g. Modified opinion(s) in the draft audit report;
- 5. Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- 6. Reviewing, with the management, the statement of uses/application of funds raised through an issue (public issue, rights issue, preferential issue,

- etc.), the statement of funds utilised for purposes other than those stated in the offer document/ prospectus/notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
- 7. Reviewing and monitoring the auditor's independence and performance, and effectiveness of the audit process;
- 8. Approval or any subsequent modification of transactions of the Company with related parties;
- 9. Scrutiny of inter-corporate loans and investments;
- 10. Valuation of undertakings or assets of the Company, wherever it is necessary;
- 11. Evaluation of internal financial controls and risk management systems;
- 12. Reviewing, with the management, performance of statutory and internal auditors and adequacy of the internal control systems;
- 13. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- 14. Discussion with internal auditors of any significant findings and follow up there on;
- 15. Reviewing the findings of internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
- 16. Discussion with statutory auditors, before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- 17. Looking into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
- 18. Reviewing the functioning of the Whistle Blower mechanism;

- 19. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;
- 20. Carrying out any other function as is mentioned in the terms of reference of the Audit Committee.

The Audit Committee shall also mandatorily review the following information:

- 1. Management discussion and analysis of financial condition and results of operations;
- Statement of significant related party transactions (as defined by the Audit Committee), submitted by management;
- 3. Management letters/letters of internal control weaknesses issued by the statutory auditors;
- 4. Internal audit reports relating to internal control weaknesses; and

- 5. The appointment, removal and terms of remuneration of the Chief internal auditor shall be subject to review by the Audit Committee.
- Statement of deviations:
 - (a) Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to Stock Exchange(s) in terms of Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - (b) Annual Statement of funds utilized for purposes other than those stated in the offer document/ prospectus/notice in terms of Regulation 32(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board of the Company has constituted an Audit Committee, comprising three Independent and Non-Executive Directors. Four meetings of the Audit Committee were held on 27th April, 2018, 31st July, 2018, 26th October, 2018 and 31st January, 2019.

Composition of members of Audit Committee is as follows:

Composition	Mr. Pradip Pranjivan Madhavji @	Mr. Hardeep Singh Chairman	Mr. Pradeep Vedprakash Goyal	Mr. Vasant Prakash Gandhi
Meetings attended during the year	1	4	4	4

@ Resigned with effect from 27th April, 2018.

The constitution of Audit Committee also meets the requirements under Section 177 of the Companies Act, 2013. All the members of Audit Committee are financially literate and Mr. Hardeep Singh who has accounting and financial management expertise has been nominated as the Chairman of the Audit Committee.

The role and terms of reference stipulated by the Board to the Audit Committee covers areas specified in Part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the Companies Act, 2013 besides other terms as may be referred by the Board of Directors.

Mr. M. B. Trivedi, Company Secretary acts as the Secretary to the Audit Committee.

4. Nomination and Remuneration Committee

Terms of reference:

The broad terms of reference of Nomination and Remuneration Committee of the Company are as under:

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy,

- relating to the remuneration of the Directors, key managerial personnel and other employees;
- 2. Formulation of criteria for evaluation of Independent Directors and the Board of Directors;
- 3. Devising a policy on diversity of Board of Directors;
- 4. Identifying qualified candidates for Directorship, who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal.
- 5. Whether to extend or continue the terms of appointment of Independent directors, on the basis of report of performance evaluation of Independent Directors.

The Board of the Company has constituted a Nomination and Remuneration Committee, comprising three Independent and Non-Executive Directors viz. Dr. Reena Ramachandran, Chairman, Mr. Pradeep Vedprakash Goyal and Mr. Hardeep Singh.

One meeting of the Nomination and Remuneration Committee was held on 27th April, 2018.

Composition of members of Nomination and Remuneration Committee is as follows:

Composition	Dr. (Mrs.) Reena	Mr. Pradeep	Mr. Pradip	Mr. Hardeep Singh
	Ramachandran,	Vedprakash Goyal	Pranjivan	
	Chairman		Madhavji@	
Meeting attended during the year	1	1	1	1

[@] Resigned with effect from 27th April, 2018.

Performance evaluation criteria for Independent Directors:

Qualifications, meeting the independence criteria, observing ethical standards, integrity, exercise of responsibilities, safeguarding interest of all stakeholders, skills and knowledge updation, adhering to Company's Code of conduct, regular attendance and active participation at the meetings of the Company, maintaining confidentiality, transparency, assistance in implementing best corporate governance practices and absence of conflict of interest with business of the Company.

5. Remuneration of Directors:

The Board has, on the recommendation of the Nomination and Remuneration Committee, framed and adopted the policy for selection and appointment of Directors, senior management and their remuneration. The policy lays down criteria for selection of Directors and senior management such as expertise, experience and integrity of the Directors, independent nature of the Directors, personal and professional standing, diversity of the Board, etc. The remuneration policy lays down the entitlements of remuneration to Non-Executive Directors such as sitting fees, commission and other reimbursement. Remuneration to the Managing Director and other Executive Directors will consist of monthly salary, allowances, perquisites, bonus, commission and other retiral benefits. In respect of senior management, the remuneration will be based on the performance, working of the Company, targets achieved, KPI, industry benchmark and current compensation trends in the industry.

Details of the remuneration to all the Directors for the year:

The aggregate value of salary, perquisites and commission for the year ended 31st March, 2019 to three Whole-time Directors is as follows:

₹ In lacs

Name of Director	Salary	Perquisites	Retirement	Commission	Total
			Benefits		
Mr. Rajnikant Devidas Shroff	510	211	162	450	1333
Chairman and Managing Director					
Mr. Kalyan Mohan Banerjee @	8	44	3	15	70
Whole-time Director					
Mr. Arun Chandrasen Ashar	126	77	40	60	303
Whole- time Director					

[@] Resigned with effect from 1st August, 2018.

The Company has paid the sitting fees for the year ended 31st March, 2019 to Independent and Non-Executive Directors for attending Board Meeting, Audit Committee Meetings, Remuneration Committee Meeting, CSR Committee Meeting and Stakeholders Relationship Committee Meeting as follows:

Mr. Pradeep Vedprakash Goyal ₹4,00,000/-, Dr. Reena Ramachandran ₹2,75,000/-, Mr. Pradip Pranjivan Madhavji ₹90,000/-, Mr. Vinod R. Sethi ₹2,50,000/-, Mr. Hardeep Singh ₹3,25,000/-and Mr. Vasant P. Gandhi ₹3,25,000/-.

In addition, the Company has paid commission to Independent and Non-Executive Directors of ₹10 lacs each to Mr. Pradeep Goyal, Dr. Reena Ramachandran, Mr. Pradip Madhavji, Mr. Vinod Rajindranath Sethi, Mr. Hardeep Singh and Mr. Vasant Prakash Gandhi.

Remuneration of the executive directors are broadly divided into fixed and variable components. The fixed components comprises of salary, allowances, perquisites, amenities and retirement benefits. The variable components comprises of performance based annual commission. The performance criteria are individual performance based on annual targets, Company's performance and recent compensation trends in the industry.

The appointment of executive directors is for a period of five years. The service agreement provides for a notice period of three months on either side.

6. Stakeholders Relationship Committee

The Board of the Company has constituted a Stakeholders Relationship Committee, comprising one Independent, one Promoter and one Executive Director to look into the redressal of grievances of security holders including complaints related to transfer of shares, non-receipt of balance sheet, non-receipt of declared dividends. One meeting of the Stakeholders Relationship Committee was held on 31st January, 2019.

Composition of members of Stakeholders Relationship Committee is as follows:

Composition	Mr. Pradip Pranjivan	Mr. Pradeep	Mrs. Sandra	Mr. Arun
	Madhavji @	Vedprakash Goyal	Rajnikant Shroff	Chandrasen Ashar
	_	Chairman		
Meeting attended during the year	-	1	1	1

[@] Resigned with effect from 27th April, 2018.

Compliance Officer:

Mr. M. B. Trivedi, Company Secretary

The Company also has its separate shares transfer committee consisting of Mrs. Sandra Rajnikant Shroff and Mr. Arun Chandrasen Ashar, Directors and two other senior executives of the Company. This committee normally meets weekly to approve transfer of shares, issue of duplicate certificates, redressal of Stakeholders Grievances, among others. Share certificates submitted for dematerialisation and request for rematerialisation were also approved by the committee.

No complaint was pending at the beginning of the year and the total number of complaints received during the year under review were 81 of which 62 complaints were addressed to the satisfaction of shareholders on or before 31st March, 2019 and 19 complaint were pending as on or before 31st March, 2019.

Twenty-one requests for transfers were pending for approval as on 31st March, 2019, out of which nine were processed under objections on or before 15th May, 2019 and twelve was approved and dealt with on 8th April, 2019.

7. General Body Meetings

(A) Annual General Meetings:

Location and time for last three Annual General Meetings were:

Year	AGM	Location	Date	Time
2015-16	32nd AGM	Hotel Green View Hall	29/06/2016	10.00 a.m.
		N. H. No. 8, Vapi, Gujarat - 396 195.		
2016-17	33rd AGM	Hotel Green View Hall	08/07/2017	11.00 a.m.
		N. H. No. 8, Vapi, Gujarat - 396 195.		
2017-18	34th AGM	Hotel Green View Hall	23/08/2018	11.00 a.m.
		N. H. No. 8, Vapi, Gujarat - 396 195.		

The following special resolutions were passed by the members during the last three Annual General Meetings:

2015-16

a) Private placement of Non-Convertible Debentures.

2016-17

- a) Private placement of Non-Convertible Debentures.
- b) Approval of UPL Limited -Employees Stock Option Plan 2017.
- c) Grant of options to the employees of the Subsidiary Company(ies) of the Company under Employees Stock Option Plan 2017.

2017-18

- a) Private placement of Non-Convertible Debentures.
- b) Re-appointment of Mr. Rajnikant Devidas Shroff as Chairman and Managing Director for a further period of five years from the expiry of his present term of office, i.e., with effect from 1st October, 2018 and of payment of remuneration.

c) Re-appointment of Mr. Arun Chandrasen Ashar as Whole-time Director designated as Director-Finance for a further period of five years from the expiry of his present term of office, i.e., with effect from 1st October, 2018 and of payment of remuneration.

The following special resolutions were passed by the members during Extra-Ordinary General Meeting of the members of the Company held on 22nd March, 2019.

- Continuation of Directorship by Mrs. Sandra Rajnikant Shroff (DIN: 00189012) as Non-Executive Director of the Company, liable to retire by rotation.
- Continuation of Directorship by Dr. Reena Ramachandran (DIN: 00212371) as an Independent Non-Executive Woman Director of the Company.

Details of resolution passed through postal ballot, the persons who conducted the postal ballot exercise and details of voting pattern

2018-19

- No resolution, pursuant to Section 110 of the Companies Act, 2013 read with Companies (Management & Administration) Rules, 2014, was passed through Postal Ballot during the year.
- None of the resolutions, pursuant to Section 110 of the Companies Act, 2013 read with Companies (Management & Administration) Rules, 2014, are proposed to be passed in the ensuing Annual General Meeting which require passing a special resolution through Postal Ballot.

8. Means of communication

The quarterly and annual results are published by the Company in the English and Gujarati editions of the The Economics Times/DNA/Business Standard/ Business Line/The Financial Express/Western Times and are also displayed on the corporate website, www. upl-ltd.com. The Company's website also contains a separate dedicated section called 'Investors' wherein shareholder-related information like the Annual Report of the Company, shareholding pattern among others, are available. Official news releases are sent to the Stock Exchanges at BSE Ltd. and National Stock Exchange of India Ltd., where the equity shares of the Company are listed.

Further, the Company also holds an Analysts' meet after the audited Annual Financial Statements have been adopted by the Board of Directors, where information is disseminated and analyzed. The presentation made at this meet has been posted on the corporate website, www.upl-ltd.com.

The Management Discussion and Analysis (MD&A) forms a part of the annual report.

9. General Shareholder Information

9.1. Annual General Meeting		
Date	28th August, 2019 at 11.00 a.m.	
Venue	: Hotel Green View Hall	
	N. H. No. 8, Vapi - 396195, Gujarat.	
9.2. Financial calendar		
Annual General Meeting –	28th August, 2019	
Results for quarter ending June 30th, 2019	On or before 14th August, 2019	
Results for quarter ending September 30th, 2019	On or before 14th November, 2019	
Results for quarter ending December 31st, 2019	On or before 14th February, 2020	
Results for quarter/ year ending March 31st, 2020	Last week of April, 2020/May, 2020.	
9.3. Dividend payment date	On or after 2nd September, 2019	
9.4. (a) Listing of Equity Shares on Stock Exchanges at	BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 and National Stock Exchange of India Ltd. Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (East), MUMBAI 400 051	
(b) Listing of GDR on the Stock Exchange at	·	
The Company has paid the annual listing fees to	each of the stock exchange.	
9.5. (a) Security Code/Symbol	BSE Ltd.: 512070 National Stock Exchange of India Ltd.: UPL Singapore Stock Exchange Ltd.: BYS	
(b) Demat ISIN Number in NSDL & CDSL for Equity Shares of ₹2/- each	INE628A01036	

9.6. Market Price Data

Month	BSE Ltd. (BSE)		National Stock Exchange of India Ltd.(NSE)	
	Month's High	Month's Low	Month's High	Month's Low
	Price (In ₹)	Price (In ₹)	Price (In ₹)	Price (In ₹)
April, 2018	776.75	725.00	774.90	725.10
May, 2018	742.00	673.25	741.00	672.75
June, 2018	715.70	603.15	716.85	604.30
July, 2018	662.10	537.90	662.65	537.25
August, 2018	721.00	599.60	721.90	599.20
September, 2018	738.40	590.00	738.90	588.50
October, 2018	677.50	582.20	677.20	582.15
November, 2018	790.00	660.00	789.40	670.00
December, 2018	794.25	722.20	794.30	771.20
January, 2019	790.00	743.60	789.90	743.10
February, 2019	881.00	758.65	881.60	758.00
March, 2019	958.90	862.75	962.90	863.55

9.7. Share price performance in comparison to broad-based indices - BSE Sensex.UPL closing share price performance relative to BSE Sensex based on share price during the year.



9.8. Registrar and Share Transfer Agent (Share for transmission/transposition and Unit: UPL Limited communication regarding share certificate, C-101, 247 Park, LBS Marg, dividends and change of address).

Also, for the benefit of the Shareholders, the UPL Limited documents will be accepted at the following Secretarial Department office of the Company:

Link Intime India Pvt. Ltd. Vikhroli (West), Mumbai- 400 083.

Uniphos House,

C. D. Marg, 11th Road,

Madhu Park, Khar (West),

Mumbai 400 052.


9.9. Share Transfer System

Presently, the share transfers which are received in the physical form are processed and the share certificates are returned within a period of 15 days from the date of receipt, subject to the documents being valid and complete in all respects.

9.10. Distribution of shareholdings as on 31st March, 2019:

Shareholding of Nominal Value of (₹)	Shareholders		Share Amount	
	Numbers	% of Total	In (₹)	% of Total
		Nos.		Amt.
1 – 1,000	74119	86.55	12169722	1.19
1,001 – 2,000	4132	4.82	6668936	0.65
2,001 – 4,000	3184	3.72	10254930	1.01
4,001 – 6,000	1053	1.23	5322828	0.52
6,001 – 8,000	727	0.85	5314146	0.52
8,001 – 10,000	388	0.45	3524582	0.35
10,001 – 20,000	894	1.04	12483606	1.23
20,001 and above	1145	1.34	962946590	94.53
Total	85642	100	1018685340	100

9.11 Shareholding pattern as on 31st March, 2019:



9.12. Dematerialization of shares	99.03% of the outstanding shares have been dematerialized up to 31st March, 2019. Trading in Equity Shares of the Company is permitted only in dematerialized form w.e.f. 28th August, 2000 as per notification issued by the Securities and Exchange Board of India (SEBI).		
Liquidity:			
The shares of the Company are among the most turnover for the financial year 2018–2019 is give		led shares. Relevant data f	or the average daily
	BSE Ltd. (BSE)	National Stock Exchange of India Ltd. (NSE)	BSE+NSE
In no. of shares (in thousand)	152.02	2070.82	2222.84
(Source: This information is compiled from the da	ata available from the w	ebsites of BSE and NSE)	
9.13. Outstanding GDR/Warrants and Convertible Bonds, their conversion dates and their likely impact on the equity	As on 31st March, 2 42353062 shares (8.3	2019 there are Outstand 32%).	ing GDRs represent
9.14 Commodity price risk or Foreign Exchange Risk and Hedging activities	The Company has exports of finished products and imports by sourcing of raw materials from outside India. The international trade is primarily in USD and Euro which are major convertible currencies, and to that extent the exposure to forex exchange risk exists. However, the Company exports and imports are in same currencies, there is a natural hedge for these currencies. To mitigate this foreign exchange risk, the Company works out the net open position relating to trade operations and such net open positions are hedged by taking simple Forward Contracts for a period not exceeding twelve months. Similarly, for exposure on account of capital operations in Foreign Currency, the net open position is hedged by taking Forward Contracts for a period not exceeding twelve months. The Company has a Risk Management Policy in place which as approved by the Board of Directors, which monitors foreign currency risk on a continuous basis. The various derivative transactions relating to Foreign Exchange and all the outstanding Derivative Contracts are periodically reported to and ratified by the		
9.15 Plant locations		nts in India are located a	
9.16 Address for Correspondence (i) Investor correspondence	For Shares held in Ph Link Intime India Pvt. Unit: UPL Limited C-101, 247 Park, LBS Vikhroli (West), Mum	Ltd. Marg,	учегараб.
		6060 Plinkintime.co.in	

	UPL Limited
	Secretarial Department
	Uniphos House,
	C. D. Marg, 11th Road,
	Madhu Park, Khar (West),
	Mumbai 400 052.
	Telephone No.: 91-22-26468009/10
	For Shares held in Demat form
	To the Depository Participant(s)
(ii) Any query on Annual Report	Mr. M. B. Trivedi, Company Secretary
	UPL Limited
	Legal & Secretarial Department
	Uniphos House, C. D. Marg
	Madhu Park, Khar (West), Mumbai 400 052.
	E-Mail : trivedimb@uniphos.com
(iii) Exclusive e-mail ID of the grievance	upl.investors@upl-ltd.com
redressal division	
(iv) Corporate website	www.upl-ltd.com

10. Other Disclosures:

(a) Disclosures on materially significant related party transactions that may have potential conflict with the interests of the Company at large.

During the year, the Company had no materially significant related party transactions which were considered to have potential conflict with the interests of the Company at large.

(b) Details of non-compliance by the Company, penalties, strictures imposed on the Company by Stock Exchanges or SEBI, or any statutory authority, on any matter related to capital markets, during the last three years.

None.

(c) Details of establishment of vigil mechanism, whistle Blower Policy and affirmation that no personnel has been denied access to the audit committee.

The Company has devised an effective whistle blower mechanism enabling stakeholders, including individual employees and their representative bodies, to communicate their concerns about illegal or unethical practices freely. The Company has also established a vigil mechanism for directors and employees to report concerns about unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or ethics policy and placed on the website of the Company www. uplonline.com and no personnel has been denied access to the audit committee.

(d) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements.

Mandatory Requirements

The Company has complied with the mandatory requirements of para C (10) (d) of Schedule V SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

- (e) Policy for determining 'material' subsidiary has been disclosed on the Company's website www.upl-ltd. com.
- (f) Policy on dealing with related party transaction has been disclosed on the Company's website www. upl-ltd.com.
- 11. There are no non-compliance of any requirements of Corporate Governance Report of sub-paras (2) to (10) above.

12. Discretionary Requirements as specified in Part E of Schedule II

A. Chairman of the Board

The Chairman of the Board is Executive.

B. Shareholder Rights - Half yearly results

As the Company's half yearly results are published in English newspapers circulated all over India and in a Gujarati newspaper (circulated in Gujarat) and also posted on the website of the Company www.upl-ltd.com, the same are not sent to the households of the shareholders of the Company.

C. Modified opinion in audit report

There are no modified opinion contained in the Audit Report.

D. Separate Posts of Chairman and Chief Executive Officer

The Posts of Chairman and Managing Director are not separate.

E. Reporting of Internal Auditors

The Internal Auditors of the Company report directly to the Audit Committee.

13. The Company has complied with Corporate Governance requirements specified Regulations 17 to 27 and clauses (b) to (i) of subregulation (2) of Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

On behalf of the Board of Directors

Mumbai, May, 2019

Rajnikant Devidas Shroff (Chairman and Managing Director) (DIN: 00180810)

Declaration

As provided under Clause D of Schedule V pursuant to Regulation 34(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Members of Board of Directors and Senior Management Personnel have affirmed compliance with the Code of Conduct of Board of Directors and Senior Management laid down by the Company for the year ended 31st March, 2019

> On behalf of the Board of Directors of **UPL Limited**

Mumbai, May 17, 2019

Rajnikant Devidas Shroff

(Chairman and Managing Director) (DIN: 00180810)

Compliance Certificate

Pursuant to Regulation 17(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We, Rajnikant Devidas Shroff, Chairman and Managing Director and Anand Vora, Chief Financial Officer do hereby certify that in respect of annual accounts and cash flow statement for the year 2018-2019.

- We have reviewed financial statements and the cash flow statement for the year and that to the best of our knowledge and belief:
 - (1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (2) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- D. We have indicated to the auditors and the Audit Committee
 - (1) significant changes in internal control over financial reporting during the year;
 - (2) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - (3) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

RAJNIKANT DEVIDAS SHROFF Chairman and Managing Director

ANAND VORA Chief Financial Officer

Auditor's certificate on Corporate Governance

The Members of **UPL** Limited **UPL** House 610 B/2, Bandra Village Off Western Express Highway Bandra (East) Mumbai 400 051 17 May 2019

Independent Auditors' Certificate on Compliance with the Corporate Governance requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and 2018.

- 1. This Certificate is issued in accordance with the terms of our agreement dated 09 March 201 9.
- 2. This Report contains details of compliance of conditions of Corporate Governance by UPL Limited ('The Company') for the year ended 31 March 2019, as stipulated in Regulations 17-27, clause (b) to (i) of Regulation 46 (2) and paragraphs C, D and E of Schedule V of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 and 2018 ('Listing Regulations') pursuant to the Listing Agreement of the Company with Stock Exchanges.

Management's Responsibility for compliance with the conditions of Listing Regulations

The compliance with the terms and conditions contained in the Corporate Governance is the responsibility of the Management of the Company including the preparation and maintenance of all relevant supporting records and documents.

Auditor's Responsibility

- 4. Our examination was limited to procedures and implementation thereof adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.
- 5. Pursuant to the requirements of the Listing Regulations, it is our responsibility to provide a reasonable assurance Whether the Company has complied with the conditions of Corporate Governance as stipulated in Listing Regulations for the year ended 31 March 2019.
- 6. We conducted our examination in accordance with the Guidance Note on Reports or Certifications for Special Purposes issued by the Institute of Chartered Accountant of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
- 7. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

Opinion

- 8. In our opinion, and to the best of our information and according to explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Regulations.
- We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Restriction on Use

10. The certificate is addressed and provided to the members of the Company solely for the purpose to enable the Company to comply with the requirement of the Listing Regulations, and it should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

Yours faithfully,

For B S R & Co. LLP

Chartered Accountants

ICAI Firm Registration Number: 101248W/W-100022

Bhavesh Dhupelia

Membership No: 042070

Certificate UDIN No: 19042070AAAAA07139

Partner

17 May 2019 Mumbai

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To, The Members **UPL** Limited

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of UPL Limited having CIN: L24219GJ1985PLC025132 and having registered office at 3-11, G.I.D.C., Vapi, Distt. Valsad-396195 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C sub clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca. gov.in) as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the financial year ended March 31, 2019 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of appointment in Company
1.	Rajnikant Devidas Shroff	00180810	01/10/1992
2.	Sandra Rajnikant Shroff	00189012	01/10/1992
3.	Hardeep Singh	00088096	02/02/2015
4.	Pradeep Vedprakash Goyal	00008370	31/01/2002
5.	Vinod Rajindranath Sethi	00106598	30/01/2006
6.	Jaidev Rajnikant Shroff	00191050	01/10/1992
7.	Vikram Rajnikant Shroff	00191472	22/04/2006
8.	Arun Chandrasen Ashar	00192088	01/03/1993
9.	Reena Ramachandran	00212371	21/10/2003
10.	Vasant Pakash Gandhi	00863653	23/11/2015
11.	Kalyan Banerjee *resigned w.e.f August 01, 2018	00276866	01/10/2008
12.	Pradip Madhavji *resigned w.e.f. April 27, 2018	00549826	29/01/2004

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

> For N. L. Bhatia & Associates Practising Company Secretaries UIN: P1996MH055800

> > **Bharat Upadhyay** Partner FCS: 5436 CP. No. 4457

Date: 17th May, 2019 Place: Mumbai

Business Responsibility Report

For the year 2018-2019

Section A: General Information about the Company

1.	Corporate Identity Number (CIN) of the Company	L24219GJ1985PLC025132
2.	Name of the Company	UPL Limited
3.	Registered Address	3-11, GIDC, VAPI, DIST VALSAD, GUJARAT
4.	Website	www.upl-ltd.com
5.	E-mail id	trivedimb@upl-ltd.com
6.	Financial Year Reported	April 2018 to March 2019
7.	Sector(s) that the Company is engaged in (industrial activity code-wise)	2021 - Agrochemicals
8.	List three key products/services that the Company manufactures/	a) Industrial chemicals
	provides (as in balance sheet)	
		b) Agrochemicals
		c) Hybrid seeds
9.	Total number of locations where business activity is undertaken by the	
	Company:	
	a. Number of International Locations	75
	b. Number of National Locations	26 Depots & 10 companies
10.	Markets served by the Company – Local/State/National/International:	a. Global Market, 120 countries in the world

Section B: Financial Details of the Company

1.	Paid Up Capital (INR)	₹10	2 crores
2.	Total Turnover (INR)	8,6	60 crores
3.	Total Profit after Taxes (INR)	405	5 crores
4.	Total Spending on Corporate Social Responsibility	18.	00 crores
	(CSR as percentage of Profit after Tax)	(4.4	14% of Profit after Tax)
5.	List of activities in which the expenditure in 4 above has been incurred.	>	National Institutions (Gnyandham, EMRS, Nursing, SRICT, U-CAE)
		>	Sustainable Livelihood
		>	Nature conservation
		>	National & Local Area needs

Section C: Other Details

1. Does the Company have any Subsidiary Company/Companies?

Yes. The Company has subsidiaries

2. Do the Subsidiary Company/Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s)

No. The subsidiaries conduct BR initiatives independently.

3. Do any other entity / entities (e.g. Supplier, distributor etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes indicate the percentage of such entities? (Less than 30%, 30 - 60% and More

Yes. All the Supplier/ Vendors which cater to the needs of UPL in terms of good and services as well as our affiliates globally come under the purview of our Supplier Code of Conduct. These entity include our supplier, contractors, contract manufacturers, tollers and joint venture partners whom share a contractual and commercial relationship with us. The policy specifies lays down our expectations from our value chain partners.

Section D: BR Information

1. Details of Director/Directors responsible for BR

a) Details of the Director/Director responsible for implementation of the Business Responsibility policy/policies

Name	DIN Number	Designation
Mr. R. D. Shroff	00180810	Chairman & Managing Director

b) Details of the Business Responsibility Head

DIN Number (if applicable)	00180810
Name	Mr. R. D. Shroff
Designation	Chairman & Managing Director
Telephone number	2271528000
E-mail ID	shroffrd@upl-ltd.com

2. Principle-wise (as per NVGs) BR Policy/Policies

a) Details of compliance (Reply in Y/N)

No.	Questions	P1	P2	Р3	P4	P5	P6	P7	P8	P9
1	Do you have policy/policies for	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
2	Has the policy been formulated	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Y	Υ
	in consultation with relevant	Yes, all	the po	blicies h	ave bee	n deve	loped in	consul	tation w	ith the
	stakeholders?	Manage	ement of	the Cor	npany.					
3	Does the policy conform to any		Y	Υ	Υ	Y	Υ	Y	Y	Υ
	national /international standards? If yes, specify? (50 words)	- 1	olicies ar nes (NVG		ulated a	s per p	rinciples	of Nat	tional Vo	oluntary
4	Has the policy been approved by the Board?									
	If yes, has it been signed by the	Υ	Υ	Υ	Υ	Y	Υ	Υ	Υ	Υ
	MD/owner/CEO/appropriate Board				ed by th					
	Director?				esponsik			1		i
5	Does the Company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	Y	Y	Y	Y	Y	Y	Y	Y	Y
6	Indicate the link to view the policy	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ
	online?	The pol	licies are	availab	le on ou	r interne	et portal	which c	an be vi	ewed at
		http://w	/ww.upl-l	td.com						
7	Has the policy been formally communicated to all relevant internal and external stakeholders?	Y	Y	Y	Υ	Y	Y	Y	Y	Y
8	Does the Company have in-house structure to implement its policy/policies?	Y	Y	Y	Υ	Y	Y	Y	Y	Y
9	Does the Company have a grievance redressal mechanism related to the policy/policies to address stakeholders' grievances related to policy/policies?		Y	Y	Y	Y	Y	Y	Y	Y
10	Has the Company carried out independent audit/evaluation of the working of this policy by an internal or external agency?		Y	Y	Υ	Y	Υ	Υ	Υ	Y

b) If answer against any principle, is 'No', please exp	plain why: (Tick up to 2 options):
---	------------------------------------

No.	Questions	P1	P2	Р3	P4	P5	P6	P7	P8	P9
1	The Company has not understood									
	the principles									
2	The Company is not at a stage where									
	it finds itself in a position to formulate									
	and implement the policies on									
	specified principles									
3	The Company does not have financial									
	or manpower resources available for									
	the task									
4	It is planned to be done in the next									
	6 months									
5	It is planned to be done in the next									
	year									
6	Any other reason (please specify)									

3. Governance related to BR

- a) Indicate the frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR performance of the Company. Within 3 months, 3-6 months, Annually, More than 1 year.
 - The board of directors meet annually to access the BR related performance.
- b) Does the Company publish a BR or a Sustainability Report? What is the hyperlink for viewing this report? How frequently it is published?
 - Yes, UPL Ltd publishes a Business Responsibility Report. The report is part of the annual report of FY 2017-18

Section E: Principle Wise Performance

Principle 1: Businesses should conduct and govern themselves with Ethics, Transparency and Accountability

A. Does the policy relating to ethics, bribery and corruption cover only the Company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/Contractors/NGOs / Others?

Yes. Ethics & transparency is in the core of all our business practices and activities. Being a responsible brand we have policies in place that establish a robust mechanism to ensure ethical conduct and transparency. Clauses pertaining to our anti-bribery, conflict of interest, compliance with Government rules, intellectual property, confidentiality, advertising, fair dealings and equal opportunity are covered in our Code of Conduct. This Code extends to all employees, directors and senior management personnel. Our strict adherence to ethical practices trickles down to our value chain through a separate code of conduct guidance for our suppliers, contractors, contract manufacturers, tollers and joint venture partners. This policy guideline lays down principles with respect to ethics, intellectual property, legal requirements, employment practices, health, safety, environmental and quality practices, conflict minerals, procurement from civil war zones, communications, monitoring and compliance.

B. How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about 50 words or so.

The Company has incorporated a stakeholder relationship committee which comprises of three independent directors. UPL's whistle blower policy is applicable to all our relevant stakeholders. In the current financial year we have received 01 number of complains and same was resloved.

Principle 2: Businesses should provide goods and services that are safe and contribute to sustainability throughout their life cycle

1. List up to 3 products or services whose design has incorporated social or environmental concerns, risks, and/or opportunities.

UPL understands impacts of its business on environment & society and takes responsibility to develop its products, favoring betterment of environment and society. In every action of the Company, the farmer is at the beginning and in the center of our activities. UPL invests in cost efficient products for our beneficiaries. Our products are energy efficient & consumes lower resources during utilization resulting in creating positive environmental footprint. Following are the three key products whose design address social and environmental concerns:

- a. Herbicide
- b. Insecticide
- c. Fungicide

UPL believes in adapting new technologies which has a positive impact on environment and social dimensions along with economic dimensions. UPL has an in-house team for the evaluation and development of new technologies which helps us to make our processes more efficient.

Following are some technological upgradation adopted by UPL;

- We have implemented DAF-MBBR technology to reduce physical and organic impurities of wastewater
- We have implemented Zero Liquid discharge (ZLD) system at Unit-10 Tarapur (Maharashtra) to make it **ZLD Plant**
- We have started recycling 140 m3/day Sewage treated plant water in DVACI plant's cooling tower at Unit-0 Vapi, Gujarat.
- Installed rain water Harvesting system at Unit-4 Halol
- Installed Scaleban technology to recycle & reuse ETP treated wastewater in cooling tower at Unit- 1 Ankleshwar and Unit-5 Jhagadia, Gujarat
- We have signed and executed Green power purchase agreement of total 4.2 MWh wind energy for Unit-1 Ankleshwar and Unit-5 Jhagadia, Gujarat.
- Improved Loss on dry (LOD) of ETP waste at Unit-5 Jhagadia (Gujarat) and Unit-10 Tarapur (Maharashtra) to reduce moisture content by installing Volute dewatering system
- 1. For each product, provide the following details in respect of resources (energy, water, raw material etc.) per unit of product.
- (i) Reduction during sourcing/production/ distribution achieved since the previous year throughout the value chain?

The Company is actively working on its products to reduce overall impacts through incorporation of advance and effective technologies, few of the achievements are mentioned below.

- 1. In reporting year, we have recycled around 12% of water by various water recycling system like Reverse Osmosis (RO), Rain water Harvesting, steam condensate recovery and STP treated effluent recycling.
- 2. By Using renewable energy through Green Power purchase agreement, we have reduced around 6755 tons CO2
- (ii) Reduction during usage by consumers (energy, water) has been achieved since the previous year?

The Company is committed to reduce its environmental and social footprints through its activities. We thoughtfully design our products keeping our customers in mind and their requirements. We train farmers through our CSR activities on modern agricultural techniques which helps them to reduce their overall water consumption and electricity consumption.

2. Does the Company have procedures in place for sustainable sourcing (including transportation)? If yes, what percentage of your inputs was sourced sustainably? Provide details thereof, in about 50 words or so.

Yes, the Company has a sustainable procurement policy in place which is a guidance to our internal team and for suppliers/ vendors before onboarding them. Our internal team performs audits and our suppliers/ vendors also sign a declaration on "commitment to sustainability" which is the agreement from their side to maintain the laws and standards set by the Company.

The Company is also working with its Global Sustainability team to design sustainable practices, particularly for its supply chain. These practices primarily focus on improvements in process to improve energy efficiency, waste management, water management, and compliances regarding sustainability.

3. Has the Company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work? If yes, what steps have been taken to improve their capacity and capability of local and small vendors?

Yes, the Company understands the importance of development of its local suppliers and vendors and takes special initiatives to build their capacity and capability. UPL has training calendar in place on sustainable practices for suppliers and vendors, this includes physical interactions and online training modules.

We connect with local suppliers and vendors located nearby our plants to procure most of our packaging materials, this includes materials as Plastic bottles, Corrugated boxes, Fiber drums, Flexible laminates, HDPE Woven bags, etc. UPL also procures raw materials locally such as MnSO4, Salt, Caustic soda, Chlorine, Hydrated Lime, ZnSO4, 3-4 DCA, Specialized Starch, China clay, Mg turning, Ethanol, Sulphur, Ammonia, Chloral, Acids etc.

4. Does the Company have mechanism to recycle products and waste? If yes, what is the percentage of recycling waste and products?

Yes, UPL has mechanisms in place to recycle its waste, most of our plants are "Zero Liquid Discharge". We recycled certain waste by 100%, which includes Ammonium chloride, Ammonium acetate, Methyl chloride, sodium sulfate, ammonium sulphate, calcium chloride, hydrochloric acid, MDC residue, HNO3, etc. Product recoveries are above 95 %, however some products are recovered 100%.

Other waste is treated as per required process and disposed safely.

Principle 3: Businesses should promote the wellbeing of all employees

- 1. Please indicate the total number of employees-Total number of employees as on 31st March, 2019 is 4,703.
- Please indicate the total number of employees hired on temporary/contractual/casual basis -

Total number of employees hired on temporary/ contractual/ casual basis as on 31st March, 2019 is 7,773.

3. Please indicate the number of permanent women employees -

Total number of permanent women employees as on 31st March, 2019 is 166.

4. Please indicate the number of permanent employees with disability -

Total number of permanent employees with disability as on 31st March, 2019 is 22.

5. Do you have an employee association that is recognized by management?

The Company does not have any recognized employee association.

- 6. What percentage of your permanent employees are a member of this recognized employee association? Not Applicable
- 7. Please indicate the Number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last financial year and pending, as on the end of the financial year.

The Company has implemented a policy on sexual harassment, UPL has initiated e-learning program for awareness of the policy and was mandated for employees. The Company has incorporated a corporate level committee to monitor the implementation of this policy with a presiding officer along with a unit level committee at all manufacturing units. This committee consist of male and female members both.

We also have a Child Labor Policy which is strictly followed and it is applicable to all contract and permanent workforce.

Category	No. of	No. of complaints
	complaints	pending at
	during	the end of the
	financial year	financial year
Child Labour /	Nil	Nil
Forced Labour		
/ Involuntary		
Labour		
Sexual	Nil	Nil
Harassment		
Discriminatory	Nil	Nil
employment		

8. What percentage of your under mentioned employees were given safety & skill up-gradation training in the last year?

UPL takes safety of its employees very seriously and has taken up programmes to train our workforce on how to main occupation health and safety.

Safety - 14 PSM elements are the basis for Safety Processes. Trainings are provided accordingly to the workforce. Our internal team has developed few rituals on safety which is followed with full respect.

- Daily Safety Talk: Daily briefing on safety before start of the shift.
- Monthly we cover a particular safety theme by the unit safety representative.

The Company also invests in trainings to upgrade the skills of our employees based on requirements and demand. A Calendar based training program is published for both behavior and functional development of the employees. Based on the availability and nominations the employees are provided with the trainings and certifications. No employee in manufacturing functions can take charge of respective activities unless they have undergone Level 0, 1 & 2 training minimum duration for which is 23 days. This training basically is intended for safety and functional expertise including safety in operating related functions.

Company has several other training programmes which essentially addresses the areas of safety on various activities like construction safety, Chemical safety, emergency response, Process Safety Management, electrical safety etc. UPL does not differentiate between company employees or contractual employees.

UPL has a defined Health and Safety policy which is available on the Intranet and accessible to all employees.

Category	Total F	lours of	Hou	irs of	Hou	irs of	Temp	orary	Contr	actual	Permanent						
	Trai	ning	Traini	ng for	Train	ng for	Empl	oyees	Empl	oyees	Employees with Disabilities						
			Emplo	yees at	Empl	oyees											
			Manag	gement	at N	Von-											
			le	vel	Manag	gement											
					le	vel											
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female					
a) Safety	26013	126	102	0	25911	126	-	-	-	-	-	-					
b) Skill Upgradation	41874	366	1764	764 24 40		342	-	-	-	-	-	-					
c) Others	16597	241	931	4	15665	236	-	-	-	-	-	-					

Principle 4: Businesses should respect the interests of, and be responsive to the needs of all stakeholders, especially those who are disadvantage vulnerable, and marginalized.

1. Has the Company mapped its internal and external stakeholders? Yes/No

Yes, UPL has identified and mapped all its stakeholders

2. Out of the above, has the Company identified the disadvantaged, vulnerable & marginalized stakeholders?

Yes, UPL has identified its disadvantaged, vulnerable & marginalized stakeholders.

3. Are there any special initiatives taken by the Company to engage with the disadvantaged, vulnerable, and marginalized stakeholders? If so, provide details thereof, in about 50 words or so.

Yes, the Company has taken initiatives to engage with its disadvantaged, vulnerable and marginalized stakeholders through its Corporate Social Responsibility projects. The initiatives are planned and focused to generate livelihoods in a sustainable way for the targeted groups of Small farmers, Unemployed youth and Poor women. The Company focus on three development parameters, which are;

- 1. Agriculture development
- 2. Skill development
- 3. Entrepreneurship

Principle 5: Businesses should respect and promote human rights

1. Does the policy of the Company on human rights cover only the Company or extend to the Group/Joint Ventures/Suppliers/Contractors/NGOs/Others?

Yes, the human rights policy is applicable to the contractors associated with UPL limited.

UPL has policies on Human Rights which are very robust and stringently followed by our stakeholders.

These policies are for the protection of dignity and selfrespect of our stakeholders and focus on to provide a harassment free work culture. The Company has adopted a fair culture and encourages its stakeholders to utilize our grievance redressal mechanisms which is accessible to all. This helps us to resolve the grievances with top scrutiny and urgency.

The Company eludes all kind of discrimination based on the gender, caste, creed, religion, disability, marital status, pregnancy, culture, ancestry, socioeconomic status etc.

2. How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management?

As part of our policy, we have ethics committee, chaired by the principal ethics Counsellor with sub committees at every plant to redress any violation pertaining to human rights. No complaint received during the reporting period.

Principle 6: Business should respect, protect, and make efforts to restore the environment

1. Does the policy related to Principle 6 cover only the Company or extends to the Group/Joint Ventures/ Suppliers/Contractors/NGOs/others.

Yes, the environmental policy of the Company is applicable to group, joint venture, vendors & contractors.

2. Does the Company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc? Y/N. If yes, please give hyperlink for webpage etc.

Yes, UPL has undertaken several initiatives to address issues related to climate change. To know more details please prefer our Annual Sustainability report and excusive sustainability website on following link: http:// sustainability.upl-ltd.com/

3. Does the Company identify and assess potential environmental risks? Y/N

Yes

4. Does the Company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if Yes, whether any environmental compliance report is filed?

Yes, UPL had undertaken the project of fuel change from Naptha to Natural Gas at power plant. The Company also got registered under CDM.

5. Has the Company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc. Y/N. If yes, please give hyperlink for web page etc.

Yes, the Company has taken various initiatives to make its processes clean and energy efficient, details are as mentioned below;

- 1. Clean technology adopted for manufacturing
 - Membrane cell Technology for caustic chlorine manufacturing
 - CS2 manufacturing using natural gas
 - Use of natural gas in Boiler
 - Recycle of steam condensate
 - Installed water recycling system (RO) & water recycled in to process
 - MDC residue (Spent solvent) Sold to recyclers / end users
 - Use of energy efficient LED lighting system across UPL sites
- 2. Recovery of products from Waste streams
 - Sodium sulphate from waste ML
 - NaSH from H2S scrubber
 - Calcium chloride, ammonia and di calcium phosphate sludge from ML
 - Recovery of Sodium Sulphate from effluent
 - Recovery of HNO3 & H2SO4 from ML
 - Manufacture NaSH as by-product from CS2 plant by utilizing excess H2S gas which was previously sent for thermal destruction in TGTU
 - Mn(OH)2 recovered from ML
 - Recycle of drums for packaging
- 6. Are the Emissions/Waste generated by the Company within the permissible limits given by CPCB/SPCB for the financial year being reported?

UPL always monitors its waste generation limits, this helps the Company to ensure that generated waste is within the limits provided by Central Pollution Control Board (CPCB)/ State Pollution Control Board (SPCB).

7. Number of show cause/ legal notices received from CPCB/SPCB which are pending (i.e. not resolved to satisfaction) as on end of Financial Year.

Principle 7: Businesses, when engaged in influencing public and regulatory policy, should do so in a responsible

1. Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with:

Yes, the Company is member of various trade associations and chambers which helps UPL to identify and understand the common concerns of the business and its impacts on the communities. UPL is currently a part of the following associations:

- Vapi Industrial Association
- II. Indian Merchant Chambers
- III. Crop Care Federation of India
- IV. Asmechem
- V. Centigro Environment of Agriculture
- VI. CII
- 2. Have you advocated/lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas (drop box: Governance and Administration, Economic Reforms, Inclusive Development Policies, Energy security, Water, Food Security, Sustainable Business Principles, Others)

Yes, the Company lobbies with industry association and also with Government bodies to resolve the issues related to chemical and pesticide industry. UPL gets actively involved at industry forums and with Ministry through meetings and dialogues providing valuable suggestions favoring business and public good.

Company has lobbied or advocated through public associations on the below topics:

- Problems of Chemical Industries in Gujarat and
- II. Customs and Excise laws effecting faster industrial development
- III. Environment and pollution matters
- IV. Agriculture and Agro Chemical inputs
- V. Fight against foreign funded NGO's
- VI. Promoting and educating public about advantage of scientific agriculture and use of agro chemicals
- VII. Other matters connected with government policy "Make in India"

VIII. Removal of hurdles and exports

Principle 8: Businesses should support inclusive growth and equitable development

1. Does the Company have specified programmes/ initiatives/projects in pursuit of the policy related to Principle 8? If yes details thereof.

UPL Philosophy always believes in holistic and sustainable growth of society. Three simple words, which lie at the core of the UPL philosophy (Doing Things Better), have been the guiding force in all our community interventions. All our CSR programs are determined with the trust that humankind is one community, where each member is responsible for the wellbeing of the other, hence our interventions are not restricted to the development of our neighboring communities only. We work on programs that cater to the wider national interest, our CSR efforts are focused in Gujarat and they have also touched lives in many other states including Maharashtra, West Bengal, Kashmir, Tamil Nadu and Himachal Pradesh.

Our commitment and interventions cater all the segment of the society and have been classified in 4 focus areas, they are:

- Institutions for Nation Buildings
- Sustainable Livelihoods
- Nature Conservation
- Local and National Needs

For more detail's login to https://www.upl-ltd.com/ sustainability

2. Are the programmes/projects undertaken through in-house team/own foundation/external NGO/ government structures/any other organization?

Yes, the Company has a dedicated in-house experienced CSR team/ UPL promoted foundation to make the blueprint and execute the CSR programmes. UPL also engages with third parties, Government organizations, NGO's and CBO's to perform specific programmes based on community needs and requirements.

3. Have you done any impact assessment of your initiative?

Yes, the Company conducts third-party impact assessment for all the CSR initiatives to measure the long-term impact of the interventions in a period of three years. Lately, the Company has conducted the study in 2016 where the results were very encouraging both at the macro and micro level. Few highlights of the assessment are pointed as below:

- a. Impact on Financial wellbeing of neighboring community:
 - i. Under skill development initiatives, an average monthly income of youth in the region increased from ₹4,750 to ₹7,750 after getting trained from the center and getting gainfully employed. which is an increment of 63%.
 - ii. Under women empowerment program, the study found that an average monthly income of an SHG member is ₹3,155 as compared to a non SHG members ₹1,500, where both were engaging in income generation activity.
 - iii. Under skill based entrepreneurial development program, an average monthly income

- increased from ₹1,240 to ₹2,060 after getting trained, which is an increment of 66%.
- iv. 18% increase in land productivity there by improving the profitability from paddy farming. Profits per acre from paddy increased from ₹ 1,472 to ₹3,199 after SRI application.
- v. Under the initiative of Kitchen Garden development, weekly expense on green vegetables reduced from ₹146 to ₹99 after the interventions.
- vi. The average monthly income of a nursing graduate of Sandra Shroff ROFEL College of Nursing, Vapi is ₹23,200 as compared to that of a simple graduate who gainfully employed ₹14,333/

b. Impact on Socio Cultural Environment

- Women members experience enhances selfreliance, self-expression and advocacy, 100% of the women have advocated the program to others and have successfully enrolled more women in to SHGs. All the SHGs have experienced an increase in decision making powers in social and economic domains.
- ii. 67% students feel more empowered to take decisions, while 44% felt their social status has improved after graduating from SRICT.

c. Impact on Human Resource Development

- i. 69% of the youth experienced improvement in knowledge and skills at the skill development institute.
- ii. 100% respondent children know the important of wearing footwear, washing hands, using dustbins and brushing teeth under School Sanitation program.
- iii. 56% members improved their skills, 31% improved their knowledge and 13% experienced enhanced confidence in Valsad under women empowerment initiatives.

Additionally, the in-house team conducts need assessment survey before execution of the programmes/ projects and performs regular internal monitoring to validate the initiative in between.

4. What is your company's direct contribution to community development projects Amount in INR and the details of the projects undertaken.

Direct contribution to community development projects is ₹ 18.00 crores which is 4.4 % of profit after tax.

Our CSR footprint in India

- 1. Gujarat
 - Vapi Cluster
 - Dang Cluster
 - Ankleshwar Cluster (Bharuch)
 - Jhagadia Cluster (Bharuch)
 - Dahej Cluster (Bharuch)
 - Vandri Cluster (Narmada)



2. Maharashtra

- Mumbai Cluster
- Marathwada Cluster



3. Other parts of country

- Samba in Jammu
- Haldia in West Bengal
- Tiruvarur in Tamil Nadu
- Kullu in Himachal Pradesh

Efforts and impacts at a glace

Sustainable livelihoods - through agriculture interventions

UPL Agriculture Development @ Dang

5 years

45 villages

20 farmer groups

2,050 farmers



UPL Agriculture Development @ Ankleshwar

4 years

14 villages

18 farmer groups

276 farmers



UPL Agriculture Development @ Jhagadia

4 years

13 villages

9 farmer groups

145 farmers



UPL Agriculture Development @ Vapi

3 years

10 villages

10 farmer groups

200 farmers



UPL AKRSP(I) SRI

6 years

25 villages

1,500 farmers



Livelihood Enhancement of Tribals (Waghai block)

2 years

2 villages



UPL BoriBagicha

4 years

58 villages

2,191 farmers



Animal Husbandry

3 years

21 villages

185 households

1,992 artificial insemination



Agriculture Market Linkage 1 year (pilot phase)



UPL Agriculture Development @ Vandri

3 Years

4 Villages

436 Farmers



UPL Centre for Agriculture Excellence 17 Years 15181 Farmers





Sustainable livelihood through skill development of youth and women

UPL Niyojaniy (Skill development program for dropouts)

5 Years

1327 Youth Trained

798 Placed in Industries



Skill Based Entrepreneurial Development Program 5 Years 1054 Participants trained



UPL Udyamita

5 Years

113 SHGs

36 Villages

1364 Women Members



Establishment of Micro-Enterprise

4 Micro-Enterprise

58 Members



Environment and Nature Conservation (UPL VASUDHA)

Eco Club Project

Eco Club 5 Years

85 Eco Clubs

11821 members



Sarus Conservation Project, Kheda

4 Years

36 Villages

11997 Students

2306 Villagers

726 Sarus Officially Documented in Kheda



UPL Social Forestry

3 Years

84633 Saplings Planted

1,20,000 Mangroves Planted



Green Ganesha Workshop

4 Years

77 Schools

8590 Students



Water Conservation/ Resource Development Activities

- 1 Year
- 7 Group Wells,
- 2 Check dam
- 5 Deepening Ponds
- 25812 Cubic meter water conserved



Projects of Local and National Interests UPL School Sanitation

- 4 years
- 47 school sanitation blocks built
- 9,225 students are using the facility regularly
- 3,000 commuters/ day are using the facility



Safety Trainings

5 years

37,415 participants trained



UPL Unnati

- 3 years
- 9 Community Based Organizations empowered



United Against Child Labour

- 1 year
- 131 volunteers associated
- 3,010 growers made aware



Support to Motihari Farmer Producer Company(FPC)

10 FPCs formed

3,000 farmer members



Global Parli

3 years

106 villages

726 farmers



Vandri Cluster Development

3 years

4 villages

436 farmer families



UPL Deer & Ungulate Breeding Project

1 Year



Project "Asptal" - Mobile Medical Service at Hamirpur, Himachal Pradesh

1 Year

1 Medical Unit



Support to Seva Yagna Samiti, Bharuch for Neonatal Care

2 Years

198 new-born treated



Employee Engagement Program of UPL (We are United)

Financial Year	No. of volunteers	Volunteer Hours	Man-days devoted for Community Development Program
2014-2015	102	2727	341
2015-2016	152	3871	484
2016-2017	123	3866	483
2017-2018	125	3023	378
2018-2019	147	4863	608
Total		18350	2294



Institutions for Nation Building:

Smt. Sandraben Shroff GnyanDham School, Vapi 46 years

1600 students/year



5. Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so.

Our approaches of CSR initiatives emphasis on community participation in all stages of the project cycle. All our interventions focus on the needs, strengths and growth of the community. The below diagram explains the approaches, we adopt to implement any interventions





Figure: 1. Left above-Net Planning with community, 2. Right above-Transect walk -PRA, 3 & 4: Below Left & Right: Technical Survey and physical verification at ground (at Vandri)

Multiple interventions have been designed and implemented in Dang district to provide sustainable livelihood through improved agricultural practices, where all the interventions were planned and implemented with the support of farmers groups at the village level.

In Vandri Cluster development program, each activity was implemented through community from planning to final execution. It was ensured that the communities were involved in planning, procuring, implementing and ensuring quality of work implementation. Apart from their participation, they also contributed financially/through labour for individual work (25 %) and community work (10%). The whole project owned by the community at Vandri.

Principle 9: Businesses should engage with and provide value to their customers and consumers in a responsible manner

1. What percentage of customer complaints/consumer cases are pending as on the end of financial year.

AT UPL, several internal mechanisms have been devised to track and attend to any consumer/customer complaints that arise. ERP systems track any complaint entered from the front -end sales team and ensure auto escalation if the same is not addressed expeditiously.

2. Does the Company display product information on the product label, over and above what is mandated as per local laws? Yes/No/N.A. /Remarks(additional information)

UPL is a responsible corporate and our product labels display all information that is essential to ensure safe and efficacious use of our products. Product labels are compliant with all CIB regulations and legal metrology guidelines.

3. Is there any case filed by any stakeholder against the Company regarding unfair trade practices, irresponsible advertising and/or anti-competitive behavior during the last five years and pending as on end of financial year. If so, provide details thereof, in about 50 words or so.

No such cases were filed against the Company.

4. Did your company carry out any consumer survey/ consumer satisfaction trends?

The Company strives to meet customer needs and

provide best possible solutions to help them tide of their agriculture problems. Customer/consumer feedback is taken on a regular basis by deploying different kinds of surveys.

Both inhouse surveys as well as third party surveys through market research agencies were carried out. Internal surveys focussed mainly on dealer and farmer satisfaction and insights on need gaps.

An inhouse Survey with customers was carried out as a part of the manufacturing excellence by the factory team in Punjab, Haryana, Gujarat, Maharashtra to understand satisfaction with UPL products and services in terms of quality of packaging, delivery and product efficacy. The survey revealed high levels of satisfaction. Some shortcomings that were identified were acted upon systematically in a phase wise manner.

Inhouse customer surveys are also done by UPL Adarsha Kisan Center on regular basis with Farmer and Dealer to understand satisfaction levels and concerns if any.

The Company has its call centers at various locations in India like Mumbai, Visakhapatnam and Chandigarh under the brand of "Adarsh Kisan Center" (AKC). Our customers can connect with us through a toll-free number provided on all product packaging, they can lodge a complaint against any of our products or services as well. All the gueries and complaints from customers are taken on priority and resolved. In case if a customer requires further assistance, the case is escalated to the field executive team of UPL, a person from our field team visits the location and resolves the issue personally. We use our call centers to take feedback from registered farmers at AKC, this scope of survey is broad which includes product availability, usage and market access of harvest.

External Surveys through Market Research agencies were done with farmers to understand insights on product usage, need gaps, and farmer satisfaction. Quality, ease of use, value for money when compared to competing brands were also measured.

Statement of AOC 1 Form

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries

Part A Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in $\ensuremath{\mathfrak{F}}$)

Amount in crores (₹)

Proposed | % of share-100% 78% 78% 100% 100% 100% 78% 78% 78% 78% 78% 78% 100% 78% 78% 78% 78% 78% 78% holding Dividend (14) 25 (0) 24 24 (0) (0) 13 0 12 4 (12) 4 1 5 9 (5) (10)0 Profit after taxation Provision taxation (6) 21) (2) (9) LO (2) 0 0 8 (8) 3 9 5 for taxation Profit 0 0 (109) before 32 17 32 (16) 0 (15) 19 20 21 (3) 31 0 4 1,583 410 Turnover 207 634 132 364 285 Investments (excluding investments subsidiaries) 23 68 made in Liabilities 0 13,357 6,804 2,015 468 132 310 269 68 30 549 321 121 Total 577 605 465 33 43 18,421 13,694 6,438 29 170 3,130 332 127 133 assets Total Reserves & 2,910 63 57 101 35 0 88 0 (108) 4,447 0 37 231 24 surplus Share 0 4,178 0 0 0 0 67 103 2 capital 6,998 29 Exchange 00.1 18.05 99.77 27.66 77.66 77.66 77.66 77.66 77.66 77.66 1.00 1.00 1.00 77.66 77.66 77.66 77.66 77.66 77.66 77.66 Closing Rate) rate Reporting currency PLN EUR EUR EUR EUR EUR EUR EUR R R EUR EUR EUR INR INR INR Reporting period for the subsidiary reporting period different from the holding company's **Jnited Phosphorus Holdings** United Phosphorus Holdings United Phosphorus Holding, Decco Iberica Postcosecha, SWAL Corporation Limited United Phosphorus (India) United Phosphorus Globa Shroffs United Chemicals JPL Deutschland GmbH Transterra Invest, S. L. U. Optima Farm Solutions Decco Worldwide Post-Post-Harvest Holdings Harvest Holdings B.V. JPL Europe Limited Name of Subsidiary JPL Polska Sp z.o.o. Decco Worldwide JPL Benelux B.V. Cooperatief U.A. Cooperatief U.A. UPL Italia S.R.L. Cerexagri S.A.S. JPL Iberia, S.A. Cerexagri B.V. Blue Star B.V. Neo-Fog S.A. Brazil B.V. imited Sr. $\frac{1}{3}$ 7 16 10 $\;\; \stackrel{\smile}{\vdash} \;\;$ 178 20 21 22 22 9 / 8 0

Amount in crores (₹) Proposed % of share-78% 78% 78% 55% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% Dividend (113) 2 (8) 22 0 8 7 0 (9) 22 385 27 523 (8) (4) (75) Profit after taxation Provision taxation € ± 4 55 3 6 0 0 for taxation 0 4 (2) Profit 22 (214) 31 0 (5,924)2 (8) before 27 **⊗** 4 (89) (168)(9) Turnover 3,617 4,446 166 31 2,802 487 356 128 ,692 188 332 70 Investments subsidiaries) 4 investments (excluding made in Liabilities 0 4 0 8,978 5,587 622 0 24 63 131 411 237 113 122 38 Total Total assets 0 121 3 73 76 10,996 7,248 225 106 414 251 ,021 Reserves & 19 84 0 41 (6) (4,680)2,957 355 (5) 11,301 157 (42) surplus 0 0 0 23 227 E 80 E 0 capital 1,908 1,306 27 Exchange 69.16 69.16 69.16 69.16 69.16 69.16 69.16 69.16 69.16 69.16 77.66 77.66 69.16 59.16 69.44 1.07 77.66 10.01 (Closing 0.01 rate Rate) Reporting currency EUR CHF DKK EUR RUB CRC BOB PYG USD BRL JSD BRL Reporting period for the subsidiary reporting period concerned, if different from the holding company's Decco Portugal Post Harvest, **DVA Technology Argentina** Decco US Post-Harvest Inc -imited Liability Company Unipessoal LDA (formerly **Decco Jifkins Mexico Sapi** JPL Corporation Limited JPL Management DMCC Riceco International, Inc. Jnited Phosphorus Inc. Perrey Participações S.A e Comércio de Insumos known as UPL Portugal Comercio de Produtos Jpl do Brasil Industria JPL Agro S.A. de C.V. Uniphos Industria e Name of Subsidiary **Jnited Phosphorus** Switzerland Limited Cerexagri, Inc. (PA) Agropecuários S.A. JPL Costa Rica S.A. JPL Argentina S A JPL Delaware, Inc. JPL Paraguay S.A. cona Sanluis S.A. Jnipessoal LDA) JPI Finance LLC JPL Bolivia S.R.L Decco Chile SpA Decco Italia SRL Canegrass LLC Quimicos Ltda. Agrodan, ApS JPL Limited **Essentiv LCC** JPL Limited RiceCo LLC Sr. No. 23 25 26 27 28 29 30 30 31 32 33 33 34 44 44 44 45 45 46 44 48 49 50 51

% of share-holding	78%	78%	78%	78%	78%	78%	25%	78%	78%	78%	78%	78%	78%	78%	43%	78%	78%	78%	78%	ı	78%	20%	78%	78%	78%	700%	780%	7.0%	%8/	78%	78%	78%	78%
Dividend proposed pro	,	ı			1		ı	1	1	1	1	1	1	ı	1	1	1	ı	1	1		ı	,	ı	1		1	1	1	1	ı	1	ı
Profit after taxation	(13)	(15)	4	7	0	1	ı	(2)	(4)	2	24	_	25	(45)	2	(32)	(29)	(12)	_	1	(3)	(0)	(36)	(14)	ı	7	C/	(6)	(83)	(80)	46	109	0
Provision for taxation	(2)	ĽΩ	1	(2)	0)	1	1	1	1	(3)	(0)	(1)	(9)	(1)	(1)	7	7	(1)	_	'		1	(8)	1	1	Ć	(c)	'	1	1	(17)	(27)	ı
Profit before taxation	(11)	(20)	4	∞	_	1	1	(2)	(4)	9	24	_	31	(44)	9	(42)	(31)	(12)	0	'	(3)	(0)	(28)	(14)	ı	712	0 (1)	(c)	(83)	(80)	63	136	0)
Turnover	174	385	1	120	9	1	1	2	70	72	744	66	237	207	34	247	16	35	35	,	0	1	,	4	ı	000	502	70 6	133	200	259	432	1
Investments (excluding investments made in subsidiaries)	1	1	1	1	1	1	1	1	ı	1	ı	ı	ı	82	1	ı	1	1	1	1	1	2	1	1	1		ı	7	061	1	20	ı	ı
Total Liabilities	199	640	35	51	0		1	6	73	78	435	97	113	3,020	5	222	43	37	31	,	2	0	1,415	20	ı	000	900	y (200	239	74	153	0
Total	194	969	47	94	4	1	1	6	74	67	289	104	223	6,965	35	300	29	29	27	'	2	_	2,012	391	ı	000	000,1	107	987	181	301	547	156
Reserves & surplus	(9)	56	12	42	8		1	0	_	(11)	252	M	105	4,022	22	(40)	(24)	30	(4)	,	(0)	_	367	341	1	000	000	+C-	(294)	(122)	252	381	156
Share	_	1	0	0	0	1	ı	0	0	_	0	4	4	9	∞	118	10	ı	0	1	1	2	230	0	1	7	0 -	1 -	/ XX	63	25	13	0
Exchange rate (Closing Rate)	21.78	69.16	69.16	49.05	47.02	10.30	10.30	0.06	4.86	4.86	69.16	1.31	2.98	62.44	10.30	12.26	12.26	19.05	4.76	0.12	19.05	1.00	77.66	77.66	69.16	7	1000	0.00	17.75	1.59	49.05	2.18	2.18
Reporting currency	COP	USD	OSD	AUD	NZD	RMB	RMB	KRW	IDR	IDR	OSD	PHP	NN	ЪY	RMB	TRY	TRY	ILS	ZAR	XOF	ILS	INR	EUR	EUR	USD	_	0.00	7	DXL	ARS	AUD	THB	THB
Reporting period for the subsidiary concerned, if different from the holding company's reporting period																																	
Name of Subsidiary	UPL Colombia SAS	United Phosphorus Cayman Limited	UP Aviation Limited	UPL Australia Limited	UPL New Zealand Limited	UPL Shanghai Limited	UPL Jiangsu Limited	UPL Limited (Korea)	PT.UPL Indonesia	PT Catur Agrodaya Mandiri	UPL Limited	UPL Philippines Inc.	UPL Vietnam Co. Limited	UPL Limited, Japan	Anning Decco Fine Chemical Co. Limited	UPL Ziraat Ve Kimya Sanayi Ve Ticaret Limited Sirketi	UPL Agromed Tarim Ilaclari ve Tohumculuk Sanayi ve Ticaret A.S.	Safepack Products Limited	Citrashine (Pty) Ltd	UPL Africa SARL	Prolong Limited	Agrinet Solutions Limited	Advanta Holdings B.V.	Advanta Netherlands Holding B.V.	Advanta US LLC (formerly	Known as Advanta U.S. Inc.)	Advanta Seeds Illellladollal	Advanta seeds DIVICO	Advanta Comercio De Sementes LTDA.	Advanta Semillas SAIC	Advanta Seeds Pty Ltd	Pacific Seeds (Thai) Limited	Pacific Seeds Holdings (Thailand) Limited
Sr. No.	54	55	26		28	59	09				64		99	29	89	69	70		72	73		_		1	78	2			-	82			82

Amount in crores (₹) Proposed % of share-78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% %89 78% 78% holding Dividend 3 (2) 412 0 m 9 4 2 92 0 4 m 0 9 0 0 4 (13) 0 _ Profit after taxation Provision taxation \subseteq . . \equiv \subseteq 0 7 0 (10 (3) (2) 0 4 (5)(5) 0 for taxation Profit before 3 (2) 412 o 4 36 0 4 0 4 0 (16) 73 0 (9) 10) (46) 83 2,488 Turnover 33 90 136 39 82 46 59 45 157 Investments subsidiaries) 27 0 investments (excluding made in Liabilities 0 29 83 210 ,825 99 0 121 182 650 505 154 12 36 1,291 Total 256 117 2,917 373 \sim 53 36 129 758 317 897 _ assets Total Reserves & 241 (20) 0 28 (37) 74 32 135 (9/) 534 (3) 267 523 \subseteq \equiv surplus 0 0 0 99 0 capital 3 44 220 349 699 256 Exchange 69.16 16.94 77.66 77.66 77.66 4.86 10.30 3.58 3.58 0.11 (Closing rate Rate) Reporting currency $\mathbb{M} \mathbb{Y} \mathbb{R}$ EUR EUR USD RMB IDR UAH USD USD $\stackrel{\times}{\mathbb{Z}}$ ZΧΣ ZAR JSD BDT TRY BRL BRL CRC for the subsidiary Reporting period reporting period concerned, if different from the holding company's Arysta LifeScience Iberia SLU Arysta LifeScience (Mauritius) Formely known as UPL Agro Grupo Bioquimico Mexicano, Arysta LifeScience Argentina PT Advanta Seeds Indonesia Arysta LifeScience Colombia Advanta Seeds Ukraine LLC Arysta LifeScience Australia Arysta LifeScience Chile S.A. Jniphos Malaysia Sdn Bhd Arysta Lifescience Italia SrL Anysta LifeScience Benelux Brasil Indústria Química e Defensivos Agricolas Ltda Decco Gıda Tarım ve Zirai Arysta LifeScience France Arysta LifeScience Mexico, Anysta LifeScience South industria e Comercio de Arysta LifeScience Costa MacDermid (Shanghai) JPL Limited Mauritius Arysta LifeScience do Volcano Agrociencia Name of Subsidiary Riceco International Ürünler San. Tic A.S. .imited Mauritius) Agropecuária SA Bangladesh Ltd Africa (Pty) Ltd Chemical Ltd. ANESA S.A. S.A.de C.V 100 102 103 105 106 107 108 101 ۶. S 66 88 89 96 92 93 96 97

Amount in crores (₹) Proposed % of share-78% Dividend 35 (80) 9 9 10 4 0 \equiv 0 6 \subseteq 31 0 0 0 39) taxation Profit after Provision for taxation \equiv 0 0 0 4 (2) 6 0 Profit before taxation (39) 10 0 0 35 0 (80) 39 0 0 4 \equiv 6 52 8 0 53 22 22 Turnover Investments subsidiaries) investments (excluding made in ,081 Liabilities 2,156 2,335 6,658 0 600 108 ,398 733 \sim 0 19 32 2,974 6,276 120 1,193 389 10,511 1,056 315 11,382 5,004 6,657 4.959 42 594 assets Total 161 Reserves & (387) \subseteq (375)(167) \equiv (266)2,562 3,737 52 234 10 86 (106)000 363) 199 131 surplus 4,108 0 . 0 4 capital 1,193 19 54 4,867 4,950 6,645 4,872 61 1,291 923 680 248 Exchange 69.16 69.16 51.56 69.16 77.66 77.66 77.66 62.44 90.64 90.64 69.16 77.66 77.66 77.66 77.66 77.66 77.66 (Closing 16.31 rate Reporting currency EUR EUR EUR EUR RON SAD EUR EUR EUR EUR EUR EUR GBP OSD USD JSD GBP JSD BGN Pγ for the subsidiary Reporting period reporting period concerned, if different from the holding company's Arysta LifeScience European Platform Sales Suisse GmbH Arysta LifeScience Romania Arysta LifeScience U.K. CAD Arysta LifeScience U.K. USD Arysta LifeScience U.K. EUR Anysta LifeScience Bulgaria Arysta LifeScience U.K. JPY Arysta LifeScience Global Netherlands Agricultural Arysta LifeScience Great MacDermid Agricultural Solutions Netherlands MacDermid Agricultural MacDermid Agricultural Natural Plant Protection Anysta Lifescience U.K. Solutions Holdings BV Arysta LifeScience U.K. Investments Limited Name of Subsidiary Santamix Iberica SL Anysta LifeScience Arysta LifeScience **Dutch Agricultural** Solutions Italy Srl Holdings Limited **Technologies CV** Veto-Pharma SA Netherlands BV **Cooperatief UA** Formations CV Technology BV Wyjolab S.A. **Britain Ltd** imited Limited imited _imited 132 133 135 136 137 8 139 140 142 143 145 134 14 4 146 147 148 149 150 152 153 154

Sr. No.

Amount in crores (₹)	% of share- holding	78%	78%	78%	78%	51%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%	78%
Amount	Proposed Dividend	1	1	,	•	,		1	1	1	1	1	1	,	1	1	1	ı	1	1	1	1	1	1	1	1
	Profit after taxation	(/)	(1)	19	2	0)	(0)	m	7	(E)	15	-	17	1	1	1	1		-	m	1	1	1	_	'	(0)
	Provision for taxation	(3)	'	(8)	$^{\circ}$	1	ı	(1)	(0)	(1)	M	(0)	m	'	'	1	,		4	5	1	ı	1	1	1	0
	Profit before taxation	(4)	(1)	28	(1)	(0)	(0)	4	7	0)	18	2	20	1	'	,	1		7	(2)	'	1	1	_	'	(0)
	Turnover	ı	1	57	15	_	1	22	41	ı	99	10	31		1	1	1		84	7	1	1	1	<u></u>	1	1
	Investments (excluding investments made in subsidiaries)	1	1	0	ı	1	1	1	0	1	1	1	ı	ı	1	1	ı	ı	1	ı	1	1	1	ı	1	1
	Total Liabilities	587	98	110	24	_	12	33	99	28	225	25	114	1	1	•	1	,	515	1,691	,	'	,	0	•	13
	Total	871	287	240	173	5	12	09	116	0	359	33	154	0	1	1	0	1	1,866	2,663	1	1	m	49	1	89
	Reserves & surplus	(97)	108	113	136	M	(0)	25	46	(47)	82	N	39	0	1	1	,	ı	431	972	,	'	,	2	1	(265)
	Share	381	93	17	14	2	0	2	m	28	53	7	0	0	'	1	0	1	920	1	1	1	m	46	1	319
	Exchange rate (Closing Rate)	77.66	77.66	77.66	77.66	77.66	77.66	3.01	0.24	1.07	1.07	77.66	2.54	2.54	69.16	69.16	69.16	69.16	51.56	51.56	69.16	69.16	69.16	69.16	69.16	3.58
	Reporting currency	EUR	EUR	EUR	EUR	EUR	EUR	CZK	HUH	RUB	RUB	EUR	NAH	NAH	OSD	USD	OSD	OSD	CAD	CAD	USD	OSD	OSD	OSD	OSD	NXW
	Reporting period for the subsidiary concerned, if different from the holding company's reporting period																									
	Name of Subsidiary	Arysta LifeScience Holdings France SAS	Goëmar Développement SAS	Laboratoires Goëmar SAS	Anysta Animal Health SAS	Betel Reunion S.A.	Arysta LifeScience Europe Sarl	Arysta LifeScience Czech s.r.o.	Arysta LifeScience Magyarorszag Kft.	Arysta LifeScience Vostok Ltd.	Arysta LifeScience RUS LLC	Arysta LifeScience Slovakia S.R.O.	Arysta LifeScience Ukraine LLC	Arysta LifeScience Kiev LLC	Anysta LifeScience Inc.	Arysta LifeScience Management Company, LLC	Arvsta LifeScience SPC, LLC	Arysta LifeScience America Inc	Arysta LifeScience Canada, Inc	Anysta LifeScience Canada BC Inc.	Anysta LifeScience North America, LLC	Anysta LifeScience NA Holding LLC	Dutch Agricultural Investment Partners LLC	Netherlands Agricultural Investment Partners LLC	Anysta LifeScience Investments LLC	Arysta LifeScience Mexico Holding S.A.de C.V
	Sr. No.	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179

Amount in crores (₹) Proposed % of share-78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% Dividend 4 0 0 0 0 0 (3) \sim 0 \equiv © € \subseteq 0 0 (2) Profit after taxation Provision for taxation 0 0 0 0 \equiv 0 ' 0 0 0 Profit before taxation 9 0 2 0 0 (0) \sim (3) \equiv \subseteq 0 © E \subseteq 0 (2) - 1 0 ' Turnover 4 Investments subsidiaries) investments (excluding made in Liabilities - 0 24 0 € ∞ S 46 114 36 29 12 9 89 10 0 23 3 86 Total Total assets 0 71 7 27 19 94 57 35 48 96 63 4 4 10 4 84 17 6 93 Reserves & 16 12 0 84 0 5 13) 67 (20)7 45 93 surplus 0 0 0 9 0 3 0 0 7 0 - 0 0 capital 16 \sim 9 Ŋ 29 Exchange 4.76 47.02 0.06 3.58 3.58 3.58 3.58 3.58 2.18 1.09 2.98 (Closing 1.31 rate Rate) Reporting currency Z Z X X \mathbb{X} XX $\stackrel{\times}{\times}$ X $\stackrel{\times}{\times}$ GTO NZD CNY KRW PKR THB IDR MZN ZAR ZAR JSD JSD TRY for the subsidiary Reporting period reporting period concerned, if different from the holding company's Farim Urunleri Limited Sirketi Agroquimicos y Semillas, S.A Anysta LifeScience Korea Ltd. Arysta LifeScience (Thailand) Tesaurus Mexico S.A. de C.V. Arysta LifeScience Paraguay Myanmar Arysta LifeScience Etec Crop Solutions Limited Anysta LifeScience Holdings Arysta LifeScience Pakistan Omega Agroindustrial, S.A. Tecno Extractos Vegetales, Arysta LifeScience Vietnam Anysta LifeScience Asia Pte. Pt. Anysta LifeScience Tirta Desarrollos Inmobiliarios Anchorprops 39 (Pty) Ltd Arysta LifeScience Turkey Alianza de Coahuila, S.A. Chemtura (Thailand) Ltd Bioenzymas S.A. de C.V. Arysta LifeScience de MacDermid (Nanjing) Mundiales SA de CV Name of Subsidiary Servicios Agricolas Agrifocus Limitada Anysta LifeScience Guatemala, S.A. Philippines Inc. Chemical Ltd. S.A. de C.V. Pvt.) LTD. Co., Ltd. 180 185 186 187 88 189 201 202 203 182 183 184 191 193 194 195 196 197 198 199 200 Sr. No.

5. Manne of Subporting Particle Reporting Particle Standard Subporting Particle Reporting Particle Standard Subporting Particle Particle Subport															Amount	Amount in crores (₹)
Californian Processments (PA) A26 A26 O 124 131 A27 O 124 A26 O O O O O O O O O	Sr. No.	Name of Subsidiary	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Reporting	Exchange rate (Closing Rate)	Share capital	Reserves & surplus	Total	Total Liabilities	Investments (excluding investments made in subsidiaries)	Turnover	Profit before taxation	Provision for taxation	Profit after taxation	Proposed Dividend	% of share-holding
Obstation Agricoleme (Phy) 2AR 476 124 151 37 110 2A 1 124 151 37 110 2A 1 2 1 1 2 1 1 2 1 1 2 1 1 2 2 1 1 2<	204	Callietha Investments (Pty)		ZAR	4.76	0	16	23	7	1	1	1	1	1	ı	78%
Application of Application o	205	Volcano Agroscience (Pty) Ltd		ZAR	4.76	0	124	151	37	10	42	<u></u>	(1)	<u></u>	1	78%
Sidewalk Trading Pay List A 778 a 1	206	Volcano Chemicals (Pty) Ltd		ZAR	4.76	0	0	0	,	1	,	1	1	,	1	78%
Ayşa LifeScience Tanzaria (1971) Ayşa L	207	Kempton Chemicals (Pty) Ltd		ZAR	4.76	1		1	1	1	1	1	1	1	1	78%
Ayysa UreSelence Renyal Let RES 0.69 0.6 6.3 4.7 1.2 2 (0) 1.1 2 1.0 1.1 2 1.0 1.1 1.0	208	Sidewalk Trading (Pty) Ltd		ZAR	4.76	0	(0)	0	0	1	1	(0)	1	(0)	1	78%
Ayysta Utécidence Gapartital TGS QQB 15 15 15 15 15 15 15 15 17 2 00 00 10 10 10 Ayysta Utécidence Egypt Ltal EGP 3.29 1 2 3 1 0 00 00 0 0 Ayysta Utécidence Togo SAU GHE 12.29 1 (10) 23 3 1 0	209	Arysta LifeScience Kenya Ltd.		KES	0.69	0	9	53	47	1	12	2	(0)	_	1	78%
Ayysta LifeScience EgyptLid EGP 339 1 1 3 1 2 1 2 0 <t< td=""><td>210</td><td>Arysta LifeScience Tanzania Ltd</td><td></td><td>SZL</td><td>0.03</td><td>0</td><td>(3)</td><td>15</td><td>17</td><td>1</td><td>2</td><td>(0)</td><td>(0)</td><td>(1)</td><td>1</td><td>78%</td></t<>	210	Arysta LifeScience Tanzania Ltd		SZL	0.03	0	(3)	15	17	1	2	(0)	(0)	(1)	1	78%
Apprise Lifescence Togo SAU XXF Q12 S S S S C <t< td=""><td>211</td><td>Arysta LifeScience Egypt Ltd</td><td></td><td>EGP</td><td>3.99</td><td>_</td><td>_</td><td>m</td><td>_</td><td>1</td><td>0</td><td>(0)</td><td>(0)</td><td>(0)</td><td>1</td><td>78%</td></t<>	211	Arysta LifeScience Egypt Ltd		EGP	3.99	_	_	m	_	1	0	(0)	(0)	(0)	1	78%
Califichana Lidd Califichana Commissa SA Califichana Lidd Califichana Commissa SA Califichana Commissa SA Califichana Commissa SA Califichana Califichana Commissa SA Califichana Cali	212	Arysta LifeScience Togo SAU		XOF	0.12	2	(2)	4	2	1	0	(0)	(0)	(0)	1	78%
Authority SCHOS A.A NOF 0.12 2.4 1.5 1.14 1.	213	Calli Ghana Ltd.		GHS	12.93	_	(10)	23	33	1	M	(1)	1	(1)	1	78%
Maji Potestion Des Cultures XOF 0.12 4 3 123 116 4 2 3 9 3 9 9 MAPP C.S.A. PLN 18.05 0	214	Callivoire SGFD S.A.		XOF	0.12	2	45	151	104	1	21	(2)	<u></u>	(1)	1	78%
Agriphar Poland Sp. Zoo PLN 18.05 0	215	Mali Protection Des Cultures (M.P.C.) SA		XOF	0.12	4	M	123	116	1	42	m	0	m	1	%99
Aysta LifeScience CHF 6944 0	216	Agriphar Poland Sp. Zoo		PLN	18.05	0	(0)	1	0	1	,	0	1	0	'	78%
Arysta LifeScience GTQ 8.99 0 - 0 -	217	Arysta LifeScience Switzerland Sarl		CHF	69.44	0	0	0	0	1	1	(0)	(0)	(0)	1	78%
Anvesta Corporation USD 69.16	218	Arysta LifeScience CentroAmerica, S.A.		GTQ	8.99	0	1	0	ı	1	1	ı	1			78%
Ayysta LifeScience GBP 90.64	219	Arvesta Corporation		USD	69.16	1	,	1	1	1	1	1	1	1	,	78%
Led WMR 16.94	220	Arysta LifeScience		GBP	90.64	1		1	1		1	1	,	1	1	78%
Agriphar SDN BHD MMR 16.94 -		Registrations Great Britain Ltd														
Agriphar de Costa Rica SA CRC 0.11 - <th< td=""><td>221</td><td>Agriphar SDN BHD</td><td></td><td>MYR</td><td>16.94</td><td>1</td><td>,</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>78%</td></th<>	221	Agriphar SDN BHD		MYR	16.94	1	,	1	1	1	1	1	1	1	1	78%
Agriphar de Colombia SAS COP 21.78 - <th< td=""><td>222</td><td>Agriphar de Costa Rica SA</td><td></td><td>CRC</td><td>0.11</td><td>1</td><td>ı</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td></td><td>1</td><td>78%</td></th<>	222	Agriphar de Costa Rica SA		CRC	0.11	1	ı	1	1	1	1	1	1		1	78%
Agriphar SA GTQ 8.99 -	223	Agriphar de Colombia SAS		COP	21.78	ı	,	1	1	1	1	1	1	1	1	78%
Agripraza Ltda. EUR 77.66 -	224	Industrias Agriphar SA		GTQ	8.99	1	1	1	1	1	•	1	1		•	78%
Arysta LifeScience USD 69.16 - <td>225</td> <td>Agripraza Ltda.</td> <td></td> <td>EUR</td> <td>77.66</td> <td>1</td> <td>'</td> <td>1</td> <td>1</td> <td>ı</td> <td>1</td> <td>1</td> <td>'</td> <td>1</td> <td>'</td> <td>78%</td>	225	Agripraza Ltda.		EUR	77.66	1	'	1	1	ı	1	1	'	1	'	78%
Grupo Bioquimico Mexicano DOP 1,36 - <th< td=""><td>226</td><td>Arysta LifeScience Corporation Republica Dominicana, SRL</td><td></td><td>OSD</td><td>69.16</td><td>1</td><td>1</td><td></td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>ı</td><td>78%</td></th<>	226	Arysta LifeScience Corporation Republica Dominicana, SRL		OSD	69.16	1	1		1	1	1	1	1	1	ı	78%
Arysta LifeScience Ecuador USD 69.16	227	Grupo Bioquimico Mexicano Republica Dominicana SA		DOP	1.36	1	1	1	1	1	1	1	1	1	1	78%
Arvesta Paraguay S.A. USD 69.16 -<	228	Arysta LifeScience Ecuador S.A.		USD	69.16	ı	1	ı	1	1	1	1	1	1	ı	78%
Arysta Agroquimicos y USD 69.16 -<	229	Arvesta Paraguay S.A.		OSD	69.16	1	,	1		1	1	1	1		1	78%
Arysta LifeScience U.K. USD- GBP 90.64	230	Arysta Agroquimicos y Fertilzantes Uruguay SA		OSD	69.16	1	1	ı	1	1	1	1	1	1	1	78%
	231	Arysta LifeScience U.K. USD-2 Limited		GBP	90.64	1	1	1	1	1	1	ı	1	1	1	78%

	Details of Investments of subsidiary companies:	INR Crs
1	200 [March 2018: 200] Equity shares fully paid up in Hodogaya UPL Co. Ltd	23
2	5,675 [March 2018: 5,675] Equity Shares fully paid-up in 3SB Produtos Agricolas SA [includes goodwill of ₹66 Crores [March 2018 ₹73 Crores]	89
3	Equity shares in Amira Nature foods Limited	35
4	1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ)	44
5	103,016,215 [March 2018:103,016,215] Equity shares of ₹1 each, fully paid-up in Serra Bonita Sementes S.A.[includes goodwill of ₹(12) Crores [March 2018 ₹(14) crores]	190
6	11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kaisha Ltd.	82
7	415 [March 2018: 415] Optionally convertible Debentures of ₹50,000 each of Bloom Packaging Pvt. Ltd.	2
8	88,223 [March 2018: 88,223] Equity shares of 1 AUD each fully paid-up in Longreach Plant Breeders Management Private Limited [includes goodwill of ₹18 Crores, [March 2018: ₹18 Crores]	50
9	Investment in task force	7
10	17,85,000 [March 2018: Nil] Equity shares of CNY 0.30 each, fully paid up in DAC (Dillian Advanced Chemical)	1
11	260 [March 2018: Nil] Equity shares of ₹1 each, fully paid-up in Agronamics [includes goodwill of ₹4 crores]	5
12	7,44,526 [March 2018: Nil] Equity shares of ₹1 each, fully paid-up in Novon Protecta [includes goodwill of ₹(2) crores]	7
13	2,510 [March 2018: Nil] Equity shares of ₹0.01 each, fully paid-up in Agrifokus [includes goodwill of ₹(5) crores]	4
14	1,004 [March 2018: Nil] Equity shares of ₹1 each, fully paid-up in Novon Retail [includes goodwill of ₹4 crores]	7
15	251 [March 2018: Nil] Equity shares of ₹1 each, fully paid up in Silvix Forestry [includes goodwill of ₹1 lakh]	0
16	1,920 [March 2018: Nil] Equity shares of ₹0.10 each, fully paid-up in Nexus AG [includes goodwill of ₹4 crores]	10
17	4,478 [March 2018: Nil] Equity shares of XOF 10,000 each, fully paid-up in Société des Produits Industriels et Agricoles	4
18	7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd.	2
19	3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri	6
20	5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B)	5
21	126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber	0
22	1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz	0
23	1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A)	9
24	MEIJI LUKANG PHARMACEUTICAL CO.,LTD	8
	Grand Total	590

Note:

- United Phosphorus Inc., U.S.A. results include the results of UPL Delaware, Inc., Cerexagri Inc; Canegrass LLC, Riceco LLC, UPI Finance LLC, Advanta US LLC (formerly known as Advanta U.S. Inc.), Arysta LifeScience Inc., Arysta LifeScience Management Company, LLC, Arysta LifeScience America Inc., Arysta LifeScience NA Holding LLC, Arysta LifeScience North America, LLC and Arysta LifeScience Investments
- 2 Decco US Post-Harvest Inc results include the results of Essentiv LCC.
- United Phosphorus Limited, Hongkong results includes the results of United Phosphorus (Shanghai) Company Limited and UPL Jiangsu
- 4 UPL Agro Limited, Riceco Bangladesh and Uniphos Malaysia Sdn Bhd have been acquired in previous year.
- 5 UPL Jiangsu Limited has been formed in previous year.
- 6 UPL Mauritius got merged with UPL Corporation in previous year.
- 7 Exchange rate in INR is per thousand of COP, IDR & VND and for JPY Exchange rate in INR is per hundred.
- During the year, The Group has acquired Arysta life science Inc and its subsidiaries which are part of above entity wise detail of part A.

Statement of AOC 1 Form

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014) Statement containing salient features of the financial statement of associate companies/joint ventures

Part B Associates and Joint Ventures

venture	
loint	
and	
panies	
Comp	
ciate	
ASSO	
d to	
elate	
13	
t 20	
s Aci	
mpanies ,	
0	
the	
) of	
129(3	
ectior	
to S	
pursuant	
Statement	

₹In. Crores

VIII. CI CI CI	Société des Produits	Industriels et	31.03.2019							4,478	4		32%	By Holding	Equal to more	than 20% shares and as	Joint venture	Agreement		Š	Ĭ.		4					,	
-	Nexus AG S		31.03.2019							1,920	10		25%	g		to more than 20% sh	_		venture	Agreement	Ź		9					0	
	Dalian	Chemical	31.03.2019							17,85,000	_		21%	By Holding	Equal to	more than 20% shares	and as Joint	venture	Agreement	\$ 2	Ĭ.		_					(0)	
	Silvix	(Pty) Ltd. #	31.03.2019							251	0		25%	By Holding	Equal to	more than 20% shares	and as Joint	venture	Agreement	< 2	Ž		0					0	
	Novon Retail	(Pty) Ltd. #	31.03.2019							1,004	7		25%	By Holding	Equal to	more than 20% shares	and as Joint	venture	Agreement	\$ 2	Í.		m					0	
Ī	Novon	(Pty) Ltd #	31.03.2019							2,510	4		25%	By Holding	Equal to	more than 20% shares	and as Joint	venture	Agreement	Š	<u> </u>		00					0	
	Novon	(Pty) Ltd #	31.03.2019							7,44,526	7		75%	By Holding	Equal to	more tnan 20% shares	and as Joint	venture	Agreement	<u> </u>	Ç Z		6					0	
	Agronamic (Ptv) I td #	"	31.03.2019							260	5		28%	By Holding	Equal to	more than 20% shares	and as Joint		Agreement	Š	<u> </u>		_					0	
-	Hodogaya	Ltd.	31.03.2019							200	23		40%	By Holding	Equal to	20% shares	and as Joint		Agreement	\$	Ę		23					2	
	LongReach		31.03.2019							88,223	20		%02	ш		20% shares	and as Joint	venture	Agreement	<u> </u>	<u> </u>		32					6	
	Polycoat Technologies	2010 Limited	31.12.2018							200	1		>0%	By Holding	Equal to more	than 20% shares				< 2	Ĭ.		1					,	
	Serra Bonita	S.A. @	31.12.2018							10,30,16,215	190		33%	By Holding	Equal to	more than 20% shares				\$ 2	Ĭ.		202					2	
İ	3SB Produtos		31.12.2018							5,675	68		45%	By Holding	Equal to	20% shares				2	Ĭ,		25					(1)	
	Sinagro	Agropecuários	31.12.2018							8,72,98,237	0		45%	By Holding	Equal to more	than 20% shares				\$	Ź		0					0	
	Kerala Enviro		31.03.2019							33,50,000	2		%80		9	than 20% shares				<u> </u>	<u> </u>		2					_	
	Weather Risk	Pvt LTD	31.03.2019							37,681	13		32%		9	than 20% shares				\$ 2	Ź		o					(1)	
	Names of Associate		Last Audited/ Reviewed Balance	Sheet date Date on which	Joint Venture was	acquired	Shares of	Associates/Joint ventures held by the	Company for the	No.	Amount of	Investment in Associate/Joint	venture Extend of Holding %		gnificant	Influence				() () () () () () () () () ()	associate/joint	venture is not	Networth	attributable to snare	Audited/Reviewed	Balance sheet	Profit/(Loss) for	Considered in	
ŀ	s z		- S S -	2 50 5	<u> </u>	<u>8</u> 8	ж г	Α »	<u> </u>	χŽ	Ã	T &	* £	4	두.	⊆				Č		* 6	9 9	al h	. ₹		_ ₽ ₹	<u> </u>	

[©] Serra Bonita Sementes S.A. was acquired in previous year ended 31 March 2018 # All names of Arysta associates, are acquired along with Arysta Group acquisition during the year.

Independent Auditors' Report

To the members of **UPL** limited

Report on the Audit of the Standalone Financial **Statements Opinion**

We have audited the standalone financial statements of UPL Limited ("the Company"), which comprise the standalone balance sheet as at 31 March 2019, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2019, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements

that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter

We draw attention to Note 45 of the standalone financial statements, relating to the accounting treatment of goodwill aggregating Rs. 3,697 crores arising on amalgamation of erstwhile Advanta limited with the Company accounted during the year ended 31 March 2017 and amortization of the said goodwill arising therefrom both of which are different from the treatment prescribed under Indian Accounting Standard (Ind AS) 103 - 'Business Combinations' for business combination of entities under common control. Had the accounting treatment prescribed under Ind AS 103 been followed, profit after tax reported for the year ended 31 March 2019 would have been higher by Rs. 370 crores. Our opinion is not modified in respect of this matter.

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter

Revenue recognition and rebates accrual

(Refer note 2.2(b) to accounting policies.)

a) Revenue recognition

The timing of revenue recognition is relevant to the reported performance of the Company.

b) Rebates accrual

The Company provides rebates and has arrangements with various customers. Some of these arrangements involve estimation when determining the amount of liability to be recognised as at the year end.

Our focus was on assessing if the rebates and related provisions made were based on relevant agreements and Company policies and approvals

How the matter was addressed in our audit

a) Revenue recognition

We tested the accuracy of revenue cut off around the year end. Our work comprised the agreement of sales transactions to supporting documentation and performing analytical procedures across various sales categories.

b) Rebates accrual

We have reviewed business processes and tested the design and implementation of controls surrounding the rebate expense accrual provision. We also compared year end customer rebate accruals and rebate costs in the year, to prior year amounts and analysed the rebate trend. We have also verified the appropriateness of rebate provision calculations by agreeing amounts recognised to terms of agreements, approvals and other supporting workings.

The key audit matter

Inventory valuation

(Refer note 2.2(i) to accounting policies.)

We identified valuation of inventories as a key audit matter because the Company held significant inventories at the reporting date and because of the significant degree of management judgment involved in evaluating slowmoving, obsolete inventory and the net realizable value of such inventories.

How the matter was addressed in our audit

We obtained the inventory ageing report and understood with management their procedures to identify slow moving and obsolete inventories.

We analysed the ageing profile of inventories to identify slow and obsolete inventories.

We tested the standard cost assessment and year-end adjustment to actual cost by performing walkthroughs of the costing exercise and testing the actual costs of production for a representative sample of products.

We assessed the adequacy of the allowance for obsolete inventories by checking, on a sample basis, whether inventory items were categorized appropriately in the relevant ageing bracket and assessed the reasonableness of the allowance percentages applied.

We also inquired for any obsolete or slow-moving inventories identified during our inventory count observation and also separately performed net realisable value testing on selected inventory items to check that inventories are carried at the lower of cost and net realisable value.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone **Financial Statements**

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Standalone **Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

- 1. As required by the Companies (Auditor's Report) Order, 2016 ('the Order'), issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A", a statement on the matters specified in the paragraphs 3 and 4 of the Order, to the extent applicable.
 - (A) As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books:
 - (c) The standalone balance sheet, the statement of profit and loss (including other comprehensive income), the standalone statement of cash flows and the standalone statement of changes in equity dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under section 133 of the Act;
 - (e) On the basis of the written representations received from the directors as on 31 March 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2019 from being appointed as a director in terms of Section 164(2) of the Act;
 - (f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
 - (B) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in

our opinion and to the best of our information and according to the explanations given to us:

- (a) The Company has disclosed the impact of pending litigations as at 31 March 2019 on its financial position in its standalone financial statements; Refer Note 35(c) to the standalone financial statements;
- (b) The Company did not have any long-term contracts including derivative contracts as at the year end for which there were any material foreseeable losses;
- (c) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company;
- (d) The disclosures in the standalone financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made in these financial statements since they do not pertain to the financial year ended 31 March 2019.

(C) With respect to the matter to be included in the Auditors' Report under section 197(16):

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us

For B S R & Co. LLP Chartered Accountants Firm's Registration No: 101248W/W-100022

Place: Mumbai Partner
Date: 17 May 2019 Membership No: 042070

Annual Report 2018-19 | 139

Annexure A to the Independent Auditors' Report - 31 March 2019

(Referred to in our report of even date)

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
 - (b) The Company has a regular programme of physical verification of its fixed assets by which all fixed assets are verified in a phased manner over a period of three years. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, certain fixed assets were physically verified by the management during the year. In our opinion, and according to the information and explanations given to us, no material discrepancies were noticed on such verification
 - (c) In our opinion and according to the information and explanations given to us by the management and on the basis of an examination of the records of the Company, the title deeds of the immovable properties as disclosed in Note 3 of the standalone financial statements are held in the name of the Company, except in the case of leasehold land, freehold land and buildings with a carrying value of Rs. 11 crores, Rs. 2 crores and Rs.47 lakhs (Gross block of Rs. 11 crores, Rs. 2 crores and Rs.1 crore) as at 31 March 2019 respectively, wherein as explained to us, the Company is not able to reconcile with fixed assets register with the title deeds and hence we are unable to comment on the same
- (ii) The inventory, except goods in transit and stocks lying with third parties, has been physically verified by the management at reasonable intervals during the year. In our opinion, the frequency of such verification is reasonable. For stocks lying with third parties at the year- end, written confirmations have been obtained by management and in respect of goods-in-transit, subsequent goods receipts have been verified or confirmations have been obtained from the parties. The discrepancies noticed on verification between the physical stocks and the book records were not material and have been dealt with in the books of account
- (iii) The Company has granted unsecured loan to two companies covered in the register maintained under Section 189 of the Act.
 - (a) In respect of the aforesaid loans, the terms and conditions under which such loans were granted are not prejudicial to the Company's interest.
 - (b) One of the aforesaid loans along with interest thereon has been fully repaid during the year. In respect of another loan, which is repayable on demand, we are informed that the amount of

- interest and principal demanded by the company has been fully paid during the year and thus, there has been no default on the part of parties to whom the money has been lent.
- (c) There are no amounts overdue for more than ninety days at the balance sheet date in respect of the aforesaid loan
- (iv) In our opinion and according to the information and explanation given to us, the Company has complied with provisions of Section 185 and 186 of the Act in respect of loans granted, investments made and providing guarantees, as applicable.
- (v) In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits under Sections 73 to 76 or any other relevant provisions of the Act and the rules framed thereunder. Accordingly, para 3(v) of the Order is not applicable to the Company.
- (vi) We have broadly reviewed the books of account maintained by the Company as specified under Section 148(1) of the Act, for maintenance of cost records in respect of the products manufactured by the Company, and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of cost records with a view to determine whether they are accurate or complete.
- (vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service tax, Duty of Customs and other material statutory dues have generally been regularly deposited during the year by the Company with the appropriate authorities though there has been slight delay in a few cases except for the provident fund dues as referred to in Note 35(d) of financial statements.
 - (b) According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of customs and other material statutory dues were in arrears as at 31 March 2019 for a period of more than six months from the date they became payable. Also, refer note 35 (d) to the standalone the financial statements. Refer Note 35(d) of financial statements.

(c) According to the information and explanations given to us and based on our examination of the records of the Company, there are no dues of Income-tax, Sales Tax, Service tax, Duty of customs, Goods and service tax, duty of excise and value added tax as at 31 March 2019, which have not been deposited with the appropriate authorities on account of any dispute, except as stated below

Nature of the Statute	Nature of dues	Amount (in Crores)	Amount paid under protest (in Crores)	Period to which amounts relates	Forum where dispute is pending
Income tax Act, 1961	Income tax demands	5	-	AY*1995-96 to AY 1997- 98, AY 2008-09 to AY 2010-11 and AY 2015-16	Supereme Court, High Court, Commisioner Income-tax and Income- tax Appellate Tribunal
Sales tax Act	Sales tax demands	22	9	FY 1985-86, 1995-96, 2005-06 to 2007-08, 2011-12, to 2014-15	Supreme Court, Jt Commissioner of Sales tax, Sales tax Tribunal
Central Excise/ Finance Act	Excise duty/ Service tax demands	68	1	FY 1989-90, 1994-2004 and 2007-2015	Commissioner (Appeals) Central Excise and Service tax Appellate Tribunal
Custom Act	Custom duty demands	34	-	FY 1992 to 1997, 2000, 2001 and 2004	Commissioner (Appeals) Central Excise and Service tax Appellate Tribunal
Foreign Trade (Development and regulation) Act	Fiscal Penalty	33	-	FY 1992 to 1997	Bombay High Court

^{*} AY - Assessment year, FY - Financial year

- (viii) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings from financial institution, bank or dues to debenture holders. The Company did not have any loans or borrowings from the government during the year.
- (ix) According to the information and explanations given to us, the Company did not raise money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, para 3(ix) of the Order is not applicable to the Company.
- (x) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or fraud on the Company by its officers or employees has been noticed or reported during the year nor have we been informed of such case by the management.
- (xi) According to the information and explanations given to us, the managerial remuneration has been paid/ provided in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi company as prescribed under Section 406 of the Act. Accordingly, para 3(xii) of the Order is not applicable to the Company.
- (xiii) According to the information and explanations given to us, all transactions with the related parties are in compliance with provisions of Section 177 and 188 of

- the Act, where applicable and the details have been disclosed in the standalone Ind AS financial statements as required by the applicable Indian accounting standards.
- (xiv)According to the information and explanations given to us and based on our examination of the records of the Company, no preferential allotment or private placement of shares or fully or partly convertible debentures was made during the year. Accordingly, para 3(xiv) of the Order is not applicable to the Company.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with directors or persons connected with them. Accordingly, para 3(xv) of the Order is not applicable to the Company.
- (xvi)According to the information and explanations given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, reporting under the clause 3(xvi) of the Order is not applicable to the Company

For B S R & Co. LLP Chartered Accountants Firm's Registration No: 101248W/W-100022

Place: Mumbai Date: 17 May 2019 Mem

Bhavesh Dhupelia Partner Membership No: 042070

Annexure B to the Independent Auditors' Report - 31 March 2019

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to the standalone financial statements of UPL Limited ("the Company") as of 31 March 2019 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2019, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's Responsibility for Internal Financial

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

Auditors' Responsibility (Continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with reference to financial statements.

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements.

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For B S R & Co. LLP Chartered Accountants Firm's Registration No: 101248W/W-100022

Bhavesh Dhupelia

Place: Mumbai Partner
Date: 17 May 2019 Membership No: 042070

Standalone Balance Sheet as at March 31, 2019

₹ In Crores

	Notes	As at	As at
Assets		March 31, 2019	March 31, 2018
Assets Non-current assets			
Property, plant and equipment	3	2,455	1.947
Capital work-in-progress	3	821	624
Goodwill	4	2,225	2,595
Other intangible assets	4	301	360
Intangible assets under development	4	68	39
<u>Financial assets</u>			
(i) Investments	5	1,441	594
(ii) Loans	6	76	905
(iii) Other financial assets	7	35	35
Income tax assets (Net)	0	148	166
Other non-current assets	8	181 7,751	7,489
Current assets		7,751	7,409
Inventories	9	1,866	1,452
<u>Financial assets</u>			
(i) Trade receivables	10	2,733	2,017
(ii) Cash and cash equivalents	11	77	93
(iii) Bank balances other than cash and cash equivalents	11A	23	33
(iv) Loans (v) Other financial assets	6 7	79 243	105 174
Other current assets	8	1,131	687
Other current assets		6,152	4,561
Total Assets		13,903	12,050
Equity and liabilities		,	1=/111
Equity			
Equity share capital	12	102	102
Other equity	13	7,870	7,867
		7,972	7,969
Liabilities			
Non-current liabilities: <u>Financial liabilities</u>			
(i) Borrowings	14	458	682
(ii) Other financial liabilities	15	4	139
Deferred tax liabilities (net)	19	67	64
		529	885
Current liabilities:			
<u>Financial liabilities</u>			
(i) Borrowings	14	907	313
(ii) Trade payables	47	26	4.7
 Outstanding dues of micro and small enterprises Outstanding dues of other than micro and small enterprises 	17 18	26 2,791	17 2,336
(iii) Other financial liabilities	15	429	2,330
Other current liabilities	16	1,146	62
Provisions	20	103	91
		5,403	3,196
Total equity and liabilities		13,903	12,050
Summary of significant accounting policies	2.2		
See accompanying notes to the financial statements	1-49		

As per our report of even date attached.

For BSR&Co.LLP Chartered Accountants

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

Standalone Statement of Profit and Loss for the year ended March 31, 2019

			V 111 C101C3
	Notes	Year ended	Year ended
		March 31, 2019	March 31, 2018
Revenue			
Revenue from operations	21	8,660	7,374
Other income	22	560	435
Total Income		9,220	7,809
Expenses			
Cost of materials consumed	23	4,741	3,517
Purchases of stock-in-trade		521	404
Changes in inventories of finished goods (including stock-in-trade) and	24	(160)	2
work-in-progress			
Excise duty		-	111
Employee benefit expenses	25	551	486
Finance costs	26	185	135
Depreciation and amortisation expenses	27	724	666
Other expenses	28	2,168	1,905
Total Expenses		8,730	7,226
Profit before exceptional items and tax		490	583
Exceptional items	43	4	7
Profit before tax		486	576
Tax expenses			
Current tax	19	83	180
Adjustments of tax relating to earlier years	19	(3)	(83)
Deferred tax (credit)/charge	19	1	(69)
Total tax expenses		81	28
Profit For The Year		405	548
Other Comprehensive Income (OCI)	30		
(i) Items that will not be reclassified to profit or loss		6	3
(ii) Income tax relating to items that will not be reclassified to profit or loss		2	0
Total Other Comprehensive Income for the year, net of tax		4	3
Total Comprehensive Income for the year		409	551
Earnings per equity share (in INR) of face value of Rs. 2 each			
Basic	31	7.96	10.78
Diluted	31	7.96	10.78
Summary of significant accounting policies	2.2		
See accompanying notes to the financial statements	1-49		

As per our report of even date attached.

For BSR&Co.LLP Chartered Accountants

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088

Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

Standalone Statement of Cash Flows for the year ended March 31, 2019

₹ In Crores

	Year ended	Year ended
	March 31, 2019	March 31, 2018
Cash flow from operating activities		
Profit before exceptional items and tax	490	583
Adjustments for		
Depreciation of property, plant and equipment	284	226
Amortization of intangible assets	440	440
Assets written off	5	9
Interest Income	(65)	(69)
Profit on sale of assets (net)	(0)	_
Profit on sale of Investment	(46)	_
Fair value gain/(loss) on financial instruments at fair value through profit or loss	(7)	7
Dividend Income on Long-term investments in Subsidiary	(412)	(356)
Share in profit from investment in United Phosphorus (India) LLP	(19)	(6)
Allowances for doubtful debts and advances (net)	31	8
Finance costs	185	135
Unrealised exchange difference (net)	(6)	1
Liabilities / provisions no longer required written back (net)	(12)	(45)
Working capital adjustments	(· – /	(/
(Increase)/decrease in trade receivables	(791)	(51)
(Increase)/decrease in inventories	(414)	(97)
(Increase)/decrease in non-current and current financial assets	(2)	2
(Increase)/decrease in other non-current and current assets	(445)	(299)
Increase/(decrease) in other non-current and current trade payables	472	151
Increase/(decrease) in other non-current and current financial liabilities	(58)	1
Increase/(decrease)in other current liabilities	1,084	(32)
Increase/(decrease) in provisions and Net employee defined benefit liabilities	17	11
	730	619
Income tax paid (including TDS) (net)	(62)	(115)
Cash Flow Before Exceptional items	639	504
Exceptional Items	(4)	(7)
Net cash flows from / (used in) operating activities	635	497
Cash flow from investing activities		
Purchase of property, plant and equipment (including CWIP)	(987)	(741)
Purchase of intangible assets (including CWIP)	(40)	(28)
Proceeds from sale of property, plant and equipment	0	_
Profit on sale of Mutual funds	2	_
Proceeds from redemption of preference shares of subsidiary	254	_
Purchase of non current investments	(1,029)	_
Dividend on investments	412	356
Interest received	82	50
Sundry loans - Given	-	(12)
Sundry loans - Repayment received	5	9
Fixed deposits and margin money (net)	10	(21)
Advances and loans to subsidiaries - Given	(77)	(102)
Advances and loans to subsidiaries - Repayment received	929	184
Net cash flows from / (used in) investing activities	(439)	(305)

Standalone Statement of Cash Flows for the year ended March 31, 2019

₹ In Crores

	Year ended	Year ended
	March 31, 2019	March 31, 2018
Cash flow from financing activities		
Interest and finance cost paid	(351)	(95)
Proceeds from borrowings	2,737	425
Repayments of borrowings	(2,221)	(127)
Redemption of Optionally convertible preference shares	-	(2)
Proceeds from exercise of share options	0	1
Payment of dividend	(406)	(360)
Net cash flows from / (used in) financing activities	(241)	(158)
Net increase / (decrease) in cash and cash equivalents	(16)	34
Cash and cash equivalents at the beginning of the year (Refer note 11)	93	59
Cash and cash equivalents at the end (Refer note 11)	77	93

Reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities.

Particulars	Notes	March	Cash	Accquisition	Foreign	Fair	Other	March
		31, 2018	flows		exchange	value	adjustments	31, 2019
					movement	change		
Unsecured Redeemable	14 and	809	(75)	-	-	-	(3)	731
Non convertible	15							
Debentures (NCDs)								
Cash credit, packing	14	313	594					907
credit and working capital								
demand loan accounts								
Total liabilities from		1,122	519	-	-	-	(3)	1,638
financing activities								

Notes:

The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard (IND AS 7) Statement of Cash Flows.

See accompanying notes to the financial statements

As per our report of even date attached.

For BSR&Co.LLP **Chartered Accountants**

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director

Din No.-00180810 Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

Standalone Statement of Changes in Equity for the year ended March 31, 2019

A. Equity Share Capital

₹ In Crores

	Equity shares	of INR 2 each	Compulsorily Preference S	/ Convertible hares (CCPS)
Issued, subscribed and fully paid	Nos.	INR Crores	Nos.	INR Crores
As at April1, 2017	50,70,17,118	101	8,19,40,125	82
Changes during the year	23,15,963	1	(8,19,40,125)	(82)
At March 31, 2018	50,93,33,081	102	-	-
Changes during the year	9,589	0	-	-
At March 31, 2019	50,93,42,670	102	-	-

B. Other Equity

For the year ended March 31, 2019

₹ In Crores

			Res	erve and Sur	olus			Equity	Total
	Capital redemption reserve	Capital reserve	Debenture redemption reserve	Securities premium reserve	Share Based Payment reserve	General reserve	Retained earnings	Instruments through Other Comprehensive Income	Equity
As at April1, 2018	38	86	141	4,607	0	1,848	1,143	5	7,868
Profit for the year	-	-	-	-	_	_	405	-	405
Other comprehensive income (refer note 30)	-	-	-	-	-	-	3	1	4
Total comprehensive income	-	-	-	-	-	-	-	-	-
Dividends paid during the year (refer note 12B)	-	-	-	-	-	-	(407)	-	(407)
Share options received (refer note 34)	-	-	-	0	0	-	-	-	0
Transfer from retained earnings/(Debenture Redemption Reserve)	-	-	(1)	-	-	-	1	-	-
As at March 31, 2019	38	86	140	4,607	0	1,848	1,144	6	7,870

Standalone Statement of Changes in Equity for the year ended March 31, 2019

For the year ended March 31, 2018

₹ In Crores

				Reserve an	d Surplus				Equity	Total
	Capital redemption reserve	Capital reserve	Debenture redemption reserve	Securities premium reserve	Share Based Payment reserve	General reserve	Equity Component of convertible preference shares	Retained earnings	Instruments through Other Comprehensive Income	Equity
As at April1, 2017	36	86	127	4,498	2	1,848	0	968	2	7,567
Profit for the year	-	-	-	-	-	-	-	548	-	548
Other comprehensive income (refer note 30)	-	-	-	-	-	-	-	0	3	3
Total comprehensive income										
Dividends paid during the year (refer note 12c)	-	-	-	-	-	-	-	(357)	-	(357)
Share options received (refer note 34)	-	-	-	4	(2)	-	-	-	-	2
Conversion of Optionally convertible preference shares and Compulsorily convertible preference shares	-	-	-	105	-	-	(0)	-	-	104
Transfer from retained earnings	2	-	14	-	-	-	-	(16)	-	-
As at March 31, 2018	38	86	141	4,607	0	1,848	-	1,143	5	7,867

See accompanying notes to the financial statements

As per our report of even date attached.

For BSR&Co.LLP Chartered Accountants

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

1. Corporate Information

UPL Limited (the Company) is a public company domiciled in India and is incorporated under the provisions of the companies act applicable in India. Its shares are listed on two recognised stock exchanges in India. The registered office of the company is located at 3-11, G.I.D.C., Vapi, Dist-Valsad, Gujarat.

The Company is principally engaged in the business of agrochemicals, industrial chemicals, chemical intermediates, speciality chemicals and production and sale of field crops and vegetable seeds.

The standalone financial statements were authorised for issue in accordance with the resolution of the directors on May 17, 2019.

2. Accounting Policies

2.1 Basis of Preparation

The standalone financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act 2013 ("the Act") as amended thereafter and other relevant provision of the Act.

The standalone financial statements have been prepared on an accrual basis and under the historical cost convention, except for the following assets and liabilities which have been measured at fair value:

- Derivative financial instruments
- Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments),

The standalone financial statements are presented in Indian Rupees ('INR') or ('Rs') which is also the Company's functional currency and all values are rounded to the nearest crores, except when otherwise indicated. Wherever an amount is represented as Rs. '0' (zero) it construes a value less than rupees fifty lakhs.

Significant accounting estimates, assumptions and judgements

The preparation of the Company's standalone financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities effected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the standalone financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts initially recorded, such differences will impact the current and deferred tax provisions in the period in which the tax determination is made. The assessment of probability involves estimation of a number of factors including future taxable income.

Defined benefit plans (gratuity benefits)

A liability in respect of defined benefit plans is recognised in the balance sheet, and is measured as the present value of the defined benefit obligation at the reporting date less the fair value of the plan's assets. The present value of the defined benefit obligation is based on expected future payments at the reporting date, calculated annually by independent actuaries. Consideration is given to expected future salary levels, experience of employee departures and periods of service. Refer note 33 for details of the key assumptions used in determining the accounting for these plans.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk,

credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See Note 39 and 40 for further disclosures.

Provision against obsolete and slow-moving inventories

The Company reviews the condition of its inventories and makes provision against obsolete and slow-moving inventory items which are identified as no longer suitable for sale or use. Company estimates the net realisable value for such inventories based primarily on the latest invoice prices and current market conditions. The Company carries out an inventory review at each balance sheet date and makes provision against obsolete and slow-moving items. The Company reassesses the estimation on each balance sheet date.

Impairment of financial assets

The Company assesses impairment based on expected credit losses (ECL) model on trade receivables. The Company uses a provision matrix to determine impairment loss allowance on the portfolio of trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

Impairment of non-financial assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's fair value less costs of disposal and its value in use. It is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre- tax discount rate that reflects current market assessment of the time value of money and the risk specific to the asset. In determining fair value less cost of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share price for publicly traded subsidiaries or other available fair value indicators.

2.2 Summary of significant accounting policies

a. Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has identified twelve months as its operating cycle for the purpose of current / non current classification of assets and liabilities.

b. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value

of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

Revenue is stated inclusive of excise duty and excludes sales tax/ value added tax (VAT)/Goods and Service Tax (GST).

The specific recognition criteria described below must also be met before revenue is recognised.

Sale of goods

Revenue is recognised upon transfer of control of promised goods to customers in an amount that reflects the consideration which the Company expects to receive in exchange for those goods.

Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer which is usually on shipment.

Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, rebates, scheme allowances, price concessions, incentives, and returns, if any, as specified in the contracts with the customers. Revenue excludes taxes collected from customers on behalf of the government. Accruals for discounts/incentives and returns are estimated (using the most likely method)based on accumulated experience and underlying schemes and agreements with customers. Due to the short nature of credit period given to customers, there is no financing component in the contract.

Rendering of services

Income from services are recognized as and when the services are rendered.

Interest income

For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in other income in the statement of profit and loss.

Export Incentive

Duty free imports of raw materials under Advance License for Imports as per the Export and Import Policy are matched with the exports made against the said licenses and the benefit / obligation is accounted by making suitable adjustments in raw material consumption.

The benefit accrued under the Duty Drawback scheme and other schemes as per the Export and Import Policy in respect of exports made under the said Schemes is included under the head "Revenue from Operations" as 'Export Incentive'

Dividends and Royalties

Dividend income is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend. Royalty income is recognized on an accrual basis in accordance with the substance of the relevant agreement.

Property, Plant and Equipment

Items of Property, plant and equipment including capital-work in-progress are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost comprises the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in statement of profit or loss as incurred. In respect of additions to /deletions from the Fixed Assets, depreciation is provided on pro-rata basis with reference to the month of addition/ deletion of the Assets.

The company, based on technical assessment made by technical expert and management estimate, depreciates certain items of plant and equipment over estimated useful lives which are different from the useful life prescribed in Schedule

II to the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used.

Estimated useful life's of the assets are as follows:

Nature of tangible Assets	Useful Life (years)
Plant & Equipment's	3 to 25
Building	30 to 60
Laboratory Equipment's	10
Office Equipment's	5
Furniture, Fixtures & Equipment's	10
Vehicles	8
Leasehold improvements	over the period of lease

Leasehold Land:

No depreciation is provided for leasehold land since as per the lease agreements, the leases are renewable at the option of the Company for a further period of 99 years at the end of the lease period of 99 years, without / with marginal payment of further premium.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

d. Intangible assets

Goodwill

a) Goodwill arising on amalgamation in accordance with court scheme.

Goodwill arising on amalgamation of Advanta Limited has been recognised in accordance with court scheme. Said goodwill has been amortised in accordance with the court scheme for which Company has estimated useful life of 10 years. (Refer note 45)

- b) Goodwill other than mentioned above
 - Goodwill is initially measured at cost, being the excess of the aggregate fair value of the consideration transferred over the net of fair value of identifiable assets acquired and liability assumed.
 - Subsequent measurement is at cost less any accumulated impairment losses.
 - Goodwill is not amortised and is tested for impairment annually.

ii. Other intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets with finite life are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in statement of profit or loss in the period in which the expenditure is incurred.

The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at the end of each reporting period.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is de-recognised.

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Company can demonstrate technical and commercial feasibility of making the asset available for use or sale.

Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation expense is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

A summary of the policies applied to the Company's intangible assets is as follows

Nature of tangible Assets	Useful Life (years)	Amortisation method used
Product Acquisitions	Fifteen years	Amortised on straight-line basis from the month of additions to match their future economic benefits
Germ plasm	Ten to fifteen years	Amortised on straight-line basis
Other Intangible assets	Five years	Amortised on straight-line basis

e. Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

f. Foreign Currency

Transactions and balances

Transactions in foreign currency are recorded applying the exchange rate at the date of transaction. Monetary assets and liabilities denominated in foreign currency remaining unsettled at the end of the year, are translated at the closing rates prevailing on the Balance Sheet date. Non-monetary items which are carried in terms of historical cost denominated in foreign currency are reported using the exchange rate at the date of transaction. Exchange differences arising as a result of the above are recognized as income or expenses in the statement of profit and loss. Exchange difference arising on the settlement of monetary items at rates different from those at which they were initially recorded during the year, or reported in previous standalone financial statements, are recognised as income or expenses in the year in which they arise.

Foreign exchange difference on foreign currency borrowings, loans given, settlement gain/loss and fair value gain/loss on derivative contract relating to borrowings are accounted and disclosed under finance cost. Such exchange difference does not include foreign exchange difference regarded as an adjustment to the borrowings cost and capitalised with cost of assets.

Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date on a portfolio basis.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the standalone financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 Valuation techniques for which the lowest level input that is significant to the fair value measurement is

directly or indirectly observable

- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the standalone financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

This note summaries accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

- Quantitative disclosures of fair value measurement hierarchy (note 40)
- Financial instruments (including those carried at amortised cost) (note 5, 6, 7, 10, 11, 11A, 14, 15, 17,18, 38, 39, 40 and 41)

h. Leases

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

For arrangements entered into prior to 1 April 2015, the company has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

Company as a lessee

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Company is classified as a finance lease.

Finance leases are capitalised at the commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in finance costs in the statement of profit and loss, unless they are directly attributable to qualifying assets, in which case they are capitalized in accordance with the Company's general policy on the borrowing costs. Contingent rentals are recognised as expenses in the periods in which they are incurred.

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Company will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term.

Operating lease payments are recognised as an expense in the statement of profit and loss on a straight-line basis over the lease term.

Company as a lessor

Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognised on a straight-line basis over the term of the relevant lease.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Company to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

i. Inventories

Stores and spares, packing materials and raw materials are valued at lower of cost or net realisable value. Cost is determined on moving weighted average basis. The aforesaid items are valued below cost if the finished products in which they are to be incorporated are expected to be sold at a loss.

Work in progess, finished products and by-products are valued at lower of cost or net realisable value. Cost is determined on standard cost basis which approximates the actual cost. Cost of finished goods includes excise duty, as applicable. Variances, exclusive of abnormally low volume and operating performance, are adjusted to inventory.

Traded goods are valued at lower of cost and net realizable value. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on a weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss.

Goodwill is tested for impairment annually as at 31 March and when circumstances indicate that the carrying value may be impaired.

Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. Impairment losses relating to goodwill are not reversed in future periods.

Intangible assets with indefinite useful lives are tested for impairment annually as at 31 March at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

k. Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. Provisions are reviewed at each balance sheet and adjusted to reflect the current best estimates.

Retirement and other employee benefits

Provident Fund is a defined contribution scheme established under a State Plan. The contributions to the scheme are charged to the statement of profit and loss in the year when employee rendered related services.

Superannuation Fund is a defined contribution scheme and contributions to the scheme are charged to the statement of profit and loss in the year when the contributions are due. The scheme is funded with an insurance Company in the form of a qualifying insurance policy.

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets

a gratuity on post employment at 15 days salary (last drawn salary) for each completed year of service as per the rules of the Company. The aforesaid liability is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of the financial year. The scheme is funded with an insurance Company in the form of a qualifying insurance policy.

The Company has other long-term employee benefits in the nature of leave encashment. The liability in respect of leave encashment is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of the financial year. The aforesaid leave encashment is funded with an insurance Company in the form of a qualifying insurance policy.

Re-measurements, comprising of actuarial gains and losses, the effect of asset ceiling, excluding amounts included in the net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Re-measurements are not reclassified to statement of profit or loss in subsequent periods.

m. Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at cost and then measured at fair value at each reporting date plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both its following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in other income in the statement of profit or loss. The losses arising from impairment are recognised in the statement of profit or loss.

Debt instrument at FVTOCI

A 'debt instrument' is classified at FVTOCI if both of the following criteria are met:

- a) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- b) The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income (OCI). However, the company recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the Profit and Loss. On de-recognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to Profit and Loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

In addition, the company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The company has designated certain debt instrument as at FVTPL.

Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Equity investments

All equity investments in the scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, the company may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss, even on sale of investment. However, the company may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a company of similar financial assets) is primarily de-recognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the company has transferred substantially all the risks and rewards of the asset, or (b) the company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a quarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the company could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- a) Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, trade receivables and bank balance
- b) Financial assets that are debt instruments and are measured as at FVTOCI
- c) Lease receivables under Ind AS 17
- d) Trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 18 (referred to as 'contractual revenue receivables' in these standalone financial statements)
- e) Financial guarantee contracts which are not measured as at FVTPL

The company follows 'simplified approach' for recognition of impairment loss allowance on:

- Trade receivables and
- Other receivables

The application of simplified approach does not require the company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- All contractual terms of the financial instrument (including prepayment, extension, call and similar options) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial
- Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.
- Financial assets measured as at amortised cost, contractual revenue receivables and lease receivables: ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the company does not reduce impairment allowance from the gross carrying amount.

n. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, or payables, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognised in the statement of profit and loss.

Loans and borrowings

This is the category most relevant to the company. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are de-recognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings. For more information refer Note 14.

Financial guarantee contracts

Financial guarantee contracts issued by the company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the quarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less cumulative amortisation.

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of

an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

o. Derivative financial instruments

Initial recognition and subsequent measurement

The Company uses derivative financial instruments, such as forward currency contracts, full currency swaps and interest rate swaps contracts to hedge its foreign currency risks and interest rate risks respectively. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Fair value changes are recognised in the statement of profit and loss.

p. Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

Cash dividend

The Company recognises a liability to make cash distributions to equity holders when the distribution is authorised and the distribution is no longer at the discretion of the Company. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

r Taxes

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities in accordance with the Income-tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses are recognised to the extent that it is reasonably certain that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become reasonably certain that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Minimum Alternate Tax (MAT)

Minimum Alternate Tax (MAT) paid as per Indian Income Tax Act, 1961 is in the nature of unused tax credit which can be carried forward and utilised when the Company will pay normal income tax during the specified period. Deferred tax assets on such tax credit is recognised to the extent that it is probable that the unused tax credit can be utilised in the specified future period. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

s. Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related assets.

Export Benefits:

Duty free imports of raw materials under Advance License for imports as per the Import and Export Policy are matched with the exports made against the said licenses and the net benefit/obligation has been accounted by making suitable adjustments in raw material consumption.

The benefit accrued under the Duty Drawback, Merchandise Export Incentive Scheme and other schemes as per the Import and Export Policy in respect of exports made under the said schemes is included as 'Export Incentives' under the head 'Other operating revenue'.

t. Convertible preference shares

Convertible preference shares are separated into liability and equity components based on the terms of the contract.

On issuance of the convertible preference shares, the fair value of the liability component is determined using a market interest rate for an equivalent non-convertible instrument. This amount is classified as a financial liability measured at amortised cost (net of transaction costs) until it is extinguished on conversion or redemption.

The remainder of the proceeds are allocated to the conversion option that is recognised and included in equity if the conversion option meets Ind AS 32 criteria for fixed to fixed classification. Transaction costs are deducted from equity, net of associated income tax. The carrying amount of the conversion option is not remeasured in subsequent years.

Transaction costs are apportioned between the liability and equity components of the convertible preference shares based on the allocation of proceeds to the liability and equity components when the instruments are initially recognised.

u. Earnings Per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

v. Segment Reporting:

Based on "Management Approach" as defined in Ind AS 108 -Operating Segments, the Chief Operating Decision Maker evaluates the Company's performance and allocates the resources based on an analysis of various performance indicators by business segments. Inter segment sales and transfers are reflected at market prices.

Unallocable items includes general corporate income and expense items which are not allocated to any business segment.

Segment Policies:

The Company prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the standalone financial statements of the Company as a whole. Common allocable costs are allocated to each segment on an appropriate basis.

w. Contingent Liability and Contingent assets

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non—occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the standalone financial statements.

A contingent asset is not recognised unless it becomes virtually certain that an inflow of economic benefits will arise. When an inflow of economic benefits is probable, contingent asset are disclosed in the standalone financial statements.

Contingent liabilities and contingent assets are reviewed at each balance sheet date.

Share Based Payments:

Measurement and disclosure of the employee share based payment plans is done in accordance with Ind AS 102, Share Based Payment. The Company measures compensation cost relating to employee stock options using the fair value method. Compensation expense is amortised over the vesting period of the option on a straight line basis.

Standards issued but not yet effective

Ind AS 116-Leases:

The new standard on leases sets out the principles for the recognition, measurement, presentation and disclosure of the leases. The core objective of this standard is to ensure that lessees and lessors provide relevant information in a manner that faithfully represent those transactions.

The Company is required to adopt Ind AS 116, Leases from 1 April, 2019. Ind AS 116 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognises a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. Lessor accounting remains similar to the current standard – i.e. lessors continue to classify leases as finance or operating leases. It replaces existing leases guidance, Ind AS 17, Leases.

The Company has completed an initial assessment of the potential impact (summarised below) on its standalone financial statements but has not yet completed its detailed assessment. The quantitative impact of adoption of Ind AS 116 on the standalone financial statements in the period of initial application is not reasonably estimable as at present.

- the total assets and liabilities on the balance sheet will increase with a decrease in net total assets, due to the depreciation of right of use assets being on a straight-line basis whilst the lease liability reduces by the principal amount of repayments;
- Interest expense will increase due to the unwinding of the effective interest rate implicit in the lease liability. Interest expense will be greater earlier in a lease's life, due to the higher principal value, causing profit variability over the term of lease. This effect may be partially mitigated due to the number of leases held by the Company at various stages of their terms; and
- operating cash flows will be higher and financing cash flows will be lower, as repayment of the principal portion of all lease liabilities will be classified as financing activities.

The Company plans to apply Ind AS 116 initially on 1 April 2019, using the modified retrospective approach. Therefore, the cumulative effect of adopting Ind AS 116 will be recognised as an adjustment to the opening balance of retained earnings at 1 April 2019, with no restatement of comparative information.

The Company plans to apply the practical expedient to grandfather the definition of a lease on transition. This means that it will apply Ind AS 116 to all contracts entered into before 1 April 2019 and identified as leases in accordance with Ind AS 17.

In addition to the above, the following amendments to existing standards have been issued, are not yet effective and are not expected to have a significant impact on the Company's standalone financial statements:

- Amendments to Ind AS 103, Business Combinations, and Ind AS 111, Joint Arrangements: This interpretation clarifies how an entity accounts for increasing its interest in a joint operation that meets the definition of a business.
- Amendments to Ind AS 109, Financial Instruments: amendments relating to the classification of particular pre payable financial assets.
- Amendments to Ind AS 12, Income Taxes, clarify that all income tax consequences of dividends (including payments on financial instruments classified as equity) are recognized consistently with the transactions that generated the distributable profits – i.e. in profit or loss, other comprehensive income or equity. Further Appendix C, uncertainty over income tax treatments has been added to clarify how entities should reflect uncertainties over income tax treatments, in particular when assessing the outcome a tax authority might reach with full knowledge and information if it were to make an examination.
- Amendment to Ind AS 19, Employee Benefits The amendment to Ind AS 19 clarifies that on amendment, curtailment or settlement of a defined benefit plan, the current service cost and net interest for the remainder of the annual reporting period are calculated using updated actuarial assumptions - i.e. consistent with the calculation of a gain or loss on the plan amendment, curtailment or settlement. This amendment also clarifies that an entity first determines any past service cost, or a gain or loss on settlement, without considering the effect of the asset ceiling. This amount is recognized in profit or loss. The entity then determines the effect of the asset ceiling after plan amendment, curtailment or settlement. Any change in that effect is recognized in other comprehensive income (except for amounts included in net interest).
- Amendments to Ind AS 23, Borrowing Costs, clarify that the general borrowings pool used to calculate eligible borrowing costs excludes only borrowings that specifically finance qualifying assets that are still under development or construction.

Impact on adoption of above changes in standards is not material.

2.3 Changes in accounting policies

- a. The Company applied Ind AS 115 for the first time. The nature and effect of the changes as a result of adoption of the new accounting standard are described below.
- b. Several other amendments and interpretations apply for the first time in April 1, 2018, but do not have an impact on the financial statements of the Company. The Company has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.
- The Company adopted Ind AS 115 as per the modified retrospective approach, which requires the cumulative effect on adoption of Ind AS 115 to retained earnings at April 1, 2018. The adoption of Ind AS 115 did not have any impact on the financial statements of the Company as at and for the year ended March 31, 2019.

3. Property, plant and equipment

₹ In Crores

	Land -	Land -	Building	Plant and	Laboratory	Office	Furniture,	Vehicles	Leasehold	Capital	Total
	Freehold	Freehold Leasehold)	Equipment	Equipment	Equipment	Fixtures and Equipment		Improvements	Work -in- Progress	
Cost or valuation											
At March 31, 2017	93	151	179	2,396	29	51	54	33	26	249	3,291
Additions	ı	1	35	397	5	9	9	\leftarrow	ı	561	1,011
Disposals	1	1	(1)	(71)	(0)	(0)	(0)	(1)	ı	ı	(73)
Capitalised	ı	1	1	1	1	ı	ı	ı	ı	(186)	(186)
At March 31, 2018	93	151	213	2,722	34	57	09	33	26	624	4,043
Additions	_	0	42	720	7		15	<u></u>	ı	901	1,698
Disposals	ı	1	(0)	(21)	(0)	(2)	(0)	(0)	ı	ı	(23)
Capitalised	ı	1	ı	1	1	ı	I	ı	I	(704)	(704)
At March 31, 2019	94	151	255	3,421	41	99	75	34	99	821	5,014
Accumulated Depreciation											
At March 31, 2017	1	•	48	1,119	7	42	38	24	31	ı	1,309
Depreciation (refer note 27)	ı	1	_	196	C		9	\mathbb{C}	4	I	226
Disposals	ı	1	(1)	(61)	(0)	(1)	(0)	(0)	I	I	(64)
At March 31, 2018	ı		54	1,254	10	48	44	27	35	ı	1,471
Depreciation (refer note 27)	1	1	6	249	4	8	∞	2	4	ı	284
Disposals	ı	1	(0)	(16)	(0)	(2)	(0)	(0)	I	I	(18)
At March 31, 2019	ı	1	63	1,487	14	54	52	29	39	ı	1,737
Net book value											
At March 31, 2019	94	151	192	1,934	27	12	23	2	17	821	3,276
At March 31, 2018	93	151	159	1,468	24	6	16	9	21	624	2,571

All the title deeds are in the name of the Company, except in the case of leasehold land, freehold land and buildings with a carrying value of Rs. 11 crores, Rs. 2 crores and Rs. 0 crore (Gross block of Rs. 11 crores, Rs. 2 crores and Rs.1 crore) as at 31 March 2019 and 31 March 2018 respectively.

₹ In Crores

	As at March 31, 2019 As at March 31, 2018	As at March 31, 2018
Plant, property and equipment	2,455	1,947
Capital work in progress	821	624
	3,276	2,571

Capital Work in Progress

Capital work in progress as at March 31, 2019 and March 31, 2018 comprises expenditure for the plant and building in the course of construction.

4. Intangible assets

4. Intangible assets										lh.	₹ In Crores
	Goodwill*				Other Intan	Other Intangible Assets				Intangible	Total
		Data Access Fees	Data Product Product Access Fees Registrations	Product Acquisitions	Task Force Expenses	Software/ License Fees	Brands/ Trade Marks		Germplasm	Technical Germplasm asset under Knowhow	
Cost or valuation)	-							
At March 31, 2017	3,704	97	184	603	23	25	63	1	13	23	4,746
Additions	1	0	∞	1	I	4	1	ı	I	17	29
Capitalised	1	ı	1	1	ı	ı	1	1	ı	(1)	(1)
At March 31, 2018	3,704	97	192	603	23	29	63	<u></u>	13	39	4,774
Additions	1	1	7	1	ı	4	1	1	ı	35	46
Disposals	1	ı	ı	1	I	0	1	ı	I	ı	0
Capitalised	1	ı	I	ı	I	ı	1	1	ı	(9)	(9)
At March 31, 2019	3,704	76	199	603	23	33	63	1	13	89	4,814
Amortisation											
At March 31, 2017	739	94	118	279	14	16	62	10	∞	ı	1,340
Amortisation (refer note 27)	370	_	22	40	∞	4	1	1	0	ı	440
At March 31, 2018	1,109	95	140	319	17	20	62	10	00	1	1,780
Amortisation (refer note 27)	370	_	23	40	m	M	1	1	0	1	440
At March 31, 2019	1,479	96	163	359	20	23	62	10	∞	1	2,220
Net book value											
At March 31, 2019	2,225	_	36	244	C	10	_	_	5	89	2,594
At March 31, 2018	2,595	2	52	284	9	6	_	_	5	39	2,994

Certain intangible assets which are required to be held outside India and where the Company is the beneficial owner of the said intangible assets, are held in the name of the overseas subsidiary companies.

		₹ In Crores
Net book value	As at March 31, 2019	As at March 31, 2019 As at March 31, 2018
Goodwill	2,225	2,595
Other intangible assets	301	360
Intangible assets under development	89	39
	2,594	2,994

^{*}Goodwill arising on amalgamation

Goodwill includes goodwill arising on amalgamation of Advanta Limited fully described in note 45 of the financial statements.

Goodwill is tested for impairment on an annual basis and whenever there is an indication that the recoverable amount is less than its carrying amount based on a number of factors including business plan, operating results, future cash flows and economic conditions. The recoverable amount is determined based on higher of value in use and fair value less cost to sell.

The Company generally uses discounted cash flows method to determine the recoverable amount. These discounted cash flow calculations use five-year projections that are based on financial forecasts. Cash flow projections take into account past experience and represent managements' best estimate about future developments.

5. Investments ₹ In Crores

	March 31, 2019	March 31, 2018
Investment stated at Cost		
(A) Investments in Equity Instruments		
a. Investment in Subsidiaries (unquoted)		
(i) 140,824 (March 31, 2018: 136,000) equity shares of US \$ 100 each fully paid-up in UPL Corporation Limited (formerly known as Bio-Win Corporation Ltd)	1,102	77
(ii) 3,053 (March 31, 2018: 3,053) equity shares of Euro 100 each, fully paid-up in Advanta Holdings B.V., Netherlands	171	171
(iii) 50,007 (March 31, 2018: 50,007) equity shares of Rs. 10 each fully paid-up in Shroff's United Chemicals Limited	0	0
(iv) 99,000 (March 31, 2018 : 99,000) equity shares of US\$ 1 each, fully paid-up in PT Advanta Indonesia	1	1
(v) 1,000,007 (March 31,2018: 1,000,007) equity shares of Rs. 10 each fully paid-up in SWAL Corporation Limited	17	17
(vi) 1,000,000 (March 31, 2018: 1,000,000) ordinary shares of US\$ 1 each, fully paid-up in Advanta Seed International, Mauritius	0	0
(vii) 1,000,000 (March 31, 2018: 1,000,000) equity shares of Rs.10 each fully paid-up in Agrinet Solutions Limited	2	2
(viii) United Phosphorus (India) LLP - Capital Contribution in LLP	35	15
Name of Partners: UPL Limited SWAL Corporation Limited Total capital of the firm: Rs. 15,300,000 Share of each partner: UPL Limited - 96% SWAL Corporation Limited - 4% (ix) United Phosphorus (Global) LLP	0	0
Name of Partners: UPL Limited SWAL Corporation Limited Total capital of the firm: Rs. 1,000,000 Share of each partner: UPL Limited - 95% SWAL Corporation Limited - 5% b. Investment in Associates (unquoted)		
(i) 921,000 (March 31, 2018: 921,000) equity shares of Rs 10 each fully paid-up in	0	0
Chemiesynth (Vapi) Limited (ii) 3,350,000 (March 31, 2018: 3,350,000) equity shares of Rs.10 each fully paid-up in Kerala Enviro Infrastructure Limited	3	3
(iii) 48,214 (March 31, 2018: 37,681) equity shares of Rs 10 each, fully paid-up in Weather Risk Management Services Pvt Ltd	14	10
(B) Investments in Preference Instruments in subsidiaries (unquoted) Nil (March 31, 2018: 6,393) preference shares of Euro 5,000 each, fully paid-up in Advanta Holdings B.V., Netherlands Investment stated at Amortised Cost	-	210
Investments in Government or trust securities (unquoted) Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.[March 31, 2018: Rs. 0.06 lac]	0	0
National Saving Certificates [Face Value: Current Year: Rs. 0.06 lac. [March 31, 2018: Rs. 0.06 lac]	0	0
Investments stated at Fair Value through OCI		
Investments in Equity Instruments (quoted) 28,100 (March 31, 2018: 28,100) equity shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation	0	0
50,000 (March 31, 2018: 50,000) equity shares of Rs.10 each fully paid-up in Nivi Trading Limited	0	0

5. Investments (contd.)

₹ In Crores

	March 31, 2019	March 31, 2018
41,150 (March 31, 2018: 41,150) equity shares of Rs.10 each fully paid-up in	5	5
Transpek Industry Limited		
5,307 (March 31, 2018: 5,307) equity shares of Rs.10 each fully paid-up in IDFC	0	0
Limited		
5,307 (March 31, 2018: 5,307) equity shares of Rs.10 each fully paid-up in IDFC Bank Limited.	0	0
17,990 (March 31, 2018: 17,990) equity shares of Rs.2 each fully paid-up in Bank of	0	0
Baroda Limited		
Investments stated at Fair Value through profit and loss		
a. <u>Investments in Optionally Convertible Bonds (unquoted)</u>	83	76
6,855 (March 31, 2018: 6,855) Optionally Convertible Bonds of Rs.1,00,000 each in Tatva Global Environment Private Limited		
b. <u>Investment in Others (unquoted)</u>		
10,000 (March 31, 2018:10,000) equity shares of Rs.10 each fully paid-up in	0	0
Janakalyan Sahakari Bank Limited		
1,000,000 (March 31, 2018: 1,000,000) equity shares of Rs.10 each fully paid-up	0	0
in Uniphos International Limited		
45,000 (March 31, 2018: 45,000) equity shares of Rs.10 each fully paid-up in	1	1
Bloom Packaging Private Limited		
19,025 (March 31, 2018: 19,025) equity shares of Rs.10 each fully paid-up in	1	1
Bench Bio Private Limited		
240,000 (March 31, 2018: 240,000) equity shares of Rs. 10 each fully paid-up in	2	2
UPL Investment Private Limited		
57 [March 31, 2018: 57] equity shares of 1 Rand each fully paid-up in Cropserve	0	0
[PTY] Limited	2	2
3,757,570 [March 31, 2018: 3,435,070] equity shares of Rs.10 each fully paid-up in Narmada Clean Tech Limited	3	3
Total Non-Current Investments	1,441	594
Aggregate book value and market value of quoted investments	5	5
Aggregate amount of unquoted investments	1,436	589
Impairment of investments		_

Impairment of Investments

Investment at fair value through profit and loss (fully paid) reflect investment in debt instruments and unquoted equity securities. Refer note 39 for determination of their fair values.

Investment at fair value through OCI (fully paid) reflect investment in quoted equity securities. Refer note 39 for determination of their fair values.

Extent of equity interest in subsidiaries and associates

Na	me and country of incorporation	% of equity interest	
		March 31, 2019	March 31, 2018
a.	Subsidiaries		
	UPL Corporation Limited (formerly known as Bio-Win Corporation Ltd), Mauritius	78%	100%
	Advanta Holdings B.V., Netherlands	100%	100%
	PT Advanta Indonesia	100%	100%
	SWAL Corporation Limited, India	100%	100%
	Advanta Seed International, Mauritius	100%	100%
	Agrinet Solutions Limited, India	50%	50%
	Shroffs United Chemicals Limited, India	100%	100%
	United Phosphorus (India) LLP	96%	95%
	United Phosphorus (Global) LLP, India	95%	95%

5. Investments (contd.)

Na	me and country of incorporation	% of equity interest	
		March 31, 2019	March 31, 2018
b.	Associates		
	Chemiesynth (Vapi) Limited, India	30%	30%
	Kerala Enviro Infrastructure Limited, India	28%	28%
	Weather Risk Management Services Pvt Ltd, India	27%	27%

6. Loans ₹ In Crores

	Non-cu	urrent	Curr	ent
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Security deposit				
a. Unsecured, Considered good				
- to related parties (refer note 36)	11	15	-	-
- to other than related parties	65	59	-	-
b. Unsecured, Considered doubtful	2	2	-	_
Less: Allowance for doubtful security deposit	(2)	(2)	-	_
	76	74	-	-
(B) Loans and advances to related parties (refer note 32 and 36)				
a. Unsecured, Considered good	-	831	77	98
	-	831	77	98
(C) Loans to employees				
a. Unsecured, Considered good	-	-	2	7
	-	-	2	7
(D) Sundry loans				
Unsecured, Considered doubtful	2	2	-	_
Less: Allowance for doubtful sundry loans	(2)	(2)	-	-
•	-	-	-	-
Total loans	76	905	79	105

Loans and receivables are non-derivative financial assets which generate a fixed or variable interest income for the Company.

7. Other financial assets

₹ In Crores

	Non-cı	urrent	Curr	ent
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Interest receivable				
a. Unsecured, considered good from related party (refer note 36)	-	-	7	24
b. Unsecured, considered doubtful	-	-	(0)	0
Less: Allowance for doubtful interest receivable	-	-	(0)	(0)
	-	-	7	24
(B) Receivables from related parties (refer note 36)				
a. Unsecured, considered good	-	-	115	68
	-	-	115	68
(C) Export benefits receivable				
Unsecured, considered good	35	35	121	82
	35	35	121	82
(D) Other receivables				
Unsecured, considered doubtful	-	-	2	2
Less: Allowance for doubtful other financial	-	_	(2)	(2)
assets				
Total other financial assets	35	35	243	174

8. Other assets ₹ In Crores

	Non-current		Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(a) Capital advances	22	66	-	-
(b) Statutory receivables	159	158	1,015	606
(c) Prepaid expense	-	-	35	46
(d) Other advances	-	-	81	35
Total other assets	181	224	1,131	687

9. Inventories

(Valued at lower of cost and net realisable value)

₹ In Crores

		March 31, 2019	March 31, 2018
a.	Raw materials and components [includes goods in transit: Rs. 23 crores	760	519
	(March 31, 2018: Rs. 22 crores)]		
b.	Work-in-progress	175	147
C.	Finished goods	769	638
d.	Traded goods [includes goods in transit: Rs. 8 crores (March 31, 2018: Rs. 3 crores)]	80	80
e.	Store and spares [including fuel]	48	40
f.	Packing material	30	25
g.	By products	4	3
		1,866	1,452

Amount of write down of inventories to net realisable value and other provisions / losses recognised in the statement of profit and loss as an expense is Rs. 6 crores (March 31, 2018: Rs 21 crores)

10. Trade receivables ₹ In Crores

	March 31, 2019	March 31, 2018
Unsecured, Considered good		
- from related parties	1,028	1,052
- from others	1,705	965
Unsecured, Considered doubtful		
- from others	108	77
Less: Allowance for doubtful trade receivable	(108)	(77)
Total trade receivables	2,733	2,017

No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. There are no trade or other receivables which are due from firms or private companies respectively in which any director is a partner, a director or a member.

For terms and conditions relating to related party receivables, refer note 36.

Certain trade receivables are interest bearing. Trade receivables are generally on terms of 45 to 270 days.

The Company has entered into an agreement to sell and assign its receivables to certain banks. In connection therewith, the Company sells its receivables to these banks on a non recourse basis. When the Company sells its receivables to these banks the transfer is treated as a "true sale" for both legal and financial reporting purposes. As such, the assets once transferred to these banks are not reflected on the balance sheet date of the Company. As at March 31, 2019, the Company sold receivables which have been derecognised amounting to Rs. Nil (March 31, 2018: Rs. 48 crores). For explanations on the Company's credit risk management processes, refer note 41

11. Cash and cash equivalents

₹ In Crores

	March 31, 2019	March 31, 2018
Balances with banks		
- Current accounts	77	93
Cash on hand	0	0
Total cash and cash equivalents	77	93

11A. Other bank balances

₹ In Crores

	March 31, 2019	March 31, 2018
- Unclaimed dividend accounts	8	7
- Margin money deposit **	14	14
- Deposits with original maturity for more than 3 months but less than 12 months	1	12
Total other bank balances	23	33

^{**} Margin money deposits given as security against bank guarantees

For the purpose of the statement of cash flows, cash and cash equivalents comprise the following:

₹ In Crores

	March 31, 2019	March 31, 2018
Balances with banks:		
- Current accounts	77	93
Cash on hand	0	0
Total cash and cash equivalents	77	93

12. Share Capital

Authorised share capital

	Equity shares	Equity shares of INR 2 each	
	Nos.	INR Crores	
As at April1, 2017	1,23,75,00,000	248	
Increase/(decrease) during the year	-	-	
At March 31, 2018	1,23,75,00,000	248	
Increase/(decrease) during the year	-	-	
At March 31, 2019	1,23,75,00,000	248	

Issued equity capital

Equity shares of Rs. 2 each issued, subscribed and fully paid

	Equity shares	Equity shares of INR 2 each	
	Nos.	INR Crores	
As at April1, 2017	50,70,17,118	101	
Increase/(decrease) during the year due to			
Conversion of OCPS and CCPS	22,24,287	1	
ESOP Allotments	91,676	0	
At March 31, 2018	50,93,33,081	102	
Increase/(decrease) during the year due to			
ESOP Allotments	9,589	0	
At March 31, 2019	50,93,42,670	102	

Terms/ rights attached to equity shares

The Company has one class of equity shares having par value of Rs. 2 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

During the year ended March, 2019, the amount of per share dividend proposed as distributions to equity shareholders is Rs. 8 (March, 2018: Rs. 8)

The Board has recommended issue of bonus shares in the ratio 1:2 (one bonus equity share of Rs. 2 each for every two fully paid-up equity shares held), subject to the approval of the shareholders of the company.

12. Share Capital (contd.)

Details of shareholders holding more than 5% shares in the company Name of the shareholder

Equity shares of INR 2 each fully paid	March 3	1, 2019	March 3	1, 2018
	No. in crores	% holding	No. in crores	% holding
		in the class		in the class
Nerka Chemicals Private Limited	10	20.10%	10	19.94%
Uniphos Enterprises Limited	3	5.06%	3	5.01%

As per the records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

There are 42,353,062 (March 31, 2018: 42,353,062) underlying equity shares of the Company in respect of GDR's traded on Luxemburg Stock Exchange and against conversion of each GDR ten equity shares were issued.

12A. Preference Share Capital

Authorised share capital

		Total Preference Shares of Rs. 100 each	
	No.	INR Crores	
As at April1, 2017	22,95,00,000	230	
Increase/(decrease) during the year	-	-	
At March 31, 2018	22,95,00,000	230	
Increase/(decrease) during the year	-	-	
At March 31, 2019	22,95,00,000	230	

Issued preference share capital

	the state of the s	Optionally Convertible Preference Shares		Compulsorily Convertible Preference Shares	
	No.	INR Crores	No.	INR Crores	
As at April1, 2017	2,46,42,786	25	8,19,40,125	82	
Increase/(decrease) during the year	(2,46,42,786)	(25)	(8,19,40,125)	(82)	
At March 31, 2018	-	-	-	-	
Increase/(decrease) during the year	-	-	-	-	
At March 31, 2019	-	-	-	-	

Terms/ rights attached to preference shares

Each Compulsory convertible preference share (CCPS) had a par value of Rs. 10 and was convertible at the option of the shareholders into equity shares of the Company starting within 18 months from the date of allotment i.e. from August 08, 2016 into ten new equity shares of Rs. 2 for every four hundred and seventy one CCPS held. CCPS not converted within 18 months from the date of allotment, were to be automatically converted into equity shares of the Company at the end of 18 months from the date of allotment. The CCPS carry a dividend of 5% per annum, payable annually, subject to deduction of taxes at source, if applicable. The CCPS were non-cumulative and non-participating in nature. The holder of CCPS had the right to vote in accordance with Section 47 of the Companies Act, 2013.

Each optionally convertible preference share (OCPS) has a par value of Rs. 10 and was convertible at the option of the shareholders into equity shares of the Company starting within 18 months from the date of allotment i.e. from August 08, 2016 into ten new equity shares of Rs. 2 for every four hundred and seventy one OCPS held. OCPS not converted within 18 months from the date of allotment, were to be automatically redeemed at par. The OCPS carried a dividend of 5% per annum, payable annually, subject to deduction of taxes at source, if applicable. The OCPS were to be non-cumulative and non-participating in nature. The holder of OCPS had the right to vote in accordance with Section 47 of the Companies Act, 2013. The presentation of the liability and equity portions of these shares is explained in the summary of significant accounting policies.

12B. Distribution made & proposed

	March 31, 2019	March 31, 2018
Cash dividends on equity shares declared and paid:		
Final dividend for the year ended 31 March 2018: Rs. 8 per share (31 March 2017: Rs.	407	357
7 per share)		
Proposed dividends on equity shares:		
Proposed cash dividend for the year ended 31 March 2019: Rs. 8 per share (March 31,	407	407
2018: Rs. 8 per share)		

Proposed dividend on equity shares is subject to approval at the annual general meeting and is not recognised as a liability as at the year end.

12C. Shares reserved for issue under options

For details of shares reserved for issue under the Employee Stock Option Plan (ESOP) of the Company (refer note 34)

13. Other equity

Securities Premium

	INR Crores
As at April1, 2017	4,498
Increase/(decrease) during the year due of conversion of OCPS,CCPS and ESOP allotments	109
At March 31, 2018	4,607
Increase/(decrease) during the year	-
At March 31, 2019	4,607

Retained Earnings

	INR Crores
As at April1, 2017	968
Add: Profit for the year	548
Add: Re-measurement gains (losses) on defined benefit plans	0
Less: Appropriations:	
Dividend on Equity Shares	(357)
Transfer to debenture redemption reserve	(14)
Transfer to capital redemption reserve	(2)
At March 31, 2018	1,143
Add: Profit for the year	405
Add: Re-measurement gains (losses) on defined benefit plans	3
Add: Transfer from debenture redemption reserve	1
Less: Appropriations:	
Dividend on Equity Shares	(407)
At March 31, 2019	1,145

iii) Other Reserves

Capital Redemption Reserve

	INR Crores
As at April1, 2017	36
Increase/(decrease) during the year due of conversion of OCPS and CCPS	2
At March 31, 2018	38
Increase/(decrease) during the year	-
At March 31, 2019	38

13. Other equity (contd.)

	INR Crores
As at April1, 2017	86
Increase/(decrease) during the year	-
At March 31, 2018	86
Increase/(decrease) during the year	-
At March 31, 2019	86

Debenture Redemption Reserve

	INR Crores
As at April1, 2017	127
Add: Amount transferred from retained earnings	14
At March 31, 2018	141
Less: Amount transferred to retained earnings	(1)
At March 31, 2019	140

Share based payment reserve

	INR Crores
As at April1, 2017	2
Increase/(decrease) during the year	(2)
At March 31, 2018	0
Increase/(decrease) during the year	-
At March 31, 2019	0

General Reserve

	INR Crores
As at April1, 2017	1,848
Increase/(decrease) during the year	-
At March 31, 2018	1,848
Increase/(decrease) during the year	-
At March 31, 2019	1,848

Equity Component of convertible preference shares

	INR Crores
As at April1, 2017	0
Increase/(decrease) during the year	(0)
At March 31, 2018	-
Increase/(decrease) during the year	-
At March 31, 2019	-

Equity Instruments through Other Comprehensive Income

	INR Crores
As at April1, 2017	2
Increase/(decrease) during the year	3
At March 31, 2017	5
Increase/(decrease) during the year	1
At March 31, 2018	6

Securities Premium Reserve - Where the Company issues shares at a premium, whether for cash or otherwise, a sum equal to the aggregate amount of the premium received on those shares shall be transferred to "Securities Premium Reserve". The Company may issue fully paid-up bonus shares to its members out of the securities premium reserve and the Company can use this reserve for buy-back of shares.

Capital Redemption Reserve - Capital Redemption Reserve was created for buy-back of shares and can be utilised for issuance of fully paid up bonus shares.

13. Other equity (contd.)

Capital Reserve - The Company recognizes profit or loss on purchase, sale, issue or cancellation of the Company's own equity instruments to capital reserve.

Debenture Redemption Reserve (DRR)-The Company has issued redeemable non-convertible debentures. Accordingly, the Companies (Share capital and Debentures) Rules, 2014 (as amended), require the company to create DRR out of profits of the Company available for payment of dividend. DRR is required to be created for an amount which is equal to 25% of the value of debentures issued.

Share Based Payment Reserve - The Company has an employee stock option scheme under which the option to subscribe for the companies share have been granted to the key employees and directors. The share-based payment reserve is used to recognize the value of equity-settled share-based payments provided to the key employees as part of their remuneration. Refer to note 34 for further details of the scheme.

General Reserve - General Reserve is created out of the profits earned by the Company by way of transfer from surplus in the statement of profit and loss. The Company can use this reserve for payment of dividend subject to compliance with declaration of dividend out of reserve rules and issue of fully paid-up and not paid-up bonus shares.

Other reserves ₹ In Crores

	March 31, 2019	March 31, 2018
Capital Redemption Reserve	38	38
Capital Reserve	86	86
Debenture Redemption Reserve	140	141
Share based payment reserve	0	0
General Reserve	1,848	1,848
Equity Component of convertible preference shares	-	-
Equity Instruments through Other Comprehensive Income	6	5
Total other reserves	2,118	2,118

14. Borrowings

Non-current Borrowings ₹ In Crores

	Effective interest rate	Maturity	March 31, 2019	March 31, 2018
Debentures				
Unsecured Redeemable non convertible	10.53% to	2019-2026	458	682
debentures (NCDs) (Refer note a below)	10.85%			
Current maturities of Non-current Debentures			273	127
Total Non-current Borrowings			731	809
Less: Amount clubbed under "other current			(273)	(127)
financial liabilities" (refer note 15)				
Net Non-current Borrowings			458	682
Aggregate secured loans (non-current)			_	_
			450	-
Aggregate unsecured loans (non-current)			458	682

Current Borrowings ₹ In Crores

	Maturity	March 31, 2019	March 31, 2018
Loans repayable On demand			
Cash credit, packing credit and working capital demand loan			
accounts from Banks (Refer note b below)			
- Secured	On demand	0	65
- Unsecured (6 months LIBOR+48 to 85bps,1month GSEC+5bps)	On demand	507	248
Unsecured Commercial papers from Banks and others (Refer	74-90 days	400	_
note c below)			
Total current Borrowings		907	313
Aggregate secured loans (current)		0	65
Aggregate unsecured loans (current)		907	248

14. Borrowings (contd.)

a. Unsecured Redeemable Non-Convertible Debentures (NCD's)

- The borrowings and current maturities of long term borrowings include Rs 48 crores (March 31, 2018; Rs. 49 crores) pertaining to interest accrued but not due on account of recognition of debentures at amortised cost as per EIR method.
- ii) NCDs of face value amounting to Rs. 300 crores (March 31, 2018: Rs. 300 crores) have been issued under two series and are redeemable at par at the end of 7th year Rs. 150 crores i.e June, 2019 and 0th year Rs. 150 crores i.e June, 2022 from the date of allotment. Out of the above, NCDs amounting to Rs. 90 crores have been bought back by the Company.
- iii) NCDs of face value amounting to Rs. 250 crores (March 31, 2018: Rs. 250 crores) are redeemable at par at the end of 15th year i.e July 2026 from the date of allotment. The NCDs carry a call option at the end of 10th year from the date of allotment.
- iv) NCDs of face value aggregating to Rs. 225 crores (March 31, 2018: Rs. 300 crores) have been issued under three series and are redeemable at par of Rs 75 crores each at the end of 12th year, 11th year, 9th year and 8th year i.e. October 2022, October 2021 and October 2019 respectively from the date of allotment.
- v) NCDs mentioned above carry a coupon rate ranging from 10.35% to 10.70%.

b. Secured Loan repayable on demand from Banks

Outstanding loan is secured by hypothecation of inventories, bills receivables, book debts and all movable assets of the Company both present and future, wherever situated.

c. Unsecured Commercial papers from Banks and others

Commercial paper carry an interest rate of 7.29% to 7.55% per annum for the current year (March 31, 2018: NA) which are maturing in may 2019. These are repayable within 74 to 90 days.

15. Other financial liabilities

₹ In Crores

	Non-current		Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Financial liabilities at fair value through profit or loss				
Derivatives contract (net)	-	135	-	36
Total financial liabilities at fair value through profit	-	135	-	36
or loss				
Other financial liabilities carried at amortised Cost				
Current maturities of long-term borrowings (note 14a)	-	-	273	127
Trade Deposits	-	-	43	51
Creditors for capital goods	-	-	67	154
Interest accrued on borrowings	-	-	1	1
Unpaid dividend	-	-	8	7
Others	4	4	37	1
Total other financial liabilities carried at amortised	4	4	429	341
Cost				
Total other financial liabilities	4	139	429	377

16. Other current liabilities

₹ In Crores

	March 31, 2019	March 31, 2018
Advances against orders	1,135	52
Statutory liabilities	9	7
Other liabilities	2	3
Total other current liabilities	1,146	62

17. Trade payables

Outstanding dues of micro and small enterprises

₹ In Crores

		Current March 31, 2019 March 31, 2018	
	March 31		
Trade payables		26	17
		26	17

18. Trade payables

Outstanding dues of micro and small enterprises

₹ In Crores

	Current	
	March 31, 2019	March 31, 2018
- Outstanding dues of other than micro and small enterprises	2,791	2,336
	2,792	2,336

Terms and conditions of the above financial liabilities:

Trade payables are non-interest bearing and are normally settled on 90-360 days terms For explanations on the Company's credit risk management processes, refer note 41

19. Income taxes

a) The major components of income tax expense for the year are as under:

Income tax expenses recognised in the statement of profit and loss:

₹ In Crores

	March 31, 2019	March 31, 2018
Current tax:		
In respect of current year	83	180
Adjustments of tax relating to earlier years	(3)	(83)
Deferred tax:		
In respect of current year	1	(69)
	81	28

ii) Income tax expenses recognised in OCI:

₹ In Crores

	March 31, 2019	March 31, 2018
Deferred tax expenses on remesurement of defined benefit plan	2	0
Deferred tax expenses on remesurement of equity instruments through other	0	0
comprehensive income		
	2	0

b) Reconciliation of tax expense and the accounting profit for the year is as under:

₹ In Crores

	March 31, 2019	March 31, 2018
Accounting profit before income tax	485	576
Statutory income tax rate of 34.944% (March 31, 2018: 34.608%)	170	199
Dividend Income from Subsidiary	(144)	(123)
Profit on sale of investment to be taxed saperately	(15)	-
Additional deduction on expenditure on Research & Development	(11)	(11)
Amortisation of goodwill in books considered as not deductible in provision for tax	128	128
Agricultural Income exempt from tax	(33)	(19)
MAT credit of earlier years*	-	(63)
Others	(11)	0
	84	111
Adjustments of tax relating to earlier years*	(3)	(83)
Income tax expense reported in the statement of profit and loss	81	28

^{*} Pursuant to the completion of assessments for the past years, the Company has written back excess provision of tax of Rs. 3 crores (March 2018:Rs 83 crores) and recognised minimum alternate tax credit entitlement of Rs Nil (March 2018:Rs 63 crores) for the year ended March 31, 2019

19. Income taxes (contd.)

c) Deferred tax

The major components of deferred tax assets/ (liablities) arising on account of temprory difference are as follows: ₹ In Crores

	Balance	Sheet	Statement of p	rofit and loss
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Accelerated depreciation for tax purposes	(225)	(205)	20	16
Debentures carried at amortised cost	(1)	1	2	(3)
Minimum alternate tax credit	81	63	(18)	(63)
Provision for doubtful debts and advances	53	42	(11)	(10)
Gratuity	9	8	(1)	(2)
Leave encashment	27	24	(3)	(2)
Unwinding of interest cost of trade payables	(13)	(3)	10	(4)
Others	1	7	6	(2)
Net deferred tax assets/(liabilities)	(67)	(64)	-	-
Deferred tax expense/(income)			3	(69)

Reflected in the balance sheet as follows:

₹ In Crores

	Balance Sheet		
	March 31, 2019 March 31, 20		
Deferred tax assets	170	144	
Deferred tax liabilities:	(237)	(208)	
Deferred tax liabilities, net	(67)	(64)	

Reconciliation of deferred tax liabilities (net):

₹ In Crores

	March 31, 2019	March 31, 2018
Opening balance as of 1 April	(64)	(133)
Tax income/(expense) during the year recognised in profit or loss	(1)	69
Tax income/(expense) during the year recognised in OCI	(2)	0
Tax income/(expense) during the year recognised in Equity	-	-
Closing balance as at 31 March	(67)	(64)

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax

Given that the Company does not have any intention to dispose investments in subsidiaries and associates in the forseeable future, deferred tax asset on indexation benefit in relation to such investments has not been recognised. Similarly, the Company does not have any intention to dispose of its free hold and lease hold land in the forseeable future, therefore, deferred tax asset on indexation benefit in relation to these assets has not been recognised.

20. Provisions ₹ In Crores

	March 31, 2019	March 31, 2018
Net employee defined benefit liabilities		
Gratuity (refer note 33)	26	23
Leave encashment (refer note below)	77	68
<u>Others</u>		
Dividend (refer note below)	-	-
Total Provisions	103	91

20. Provisions (contd.)

Movement in provisions ₹ In Crores

Equity shares of INR 2 each fully paid	N	March 31, 2019 March 31, 2018		3		
	Leave	Dividend	Total	Leave	Dividend	Total
	encashment			encashment		
Opening	68	-	68	63	3	66
Arising during the year	9	-	9	5	-	5
Utilised	-	-	-	-	(3)	(3)
Closing	77	-	77	68	-	68

21. Revenue from operations

₹ In Crores

	March 31, 2019	March 31, 2018
Sale of products (including excise duty)	8,470	7,168
Sale / rendering of services		
Job-work income	28	20
Management service fees	18	13
Others	1	1
Other operating revenues		
Export Incentives	80	86
Refund of statutory receivable	10	14
Excess provisions in respect of earlier years written back (net)	10	38
Royalty income	36	24
Miscellaneous receipts	7	10
Total Revenue from operations	8,660	7,374

The Government of India introduced the Goods and Services Tax (GST) with effect from July 01, 2017, consequently revenue from operations for the period from July 31, 2017 upto March 31, 2019 is net of GST. However revenue for the quarter ended June 30, 2017 included in the year ended March 31, 2018 is inclusive of excise duty. The Net revenue from operations (Net of GST/ Excise Duty) as applicable are stated below-

₹ In Crores

	March 31, 2019	March 31, 2018
Revenue from operations	8,660	7,374
Less: Excise Duty	-	(111)
Net Revenue from operations	8,660	7,263

Dislosure under Ind AS 115 - Revenue from contracts with customers

Disaggregation of revenue from contracts with customers

- The management determines that the segment information reported under Note 47 Segment reporting is sufficient to meet the disclosure objective with respect to disaggregation of revenue under Ind AS 115 Revenue from contract with Customers. Hence, no seperate disclosures of disaggregated revenues are reported.
- b. The Company's performance obligation are satisfied upon shipment and payment is generally due by 45 to 270 days.

Contract balances ₹ In Crores

	March 31, 2019	March 31, 2018
Trade receivables (refer note 10)	2,733	2,017
Contract liablities (refer note 16)	1,135	52

Reconciliation of revenue from contract with customers with contracted price ₹ In Crores

	March 31, 2019	March 31, 2018
Revenue from contract with customer as per the contract price	9,522	8,102
Adjustments made to contract price on account of :-		
Discounts / Rebates / Incentives	(399)	(288)
Sales Returns /Credits / Reversals	(625)	(626)
Revenue from contract with customer	8,498	7,188

21. Revenue from operations (contd.)

	March 31, 2019	March 31, 2018
Sale of services	19	14
Other operating revenue	143	172
Revenue from operations	8,660	7,374

Discounts / Rebates / Incentives

The Company issues multiple discount schemes to its customers in order to capture market share. The Company makes a provision for the discount it expects to give to its customers based on the terms of the scheme as at 31 March 2019. Revenue is adjusted for the expected value of discount to be given

Sales returns

The Company recognizes a provision based on the previous history of sales return. Revenue is adjusted for the expected value of return.

22. Other income ₹ In Crores

	March 31, 2019	March 31, 2018
<u>Interest income on</u>		
Bank deposits	1	1
Loans and others	64	68
<u>Dividend Income on</u>		
Long-term investments in subsidiary (refer note 36)	412	356
Other non-operating income		
Fair value gain/(loss) on financial instruments at fair value through profit or loss	7	(7)
Rent received	8	4
Profit on sale of assets (net)	0	-
Profit on sale of investments	46	-
Sundry credit balances written back (net)	2	7
Share in profit from investment in LLP	19	6
Miscellaneous income	1	0
Total other income	560	435

23. Cost of raw material and components consumed

₹ In Crores

	March 31, 2019	March 31, 2018
Inventory at the beginning of the year	519	404
Add: Purchases	4,982	3,632
	5,501	4,036
Less: inventory at the end of the year	760	519
Cost of raw material and components consumed	4,741	3,517

24. Changes in inventories of finished goods (including stock-in-trade) and work-in-progress

	March 31, 2019	March 31, 2018
<u>Inventories at the end of the year</u>		
Finished goods	769	638
By-products	4	3
Work in progress	175	147
Traded goods	80	80
	1,028	868
<u>Inventories at the beginning of the year</u>		
Finished goods	638	647
By-products	3	6
Work in progress	147	148
Traded goods	80	91
	868	892
(Increase)/Decrease in inventory	(160)	24
Less: Excise duty on stocks	-	(22)
•	(160)	2

25. Employee benefit expenses

₹ In Crores

	March 31, 2019	March 31, 2018
Salaries, wages and bonus	435	391
Contribution to provident and other funds (refer note 33)	27	25
Share based payments to employees (refer note 34)	-	0
Retirement benefits (refer note 33)	29	21
Staff welfare expenses	60	49
	551	486

26. Finance costs ₹ In Crores

	March 31, 2019	March 31, 2018
Interest:		
- On Debentures	77	81
- On Others	47	40
Exchange Difference (net)	(55)	(21)
(Gain)/Loss on Derivatives Instruments	50	(10)
Unwinding of interest cost on trade payables	54	35
Other financial charges	12	10
	185	135

27. Depreciation and amortisation expenses

₹ In Crores

	March 31, 2019	March 31, 2018
Depreciation of tangible assets	284	226
Amortization of intangible assets	440	440
	724	666

28. Other expenses

	March 31, 2019	March 31, 2018
Power and fuel	337	237
Containers & packing materials consumed	310	286
Transport charges	217	244
Sub-contracting expenses	330	316
Sales commission	44	46
Rent (Refer note: 35)	97	76
Effluent disposal charges	94	70
Travelling and conveyance	85	74
Advertising and sales promotion	84	72
Legal and professional fees	83	83
Consumption of stores and spares	69	65
Repairs and maintenance		
Plant and machinery	36	32
Buildings	4	3
Others	30	32
Rates and taxes	8	18
Exchange differences (net)	63	9
Charity and donations [(includes Rs 18 crores (31 March 2018: Rs 22 crores) paid for political purpose)]	29	30
CSR expenses (Refer note 46)	18	20
Insurance	14	13
Allowances for doubtful debts (net)	31	8
Assets written off	5	9
Payment to auditor (Refer details below)	3	2
Directors' sitting fees	0	0
Miscellaneos expenses	177	160
•	2,168	1,905

28. Other expenses (contd.)

Payment to auditor ₹ In Crores

	March 31, 2019	March 31, 2018
Audit fee	3	2
Other services (certification fees)*	0	0
Reimbursement of expenses*	0	0
	3	2

^{*} Amount less than a Crore

29. Research and development costs

Research and Development costs, as certified by the management

₹ In Crores

		March 31, 2019	March 31, 2018
a)	Revenue expenses debited to appropriate heads of account.	101	91
b)	Capital Expenditure	12	5

30. Components of Other Comprehensive Income (OCI), net of tax

The disaggregation of changes to OCI by each type of reserve in equity is shown below:

₹ In Crores

	N	March 31, 2019		N	3	
	FVTOCI reserve	Retained earnings	Total	FVTOCI reserve	Retained earnings	Total
Re-measurement gains (losses) on defined benefit plans	-	3	3	-	0	0
Gain/(loss) on FVTOCI financial assets	1	-	1	3	-	3
	1	3	4	3	0	3

31. Earnings per share (EPS)

₹ In Crores

	March 31, 2019	March 31, 2018
Profit attributable to equity holders for basic earnings (₹ In Crores)	404	548
Weighted average number of Equity shares for basic EPS*	50,93,41,987	50,82,06,912
Effect of dilution:		
Convertible preference shares	-	-
Employee Stock options	81,587	91,176
Weighted average number of Equity shares adjusted for the effect of dilution *	50,94,23,574	50,82,98,088

Earnings per equity share (in Rupees)

7.96 Basic (Face value of Rs. 2 each) 10.78 Diluted (Face value of Rs. 2 each) 7.96 10.78

32. Details of Loans & Investment as required u/s 186 of Companies Act, 2013

₹ In Crores

	March 31, 2019		March 31, 2018	
	Loan given	Outstanding	Loan given	Outstanding
Loan given to subsidiaries for working capital /				
<u>business operations</u>				
UPL Corporation Limited (foreign currency loan)	-	-	-	929
SWAL Corporation Limited	77	77	102	-

Rate of interest charged on loans given in INR is 13% p.a and in case of foreign currency loan at 6 months LIBOR +200 to 250 bps.

Investments

Details required u/s 186 have been disclosed in note 5 of the financial statements.

^{*} There have been no other transactions involving equity shares or potential equity shares between the reporting date and the date of authorisation of these financial statements.

33. Gratuity and other post-employment benefit plans

₹ In Crores

₹ In Crores

	March 31, 2019	March 31, 2018
Gratuity Plan	26	23

The gratuity plan is governed by the Payment of Gratuity Act, 1972. Under the act, employee who has completed five years of service is entitled to specific benefit. The level of benefits provided depends on the member's length of service and salary at retirement age.

The following tables summarise the components of net benefit expense recognised in the statement of profit or loss and the funded status and amounts recognised in the balance sheet for the respective plans:

The amounts recognised in the statement of profit and loss are as follows:

Defined Benefit Plan

	Gratuity	
	March 31, 2019	March 31, 2018
Current service cost	11	9
Interest cost on benefit obligation	4	3
Return on plan assets	(2)	(2)
Amount included under the head Employee Benefit Expense in Note 25	13	10
Actuarial changes arising from changes in financial assumptions	(1)	(2)
Remeasurements recognised in Other Comprehensive Income(OCI)	(1)	(2)
Total Expenses recognised in the statement of Profit & Loss	12	8
Actual return on plan assets	2	2

(ii) Defined Contribution Plan

₹ In Crores

	Provident Fund	
	March 31, 2019	March 31, 2018
Current service cost included under the head Employee Benefit Expense in Note 25	18	16

	Superannuation Fund	
	March 31, 2019	March 31, 2018
Current service cost included under the head Employee Benefit Expense in Note 25	9	9

The amounts recognised in the Balance Sheet are as follows:

₹ In Crores

	Gratuity	
	March 31, 2019	March 31, 2018
Present value of funded obligation	55	51
Less: Fair value of plan assets	29	28
Net Liability	26	23

Changes in the present value of the defined benefit obligation representing reconciliation of opening and closing balance thereof are as follows: ₹ In Crores

	Gratuity	
	March 31, 2019	March 31, 2018
Opening defined benefit obligation	51	44
Interest cost	4	3
Current service cost	11	9
Benefits paid	(5)	(2)
Actuarial changes arising from changes in financial assumptions	(6)	(3)
Closing defined benefit obligation	55	51

33. Gratuity and other post-employment benefit plans (contd.)

Changes in the fair value of plan assets are as follows:

₹ In Crores

	Gratuity	
	March 31, 2019	March 31, 2018
Opening fair value of plan assets	28	27
Return on plan assets	2	2
Actuarial changes arising from changes in financial assumptions	(1)	(1)
Closing fair value of plan assets	29	28

Expected contribution to defined benefit plan for the year 2019-20

₹ In Crores

	Gratuity	
	March 31, 2019	March 31, 2018
Expected contribution to defined benefit plan	27	24

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

	Gratuity	
	March 31, 2019	March 31, 2018
Investments with insurer under:	%	%
Funds managed by insurer	100	100

The principal actuarial assumptions at the Balance Sheet date.

	Gratuity	
	March 31, 2019	March 31, 2018
Discount rate	7.70%	7.70%
Return on plan assets	7.70%	7.70%
Mortality Rate	Indian Assured	Indian Assured
	Lives Mortality	Lives Mortality
	(2006-08) Ult.	(2006-08) Ult.
Annual increase in Salary costs	7%	7%
Attrition Rate	8%	8%

A quantitative sensitivity analysis for significant assumption as at March 31, 2019 is as shown below:

₹ In Crores

The following the second secon		
Sensitivity Level	1% increase	1% decrease
Impact on defined benefit obligation		
Discount rate	(3)	4
Future salary increases	4	(3)
Withdrawal rate	_	_

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

34. Share based payment

During the year ended March 31, 2019, the following employee stock option plan (ESOPs) were in existence. The relevant details of the scheme and the grant are as follows:

A. Employees stock option and share plan 2006

The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on September 20, 2006 which provides for a grant of 840,000 options (each option convertible into share) to employees.

	March 31, 2019	March 31, 2018
Number of options granted (net of options lapsed)	5,08,390	5,08,390
Method of settlement (Cash/Equity)	Equity	Equity
Vesting period	Spread over 4 years	Spread over 4 years
	and 6 months	and 6 months
Contractual life of options	10 years	10 years

34. Share based payment (contd.)

The details of the activity have been summarized below

	(No. of equity shares)	
	March 31, 2019	March 31, 2018
Outstanding at the beginning of the year	16,500	52,250
Exercisable at the beginning of the year	16,500	52,250
Forfeited during the year	-	-
Exercised during the year	-	35,750
Vested during the year	-	-
Expired during the year	-	-
Outstanding at the end of the year	16,500	16,500
Exercisable at the end of the year*	16,500	16,500
Weighted average remaining contractual life (in years)	2.91	3.91

For options excercised during the current period, the weighted average share price at the exercise date was Rs. Nil (Mar 31, 2018: Rs. 833).

Stock options granted

The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

	March 31, 2019	March 31, 2018
Weighted average share price/market price	68.75	68.75
Exercise price (Rs. per share)	57.00	57.00
Expected volatility	64.49%	64.49%
Life of the options granted	Vesting period + 18 months i.e.	Vesting period + 18 months i.e.
(vesting and exercise period) in years	3 years, 4 years, 5 years, and 6	3 years, 4 years, 5 years, and 6
	years, for each Vesting tranche	years, for each Vesting tranche
	of 25%	of 25%
Expected dividends	0.30% per annum	0.30% per annum
Average risk-free interest rate	8.04% per annum	8.04% per annum

B. Employees stock option plan (ESOP) 2013

The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on December 03, 2013 which provides for a grant of 1,300,000 options (each option convertible into share) to employees.

Particulars	March 31, 2019
Dates of grant	30-Jan-14 27-May-14 27-May-14
Dates of board approval	30-Jan-14 27-May-14 27-May-14
Date of shareholders approval	03-Dec-13 03-Dec-13 03-Dec-13
Number of options granted	7,11,752 35,000 35,000
Method of settlement (Cash / Equity)	Equity Equity Equity
Vesting period	Spread over 4 years
Exercise period	60 months from the date of grant

The details of the activity have been summarized below

Particulars	March 31, 2019	March 31, 2018
Outstanding at the beginning of the year	14,676	23,723
Exercisable at the beginning of the year	13,269	2,814
Granted during the year	-	-
Forfeited during the year	-	-
Exercised during the year	9,047	9,047
Vested during the year	-	19,502
Expired during the year	-	-
Outstanding at the end of the year	5,629	14,676
Exercisable at the end of the year*	4,222	13,269
Weighted average remaining contractual life (in years)	0.32	1.02

34. Share based payment (contd.)

For options excercised during the current period, the weighted average share price at the exercise date was Rs. 756.33 (Mar 31, 2018: Rs. 703.80).

Stock options granted

The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

Particulars	March 31, 2019	March 31, 2018
Weighted average share price/market price	112.81	112.81
(Rs. per share)		
Exercise price (Rs. per share)	Grant 1 Rs 103.80	Grant 1 Rs 103.80
	Grant 2 Rs 262.75	Grant 2 Rs 262.75
	Grant 3 Rs 319.70	Grant 3 Rs 319.70
Expected volatility	49.17%	49.17%
Life of the options granted (vesting and exercise	Vesting period + 6 months	Vesting period + 6 months
period) in years		
Expected dividends	0.00%	0.00%
Average risk-free interest rate	8.71% per annum	8.71% per annum

^{*}Eligible Employees holding 1 Option shall be entitled to purchase 1.06 new equity shares as per the scheme of amalgamation.

C. Employees stock option plan (ESOP) 2017

The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on July 08, 2017 which provides for a grant of 2,500,000 options (each option convertible into share) to employees.

Particulars	March 31, 2019	March 31, 2018
Dates of grant	25-Jan-18	25-Jan-18
Dates of board approval	25-Jan-17	25-Jan-17
Number of options granted	60,000	60,000
Method of settlement (Cash / Equity)	Equity	Equity
Vesting period	Spread over 2 years	Spread over 2 years
Contractual life of Option	5 years	5 years

Vesting conditions	Grant Date	Number of Options	Contractual life of Options
1 year from grant date	25-Jan-18	20,000	4 years
2 years from grant date	25-Jan-18	40,000	5 years

The details of the activity have been summarized below

	March 31, 2019	March 31, 2018
Outstanding at the beginning of the year	60,000	-
Exercisable at the beginning of the year	-	-
Granted during the year	-	60,000
Forfeited during the year	-	-
Exercised during the year	-	-
Vested during the year	20,000	-
Expired during the year	-	-
Outstanding at the end of the year	60,000	60,000
Exercisable at the end of the year*	20,000	-
Weighted average remaining contractual life (in years)	3.49	4.49

34. Share based payment (contd.)

Stock options granted

The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

	March 31, 2019	March 31, 2018
Weighted average share price/market price (Rs. per share)	824	824
Exercise price (Rs. per share)	784	784
Expected volatility	21.49%	21.49%
Life of the options granted (vesting and exercise period) in years	2 to 3.25 years	2 to 3.25 years
Expected dividends	-	_
Average risk-free interest rate	7.22% per	7.22% per
	annum	annum

Effect of the employee option plan on the Statement of Profit and Loss and on its financial position

₹ In Crores

	March 31, 2019	March 31, 2018
Total employee compensation cost pertaining to stock option plan	1	0
Liability for employee stock option plan outstanding as at the year end	1	0

35. Commitments and contingencies

a. Leases- Operating lease commitments — Company as lessee

Lease rent debited to statement of profit and loss is Rs. 97 crores (March 31, 2018: Rs. 76 crores)

The Company has entered into operating lease arrangements for its office premises, vehicles, machinery, storage locations and residential premises.

Future minimum rentals payable under non-cancellable operating leases as at 31 March are, as follows: ₹ In Crores

	March 31, 2019	March 31, 2018
Within one year	21	21
After one year but more than five years	84	90
More than five years	-	15

Commitments ₹ In Crores

	March 31, 2019	March 31, 2018
Estimated amount of contracts remaining to be executed on capital account and	249	72
not provided for (net of advances)		

Contingent liabilities ₹ In Crores

	March 31, 2019	March 31, 2018
Disputed Income-Tax Liability (excluding interest)	26	26
Disputed Excise Duty / Service Tax liability (excluding interest)	196	203
Disputed Sales Tax liability	31	31
Disputed Custom Duty liability	34	34
Disputed Fiscal Penalty for cancellation of licenses	33	33
Claims against the Company not acknowledged as debts	4	4

e. Pursuant to the judgment of the Supreme Court of India on 28 February 2019 regarding the allowances to be considered for computing Provident Fund liability, certain components of compensation hitherto excluded from PF need to be included. There are interpretative challenges in application of the judgment retrospectively and the Company has been legally advised that the judgment would be applicable prospectively. The financial statements disclose a contingent liability in this regard. No provision has been made for the period from 28 February to 31 March 2019 as the same is not material.

36. Related party transactions

(a) Names of the related parties where control exists irrespective of whether transactions have occurred or not

(i) Name of the Subsidiary Companies:

Name	Country of incorporation/	Notes
	Principal place of business	
Shroffs United Chemicals Limited	India	
SWAL Corporation Limited	India	
United Phosphorus (India) LLP	India	
United Phosphorus Global LLP	India	
Optima Farm Solutions Limited	India	
UPL Europe Limited	United Kingdom	
UPL Deutschland GmbH	Germany	
UPL Polska Sp z.o.o.	Poland	
UPL Benelux B.V.	Netherlands	
Cerexagri B.V.	Netherlands	
Blue Star B.V.	Netherlands	#4
United Phosphorus Holdings Cooperatief U.A.	Netherlands	
United Phosphorus Holdings B.V.	Netherlands	
Decco Worldwide Post-Harvest Holdings Cooperatief U.A.	Netherlands	
Decco Worldwide Post-Harvest Holdings B.V.	Netherlands	
United Phosphorus Holding, Brazil B.V.	Netherlands	
UPL Italia S.R.L.	Italy	
UPL Iberia, S.A.	Spain	
Decco Iberica Postcosecha, S.A.U.	Spain	
Transterra Invest, S. L. U.	Spain	
Cerexagri S.A.S.	France	
Neo-Fog S.A.	France	
JPL France	France	
United Phosphorus Switzerland Limited	Switzerland	
Agrodan, ApS	Denmark	
Decco Italia SRL	Italy	
Limited Liability Company "UPL"	Russia	
Decco Portugal Post Harvest, Unipessoal LDA (formerly known as UPL	Portugal	
Portugal Unipessoal LDA)	3	
United Phosphorus Inc.	USA	
UPI Finance LLC	USA	
Cerexagri, Inc. (PA)	USA	
UPL Delaware, Inc.	USA	
Canegrass LLC	USA	
Decco US Post-Harvest Inc	USA	
RiceCo LLC	USA	
Riceco International, Inc.	Bahamas	
UPL Corporation Limited	Mauritius	
UPL Limited, Mauritius	Mauritius	#
UPL Management DMCC	United Arab Emirates	11
UPL Limited	Gibraltar	
UPL Agro S.A. de C.V.	Mexico	
Decco Jifkins Mexico Sapi	Mexico	
Uniphos Industria e Comercio de Produtos Quimicos Ltda.	Brazil	
Upl do Brasil Industria e Comércio de Froducos Químicos Edda.	Brazil	
UPL Costa Rica S.A.	Costa Rica	
	Bolivia	
UPL Bolivia S.R.L		
UPL Paraguay S.A.	Paraguay	
Icona Sanluis S.A.	Argentina	#1
DVA Technology Argentina S.A.	Argentina	#1

Name	Country of incorporation/	Notes
	Principal place of business	
UPL Argentina S A	Argentina	
Decco Chile SpA	Chile	
UPL Colombia SAS	Colombia	
United Phosphorus Cayman Limited	Cayman Islands	
UP Aviation Limited	Cayman Islands	
UPL Australia Limited	Australia	
UPL New Zealand Limited	New Zealand	
UPL Shanghai Limited	China	
UPL Limited (Korea)	Korea	
PT.UPL Indonesia	Indonesia	
PT Catur Agrodaya Mandiri	Indonesia	
UPL Limited	Hong Kong	
UPL Philippines Inc.	Philippines	
UPL Vietnam Co. Limited	Vietnam	
UPL Limited, Japan	Japan	
Anning Decco Fine Chemical Co. Limited	China	
UPL Ziraat Ve Kimya Sanayi Ve Ticaret Limited Sirketi	Turkey	
UPL Agromed Tarim Ilaclari ve Tohumculuk Sanayi ve Ticaret A.S.	Turkey	#2
Safepack Products Limited	Israel	
Citrashine (Pty) Ltd	South Africa	
UPL Africa SARL	Senegal	#6
Prolong Limited	Israel	#3
Perrey Participações S.A	Brazil	
Agrinet Solutions Limited	India	
Advanta Netherlands Holding B.V.	Netherlands	
Advanta Semillas SAIC	Argentina	
Advanta Holdings B.V.	Netherlands	
Advanta Seeds International	Mauritius	
Pacific Seeds Holdings (Thailand) Limited	Thailand	
Pacific Seeds (Thai) Limited	Thailand	
Advanta Seeds Pty Ltd	Australia	
Advanta US LLC (formerly known as Advanta U.S. Inc.)	USA	
Advanta Comercio De Sementes LTDA.	Brazil	
PT Advanta Seeds Indonesia	Indonesia	
Advanta Seeds DMCC	United Arab Emirates	
Essentiv LCC	USA	
UPL Agro Limited Mauritius	Mauritius	`@3
UPL Jiangsu Limited	China	`@2
Riceco International Bangladesh Ltd	Bangladesh	`@3
Uniphos Malaysia Sdn Bhd	Malaysia	`@3
Advanta Seeds Ukraine LLC	Ukraine	0.0
Decco Gıda Tarım ve Zirai Ürünler San. Tic A.S.	Turkey	@
Arysta LifeScience Investments LLC	USA	@1
Arysta LifeScience America Inc.	USA	@1
ANESA S.A.	Belgium	@1
Arysta LifeScience Management Company, LLC	USA	@1
Arysta LifeScience SPC, LLC	USA	@1
Arysta LifeScience India Limited	India	@1
Arysta LifeScience Agriservice Private Limited	India	@1 @1
Arysta LifeScience Togo SAU	Togo	@1
Arysta Agro Private Limited	India	@1 @1
Arysta Agro Frivate Limited Arysta LifeScience do Brasil Indústria Química e Agropecuária SA	Brazil	@1 @1
Volcano Agrociencia Industria e Comercio de Defensivos Agricolas Ltda	Brazil	@1 @1
Volcario Agrociericia friadoci la e corriercio de Derenoivos Agricolas Etda	DIUZII	<u>ا</u> س

Name	Country of incorporation/	Notes
	Principal place of business	
GBM USA LLC	USA	@1
Arysta LifeScience Canada, Inc.	Canada	@1
Arysta LifeScience Canada BC Inc.	Canada	@1
Arysta LifeScience North America, LLC	USA	@1
Arysta LifeScience NA Holding LLC	USA	@1
Arysta LifeScience Inc.	USA	@1
Arysta LifeScience Services LLP	India	@1
Arysta LifeScience France SAS	France	@1
Arysta LifeScience Benelux SPRL	Belgium	@1
Arysta LifeScience (Mauritius) Ltd	Mauritius	@1
Arysta LifeScience South Africa (Pty) Ltd	South Africa	@1
Arysta Health and Nutrition Sciences Corporation	Japan	@1
Arysta LifeScience Corporation	Japan	@1
Arysta LifeScience S.A.S.	France	@1
Arysta LifeScience Chile S.A.	Chile	@1
Arysta LifeScience Mexico, S.A.de C.V	Mexico	@1
Grupo Bioquimico Mexicano, S.A. de C.V.	Mexico	@1
MacDermid Agricultural Solutions Netherlands Cooperatief UA	Netherlands	@1
Arysta LifeScience UK & Ireland Ltd	U.K.	@1
Arysta LifeScience Europe Sarl	France	@1
MacDermid Agricultural Solutions Italy Srl	Italy	@1
Platform Sales Suisse GmbH	Switzerland	@1
MacDermid Agricultural Solutions Holdings BV	Netherlands	@1
Dutch Agricultural Investment Partners LLC	USA	@1
Netherlands Agricultural Investment Partners LLC	USA	@1
Arysta LifeScience Bulgaria EOOD	Bulgaria	@1
Arysta LifeScience Romania SRL	Romania	@1
Arysta LifeScience Kiev LLC	Ukraine	@1
Arysta LifeScience Great Britain Ltd	U.K.	@1
Arysta LifeScience Technology BV	Netherlands	@1
Arysta LifeScience Netherlands BV	Netherlands	@1
Arysta LifeScience RUS LLC	Russia	@1
Netherlands Agricultural Technologies CV	Netherlands	@1
Dutch Agricultural Formations CV	Netherlands	@1
Arysta LifeScience Turkey Tarim Urunleri Limited Sirketi	Turkey	@1
Arysta LifeScience Australia Pty Ltd.	Australia	@1
Chemtura (Thailand) Ltd	Thailand	@1
MacDermid (Shanghai) Chemical Ltd.	China	@1
Arysta-LifeScience Ecuador S.A.	Ecuador	@1
Arysta LifeScience Ougrée Production Sprl	Belgium	@1
Arysta LifeScience Hellas S.A. Plant Protection, Nutrition and Other	Greece	@1
Related Products and Services		
Arysta LifeScience Iberia SLU	Spain	@1
Arysta Lifescience Italia SrL	Italy	@1
Agriphar Poland Sp. Zoo	Poland	@1
Arysta LifeScience Switzerland Sarl	Switzerland	@1
Arysta Animal Health SAS	France	@1
PPWJ Sci	France	@1
Santamix Iberica SL	Spain	@1
Arysta LifeScience Global Services Limited	Ireland	@1
Arysta LifeScience European Investments Limited	U.K.	@1
Arysta LifeScience U.K. Limited	U.K.	@1
Arysta LifeScience U.K. CAD Limited	U.K.	@1
Arysta LifeScience U.K. EUR Limited	U.K.	@1
		<u> </u>

Anysta LifeScience U.K. JPY Limited Anysta LifeScience U.K. USD Limited Anysta LifeScience U.K. USD Limited Anysta LifeScience U.K. Holdings Limited Anysta LifeScience Lighan Holdings Goudou Kaisha Anysta LifeScience Gameroun SA Cameroon Oil Callivoire SCFD S.A Cote D'Ivoire Oil Callivoire SCFD S.A Cote D'Ivoire Oil Calli Chana Ltd. Ghana Oil Anysta LifeScience Bypt Ltd Egypt Oil Calli Chana Ltd. Ghana Oil Anysta LifeScience Renya Ltd. Mail Protection Des Cultures (M.P.C.) SA Mail Oil Angrifocus Limitada Angrifocus Limitada Angrifocus Limitada Androprops 39 (Pty) Ltd Angrifocus Limitada Anchorprops 39 (Pty) Ltd South Africa Oil Anchorprops 39 (Pty) Ltd South Africa Oil Anchorprops 39 (Pty) Ltd South Africa Oil Science Holdings SA (Pty) Ltd South Africa Oil Anchorprops 39 (Pty	Name of the state	County Six Six	NICE
Anysta Lifescience U.K. U.S. Umited Anysta Lifescience U.K. U.S. U.K. ©1 Anysta Lifescience U.K. Holdings Limited U.K. ©1 Anysta Lifescience (J.K. Holdings Limited U.K. ©1 Anysta Lifescience (J.K. Holdings Coudou Kaisha Anysta Lifescience (Sameron SA Cameron ©1 Callivoire SGFD S.A. Cate D'Ivoire ©1 Anysta Lifescience Exprt.Ltd Egypt ©1 Calli Ghana Ltd. Ghana ©1 Anysta Lifescience Exprt.Ltd Ghana ©1 Anysta Lifescience Kenya Ltd. Kenya ©1 Mall Protection Des Cultures (M.P.C.) SA Mall ©1 Angriforus Limitada Androprops 39 (Pty) Ltd Mall Protection Des Cultures (M.P.C.) SA Mall ©1 Anchoprops 39 (Pty) Ltd South Africa ©1 Callietha Investments (Pty) Ltd South Africa ©1 Soldwalk Trading (Pty) Ltd South Africa ©1 Volcano Agroscience (Pty) Ltd South Africa ©1 Volcano Agroscience (Pty) Ltd Volcano Agroscience (Pty) Ltd Volcano Chemicals (Pty) Ltd South Africa ©1 Volcano Chemicals (Pty) Ltd South Africa ©1 Volcano Chemicals (Pty) Ltd South Africa ©1 Anysta Lifescience Tanzania Ltd Tanzania ©1 Anysta Lifescience (Shangha) Co., Ltd. Tanzania ©1 Anysta Lifescience (Phangha) Co., Ltd. Tohina ©1 Pt. Anysta Lifescience Protect Ltd. Korea ©1 Anysta Lifescience Protect Ltd. Korea ©1 Anysta Lifescience Protect Ltd. South Africa ©1 Anysta Lifescience Vertamen ©1 Anysta Lifescience Ceach s.o. Cech Rpb ©	Name		Notes
Arysta Lifescience U.K. Holdings Limited U.K. @1 Arysta Lifescience U.K. Holdings Goudou Kaisha Arysta Lifescience Cameroun SA Cameroon @1 Callwoire SGFD S.A Cotte D'Ivoire @1 Arysta Lifescience Egypt Ltd Egypt @1 Callwoire SGFD S.A Cotte D'Ivoire @1 Arysta Lifescience Egypt Ltd Ghana @1 Arysta Lifescience Egypt Ltd Ghana @1 Arysta Lifescience Kenya Ltd. Mall Protection Des Cultures (M.P.C.) SA Mall @1 Arysta Lifescience Henya Ltd. Mall Protection Des Cultures (M.P.C.) SA Mall @1 Arysta Lifescience Holdings SA (Pty) Ltd Arysta Lifescience Holdings SA (Pty) Ltd Arysta Lifescience Holdings SA (Pty) Ltd South Africa @1 Callethan Investments (Pty) Ltd South Africa @1 Callethan Investments (Pty) Ltd South Africa @1 Callethan Investments (Pty) Ltd South Africa @1 Volcano Agroscience (Pty) Ltd South Africa @1 Volcano Agroscience (Pty) Ltd South Africa @1 Volcano Agroscience (Pty) Ltd South Africa @1 Volcano Chemicals (Pty) Ltd South Africa @1 Volcano Egypt Lifescience Tanzania Ltd Tanzania @1 Arysta Lifescience Tanzania Ltd Tanzania @1 Arysta Lifescience Tanzania Ltd Tanzania @1 Arysta Lifescience Tanzania Ltd Korea @1 Arysta Lifescience Falsania (N.C.) LTD Palsistan @1 Arysta Lifescience Philippines Inc Philippines @1 Arysta Lifescience Philippines Inc Philippines @1 Arysta Lifescience Holdings France SAS France @1 Arysta Lifescience Gemany GmbH Arysta Lifescience Gemany GmbH Arysta Lifescience Gemany GmbH Arysta Lifescience Gemany GmbH Arysta Lifescience Magyarorszag Kft. Hungary @1 Arysta Lifescience Magyarorszag Kft. Hungary Arysta Lifescience Magyarorszag Kft. Hungary @1 Arysta Lifescience Magyarorszag Kft. Hungary Arysta Lifescien	Anysta LifeCsiansa LLK IDV Limited		@1
Aysta Lifescience Japan Holdings Cinuted Aysta Lifescience Japan Holdings Goudou Kaisha Aysta Lifescience Gameroun SA Cameroon ©1 Collivoire SGFD SA Cote D'Ivoire ©1 Calli Chana Ltd. Ghana Q1 Aysta Lifescience Egypt Ltd Egypt Q1 Calli Chana Ltd. Kenya Q1 Mall Protection Des Cultures (M.P.C.) SA Mali Q1 Aysta Lifescience Holdings SA (Pty) Ltd Mozambique Q1 Agrifocus Limitada Arysta Lifescience Holdings SA (Pty) Ltd South Africa Q1 Anchorprops 39 (Pty) Ltd South Africa Q1 Anchorprops 39 (Pty) Ltd South Africa Q1 Aysta Lifescience Tanzania Ltd Arysta Lifescience South Africa Q1 Aysta Lifescience Titra Indonesia Q1 Aysta Lifescience Firta Indonesia Q1 Aysta Lifescience Asia Pte., Ltd. Arysta Lifescience Asia Pte., Ltd. Arysta Lifescience Asia Pte., Ltd. Arysta Lifescience Philippines Inc. Philippines Q1 Arysta Lifescience Mora Dc., Ltd. Yietnam Q1 Arysta Lifescience Challings France SAS Prance Q1 Arysta Lifescience Victoria Co., Ltd. Yietnam Q1 Arysta Lifescience Creen SAS Prance Q1 Arysta Lifescience Victoria SAS Prance Q1 Arysta L			
Arysta LifeScience Cameroun SA Cameroon Callivoire SGFD S.A. Core D'Ivoire Callivoire SGFD S.A. Core D'Ivoire Calli Ghana Ltd. Calli Ghana Ltd			_
Arysta LifeScience Egypt Ltd Callivoire SGFD S.A. Cote D'Ivoire Callivoire SGFD S.A. Cote D'Ivoire Calli Chana Ltd. Calli Chana Chan			_
Callvoire SGFD S.A. Arysta LifeScience Egypt Ltd Call Ghana Ltd. Ghana Arysta LifeScience Kerya Ltd. All Protection Des Cultures (M.P.C.) SA Mall Agrifocus Limitada Agrifocus LifeScience Holding SA (Pty) Ltd South Africa Callietha Investments (Pty) Ltd			
Arysta LifeScience Egypt Ltd Call Ghana Ltd. Call Ghana Ltd. Kenya @1 Mall Protection Des Cultures (M.P.C.) SA Mali @1 Arysta LifeScience Kenya Ltd. Marpficous Limitada Arysta LifeScience Holdings SA (Pty) Ltd Arysta LifeScience Holdings SA (Pty) Ltd South Africa @1 Arysta LifeScience Holdings SA (Pty) Ltd South Africa @1 Sidewalk Trading (Pty) Ltd South Africa @1 Sidewalk Trading (Pty) Ltd South Africa @1 Sidewalk Trading (Pty) Ltd South Africa @1 Arysta LifeScience Fina Indonesia &1 Arysta LifeScience (Shanghal) Co., Ltd. China @1 Arysta LifeScience (Shanghal) Co., Ltd. China @1 Arysta LifeScience Firta Indonesia &1 Arysta LifeScience Firta Indonesia &1 Arysta LifeScience Pakistan (Pvt.) LTD. Arysta LifeScience Pakistan (Pvt.) LTD. Pakistan @1 Arysta LifeScience Asia Pvt., Ltd. Singapore @1 Arysta LifeScience Holdings France SAS France @1 Arysta LifeScience Holdings France SAS France @1 Arysta LifeScience Holdings France SAS France @1 Arysta LifeScience Gemany GbH Arysta LifeScience Mayarorszag Kt. Hungary @1 Arysta LifeScience Michael Limited UK Arysta LifeScience Glombia S.A. Argentina @1 Arysta LifeScience Michael Limited UK Arysta LifeScience Glombia S.A. Argentina @1 Arysta LifeScience Michael Limited UK Arysta LifeScience Michael S.A. Argentina @1 Arysta LifeScience Michael S.A. Argentina @1 Arysta LifeScience Michael Limited UK Arysta LifeScience Glombia S.A. Argentina @1 Arysta LifeScience Michael S.A. Argentina @1 Arysta LifeScience Glombia S.A. Colombia @1 Arysta LifeScience Glombia S.A. Argentina @1 Arysta LifeScience Glombia S.A. Argentina @1 Arysta LifeScience Gl			
Calli Ghana Ltd. Arysta LifeScience Kenya Ltd. Mali Protection Des Cultures (M.P.C.) SA Mali Protection Sa (Pty) Ltd South Africa (I) South Africa (I) Anchorprops 39 (Pty) Ltd South Africa (I) Volcano Agroscience (Pty) Ltd South Africa (I) South Africa (I) Arysta LifeScience Tanzania Ltd Arysta LifeScience Tanzania Ltd Arysta LifeScience Tanzania Ltd Arysta LifeScience General Indonesia (Indonesia (I			
Arysta LifeScience Kenya Ltd. Mail Protection Des Cultures (M.P.C.) SA Mail (mill of Margificous Dimitada (mozambique of Arysta LifeScience Holdings SA (Pty) Ltd Arysta LifeScience Holdings SA (Pty) Ltd Anchorprops 39 (Pty) Ltd South Africa (mill of Margifica of South Africa (mill of Archorprops 39 (Pty) Ltd South Africa (mill of South Africa (mill	9		
Mali Protection Des Cultures (M.P.C.) SA Agrifocus Limitada Agrysta LifeScience Holdings SA (Pty) Ltd South Africa Anchorprops 39 (Pty) Ltd South Africa South Africa Sidewalk Trading (Pty) Ltd South Africa South A			
Agrifocus Limitada Arysta LifeScience Holdings SA (Pty) Ltd South Africa Official Obligation South Africa Official South Africa Official South Africa Official Obligation South Obligation South Africa Official Obligation South Obli			
Ansta LifeScience Holdings SA (Pty) Ltd South Africa Anchorprops 39 (Pty) Ltd South Africa Of South Africa South Africa Of Volcano Agroscience (Pty) Ltd South Africa Of Arysta LifeScience (Pty) Ltd South Africa Of Arysta LifeScience Fanzania Ltd Arysta LifeScience (Shanghai) Co., Ltd. China Of Arysta LifeScience (Shanghai) Co., Ltd. China Of Arysta LifeScience (Shanghai) Co., Ltd. China Of Arysta LifeScience Philippines Inc. Of Arysta LifeScience (Pt.) Ltd. Of Designation Co., Ltd. Of Desi			
Anchorprops 39 (Pty) Ltd South Africa Callietha Investments (Pty) Ltd South Africa Orl Sidewalk Trading (Pty) Ltd South Africa Orl Volcano Agroscience (Pty) Ltd South Africa Orl Volcano Chemicals (Pty) Ltd South Africa Orl Volcano Chemicals (Pty) Ltd South Africa Orl Arysta LifeScience Tanzania Ltd Arysta LifeScience Tanzania Ltd Arysta LifeScience (Shanghai) Co., Ltd. China Orl Arysta LifeScience Korea Ltd. Arysta LifeScience Rakistan (Ptt.), LTD. Arysta LifeScience Pakistan (Ptt.), LTD. Arysta LifeScience Philopines Inc. Orl Arysta LifeScience Holdings France Orl Arysta LifeScience Holdings France SAS France Orl Arysta LifeScience Holdings France SAS France Orl Arysta LifeScience Holdings France SAS France Orl Arysta LifeScience Cecch s.r.o. Arysta LifeScience Cecch s.r.o. Cecch Rpb Orl Arysta LifeScience Germany GmbH Germany Orl Arysta LifeScience Magyarorszag Kft. Hungary Orl Arysta LifeScience Magyarorszag Kft. Hungary Orl Arysta LifeScience Oska Sp. z.o.o Poland Orl Betel Reunion S.A. Reunion(Fr) Orl Arysta LifeScience Ukraine LLC Ukraine Orl Arysta LifeScience Ukraine LLC Ukraine Orl Arysta LifeScience CentroAmerica, S.A. Argentina Orl Arysta LifeScience CentroAmerica, S.A. Guatemalla Arysta LifeScience CentroAmerica, S.A. Orl		·	
Callietha Investments (Pty) Ltd Sidewalk Trading (Pty) Ltd South Africa Oltona Orderoscience (Pty) Ltd South Africa Oltona Orderoscience (Pty) Ltd South Africa Oltona Orderoscience (Pty) Ltd Arysta LifeScience Tanzania Ltd Arysta LifeScience (Shanghai) Co., Ltd. China Oltona Orderoscience (Trad Indonesia Arysta LifeScience Tirta Indonesia Indonesia Indonesia Oltona Orderoscience Palitippines (Pty) Ltd. Arysta LifeScience Palitippines Inc. Arysta LifeScience Philippines Inc. Arysta LifeScience Philippines Inc. Arysta LifeScience Philippines Inc. Arysta LifeScience Philippines Inc. Arysta LifeScience (Thailand) Co., Ltd. Arysta LifeScience (Indiand) Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Holdings France SAS France Oltonarro Développement SAS France Oltonarro Oltonarr			
Sidewalk Trading (Pty) Ltd Volcano Agroscience (Pty) Ltd Volcano Chemicals (Pty) Ltd South Africa			
Volcano Agroscience (Pty) Ltd South Africa @1 Volcano Chemicals (Pty) Ltd South Africa @1 Arysta LifeScience Tarania Ltd Tanzania @1 Pt. Arysta LifeScience (Shanghai) Co., Ltd. China @1 Pt. Arysta LifeScience (Shanghai) Co., Ltd. Korea @1 Arysta LifeScience Robera Ltd. Korea @1 Arysta LifeScience Pakistan (Pvt.) LTD. Pakistan @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Wild Problem Ltd. Singapore @1 Arysta LifeScience Vietnam Co., Ltd. Vietnam @1 Arysta LifeScience Vietnam Co., Ltd. France @1 Laboratoires Goëmar SAS France @1 Altural Plant Protection SAS. France @1 Arysta LifeScience Germany GmbH			
Volcano Cĥemicals (Pty) Ltd South Africa @1 Arysta LifeScience Tanzania Ltd Tanzania @1 Arysta LifeScience (Shanghai) Co., Ltd. China @1 Pt. Arysta LifeScience Tirta Indonesia Indonesia @1 Arysta LifeScience Rorea Ltd. Korea @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Asia Pte., Ltd. Singapore @1 Arysta LifeScience Vietnam Co., Ltd. Thailand @1 Arysta LifeScience Holdings France SAS France @1 Goëmar Développement SAS France @1 Laboratoires Goëmar SAS France @1 Natural Plant Protection S.A.S. France @1 Arysta LifeScience Czech s.r.o. Czech Rpb @1 Arysta LifeScience Magyarorszag Kft. Hungary @1 Arysta LifeScience Polska Sp. z.o.o Poland @1 Betel Reunion S.A. Reunion(Fr) @1 Arysta LifeScience Vostok Ltd. Russia @			
Arysta LifeScience Tanzania Ltd Arysta LifeScience (Shanghai) Co., Ltd. China @1 Pt. Arysta LifeScience Ritra Indonesia @1 Arysta LifeScience Korea Ltd. Korea @1 Arysta LifeScience Rorea Ltd. Korea @1 Arysta LifeScience Pakistan (Pvt.) LTD. Pakistan @1 Arysta LifeScience Pakistan (Pvt.) LTD. Philippines @1 Arysta LifeScience Pakistan (Pvt.) LTD. Philippines @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Philippines Inc. Arysta LifeScience (Thailand) Co., Ltd. Singapore @1 Arysta LifeScience (Thailand) Co., Ltd. Thailand @1 Arysta LifeScience (Thailand) Co., Ltd. Thailand @1 Arysta LifeScience Vietnam Co., Ltd. Thailand @1 Arysta LifeScience Vietnam Co., Ltd. Thailand @1 Arysta LifeScience With Co., Ltd. Thailand @1 Arysta LifeScience Gience Tance SAS France @1 Goëmar Développement SAS France @1 Laboratoires Goëmar SAS France @1 Arysta LifeScience Czech s.r.o. Czech Rpb @1 Arysta LifeScience Germany GmbH Germany @1 Arysta LifeScience Magyarorszag Kft. Hungary @1 Arysta LifeScience Magyarorszag Kft. Hungary @1 Arysta LifeScience Wasyarorszag Kft. Rungary @1 Arysta LifeScience Slovakia S.R.O. Poland @1 Betel Reunion S.A. Reunion(Fr) @1 Arysta LifeScience Ukraine LLC Ukraine @1 Arysta LifeScience Global Limited U.K. @1 Arysta LifeScience Global Limited U.K. Arysta LifeScience CentroAmerica, S.A. Argent LifeScience CentroAmerica, S.A. Guatemala @1 Arysta LifeScience Mexico Holding S.A.de C.V Mexico @1 Besarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico @1 Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico @1 Tecon Extractos Vegetales, S.A. de C.V. Mexico @1 Tecon Extr	3		
Arysta LifeScience (Shanghai) Co., Ltd. Pt. Arysta LifeScience Tirta Indonesia 91 Arysta LifeScience Tirta Indonesia 11 Arysta LifeScience Pakistan (Pvt.) LTD. 12 Arysta LifeScience Philippines Inc. 13 Arysta LifeScience Philippines Inc. 14 Arysta LifeScience Philippines Inc. 15 Arysta LifeScience Philippines Inc. 16 Arysta LifeScience Philippines Inc. 17 Arysta LifeScience (Thailand) Co., Ltd. 17 Arysta LifeScience Vietnam Co., Ltd. 18 Arysta LifeScience Vietnam Co., Ltd. 18 Arysta LifeScience Germany SaS 19 Arysta LifeScience Germany GmbH 19 Arysta LifeScience Germany GmbH 20 Arysta LifeScience Magyarorszag Kft. 20 Arysta LifeScience Magyarorszag Kft. 21 Arysta LifeScience Vostok Ltd. 22 Arysta LifeScience Vostok Ltd. 23 Arysta LifeScience Vostok Ltd. 24 Arysta LifeScience Slovakia S.R.O. 25 Arysta LifeScience Slovakia S.R.O. 27 Arysta LifeScience Ukraine LLC 27 Arysta LifeScience Global Limited 27 Arysta LifeScience Global Limited 28 Arysta LifeScience Magyarorszag S.A. 27 Argentina @11 Arysta LifeScience Mexico Holding S.A.de C.V 28 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 38 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 39 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 30 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 31 Arysta LifeScience Mexico Holding S.A.de C.V. 31 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 31 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 31 Bearrollos Arysta LifeScience Paraguay S.R.L. 31 Arysta LifeScience Paraguay S.R.L. 32 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 32 Bearrollos Immobiliarios Alianza de Coahuila, S.A. de C.V. 33 Bear			
Pt. Arysta LifeScience Korea Ltd. Indonesia @1 Arysta LifeScience Rorea Ltd. Korea @1 Arysta LifeScience Pakistan (Pvt.) LTD. Pakistan @1 Arysta LifeScience Philippines Inc. Philippines @1 Arysta LifeScience Asia Pte., Ltd. Singapore @1 Arysta LifeScience (Thailand) Co., Ltd. Thailand @1 Arysta LifeScience Vietnam Co., Ltd. Vietnam @1 Arysta LifeScience Holdings France SAS France @1 Goëmar Développement SAS France @1 Saboratoires Goëmar SAS France @1 Natural Plant Protection S.A.S. France @1 Arysta LifeScience Gezens r.o. Czech Rpb @1 Arysta LifeScience Germany GmbH Germany @1 Arysta LifeScience Magyarorszag Kft. Hungary @1 Arysta LifeScience Polska Sp. z.o.o Poland @1 Betel Reunion S.A. Russia @1 Arysta LifeScience Vostok Ltd. Russia @1 Arysta LifeScience Slovakia S.R.O. Slovakia @1 Arysta LifeScience Global Limited U.K. <td< td=""><td></td><td></td><td></td></td<>			
Arysta LifeScience Korea Ltd. Arysta LifeScience Pakistan (Pt.) LTD. Arysta LifeScience Philippines Inc. Arysta LifeScience Philippines Inc. Arysta LifeScience Asia Pte., Ltd. Singapore Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Holdings France SAS France Goëmar Développement SAS France Interview Comman Développement SAS France Interview Comman Développement SAS France Interview Comman			
Arysta LifeScience Pakistan (Pvt.) LTD. Arysta LifeScience Philippines Inc. Philippines Modern Singapore Modern Metal LifeScience Asia Pte., Ltd. Arysta LifeScience Modern Modern Metal LifeScience Modern Metal LifeScience Vietnam Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Holdings France SAS France Modern Développement SAS France Modern SAS France Modern Metal			
Arysta LifeScience Philippines Inc. Arysta LifeScience Asia Pte, Ltd. Arysta LifeScience (Thailand) Co., Ltd. Arysta LifeScience (Thailand) Co., Ltd. Arysta LifeScience Wetnam Co., Ltd. Arysta LifeScience Holdings France SAS France Goëmar Développement SAS France Blaboratoires Goëmar SAS France Blaboratoires Glaboratoires Glabor			
Arysta LifeScience Asia Pte., Ltd. Arysta LifeScience (Thailand) Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Vietnam Arysta LifeScience Vietnam Co., Ltd. Vietnam Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Holdings France SAS France G1 Goëmar Développement SAS France G1 Laboratoires Goëmar SAS France G1 Natural Plant Protection S.A.S. France G1 Arysta LifeScience Czech s.r.o. Czech Rpb Germany G1 Arysta LifeScience Germany GmbH Germany G1 Arysta LifeScience Magyarorszag Kft. Hungary G1 Arysta LifeScience Polska Sp. z.o.o Poland G1 Betel Reunion S.A. Reunion(Fr) G1 Arysta LifeScience Vostok Ltd. Russia G1 Arysta LifeScience Vostok Ltd. Russia G1 Arysta LifeScience Ukraine LLC Ukraine G1 Arysta LifeScience Global Limited Ukraine G1 Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Argentina S.A. Colombia G1 Arysta LifeScience CentroAmerica, S.A. Guatemala G1 Arysta LifeScience Mexico Holding S.A.de C.V. Mexico G1 Boesarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico G1 Agroquimicos y Semillas, S.A. de C.V. Mexico G1 Agroquimicos y Semillas, S.A. de C.V. Mexico G1 France G1 Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Peru G1 Arysta LifeScience Peru S.A.C			
Arysta LifeScience (Thailand) Co., Ltd. Arysta LifeScience Vietnam Co., Ltd. Vietnam @1 Arysta LifeScience Holdings France SAS Goëmar Développement SAS France @1 Laboratoires Goëmar SAS France @1 Natural Plant Protection S.A.S. France @1 Arysta LifeScience Czech s.r.o. Czech Rpb @1 Arysta LifeScience Germany GmbH Arysta LifeScience Magyarorszag Kft. Hungary @1 Arysta LifeScience Polska Sp. z.o.o Poland Betel Reunion S.A. Reunion(Fr) @1 Arysta LifeScience Vostok Ltd. Russia Arysta LifeScience Slovakia S.R.O. Slovakia @1 Arysta LifeScience Ukraine LLC Ukraine Ukraine @1 Arysta LifeScience Gobal Limited Ukraine @1 Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia @1 Arysta LifeScience CentroAmerica, S.A. Guatemala @1 Arysta LifeScience Mexico Holding S.A.de C.V. Mexico @1 Bioenzymas S.A. de C.V. Mexico @1 Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de CV Mexico @1 Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Peru @1 Arysta LifeScience Peru S.A.C Peru @1 Arysta LifeScience Peru S.A.C Peru @1 Arysta LifeScience Peru S.A.C Peru			
Arysta LifeScience Vietnam Co., Ltd. Arysta LifeScience Holdings France SAS France ©1 Goëmar Développement SAS France ©1 Laboratoires Goëmar SAS France ©1 Natural Plant Protection S.A.S. France ©1 Arysta LifeScience Czech s.r.o. Czech Rpb ©1 Arysta LifeScience Germany GmbH Germany ©1 Arysta LifeScience Magyarorszag Kft. Hungary ©1 Arysta LifeScience Polska Sp. z.o.o Poland ©1 Arysta LifeScience Vostok Ltd. Reunion S.A. Reunion(Fr) ©1 Arysta LifeScience Slovakia S.R.O. Slovakia ©1 Arysta LifeScience Ukraine LLC Ukraine ULK. ©1 Arysta LifeScience Gobal Limited U.K. ©1 Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Guatemala Arysta LifeScience CentroAmerica, S.A. Guatemala ©1 Arysta LifeScience Mexico Holding S.A.de C.V Mexico ©1 Bioenzymas S.A. de C.V. Mexico ©1 Agroquimicos y Semillas, S.A. de C.V. Mexico ©1 Agroquimicos y Semillas, S.A. de C.V. Mexico ©1 Tecno Extractos Vegetales, S.A. de C.V. Mexico ©1 Tesaurus Mexico S.A. de C.V. Mexico ©1 Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Paraguay S.R.L. Peru ©1 Arysta LifeScience Paraguay S.R.L. Peru		9 .	
Arysta LifeScience Holdings France SAS Gemar Développement SAS LifeScience Gemar SAS France Q1 Laboratoires Goémar SAS France Q1 Natural Plant Protection S.A.S. France Q1 Arysta LifeScience Czech s.r.o. Czech Rpb Q1 Arysta LifeScience Germany GmbH Germany Q1 Arysta LifeScience Magyarorszag Kft. Hungary Q1 Arysta LifeScience Polska Sp. z.o.o Poland Q1 Betel Reunion S.A. Reunion(Fr) Q1 Arysta LifeScience Vostok Ltd. Russia Q1 Arysta LifeScience Slovakia S.R.O. Slovakia Q1 Arysta LifeScience Ukraine LLC Ukraine Q1 Arysta LifeScience Global Limited U.K. Q1 Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Q1 Arysta LifeScience Colombia S.A.S Colombia Q1 Arysta LifeScience Colombia S.A.S Colombia Q1 Arysta LifeScience Mexico Holding S.A.de C.V Mexico Q1 Bioenzymas S.A. de C.V. Mexico Q1 Agroquimicos y Semillas, S.A. de C.V. Mexico Q1 Agroquimicos y Semillas, S.A. de C.V. Mexico Q1 Tecno Extractos Vegetales, S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Peru Q1 Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C			
Goëmar Développement SASFrance@1Laboratoires Goëmar SASFrance@1Natural Plant Protection S.A.S.France@1Arysta LifeScience Czech s.r.o.Czech Rpb@1Arysta LifeScience Germany GmbHGermany@1Arysta LifeScience Magyarorszag Kft.Hungary@1Arysta LifeScience Polska Sp. z.o.oPoland@1Betel Reunion S.A.Reunion(Fr)@1Arysta LifeScience Vostok Ltd.Russia@1Arysta LifeScience Slovakia S.R.O.Slovakia@1Arysta LifeScience Ukraine LLCUkraine@1Arysta LifeScience Global LimitedU.K.@1Arysta LifeScience Argentina S.A.Argentina@1Arysta LifeScience Colombia S.A.SColombia@1Arysta LifeScience CentroAmerica, S.A.Guatemala@1Arysta LifeScience Mexico Holding S.A.de C.VMexico@1Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.C.Peru@1			
Laboratoires Goëmar SASFrance@1Natural Plant Protection S.A.S.France@1Arysta LifeScience Czech s.r.o.Czech Rpb@1Arysta LifeScience Germany GmbHGermany@1Arysta LifeScience Magyarorszag Kft.Hungary@1Arysta LifeScience Polska Sp. z.o.oPoland@1Betel Reunion S.A.Reunion(Fr)@1Arysta LifeScience Vostok Ltd.Russia@1Arysta LifeScience Slovakia S.R.O.Slovakia@1Arysta LifeScience Ukraine LLCUkraine@1Arysta LifeScience Global LimitedU.K.@1Arysta LifeScience Argentina S.A.Argentina@1Arysta LifeScience Colombia S.A.SColombia@1Arysta LifeScience CentroAmerica, S.A.Guatemala@1Arysta LifeScience Mexico Holding S.A.de C.VMexico@1Bioenzymas S.A. de C.V.Mexico@1Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Paraguay S.R.L.Peru@1			
Natural Plant Protection S.A.S.France@1Arysta LifeScience Czech s.r.o.Czech Rpb@1Arysta LifeScience Germany GmbHGermany@1Arysta LifeScience Magyarorszag Kft.Hungary@1Arysta LifeScience Polska Sp. z.o.oPoland@1Betel Reunion S.A.Reunion(Fr)@1Arysta LifeScience Vostok Ltd.Russia@1Arysta LifeScience Slovakia S.R.O.Slovakia@1Arysta LifeScience Global LimitedU.K.@1Arysta LifeScience Global LimitedU.K.@1Arysta LifeScience Argentina S.A.Argentina@1Arysta LifeScience Colombia S.A.SColombia@1Arysta LifeScience CentroAmerica, S.A.Guatemala@1Arysta LifeScience Mexico Holding S.A.de C.VMexico@1Bioenzymas S.A. de C.V.Mexico@1Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1	·		
Arysta LifeScience Czech s.r.o. Arysta LifeScience Germany GmbH Germany Arysta LifeScience Magyarorszag Kft. Arysta LifeScience Polska Sp. z.o.o Poland Betel Reunion S.A. Reunion(Fr) Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Slovakia S.R.O. Slovakia Arysta LifeScience Ukraine LLC Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Besarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Olagora Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico Ola Tecno Extractos Vegetales, S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Peru Ola Paraguay Ola Paraguay Ola Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C			
Arysta LifeScience Germany GmbH Arysta LifeScience Magyarorszag Kft. Arysta LifeScience Polska Sp. z.o.o Betel Reunion S.A. Arysta LifeScience Vostok Ltd. Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Ukraine LLC Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Arysta LifeScience CentroAmerica, S.A. Argentina Arysta LifeScience Mexico Holding S.A.de C.V. Bioenzymas S.A. de C.V. Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Desarrollos Inmobiliarios Alianza de Cov. Mexico Desarrollos SA de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico Desarrollos SA de C.V. Peru Desarrollos SA de C.V.			
Arysta LifeScience Magyarorszag Kft. Arysta LifeScience Polska Sp. z.o.o Betel Reunion S.A. Reunion(Fr) Arysta LifeScience Vostok Ltd. Russia @1 Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience CentroAmerica, S.A. Argentina Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de C.V. Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Mexico @1 Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C		•	
Arysta LifeScience Polska Sp. z.o.o Betel Reunion S.A. Reunion(Fr) Arysta LifeScience Vostok Ltd. Russia @1 Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Arysta LifeScience Colombia S.A.S Argentina Arysta LifeScience Colombia S.A.S Colombia Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico @1 Agroquimicos y Semillas, S.A. de C.V. Servicios Agricolas Mundiales SA de C.V. Tecno Extractos Vegetales, S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Peru @1 Arysta LifeScience Peru S.A.C		,	
Betel Reunion S.A.Reunion(Fr)@1Arysta LifeScience Vostok Ltd.Russia@1Arysta LifeScience Slovakia S.R.O.Slovakia@1Arysta LifeScience Ukraine LLCUkraine@1Arysta LifeScience Global LimitedU.K.@1Arysta LifeScience Argentina S.A.Argentina@1Arysta LifeScience Colombia S.A.SColombia@1Arysta LifeScience CentroAmerica, S.A.Guatemala@1Arysta LifeScience Mexico Holding S.A.de C.VMexico@1Bioenzymas S.A. de C.V.Mexico@1Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Agroquimicos y Semillas, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1			
Arysta LifeScience Vostok Ltd. Arysta LifeScience Slovakia S.R.O. Slovakia @1 Arysta LifeScience Ukraine LLC Ukraine @1 Arysta LifeScience Global Limited U.K. @1 Arysta LifeScience Argentina S.A. Argentina @1 Arysta LifeScience Colombia S.A.S Colombia @1 Arysta LifeScience CentroAmerica, S.A. Guatemala @1 Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico @1 Desarrollos Inmobiliarios Alianza de C.V. Mexico @1 Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de C.V. Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Paraguay @1 Arysta LifeScience Peru S.A.C			
Arysta LifeScience Slovakia S.R.O. Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico Bioenzymas S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Mexico Omega Agricolas Mundiales SA de C.V. Mexico Omega Kuricolas Mundiales SA de C.V. Mexico Ontestractos Vegetales, S.A. de C.V. Mexico Ontestractos Vegetales, S.A. de C.V. Mexico Ontestractos Vegetales, S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Paraguay Ontestractos Vegetales Paraguay S.R.L. Paraguay Ontestractos Peru S.A.C			
Arysta LifeScience Ukraine LLC Arysta LifeScience Global Limited U.K. @1 Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia @1 Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Mexico @1 Bioenzymas S.A. de C.V. Mexico @1 Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico @1 Omega Agroindustrial, S.A. de C.V. Mexico @1 Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de CV Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Mexico @1 Arysta LifeScience Paraguay S.R.L. Paraguay @1 Arysta LifeScience Peru S.A.C			
Arysta LifeScience Global Limited Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico O1 Servicios Agricolas Mundiales SA de C.V. Mexico O1 Tecno Extractos Vegetales, S.A. de C.V. Mexico O1 Tesaurus Mexico S.A. de C.V. Mexico O1 Arysta LifeScience Paraguay S.R.L. Paraguay O1 Arysta LifeScience Peru S.A.C			
Arysta LifeScience Argentina S.A. Argentina Arysta LifeScience Colombia S.A.S Colombia Colombia Arysta LifeScience CentroAmerica, S.A. Guatemala Colombia Co			
Arysta LifeScience Colombia S.A.S Arysta LifeScience CentroAmerica, S.A. Guatemala Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Mexico Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico Officios Agricolas Mundiales SA de C.V. Mexico Officios Agricolas Mundiales SA de C.V. Mexico Officios Extractos Vegetales, S.A. de C.V. Mexico Officios Extractos Vegetales, S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Paraguay Officios Peru Officios			@1
Arysta LifeScience CentroAmerica, S.A. Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de C.V. Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Mexico @1 Arysta LifeScience Paraguay S.R.L. Paraguay @1 Arysta LifeScience Peru S.A.C		9	
Arysta LifeScience Mexico Holding S.A.de C.V Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Mexico @1 Servicios Agricolas Mundiales SA de C.V. Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Mexico @1 Arysta LifeScience Paraguay S.R.L. Paraguay @1 Arysta LifeScience Peru S.A.C			@1
Bioenzymas S.A. de C.V. Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V. Omega Agroindustrial, S.A. de C.V. Agroquimicos y Semillas, S.A. de C.V. Servicios Agricolas Mundiales SA de C.V. Tecno Extractos Vegetales, S.A. de C.V. Tesaurus Mexico S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Mexico @1 Arysta LifeScience Peru S.A.C		Guatemala	@1
Desarrollos Inmobiliarios Alianza de Coahuila, S.A. de C.V.Mexico@1Omega Agroindustrial, S.A. de C.V.Mexico@1Agroquimicos y Semillas, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1			@1
Omega Agroindustrial, S.A. de C.V.Mexico@1Agroquimicos y Semillas, S.A. de C.V.Mexico@1Servicios Agricolas Mundiales SA de CVMexico@1Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1		Mexico	@1
Agroquimicos y Semillas, S.A. de C.V. Servicios Agricolas Mundiales SA de CV Tecno Extractos Vegetales, S.A. de C.V. Tesaurus Mexico S.A. de C.V. Arysta LifeScience Paraguay S.R.L. Arysta LifeScience Peru S.A.C Mexico @1 Paraguay @1 Arysta LifeScience Peru S.A.C		Mexico	@1
Servicios Agricolas Mundiales SA de CV Mexico @1 Tecno Extractos Vegetales, S.A. de C.V. Mexico @1 Tesaurus Mexico S.A. de C.V. Mexico @1 Arysta LifeScience Paraguay S.R.L. Paraguay @1 Arysta LifeScience Peru S.A.C Peru @1			
Tecno Extractos Vegetales, S.A. de C.V.Mexico@1Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1			@1
Tesaurus Mexico S.A. de C.V.Mexico@1Arysta LifeScience Paraguay S.R.L.Paraguay@1Arysta LifeScience Peru S.A.CPeru@1		Mexico	@1
Arysta LifeScience Paraguay S.R.L. Paraguay Arysta LifeScience Peru S.A.C Peru @1		Mexico	@1
Arysta LifeScience Peru S.A.C Peru @1		Mexico	@1
	Arysta LifeScience Paraguay S.R.L.	Paraguay	@1
Arysta LifeScience Costa Rica SA. Costa Rica @1	Arysta LifeScience Peru S.A.C		@1
	Arysta LifeScience Costa Rica SA.	Costa Rica	@1

36. Related party transactions (contd.)

Name	Country of incorporation/	Notes
	Principal place of business	
Arysta LifeScience de Guatemala, S.A.	Guatemala	@1
Arysta LifeScience S.R.L.	Bolivia	@1
Myanmar Arysta LifeScience Co., Ltd.	Myanmar	@1
Arysta LifeScience U.K. BRL Limited	U.K.	@1
Etec Crop Solutions Limited	New Zealand	@1
MacDermid Agricultural Solutions Australia Pty Ltd	Australia	@1
Arvesta Corporation	USA	@1
Arysta LifeScience Registrations Great Britain Ltd	U.K.	@1
Agriphar SDN BHD	Malaysia	@1
Agriphar de Costa Rica SA	Costa Rica	@1
Agriphar de Colombia SAS	Colombia	@1
Industrias Agriphar SA	Guatemala	@1
Kempton Chemicals (Pty) Ltd	South Africa	@1
Agripraza Ltda.	Portugal	@1
Arysta LifeScience Corporation Republica Dominicana, SRL	Dominican Rpb	@1
Grupo Bioquimico Mexicano Republica Dominicana SA	Dominican Rpb	@1
Arysta LifeScience Ecuador S.A.	Ecuador	@1
Arvesta Paraguay S.A.	Paraguay	@1
Arysta Agroquimicos y Fertilzantes Uruguay SA	Uruguay	@1
Arysta LifeScience U.K. USD-2 Limited	U.K.	@1
Veto-Pharma SA	France	@1,#5
Wyjolab S.A.	France	@1,#5
MacDermid (Nanjing) Chemical Ltd.	China	@1,#1

Notes

- @ Subsidiary formed during the year
- @1 Subsidiary acquired during the year
- `@2 Subsidiary formed during the previous year
- `@3 Subsidiary acquired during the previous year
- # During the previous year UPL Limited, Mauritius merged in UPL Corporation Limited, Mauritius.
- #1 Subsidiary divested during the year.
- #2 During the previous year, the Group through its step down wholly owned subsidiary, has increased its stake from 51% to 100%
- #3 During the previous year, the Group through its step down wholly owned subsidiary, has increased its stake from 50% to 100%
- #4 During the year, Blue Star B.V. was merged into United Phosphorus Holdings B.V.
- #5 During the year, Veto-Pharma SA and Wyjolab S.A. were merged into Arysta Animal Health SAS
- #6 Subsidiary divested during the previous year.

(b) Names of the other related parties with whom transactions have taken place during the year

(i) Name of Associate Companies:

Name	Country of incorporation/	Notes
	Principal place of business	
Weather Risk Management Private Ltd	India	##
Ingen Technologies Private Limited	India	
Kerala Enviro Infrastructure Limited	India	
Polycoat Technologies 2010 Limited	Israel	
3SB Produtos Agricolas S.A.	Brazil	\$\$\$,#
Sinagro Produtos Agropecuarios S.A.	Brazil	\$\$\$,#
Seara Comercial Agricola Ltda.	Brazil	
Serra Bonita Sementes S.A.	Brazil	\$\$
Bioplanta Nutricao Vegetal,Industria e Comercio S.A.	Brazil	

36. Related party transactions (contd.)

Name	Country of incorporation/ Principal place of business	Notes
Chemisynth (Vapi) Limited	India	
Universal Pestochem (Industries) Limited	India	
Agri Fokus (Pty) Ltd.	South Africa	\$
Novon Retail Company (Pty) Ltd.	South Africa	\$
Agronamic (Pty) Ltd.	South Africa	\$
Novon Protecta (Pty) Ltd	South Africa	\$
Silvix Forestry (Pty) Ltd.	South Africa	\$
Nexus AG (Pty) Ltd	South Africa	\$
Dalian Advanced Chemical Co.Ltd.	China	\$
Société des Produits Industriels et Agricoles	Senegal	\$
CGNS Limited	U.K.	\$
Callitogo SA	Togo	\$

^{\$} Investment during the year

(ii) Joint Venture Companies:

Name	Country of incorporation/
	Principal place of business
Hodagaya UPL Co. Limited	 Japan
Longreach Plant Breeders Management Pty Limited	Australia
United Phosphorus (Bangladesh) Limited	Bangladesh

(iii) Enterprises over which key management personnel and their relatives have significant influence:

Bharuch Enviro Infrastructure Limited Sanguine Holdings Private Limited Tatva Global Environment Private Limited Bloom Packaging Private Limited Bloom Seal Containers Private Limited (formerly Tatva Global Environment Limited) Daman Ganga Pulp and Papers Private Limited Tatva Global Environment (Deonar) Limited

Demuric Holdings Private Limited Ultima Search

Enviro Technology Limited Uniphos International Limited Gharpure Engineering and Construction Private Limited Uniphos Enterprises Limited

Uniphos Envirotronic Private Limited UPL Environmental Engineers Limited

Jai Trust Vikram Farm

Pot Plants

(iv) Key Management Personnel and their relatives:

Directors and their relatives

Mr. Rajnikant D. Shroff Mrs. Sandra R. Shroff *

Mr. Kalyan Banerjee (upto 31st July, 2018)

Mr. Jaidev R. Shroff * Mr. Arun C. Ashar Mr. Vikram R. Shroff * Mrs. Asha Ashar * Mr. Navin Ashar *

Mr. Hardeep Singh Mr. Vasant Gandhi Mr. Pradeep Goyal Mr. Vinod Sethi

Dr. Reena Ramchandran

Mr. Pradip Madhavji (upto 27th April, 2018) Mr. Anand K Vora - Chief Financial Officer Mr. Mukul B Trivedi - Company Secretary

^{\$\$} Investment made during the previous year ended 2017-18

^{\$\$\$ 5%} stake divested during the year

^{##} Additional 5% stake acquired during the year

[#] Additional 9% stake acquired during the previous year

^{*} Relatives of Key management personnel.

NATURE OF TRANSACTIONS SUBSIDIARIES SUBSIDIAR	RELATI		(.5))
31-Mar-19 31-Mar-18 31-Mar-19 31-M		ONSHIP	SUBSIE) IARIES	ASSOC	IATES	VINIOL	ENTURE	ENTER OVER WH MANAG PERSONN SIGNIFICANT	PRISES HICH KEY SEMENT VEL HAVE	GRAND	TOTAL
NHCOME SALES 5,499 4,034	NATU	RE OF TRANSACTIONS:	31-Mar-19	_	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
Composition Light Comp	= 3	INCOME										
UPL Corporation Ltd. 1,881 1,892 1,993	₹		700	7007			Ц	7	Ц	V	001	7 0 7
UPL Limited Globaltar. 1,555 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,028 1,036	=		2,430 − ×× −	4,00,4 088	1 1	1 1	n '	` '	n '	D '	2,303	7 ,40,4, ○ ⊗ ⊗
SWAL Composition United Prospherus (India) \$512<		IPI Limited Gibraltar	1,00,1 7,7,7,7	7 000		1 1		1			- DOÓ, L - RR / L	1000
UPL LEG Mauritius Upled Phosphorus (India) 1,369 642		SWAL Corporation Limited	-) () ()	517		ı	1	ı	1	1	- - - - - - - - - -	, 540, - C17
United Phosphorus (India) 1,369 642 . <t< td=""><td></td><td>UPL Itd - Mauritius</td><td>- '</td><td>282</td><td>1</td><td>ı</td><td>ı</td><td>ı</td><td>1</td><td>1</td><td>- 1</td><td>282</td></t<>		UPL Itd - Mauritius	- '	282	1	ı	ı	ı	1	1	- 1	282
LLP Cohers 213 690 - - 5 7 5 6 223 Others DIVIDED RECEIVED 412 356 - - - - 412 DIVIDED RECEIVED 412 356 - - - - - 412 MANAGEMENT FEES / 36 36 - <td></td> <td>United Phosphorus (India)</td> <td>1,369</td> <td>642</td> <td>Ī</td> <td>I</td> <td>I</td> <td>I</td> <td>I</td> <td>I</td> <td>1,369</td> <td>642</td>		United Phosphorus (India)	1,369	642	Ī	I	I	I	I	I	1,369	642
Others 213 690 - - 5 7 5 6 223 OVIDIORD RECEIVED 412 356 - - - - - 412 NANAGEMENT FEES / 36 36 -		, The state of the										
DIVIDEND RECEIVED 412 356 - - - - - 412 412 A412 A412<		Others	213	069	I	ı	7	7	5	9	223	702
UPL Corporation Ltd. 412 356 - - - - - 412 42 MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT MANAGEMENT MANAGEMENT FEE / John MANAGEMENT MANAGEMENT FEE / John MANAGEMENT MANA	(B)	DIVIDEND RECEIVED	412	356	ī	I	ı	ı	ı	ı	412	356
MANAGEMENT FEES / MANAGEMENT FEED / MANAGEM		UPL Corporation Ltd.	412	356	I	1	ı	ı	ı	ı	412	356
OTHER SERVICES OTHER SERVICES Tatva Global Environment - <t< td=""><td>0</td><td>MANAGEMENT FEES /</td><td>36</td><td>7</td><td>Ī</td><td>1</td><td>1</td><td>1</td><td>9</td><td>∞</td><td>42</td><td>15</td></t<>	0	MANAGEMENT FEES /	36	7	Ī	1	1	1	9	∞	42	15
Tatva Global Environment - - - - 2 2 2 Private Limited Bharuch Environ Infrastructure - <t< td=""><td></td><td>OTHER SERVICES</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>		OTHER SERVICES										
Private Limited - - - - - 1		Tatva Global Environment	Í	I	Ĭ	I	I	I	2	2	2	2
Bharuch Enviro Infrastructure -		Private Limited										
Limited Construction Private Limited -		Bharuch Enviro Infrastructure	I	I	ì	I	I	I	<u></u>	_	_	<u></u>
Gharpure Engineering and Construction Private Limited -		Limited										
Construction Private Limited -		Gharpure Engineering and	I	ı	Ĭ	I	I	I	2	4	2	4
Uniphose Enterprises Ltd - <td></td> <td>Construction Private Limited</td> <td></td>		Construction Private Limited										
United Phosphorus (India) 36 7 - - - - - 36 - - 36 - 0 0 0 0 0 0 0 7 -		Uniphos Enterprises Ltd	ı	ı	Ī	I	ı	ı	<u></u>	_	<u></u>	$\overline{}$
LLP Others 0 - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 Charm Benvirotrom of months and months an		United Phosphorus (India)	36	7	T	I	ı	ı	I	I	36	
Others Others Others Others One of the control of		LLP										
RENT RECEIVED 7 2 - - - - 0 0 7 7 Uniphos Envirotronic Pvt. -		Others	0	1	1	I	I	I	0	0	0	0
Uniphos Envirotronic Pvt. - <td></td> <td>RENT RECEIVED</td> <td>7</td> <td>2</td> <td>ī</td> <td>ı</td> <td>1</td> <td>ı</td> <td>0</td> <td>0</td> <td>7</td> <td>2</td>		RENT RECEIVED	7	2	ī	ı	1	ı	0	0	7	2
Ltd. United Phosphorus (India) 7 2 - - - - - 7 7 United Phosphorus (India) - - - - - - - 42 Cothers - - - - - - 42 Northers - - - - - - 42 United Phosphorus (India) 42 - - - - - -		Uniphos Envirotronic Pvt.	ı	I	I	ı	I	ı	1	ı	1	1
United Phosphorus (India) 7 2 - - - - - 7 7 LLP LLP - - - - - 7 Others - - - - - - 42 ROYALTY INCOME - - - - - - 42 United Phosphorus (India) 42 29 - - - - - - 42		Ltd.										
LLP Others - - - - 0 0 0 Others 42 29 - - - - - 42 ROYALTY INCOME 42 - - - - - - 42 United Phosphorus (India) 42 - - - - - - 42		United Phosphorus (India)	_	2	I	1	Γ	ı	1		7	2
Others Cothers Coth		ILP										
ROYALTY INCOME 42 29 - - - - - 42 United Phosphorus (India) 42 29 - - - - - - 42		Others	ı	ı	Ī	I	ı	I	0	0	0	0
42 29 42	(E)	ROYALTY INCOME	42	29	1	ı	ı	ı	I	ı	42	29
		United Phosphorus (India)	42	29	ı	ı	1	ı	ı	I	42	29

Notes to Standalone Financial Statements for the year ended March 31, 2019

TIONS:	ntd.) SUBSIDIARIES	ŀ								₹ In Crores
RANSACTIONS: MISSION ON AANTEE GIVEN / IVED LUCOPE Ltd	SUBSID									
		IARIES	ASSOCIATES	TATES	VINIO	JOINT VENTURE	ENTER OVER WI MANAG PERSONI SIGNIFICAN	ENTERPRISES OVER WHICH KEY MANAGEMENT PERSONNEL HAVE SIGNIFICANT INFLUENCE	GRAND TOTA	TOTAL
	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
GUARANTEE GIVEN / RECEIVED UPL Europe Ltd		9	1	I	1	I	I	1	<u></u>	9
RECEIVED UPL Europe Ltd										
UPL Europe Ltd										
	ı	2	1	I	I	I	Ī	ı	I	2
UPL Italia SKL	0	_	1	I	I	I	Ī	1	0	$\overline{}$
Cerexagri SAS	0	_	1	I	1	I	Ī	1	0	_
Cerexagri BV	0	_	I	I	I	I	Ĭ	ı	0	_
UPL Argentina SA.	ı	<u></u>	I	I	I	ı	ı	ı	ı	<u></u>
2 EXPENSES (A) PURCHASES										
=	397	347	ı	I	1	ı	64	48	461	395
	130	140	1	1	I	ı	i)		130	140
Bloom Seal Containers Pvt	ı	1	ı	I	1	1	39	29	39	29
Ltd, Vapi										
Optima Farm Solutions Ltd.	104	122	ı	I	ı	ı	1	1	104	122
United Phosphorus (India)	74	16	I	I	1	ı	1	ı	74	16
Others	89	69	I	I	I	I	25	18	114	87
(ii) PURCHASE OF LICENCES	31	16	ı	I	1	ı	1	1	31	16
United Phosphorus India LLP	31	15	I	1	1	ı	ī	ı	31	15
Others	0	0	ı	1	1	ı	1	ı	I	0
(iii) FIXED ASSETS	10	0	0	0	ı	ı	_	0	11	_
Cerexagri BV	I	0	I	I	l	I	ī	1	I	0
Uniphos Envirotronic Pvt. Ltd.	ı	I	I	I	1	I	<u> </u>	0	<u> </u>	0
Chemie Synth (Vapi) Ltd	I	ı	0	0	ı	I	T	ı	0	0
United Phosphorus India LLP	10	ı	1	I	ı	I	T	ı	10	ı
(iv) INTANGIBLE ASSETS	_	C	ı	ı	ı	ı	Ī	ı	<u></u>	M
UPL Ltd. Japan	<u></u>	_	I	1	1	I	I	ı	_	_
UPL Europe	I	_	ı	I	ı	ı	T	ı	I	_
UPL Limited Korea	0	<u></u>	ı	I	l	I	Ī	ı	I	_
(v) INTANGIBLE ASSETS -	1	0	I	I	1	I	ī	1	1	0
UNDER-CWIP										
UPL Limited Japan	ı	0	I	1	ı	ı	Г	ı	ı	0
(vi) OTHERS	ı	ı	ı	1	ı	ı	0	0	0	0
Vikram Farm	1	ı	1	ı	Г	ı	0	0	0	0

Notes to Standalone Financial Statements for the year ended March 31, 2019

36.Related party transactions (contd.)

RELATIONSHIP

36. Re	36. Related party transactions (contd.)	contd.)									₹ In Crores
RELATI	RELATIONSHIP	SUBSID	SUBSIDIARIES	ASSOC	ASSOCIATES	VINIOL	JOINT VENTURE	ENTERPRISES OVER WHICH KEY MANAGEMENT PERSONNEL HAVE SIGNIFICANT INFLUENCE	PRISES IICH KEY EMENT IEL HAVE INFLUENCE	GRAND TOTAL	TOTAL
NATUF	NATURE OF TRANSACTIONS:	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
	Pot Plants	1	1	1	1	1	1	0	0	0	0
	Others	I	1	I	I	I	1	0	0	0	0
(B)	SERVICES	0	_	0	0	1	1	94	79	94	80
	Bharuch Enviro Infrastructure	I	1	Г	1	1	ı	92	77	92	77
	Limited										
	Others	0	_	0	0	1	ı	2	2	2	M
0	RENT	ı	ı	1	1	1	ı	_	_	_	_
	Sanguine Holdings Pvt. Ltd.	I	I	Ī	I	1	I	0	0	0	0
	Bloom Packaging Pvt. Ltd.	I	1	1	1	1	ı	0	0	0	0
	Ultima Search	ı	ı	1	ı	1	ı	0	0	0	0
	Jai Trust	I	I	Ĩ	I	I	I	0	0	0	0
	Others	İ	ı	Î	I	I	I	0	0	0	0
(D)	COMMISSION ON EXPORTS	26	31	Î	1	0	ı	I	1	26	31
	UPL Corporation Ltd.	26	31	Ī	1	ı	ı	I	ı	26	31
	Others	0	ı	Í	1	0	ı	I	ı	0	ı
(E)	RESEARCH & DEVELOPMENT	1	<u></u>	1	ı	I	1	I	1	I	_
	EXPENSES										
	Cerexagri B V	ı	<u></u>	Ī	1	1	İ	ı	ı	I	<u></u>
(F)	WRITE BACK OF PAYABLES	2	0	T	ı	1	İ	I	ı	2	0
	UPL Corporation Ltd.	_	0	T	ı	I	ı	I	ı	<u></u>	0
	Advanta Seeds PTY Ltd.	<u></u>	ı	T	ı	ı	ı	I	ı	<u></u>	ı
	Others	ı	I	I	I	I	ı	1	ı	I	I
(<u>B</u>)	WRITE OFF OF RECEIVABLES	İ	1	Ī	ı	1	ı	1	0	1	0
	Enviro Technology Ltd	ı	ı	ī	I	1	ı	ı	0	I	0
	Other	I	I	Ī	ı	ı	1	1	0	ı	0
Ξ	CONTRIBUTION TO C.S.R.	I	ı	T	ı	1	ı	I	0	1	0
	Vikram Farm	ı	ı	1	I	1	ı	ı	ı	ı	ı
	Bharuch Enviro Infrastructure	I	ı	Ĩ	ı	1	ı	I	0	1	0
	Ltd.										
т С	FINANCE	1								1	(
€	LOAN / INTER CORPORATE	`	102	Ī	1	1	ı	ı	ı	\	102
	DEPOSITS GIVEN	1	(1	(
	SWAL Corporation Limited	//	102	1	ı	1	ı	1	ı	//	102

Notes to Standalone Financial Statements for the year ended March 31, 2019

36.Re	36. Related party transactions (contd.)	(contd.)									₹ In Crores
RELATI	RELATIONSHIP	SUBSIC	SUBSIDIARIES	ASSOCIATES	IATES	JOINT VENTURE	NTURE	ENTERPRISES OVER WHICH KEY MANAGEMENT PERSONNEL HAVE SIGNIFICANT INFLUENCE	PRISES IICH KEY EMENT IEL HAVE INFLUENCE	GRAND TOTAL	TOTAL
NATU	NATURE OF TRANSACTIONS:	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
(B)	INTEREST RECEIVED	49	43	ı	1	1	1	0	0	49	43
	UPL Corporation Ltd.	41	35	ı	I	ı	ı	I	ı	41	35
	SWAL Corporation Limited	00	00	1	ı	1	ı	I	ı	00	∞
	Others	1	0	I	Ī	ı	ı	0	0	0	0
(<u>)</u>	REPAYMENT AGAINST LOAN GIVEN	929	184	ī	I	1	1	ı	<u></u>	929	185
	UPL Corporation Ltd.	929	1	1	ı	I	I	1	I	929	ı
	SWAL Corporation Limited	1	184	I	I	1	1	1	1	1	184
	Advanta Holdings BV Netherland	ı	1	ľ	I	ı	ı	1	ı	I	ı
	Others	ı	I	1	ı	ı	ı	1	_	1	_
(D	GUARANTEES CANCELLED	ī	309	ī	ı	1	ı	ī	1	1	309
	DURING THE YEAR										
	UPL Europe Ltd.	ı	291	ı	ı	ı	1	ı	1	ı	291
	Others	I	28	I	ı	1	ı	I	ı	1	2
Ξ	PURCHASE OF SHARES	1,025	ı	ı	1	ı	ı	1	ı	1,025	ı
	UPL Corporation Ltd.	1,025	ı	ı	I	I	ı	ı	ı	1,025	I
4 (A)	REIMBURSMENTS RECEIVED	09	16	ı	1	I	1	_	0	61	17
	Swal Corporation Limited	10	4	ı	ı	ı	ı	1	ı	10	4
	UPL Management DMCC	I	0	ı	ı	ı	ı	1	1	I	0
	United Phosphorus (India)	5		1	I	I	I	1	I	Ŋ	_
	UPL Ltd. Gibraltar	39								39	I
	United Phosphorus Inc	1	2	1	I	Ī	I	1	1	1	2
	Cerexagri BV	1	2	I	ı	Ī	ı	1	ı	1	2
	Others	9	_	I	I	I	ı	_	0	7	2
(B)	REIMBURSEMENTS MADE	6	_	I	I	Γ	'	0	ı	6	_
	Swal Corporation Ltd.	I	ı	ı	ı	ı	ı	1	ı	0	0
	UPL Limited Korea	4								4	0
	UPL Ltd, Hong Kong	4								4	0
	UPL Vietnam Co. Ltd.	0	0	I	I	I	ı	1	I	I	0
	UPL Paraguay S.A.	ı		1	I	Ī	ı	1	I	1	_
	Others	<u> </u>	0	1	1	1	1	0	1		0

Notes to Standalone Financial Statements for the year ended March 31, 2019 36. Related party transactions (contd.)

20.17	Jo. Nelated pairy claisactions (contu.	(collica.)										₹ In Crores
RELATI	RELATIONSHIP		SUBSIDARI	ES	ASSOC	ASSOCIATES	V TNIOL	JOINT VENTURE	ENTERPRISES	PRISES	GRAND TOTA	TOTAL
									OVER WHICH KEN	HICH KEY EMENT		
									PERSONNEL HA SIGNIFICANT INFLUENCE	PERSONNEL HAVE SIGNIFICANT INFLUENCE		
NATUF	NATURE OF TRANSACTIONS:	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
2	OUTSTANDING AT THE YEAR END											
(A)	PAYABLES	315	268	0	0	1	1	1	m	m	318	271
	UPL Corporation Ltd.	185	20	ı	I	ı	ı	ı	1	ı	185	20
	UPL Ltd, Hong Kong	88	84	I	I	ı	ı	ı	ı	ı	88	84
	United Phosphorus LLP	I	29	1	1	1	1	1	1	ı	1	29
	Optima Farm Solutions Ltd.	4	109	ı	1	1	1	1	1	1	4	109
	Others	38	26	0	0	İ	1	1	M	M	40	28
(B)	RECEIVABLE	1,028	1,052	0	0	_	_	_	19	4	1,048	1,057
	UPL Corporation Ltd.	I	29	ī	I	1	1	ı	1	ı	I	29
	UPL Limited Gibraltar	ı	223	ı	I	ı	ı	ı	1	ı	ı	223
	Swal Corporation Ltd.	232	194	1	I	ı	I	ı	1	1	232	194
	United Phosphorus (India) LLP	714	322	1	I	ı	I	ı	1	1	714	322
	Optima Farm Solutions Ltd.	I	108	I	I	ı	I	ı	1	ı	I	108
	Others	82	146	0	0	_	_	_	19	4	102	151
(<u>)</u>	LOANS AND ADVANCES GIVEN	77	929	1	1	1	1	1	0	0	77	929
	UPL Corporation Ltd.	I	929	1	ı	ı	ı	ı	ı	ı	ı	929
	Swal Corporation Ltd.	77	ı	ī	ı	ı	1	ı	ı	ı	77	1
	Advanta Holdings BV Netherland	ı	1	1	ı	ı	1	ı	1	1	1	1
	Others	I	ı	ī	ı	ı	ı	ı	0	0	0	0
0	INTEREST RECEIVABLE	I	7	1	ı	ı	ı	ı	0	0	0	7
	UPL Corporation Ltd.	ı		1	1	ı	1	1	1	1	1	_
	Others	ı	1	I	1	ı	1	ı	0	0	0	0
(E)	MANAGEMENT FEES RECEIVABLE	1	'	1	1	1	•	1	ı	10	1	10
	latva Global Environment Private	I	ı	I	I	1	1	1	ı		1	_
	Limited							,				
	Gharpure Engineering and	1	ı	ı	1	1	ı	1	ı	00	1	∞
	Construction Private Limited											
	Others	I	I	ı	I	ı	I	I	I	_	1	_
(F)	GUARANTEES GIVEN ON	133	497	1	ı	ı	ı	ı	1	1	133	497
	BEHALF OF COMPANIES.											
	UPL Europe Ltd.	1	1	1	İ	ı	1	ı	1	1	İ	1
	Cerexagri BV	ı	186	Î	1	ı	1	1	ı	1	ı	186
	UPL Italia SRL	133	133	ī	ı	ı	I	ı	1	1	133	133
	Cerexagri SAS	ı	178	ī	ı	ı	ı	ı	1	1	1	178
(D)	DEPOSIT GIVEN	ı	1	ī	ı	1	1	1	1	13	1	13
	Bloom Packaging Pvt Ltd	1	ı	ı	1	ı	1	1	1	_	1	_
	Daman Ganga Pulp And Papers	ı	ı	1	1	1	1	ı	4	4	4	4
	Bharuch Enviro Infrastrure Ltd.	I	ı	ı	ı	ı	ı	ı	9	00	9	∞ -
	Others	1	1	1	1	1	1	1	<u></u>	0	_	0
(Aboya fiortres	figures are arose of tax)											

(Above figures are gross of tax)

36. Related party transactions (contd.)

c. Transactions with Key Management Personnel and their relatives

₹ In Crores

Nature of Transaction	March 31, 2019	March 31, 2018
Remuneration (refer note 1 below)		
Mr. Rajnikant. D. Shroff	13	10
Mr. Arun C. Ashar	3	3
Others	6	5
	22	17
Rent Paid		
Mr. Rajnikant. D. Shroff	0	0
Mrs. Sandra R. Shroff	0	0
Mr. Vikram R Shroff	0	0
Mr. Jai R Shroff	0	11_
	1	2
Professional Fees		
Navin Ashar	1	0
Reimbursements Made	0	0
Outstanding's as at the Balance Sheet Date:		
Sundry Deposits given	0	2
Professional Fees Payable/(Receivable)	0	0
Rent Payable	0	0

36.1. Details of loans and advances in the nature of loans given to subsidiaries and associates and firms/companies in which directors are interested ₹ In Crores

Nature of Relationship	March 3	31, 2019	March 3	1, 2018
	Amount outstanding at the year end	Maximum amount of loan outstanding during the year	Amount outstanding at the year end	Maximum amount of loan outstanding during the year
Subsidiaries and Associates				
UPL Corporation Limited	-	929	929	979
SWAL Corporation Limited	77	77	-	83

Notes:

This includes short term employee benefits and key management personnel who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognied as per Ind AS19-Employee Benefits in the standalone financial statements. As these employee benefits are lumpsum such amounts provided on the basis of actuarial valuation, the same is not included above.

2. Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

37. Capitalization of expenditure

During the year, the Company has capitalized the following expenses of revenue nature to the cost of property, plant and equipment / capital work-in-progress (CWIP). Consequently, expenses disclosed under the respective notes are net of amounts capitalized by the Company.

₹ In Crores

	March 31, 2019	March 31, 2018
Employee cost & other expenses	29	26
Finance cost capitalised	50	-

Borrowing cost was capitalized at the rate 7.68%

38. Hedging activities and derivatives

Derivatives not designated as hedging instruments

The Company uses full currency interest rate swap and foreign exchange forward contracts to manage some of its transaction exposures. The foreign exchange forward contracts are not designated as cash flow hedges and are entered into for periods consistent with foreign currency exposure of the underlying transactions.

The Company enters into foreign exchange forward contracts with the intention to reduce the foreign exchange risk of expected sales and purchases, These contracts are not designated in hedge relationships and are measured at fair value through profit or loss.

	Currency	March 31, 2019	March 31, 2019	March 31, 2018	March 31, 2019	Purpose
		(₹ In '000)	(₹ In Crores)	(₹ In '000)	(₹ In Crores)	
Nature of Instrument						
Forward contract - Buy	USD	1,22,686	824	22,520	147	Hedging
Derivative contracts						
Full Currency Interest	USD	-	-	1,11,179	725	Hedging-
Rate Swap contracts - Buy						refer note
						below
Full Currency Interest	EUR	-	-	25,667	207	Hedging-
Rate Swap contracts - Buy						refer note
						below

Note:

Hedging against the underlying INR borrowings by which:

- Company will receive principal in INR and pay in foreign currency
- Company will receive fixed interest in INR and pay fixed / floating interest in foreign currency

Un-hedged Foreign Currency balances:

	Currency	March 31, 2019	March 31, 2019	March 31, 2018	March 31, 2018
		(₹ In '000)	(₹ In Crores)	(₹ In '000)	(₹ In Crores)
Payables					
	USD	2,14,951	1,486	2,44,823	1,596
	EUR	2,437	19	2,166	18
	GBP	177	2	183	2
	JPY	-	-	-	-
	AUD	-	-	3	0
	CHF	13	0	-	-
	AED	115	0	60	0
Receivable	USD	1,74,633	1,208	2,39,793	1,563
	EUR	13,676	106	39,192	317
	AUD	336	2	554	3
	PHP	33	0	-	-
	CHF	181	1	199	1
	GBP	21	0	-	-
	ARS	915	0	-	-
	BRL	63	0	-	-
	IDR	63,679	0	_	-
	JPY	-	-	821	0

39. Catergory-wise classification of financial instruments

	Notes	Non-cı	urrent	Curr	ent
		March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Accounting, classification and fair					
values					
Financial assets measured at fair value					
through profit or loss (FVTPL)					
Investments in unquoted equity shares	5	7	7	-	-
Investments in unquoted optionally	5	83	76	-	-
convertible bonds					
		90	83	-	
Financial assets measured at fair value					
through other comprehensive income					
(FVTOCI)					
Investments in quoted equity shares	5	5	5	-	_
		5	5	-	_
(A) Accounting, classification and fair					
values:					
Financial assets measured at amortised					
cost					
Security Deposits	6	76	74	-	_
Loans and Advances to related parties	6	-	831	77	98
Loans to employees	6	-	-	2	7
Interest receivable	7	-	-	7	24
Receivables from related parties	7	-	-	115	68
Export benefit receivable	7	35	35	121	82
Trade receivable	10	-	-	2,733	2,017
Cash and cash equivalents	11	-	-	77	93
Other bank balance	11A	-	-	23	33
		111	940	3,155	2,422
Financial liabilities measured at fair value					
through profit or loss (FVTPL)					
Derivative contracts	15	-	135	-	36
		-	135	-	36
Financial liabilities measured at					
amortised cost					
Unsecured Redeemable Non convertible	14 and	458	682	273	127
Debentures (NCDs)	15				
Loans repayable on demand					
- Secured	14	-	-	0	65
- Unsecured	14	-	-	507	248
Unsecured Commercial papers from Banks	14			400	
and others					
Trade Deposits	15	-	-	43	51
Creditors for capital goods	15	-	-	67	154
Interest accrued on borrowings	15	-	-	1	1
Unpaid dividend	15	-	-	8	7
Others	15	4	4	37	1
Trade payables MSME	17	-	17	26	-
Trade payables (current)	18	-	-	2,791	2,336
		462	703	4,153	2,990

39. Catergory-wise classification of financial instruments (contd.)

(B) Measurement of fair value:

Valuation techniques and significant unobservable inputs:

(i) Financial instruments measured at fair value

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

- The fair value of unquoted instruments, loans from banks and other financial liabilities, as well as other noncurrent financial liabilities is estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities. In addition to being sensitive to a reasonably possible change in the forecast cash flows or the discount rate, the fair value of the equity instruments is also sensitive to a reasonably possible change in the growth rates. Management regularly assesses a range of reasonably possible alternatives for those significant unobservable inputs and determines their impact on the total fair value.
- The fair values of the unquoted equity shares have been estimated using a DCF model. The valuation requires management to make certain assumptions about the model inputs, including forecast cash flows, discount rate, credit risk and volatility. The probabilities of the various estimates within the range can be reasonably assessed and are used in management's estimate of fair value for these unquoted equity investments.
- The fair values of the remaining FVTOCI financial assets are derived from quoted market prices in active markets.
- The fair values of the Company's interest-bearing borrowings and loans are determined by using DCF method using discount rate that reflects the issuer's borrowing rate as at the end of the reporting period. The own nonperformance risk as at 31 March 2019 was assessed to be insignificant.

The discount for lack of marketability represents the amounts that the Company has determined that market participants would take into account when pricing the investments.

(ii) Financial instrument measured at amortized cost:

The carrying amount of financial assets and financial liability measured at amortized cost in the financial statements are a resonable approximation of their fair value since the Company does not anticipate that the carrying amounts would be significantly different from the value that would eventually be received or settled.

40. Fair Value hierarchy

The following table provides the fair value measurement hierarchy of the Company's assets and liabilities.

Quantitative disclosures fair value measurement hierarchy for assets as at 31 March 2019:

₹ In Crores

		Fa	air value measurei	ment using	
	Date of valuation	Total	Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs
			(Level 1)	(Level 2)	(Level 3)
Assets measured at fair value:					
FVTOCI financial investments (Note 5):					
Quoted equity shares	Mar 31, 2019	5	5	-	-
FVTPL financial investments (Note 5):					
Unquoted equity shares	Mar 31, 2019	7	-	-	7
Unquoted optionally convertible bonds	Mar 31, 2019	83	-	83	-

There have been no transfers between Level 1 and Level 2 during the period.

40. Fair Value hierarchy (contd.)

Quantitative disclosures fair value measurement hierarchy for liabilities as at 31 March 2019:

₹ In Crores

		F	air value measurei	ment using	
	Date of valuation	Total	Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs
·			(Level 1)	(Level 2)	(Level 3)
Liabilities measured at fair value:					
Derivative financial liabilities (Note 15):					
Derivative contracts	Mar 31, 2019	_	_	-	_

Quantitative disclosures fair value measurement hierarchy for assets as at 31 March 2018:

₹ In Crores

		Fa	air value measurei	ment using	
	Date of	Total	Quoted prices	Significant	Significant
	valuation		in active	observable	unobservable
			markets	inputs	inputs
			(Level 1)	(Level 2)	(Level 3)
Assets measured at fair value:					
FVTOCI financial investments (Note 5):					
Quoted equity shares	Mar 31, 2018	5	5	-	-
FVTPL financial investments (Note 5):					
Unquoted equity shares	Mar 31, 2018	7	-	-	7
Unquoted optionally convertible bonds	Mar 31, 2018	76	-	76	_

There have been no transfers between Level 1 and Level 2 during the period.

Ouantitative disclosures fair value measurement hierarchy for liabilities as at 31 March 2018:

		Fair value measurement using				
	Date of valuation	Total	Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs	
			(Level 1)	(Level 2)	(Level 3)	
Liabilities measured at fair value:						
Derivative financial liabilities (Note 15):						
Derivative contracts	Mar 31, 2018	171	171	-	-	

41. Financial risk management objectives and policies

The Company's principal financial liabilities, other than derivatives, comprise loans and borrowings, trade and other payables, and financial quarantee contracts. The main purpose of these financial liabilities is to finance the Company's operations and to provide quarantees to its subsidiaries to support its operations. The Company's principal financial assets include loans, trade and other receivables, and cash and cash equivalents that derive directly from its operations. The Company also holds FVTOCI investments and enters into derivative transactions.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's senior management oversees the management of these risks. All derivative activities for risk management purposes are carried out by specialist teams that have the appropriate skills, experience and supervision. It is the Company's policy that no trading in derivatives for speculative purposes may be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk. Financial instruments affected by market risk include loans and borrowings, deposits, FVTOCI investments and derivative financial instruments.

41. Financial risk management objectives and policies (contd.)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates.

The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings.

Interest rate sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings affected. With all other variables held constant, the Company's profit before tax is affected through the impact on floating rate borrowings, as follows: ₹ In Crores

	Increase/ decrease	Increase/ decrease	Effect on profit or
	in basis points	in basis points	loss
March 31, 2019	+100	(5)	(4)
	-100	5	4
March 31, 2018	+100	(3)	(2)
	-100	3	2

The assumed movement in basis points for the interest rate sensitivity analysis is based on the currently observable market environment, showing a significantly higher volatility than in prior years.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a foreign currency).

The Company manages its foreign currency risk by hedging transactions that are expected to occur within a maximum 12-month period for hedges of actual sales and purchases and 12-month period for foreign currency loans.

When a derivative is entered into for the purpose of being a hedge, the Company negotiates the terms of those derivatives to match the terms of the hedged exposure. For hedges of forecast transactions the derivatives cover the period of exposure from the point the cash flows of the transactions are forecasted up to the point of settlement of the resulting receivable or payable that is denominated in the foreign currency.

The Company hedges its exposure to fluctuations on the foreign currency loan by using foreign currency swaps and forwards.

At March 31, 2019, the Company's hedge position is stated in Note 38. This foreign currency risk is hedged by using foreign currency forward contracts and full currency interest rate swaps.

Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD and EUR exchange rates, with all other variables held constant. The impact on the Company's profit before tax is due to changes in the fair value of monetary assets and liabilities. The Company's exposure to foreign currency changes for all other currencies is not material. ₹ In Crores

	Change in USD Rate	Effect on profit or loss	Effect on
	USD Rate	profit of loss	equity
March 31, 2019	1%	(3)	(2)
	-1%	3	2
March 31, 2018	1%	(0)	(0)
	-1%	0	0

	Change in USD Rate	Effect on profit or loss	Effect on equity
March 31, 2019	1%	1	1
	-1%	(1)	(1)
March 31, 2018	1%	3	2
	-1%	(3)	(2)

41. Financial risk management objectives and policies (contd.)

The movement in the pre-tax effect is a result of a change in the fair value of monetary assets and liabilities denominated in US dollars, where the functional currency of the entity is a currency other than US dollars. Although the derivatives have not been designated in a hedge relationship, they act as an economic hedge and will offset the underlying transactions when they occur.

Equity price risk

The Company's listed and non-listed equity securities are susceptible to market price risk arising from uncertainties about future values of the investment securities. The investment in listed and unlisted equity securities are not significant.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.

Financial instruments and cash deposits

Credit risk from balances with banks and financial institutions is managed by the Company's treasury department. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through counterparty's potential failure to make payments.

The Company's maximum exposure to credit risk for the components of the balance sheet at March 31, 2019, 31 March 2018 is the carrying amounts as illustrated in Note 10 except for financial guarantees and derivative financial instruments.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company manages liquidity risk by maintaining adequate reserves, by continuously monitoring forecast and actual cash flows and matching the maturity profiles of the financial assets and liabilities.

The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

₹ In Crores

	March 31, 2019				
	Less than 1 year	1 to 5 years	> 5 years	Total	
Borrowings (other than convertible preference shares)	507	209	249	965	
(refer note 14)					
Convertible preference shares (refer note 15)	-	-	-	-	
Other financial liabilities (refer note 15)	429	4	-	433	
Trade and other payables (refer note 17 and 18)	2,817	-	-	2,817	
Derivative contracts (refer note 15)	-	-	-	-	
	3,753	213	249	4,215	

	March 31, 2019					
	Less than 1 year	1 to 5 years	> 5 years	Total		
Borrowings (other than convertible preference shares)	313	413	269	995		
(refer note 14)						
Convertible preference shares (refer note 15)	-	-	-	-		
Other financial liabilities (refer note 15)	341	4	-	345		
Trade and other payables (refer note 17 and 18)	2,353	-	-	2,353		
Derivative contracts (refer note 15)	36	135	-	171		
	3,043	552	269	3,864		

42. Capital management

Capital includes equity attributable to the equity holders to ensure that it maintains an efficient capital structure and healthy capital ratios in order to support its business and maximise shareholder value. The Company manages its capital structure and makes adjustments to it, in light of changes in economic conditions or its business requirements. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes during the year ended March 31, 2019 and March 31, 2018.

The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. Net debt is calculated as loans and borrowings less cash and cash equivalents. ₹ In Crores

	March 31, 2019	March 31, 2018
Borrowings other than convertible preference shares (Note 14 and 15)	1,238	1,122
Less: cash and cash equivalents (Note 11)	(77)	(93)
Net debt	1,161	1,029
Optionally Convertible preference shares (Note 14)	-	_
Equity (Note 12 and 13)	7,972	7,969
Total capital	7,972	7,969
Capital and net debt	9,133	8,998
Gearing ratio	13%	11%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowings in the current period.

43. Exceptional items

₹ In Crores

	March 31, 2019	March 31, 2018
Amount payable as per final order of The Competition Commission of India	-	7
Amount payable for proceeding before Patent Trial & Appeal Board	4	_
	4	7

44. Foreign Exchange Management Act

In January 2013, the Company had received a show cause notice from the Directorate of Enforcement, alleging that the Company had contravened certain provisions of Foreign Exchange Management Act, 1999 with regard to foreign direct investment made and utilisation of proceeds of FCCB / ECB. The Company had replied to the show cause notice and had personal hearings to represent their matter and filed written submissions on the basis of which Directorate of Enforcement vide order dated 28th February, 2018 has dropped all the charges levied against the Company.

45. Amalgamation with Advanta Limited

The Hon'ble High Court of Gujarat vide its order dated June 23, 2016 had sanctioned the Scheme of Amalgamation of Advanta Limited with the Company with an appointed date of April 01, 2015. In accordance with the provisions of the scheme and as approved by the High Court, the amalgamation was accounted for under the purchase method specified in Accounting Standard 14 - 'Accounting for Amalgamations' which is different from Ind AS 103 'Business Combinations'. As per the Court approval the goodwill arising on amalgamation is being amortised over a period of ten years from the appointed date, which is not amortised under Ind AS 103 but only tested for impairment.

If the Company had accounted for amalgamation as per Ind AS 103, profit for the for the years ended March 31, 2019 and March 31, 2018 would have been higher by Rs 370 crs each.

46. CSR expenditure:

Details of CSR expenditure:

	March 31, 2019	March 31, 2018
Gross amount required to be spent by the company during the year	5	6
	5	6

46. CSR expenditure (contd.)

₹ In Crores

	March 31, 2019			
	In cash	Yet to be paid in Cash	Total	
Amount spent during the year				
Construction/acquisition of any asset	-	-	-	
On purposes other than above	17	1	18	
	17	1	18	

₹ In Crores

		March 31, 2018			
	In cash	Yet to be paid in Cash	Total		
Amount spent during the year					
Construction/acquisition of any asset	-	-	-		
On purposes other than above	19	1	20		
	19	1	20		

47. Segment information

1. Information about operating business segments

		March	31, 2019			March	31, 2018	
	Agro Activity	Non Agro Activity	Unallocated	Total	Agro Activity	Non Agro Activity	Unallocated	Total
Revenue								
External-revenue from contracts with customers	7,898	600	-	8,498	6,618	570	-	7,188
External-revenue from contracts with others	146	7	9	162	169	4	13	186
Inter segment	(285)	285	-	-	(183)	183	-	-
Total revenue	7,759	892	9	8,660	6,604	757	13	7,374
Segment Results								
Contribution	512	81	-	593	741	29	_	770
Add: Inter segment profit	(53)	53	-	-	(37)	37	-	-
Total segment results	459	134	-	593	704	66	-	770
Unallocated income net of				(82)				52
unallocated expenses								
Finance costs				185				135
Exceptional items (refer note 43)				4				7
Profit before taxation				486				576
Provision for:								
Current tax				83				180
Adjustments of tax relating to				(3)				(83)
earlier years								
Deferred tax				1				(69)
Net profit after tax				405				548
Other information								
Segment assets	10,752	1,018	2,133	13,903	9,148	738	2,164	12,050
Segment liabilities	3,819	273	1,839	5,931	2,458	176	1,447	4,081
Capital expenditure	806	144	48	998	665	65	13	743
Depreciation	236	37	11	284	187	27	12	226
Amortisation	420	0	20	440	420	0	20	440
Non cash expenses other than	30	0	0	30	17	0	7	24
depreciation								

47. Segment information (contd.)

2. Information about Geographical Business Segments

₹ In Crores

	March 31, 2019			March 31, 2018		
	India	Outside India	Total	India	Outside India	Total
Revenue by geographical market						
External	3,714	4,946	8,660	3,392	3,982	7,374
Carrying amount of non current	5,771	280	6,051	5,453	336	5,789
operating assets						

3. Notes

- (i) The business of the Company is divided into two business segments. These segments are the basis for management control and hence form the basis for reporting. The business of each segment comprises of:
 - a) Agro activity This is the main area of the Company's operation and includes the manufacture and marketing of conventional agrochemical products, seeds and other agricultural related products.
 - b) Non-agro activity Non agro activities includes manufacture and marketing of industrial chemical and other non agricultural related products.
- (ii) Segment revenue in the above segments includes sales of products net of taxes.
- (iii) Inter segment revenue is taken as comparable third party average selling price for the year.
- (iv) Segment revenue in the geographical segments considered for disclosure are as follows:
 - a) Revenue within India includes sales to customers located within India.
 - b) Revenue outside India includes sales to customers located outside India
- (v) Segment revenue, results, assets and liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.
- (vi) The Company does not have any customer (other than related parties), with whom revenue from transactions is more than 10% of Company's total revenue.
- (vii) Based on the "management approach" defined in Ind AS 108 Operating Segments, the Chief Operating Decision Maker evaluates the company's performance and allocate resources based on an analysis of various performance indicators by business segments. Accordingly information has been presented along these segments.

48. Acquisition of Arysta Lifesciences Inc. and it's subsidiaries from Element Solutions Inc. (formerly Platform Specialty Products Corporation)

On January 31, 2019, UPL Corporation Limited, Mauritius, a subsidiary of the Company completed the acquisition of Arysta Lifesciences Inc. and it's subsidiaries from Element Solutions Inc. (formerly Platform Specialty Products Corporation). The consideration for the acquisition aggregates US \$ 4,426 Million(approximately Rs 31,458 crores) and is subject to certain further adjustments as per the terms of the stock purchase agreement signed between parties on July 20,2018.

49. Details of dues to micro and small enterprises as defined under the MSMED Act, 2006

₹ In Crores

	March 31, 2019	March 31, 2018
The principal amount and interest due thereon remaining unpaid to any supplier as at the end of each accounting year:		
Principal amount due to micro and small enterprises	26	17
Interest due on above, current year Rs. 0 (March 31, 2018: Rs 0)	0	0
Total	26	17
The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006.	-	-
The amount of interest accrued and remaining unpaid at the end of each accounting year, current year Rs. 0 (March 31, 2018: Rs. 0)		
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure u/s 23 of MSMED Act, 2006.		

Note: The information has been given in respect of such vendors to the extent they could be identified as Micro, and Small enterprises on the basis of information available with the Company.

As per our report of even date attached.

For BSR&Co.LLP Chartered Accountants

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

Independent Auditors' Report

To the Members of **UPL** limited

Report on the Audit of Consolidated Financial Statements

We have audited the consolidated financial statements of UPL Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associates and its joint ventures, which comprise the consolidated balance sheet as at 31 March 2019, and the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate financial statements of such subsidiaries, associates and joint ventures as were audited by the other auditors, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group, its associates and joint ventures as at 31 March 2019, of its consolidated net profit and other comprehensive income, consolidated changes in equity and consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India, and we have fulfilled our other ethical responsibilities in accordance with the provisions of the Act. We believe that the audit evidence we have obtained and evidence obtained by other auditors in terms of their reports referred to in the 'Other Matters' paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Description of Key Audit Matters

The key audit matter

Revenue recognition and rebates accrual

(Refer note 2.3(d) to accounting policies.)

a) Revenue recognition

The timing of revenue recognition is relevant to the reported performance of the Group.

b) Rebates accrual

The Group provides rebates and has arrangements with various customers. Some of these arrangements involve estimation when determining the amount of liability to be recognised as at the year end.

Our focus was on assessing if the rebates and related provisions made were based on relevant agreements and Group's policies and approvals

How the matter was addressed in our audit

Revenue recognition

We tested the accuracy of revenue cut off around the year end. Our work comprised the agreement of sales transactions to supporting documentation and performing analytical procedures across various sales categories.

b) Rebates accrual

We have reviewed business processes and tested the design and implementation of controls surrounding the rebate expense accrual provision. We also compared year end customer rebate accruals and rebate costs in the year, to prior year amounts and analysed the rebate trend. We have also verified the appropriateness of rebate provision calculations by agreeing amounts recognised to terms of agreements, approvals and other supporting workings.

The key audit matter

Inventory valuation

(Refer note 2.3(l) to accounting policies.)

We identified valuation of inventories as a key audit matter because the Group held significant inventories at the reporting date and because of the significant degree of management judgment involved in evaluating slowmoving, obsolete inventory and the net realizable value of such inventories.

How the matter was addressed in our audit

We obtained the inventory ageing report and understood with management their procedures to identify slow moving and obsolete inventories.

We analysed the ageing profile of inventories to identify slow and obsolete inventories.

We tested the standard cost assessment and year-end adjustment to actual cost by performing walkthroughs of the costing exercise and testing the actual costs of production for a representative sample of products.

We assessed the adequacy of the allowance for obsolete inventories by checking, on a sample basis, whether inventory items were categorized appropriately in the relevant ageing bracket and assessed the reasonableness of the allowance percentages applied.

We also inquired for any obsolete or slow-moving inventories identified during our inventory count observation and also separately performed net realisable value testing on selected inventory items to check that inventories are carried at the lower of cost and net realisable value.

Business combinations

(Refer note 2.2 and 2.3(a) to accounting policies.)

On 31 January 2019, the Group acquired Arysta LifeScience from Platform Speciality products for a consideration of USD 4.2 billion.

We have assessed the accounting for acquisitions as a key audit matter due to the following:

- The judgements used in determining the value of the goodwill and intangible assets and the allocation of value between these asset classes could, if performed inaccurately, lead to a material misstatement.
- There is significant judgement and complexity involved in the allocation of purchase price over net assets of the acquiree.

How the matter was addressed in our audit

Our procedures included the following:

- Within the framework of our audit of the preliminary purchase price allocation, we evaluated the consideration transferred by the Group and the approach of the external appraiser engaged by management with regard to the identification of the acquired assets and the conceptual assessment of the valuation methods.
- We analysed the assumptions such as growth rates, capital costs or remaining useful lives used in the preliminary determination of fair values of the acquired and identifiable assets and liabilities and contingent liabilities assumed at the acquisition date.
- We retraced the presentation of the initial consolidation, including the non-controlling interest, in the consolidation.

Other Information

The Holding Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Holding Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed and based on the work done/ audit report of other auditors, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated profit/loss and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group including its associates and joint ventures in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective management and Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

 Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion,

- forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)
 (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group (company and subsidiaries) as well as associates and joint ventures to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content
 of the consolidated financial statements, including the
 disclosures, and whether the consolidated financial
 statements represent the underlying transactions and
 events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group and its associates and joint ventures to express an opinion on the consolidated financial statements, of which we are the independent auditors. We are responsible for the direction, supervision and performance of the audit of financial information of such entities. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled 'Other Matters' in this audit report.

We believe that the audit evidence obtained by us along with the consideration of audit reports of the other auditors referred to in sub-paragraph (a) of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements (Continued)

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

a) We did not audit the financial statements/financial information of 99 subsidiaries whose financial statements/financial information reflect total assets of Rs 135,582 crores as at 31 March 2019, total revenues of Rs. 26,138 crores and net cash flows amounting to Rs 823 crores for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Group's share of net profit (and other comprehensive income) of Rs.14 crores for the year ended 31 March 2019, in respect of 18 associates and 3 joint ventures, whose financial statements/financial information have not been audited by us. These financial statements/ financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries, associates and joint ventures is based solely on the audit reports of the other auditors

Certain of these subsidiaries, associates and joint ventures are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries, associates and joint ventures located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries, associates and joint ventures located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and audited by us.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

- A. As required by Section 143(3) of the Act, based on our audit and on the consideration of reports of the other auditors on separate financial statements of such subsidiaries, associates and joint ventures as were audited by other auditors, as noted in the 'Other Matters' paragraph, we report, to the extent applicable,
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.
 - c) The consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under section 133 of the Act.
 - e) On the basis of the written representations received from the directors of the Holding Company as on 31 March 2019 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies and its associate companies incorporated in India,

none of the directors of the Group companies and its associate companies incorporated in India is disqualified as on 31 March 2019 from being appointed as a director in terms of Section 164(2) of the Act.

- f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, its subsidiary companies and its associate companies incorporated in India and the operating effectiveness of such controls, refer to our separate Report in "Annexure A
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate financial statements of the subsidiaries, associates and joint ventures, as noted in the 'Other Matters' paragraph:
 - The consolidated financial statements disclose the impact of pending litigations as at 31 March 2019 on the consolidated financial position of the Group, its associates and its joint ventures. Refer Note 37 to the consolidated financial statements:
 - ii. Provision has been made in the consolidated financial statements, as required under the applicable law or Ind AS, for material foreseeable losses, on long-term contracts including derivative contracts. Refer Note 16 to the consolidated financial statements in respect of such items as it relates to the Group, its associates and joint ventures;
 - iii. There has been no delay in transferring amounts to the Investor Education and Protection Fund by the Holding Company, its subsidiary Companies and

- its associates incorporated in India during the year ended 31 March 2019; and
- iv. The disclosures in the consolidated financial statements regarding holdings as well as dealings in specified bank notes during the period from 8 November 2016 to 30 December 2016 have not been made in the financial statements since they do not pertain to the financial year ended 31 March 2019.
- C. With respect to the matter to be included in the Audit Report under section 197(16):

In our opinion and according to the information and explanations given to us and based on the reports of the statutory auditors of such subsidiary companies and associate companies incorporated in India which were not audited by us, the remuneration paid during the current year by the Holding Company, its subsidiary companies and associate companies to its directors is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director by the Holding Company, its subsidiary companies and its associate companies is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) which are required to be commented upon by us.

> For BSR&Co.LLP Chartered Accountants Firm's Registration No: 101248W/W-100022

> > Bhavesh Dhupelia Partner

Date: 17 May 2019 Membership No: 042070

Place: Mumbai

Annexure A to the Independent Auditors' Report

Report on the internal financial controls with reference to the aforesaid consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

(Referred to in paragraph A(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended 31 March 2019, we have audited the internal financial controls with reference to consolidated financial statements of UPL Limited (hereinafter referred to as "the Holding Company") and such companies incorporated in India under the Companies Act, 2013 which are its subsidiary companies and its associate companies as of that date.

In our opinion, the Holding Company and such companies incorporated in India which are its subsidiary companies and its associate companies have, in all material respects, adequate internal financial controls with reference to consolidated financial statements and such internal financial controls were operating effectively as at 31 March 2019, based on the internal financial controls with reference to consolidated financial statements criteria established by such companies considering the essential components of such internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's Responsibility for Internal Financial Controls

The respective Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls with reference to consolidated financial statements based on the criteria established by the respective Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditors' Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of the internal controls based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors of the relevant subsidiary companies and associate companies in terms of their reports referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements.

Meaning of Internal Financial controls with Reference to Consolidated Financial Statements

A company's internal financial controls with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements

due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial controls with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Other Matter

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements insofar as it relates to 10 subsidiary companies and 4 associate companies which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India.

For **B S R & Co. LLP** *Chartered Accountants*Firm's Registration No: 101248W/W-100022

Place: Mumbai Partner
Date: 17 May 2019 Membership No: 042070

Consolidated Balance Sheet as at March 31, 2019

₹ In Crores

	Notes	As at March 31, 2019	As at March 31, 2018
Assets			
Non-current assets		4.65.4	2074
Property, plant and equipment Capital work-in-progress	3	4,654 1,166	2,874 1,090
Goodwill	4	15,050	432
Other intangible assets	4	12,197	1,131
Intangible assets under development	4	617	229
Investments accounted for using the equity method	5	408	386
<u>Financial assets</u>			
(i) Investments	5	298	648
(ii) Loans (iii) Trade receivables	6 10	156 4	151
(iii) Trade receivables (iv) Other financial assets	7	167	35
Income tax assets (net)		327	194
Deferred tax assets (net)	18	731	529
Other non-current assets	8	281	319
Total non-current assets		36,056	8,019
Current assets	9	9,270	4,538
Inventories Financial assets	9	9,270	4,330
(i) Investments	5	2	_
(ii) Trade receivables	10	11,812	6,056
(iii) Cash and cash equivalents	11	2,826	2,859
(iv) Bank balance other than cash and cash equivalents	11A	25	35
(v) Loans	6	51	147
(vi) Other financial assets	7	310	167
Income tax assets (net) Other current assets	8	486 2,184	27 1,175
Total current assets	0	26,966	15,004
Assets held for sale		26	20
Total Assets		63,048	23,043
Equity and liabilities			
Equity and liabilities Equity			
Equity share capital	12	102	102
Other equity	13	14,543	9,067
Equity attributable to owners of the parent		14.645	9,169
Non-controlling interests		3,358	19
Total Equity Liabilities		18,003	9,188
Non-current liabilities:			
Financial liabilities			
(i) Borrowings	15	26,383	5,873
(iii) Other financial liabilities	16	136	232
Provisions	17	20	20
Deferred tax liabilities (net)	18	2,942	88
Total non-current liabilities Current liabilities:		29,481	6,213
Financial liabilities			
(i) Borrowings	15	2,478	634
(ii) Trade payables	19	2,170	
Total outstanding dues of Micro enterprises and Small enterprises		26	17
Total outstanding dues of creditors other than Micro enterprises and Small		9,397	5,658
enterprises			
(iii) Other financial liabilities	16	1,499	755
Provisions Other current liabilities	17 20	844	164 357
Current tax liabilities (net)	∠U	724 596	57
Carrent tax nabilities (Net)		15,564	7.642
Total liabilities		45,045	13,855
Total equity and liabilities		63,048	23,043
Summary of significant accounting policies	2.3		
The accompanying notes are an integral part of these consolidated financial statements.	1 - 48		

As per our report of even date attached.

For B S R & Co. LLP Chartered Accountants Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

Anand Vora Chief Financial Officer Place: Mumbai

A.C.Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

Date: May 17, 2019

M.B.Trivedi Company Secretary Membership no.: ACS4250 Place: San Francisco

Consolidated Statement of Profit and Loss for the year ended March 31, 2019

₹ In Crores

	Notes	Year ended	Year ended
		March 31, 2019	March 31, 2018
Revenue			
Revenue from operations	21	21,837	17,506
Other income	22	240	414
Total Income		22,077	17,920
Expenses			
Cost of materials and components consumed (including (increase)/decrease		10,904	8,112
in inventory of finished goods, work-in-progress and traded goods and			
purchase of stock-in-trade)			
Excise duty		-	128
Employee benefits expenses	23	2,095	1,713
Finance costs	24	963	783
Depreciation and amortisation expenses	25	969	675
Other expenses	26	5,025	4,048
Total Expenses		19,956	15,459
Profit before share of loss of equity accounted investee, exceptional items		2,121	2,461
and tax		,	, -
Share of Profit/(Loss) of equity accounted investees (net of income tax)	33 & 34	14	(93)
Profit before exceptional items and tax		2,135	2,368
Exceptional items	27	451	63
Profit before tax		1,684	2,305
Tax expenses		165	275
Current tax	18	442	311
Adjustments of tax relating to earlier years	18	(4)	(79)
Deferred tax	18	(273)	43
Profit for the year		1,519	2,030
Other comprehensive income (OCI)		.,,	
A (i) Items that will not be reclassified subsequently to profit or loss	28	(59)	8
(ii) Income tax relating to items that will not be reclassified to profit or loss	28	2	(5)
B (i) Items that will be reclassified subsequently to profit or loss	28	(825)	67
(ii) Income tax relating to items that will be reclassified to profit or loss	28	-	0
Total other Comprehensive Income for the year, net of tax		(882)	70
Total Comprehensive Income for the year		637	2,100
Profit for the year		1,519	2,030
Attributable to:			,
Owners of the parent		1,447	2,022
Non-controlling interests		72	8
Total comprehensive income for the year		637	2,100
Attributable to:			,
Owners of the parent		565	2,092
Non-controlling interests		72	8
Earnings per equity share (of Face Value of Rs 2 each)	29		
Basic (Face value of Rs 2 each)		28.42	39.79
Diluted (Face value of Rs 2 each)		28.41	39.78
Summary of significant accounting policies	2.3		
The accompanying notes are an integral part of these consolidated financial	1 - 48		
statements.			
- Statements.			

As per our report of even date attached.

For B S R & Co. LLP Chartered Accountants

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019

R.D. Shroff

Chairman & Managing Director Din No.-00180810 Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019

A.C.Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

Consolidated Statement of Cash Flows for the year ended March 31, 2019

					₹ In Crores
		Year e	ended	Year e	nded
		March 3	31, 2019	March 3	1, 2018
A Cash Flow from operating activities Profit before exceptional items and tax Adjustments for:			2,121		2,461
Depreciation and amortization expense Finance costs Allowance for doubtful debts and advances Assets written off Bad debts written off Gain on disposal of property, plant and equ Interest Income Unwinding of interest on trade receivables Manufacturing expenses capitalised Excess provisions in respect of earlier years Sundry credit balances written off (net) Loss/(Gain) on sale of current and non curre	s written back (net)	969 963 (41) 10 (3) (137) (82) (29) (36) (12) (9)	1,604	675 783 17 10 2 (2) (132) (282) (26) (57) 15 7	1,010
Operating profit before working capital cheworking capital adjustments (Increase) in inventories Decrease/(Increase) in non current and current (Increase) in other non current and current (Increase)/ in other non current and current Increase in non current and current trade processe in non current and current provision (Decrease) in other current liabilities Increase in other non current and current fill	rent trade receivables assets t financial assets payables ons	(674) 370 (324) (30) 277 13 (28) (167)	3,725	(383) (138) (502) (12) 663 16 (57)	3,472
Cash generated from operations Income taxes paid (net) Cash flow before exceptional items Exceptional items Net cash flow from operating activities			(564) 3,161 (354) 2,807 (451) 2,356		(322) 3,150 (249) 2,902 (63) 2,839
B Cash flow from investing activities Purchase of Property, plant and equipment work-in-progress and capital advances Purchase of intangible assets including asset development Proceeds from sale of property, plant and e Payment for acquisition of additional stake in Payment for acquisition of Arysta Life Science Payment of contingent consideration	ets under equipment in subsidiary e and its subsidiaries		(1,370) (205) 22 (30,989) (54)		(1,092) (321) 9 (22) - (126)
Purchase of equity shares of equity account Purchase of investments Proceeds from sale of non current investments Sundry loans given Sundry loans repayment received Fixed deposit, margin money and dividend a Profit on sale of investment in mutual funds Interest income Net cash flow (used in) investing activities C Cash flow from financing activities Proceeds from long term borrowings Repayment of long term borrowings Short term borrowings (net) Interest paid and other financial charges Dividend paid to minority shareholders by so	ents and subsidiary accounts (net) s/bonds		(4) (96) 427 424 (317) 10 9 175 (31,968) 20,736 (78) 1,308 (1,007) (17) (407)		(300) (423) - (14) 85 (21) (7) 140 (2,093) 1,954 (1,623) (45) (717) (12) (357)

Consolidated Statement of Cash Flows for the year ended March 31, 2019

₹ In Crores

	Year ended March 31, 2019	Year ended March 31, 2018
Proceeds from issue of shares of subsidiary to Non Controlling Interest (See Note 40)	8,358	-
Net cash flow (used in)/from financing activities	28,894	(801)
D Exchange difference arising on conversion debited to foreign currency translation reserve	(362)	37
Net (Decrease)/Increase in cash and cash equivalents (A+B+C+D)	(1,081)	(19)
Cash and cash equivalents as at the beginning of the year (Refer note 11)	2,859	2,880
Add: Cash and Cash Equivalents on acquisition of subsidiaries Cash and cash equivalents of Arysta Group as on date of	1,048	-
acquisition Cash and cash equivalents as at the end of the year (Refer note 11)	2,826	2,859

Reconciliation between the opening and closing balances in the balance sheet for liabilities arising from financing activities.

Particulars	Notes	March	Cash		Non-cash o	hanges		March
		31, 2018	flows	Accquisition	Foreign exchange movement	Fair value change	Other adjustments	31, 2019
Debentures								
Unsecured Redeemable Non	15 and	809	(78)	-	-	-	-	731
convertible Debentures (NCDs)	16							
Bonds (Unsecured)								
3.25% Senior Notes	15	3,230	-	-	207	-	-	3,437
4.50% Senior Notes	15	1,937	-	-	108	-	-	2,045
Term Loan								
From Bank (Unsecured)	15	2	20,391	-	-	-	-	20,394
From Bank (Secured)	15	7	(4)	-	-	-	-	3
From others (Unsecured)	15	19	(2)	-	-	-	-	17
Cash credit, packing credit and	15	621	1,101	423	21	-	-	2,166
working capital demand loan								
accounts and Commercial Papers								
Discounted Trade Receivables	15	13	(52)	352	_	-	-	312
Finance Lease obligation	15	-		34	-	-		34
Total liabilities from financing		6,638	21,356	809	337	-	-	29,139
activities								

- The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows.
- (ii) Figures in brackets represent cash outflow

The accompanying notes are an integral part of these consolidated financial statements.

As per our report of even date attached.

For BSR&Co.LLP **Chartered Accountants**

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director Din No.-00180810

Place: Mumbai

Anand Vora Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi Company Secretary Membership no.: ACS4250 Place: San Francisco

Consolidated Statement of Changes in Equity for the year ended March 31, 2019

A. Equity Share Capital

	Equity shares of INR 2 each	of INR 2 each	Compulsorily Convertible Preference Shares (CCPS)	Compulsorily Convertible Preference Shares (CCPS)
Issued, subscribed and fully paid	Nos.	INR Crores	Nos.	INR Crores
As at April1, 2017	50,70,17,118	101	8,19,40,125	82
Changes during the year	23,15,963	_	(8,19,40,125)	(82)
At March 31, 2018	50,93,33,081	102	1	ı
Changes during the year	685'6	0	ı	I
At March 31, 2019	50,93,42,670	102	1	1

B. Other Equity For the year ended March 31, 2019

				At	tributable	to the Ov	Attributable to the Owners of the parent) parent				Total	Non-	Total
				Reserve and	Surplus					Items of OCI			controlling interest	other
	Capital Capital Securities Debenture reserve reserve	Capital	Securities	Capital Securities Debenture reserve premium redemption reserve	General	Share Based Payment reserve	Non- Retained controlling earnings interest reserve	Retained	Cashflow hedge reserve for OCI	Equity Instruments through other comprehensive income	Exchange differences on translation of a foreign operation			
As at 1st April 2018	45	193	4,607	141	1,848	1	(3,693)	5,927	1	(44)	43	290'6	19	980'6
Profit for the year	1	1	1	1	1	1	1	1,447	1	1	ı	1,447	72	1,519
Other comprehensive income(net of tax)	1	ı	1	1	I	I	ı	m	(62)	(09)	(763)	(882)	(18)	(868)
Total comprehensive income														
Dividends paid during the year	ı	ı	1	ı	I	ı	ı	(407)	ı	1	I	(407)	(17)	(424)
Transfer to retained earnings	ı	ı	1	(1)	ı	ı	1	_	1	1	I	ı	ı	1
Foreign exchange impact	ı	(17)	1	ı	1	1	ı	ı	ı	I		(17)	(218)	(235)
Gain on equity dilution in subsidiary	ı	ı	1	ı	I	ı	ı	5,335	ı	I	I	5,335	3,023	8,358
Recognition of NCI on Arysta acquisition	ı	ı	1	ı	1	1	ı	ı	ı	I	ı	ı	496	496
As at 31 March 2019	45	176	4,607	140	1.848	1	(3 693)	12 306	(62)	(104)	(720)	11 513	2 2 2 8	17 901

Consolidated Statement of Changes in Equity for the year ended March 31, 2019

For the year ended March 31, 2018

				Attr	ibutable	to the Ow	Attributable to the Owners of the parent	parent				Total	Non-	
				Reserve and Surplus	Surplus					Items of OCI			controlling interest	other
	Capital redemption reserve			Capital Securities Debenture reserve premium redemption reserve	General	Share Based Payment reserve	Non- controlling interest reserve	Retained	Cashflow hedge reserve for OCI	Equity Instruments through other comprehensive income	Exchange differences on translation of a foreign operation			
As at 1st April 2017	36	171	4,498	127	1,848	2	(3,693)	4,303	1	(54)	(24)	7,214	33	7,247
Profit for the year	1	1	1	ı	1	1	1	2,022	1		1	2,022	∞	2,030
Other comprehensive income(net of tax)	ı	ı	1	ı	ı	1	1	(_)	ı	10	29	70	1	70
Total comprehensive income														
Dividends paid during the year	ı	ı	1	ı	1	ı	1	(357)	ı	1	ı	(357)	(12)	(369)
Conversion of optionally	1	1	105	ı	1	1	1	1	1	1	1	105	1	105
convertible preference shares														
and compulsorily convertible														
preference shares														
Capital reserve of an associate	1	18	1	ı	1	1	1	ı	1	ı	1	18	1	18
Transfer from retained	6	1	1	4	1	1	1	(23)	1	ı	1	1	1	'
earnings														
Exercise of employee stock	1	1	4	1	1	(2)	ı	ı	1	1	ı	2	1	2
options														
Acquisition of non controlling	1	'	1	ı	1	1	1	(11)	1	1	ı	(11)	(11)	(22)
interest														
Foreign exchange impact	1	4	1	1	1	ı	ı	ı	1	1	1	4	2	9
As at 31 March 2018	45	193	4,607	141	1,848	1	(3,693)	5,927	1	(44)	43	6,067	19	980'6

Notes:

(i) During the year, the company's wholly owned subsidiary UPL Corporation Limited made a fresh issue of capital thereby reducing the group's stake to 78%. The difference between the share of net assets and all funds infused has been credited to retained earnings.

The accompanying notes are an integral part of these consolidated financial statements.

As per our report of even date attached.

Chartered Accountants For BSR & Co. LLP

Firm registration number: 101248W/W-100022

Bhavesh Dhupelia

Membership no.: 042070 Partner

Date: May 17, 2019 Place: Mumbai

Whole-time Director Din No.- 00192088 A.C.Ashar Chairman & Managing Director Din No.-00180810 R.D. Shroff

For and on behalf of the Board of Directors of UPL Limited

CIN No.-L24219GJ1985PLC025132

Chief Financial Officer **Anand Vora**

Company Secretary

M.B.Trivedi

Place: Mumbai

Membership no.: ACS4250

Place: San Francisco Date: May 17, 2019

1. Corporate Information

UPL Limited (the Company) is a public Company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognised stock exchanges in India. The registered office of the Company is located at 3-11, G.I.D.C., Vapi, Dist.- Valsad, Gujarat. The consolidated financial statements comprise the financial statements of UPL Limited ('the Company' or 'the holding Company' or "the parent") and its subsidiaries (collectively, 'the Group'), its associates and joint ventures as at and for the year ended 31 March 2019.

The Group is principally engaged in the business of agrochemicals, industrial chemicals, chemical intermediates, speciality chemicals and production and sale of field crops and vegetable seeds. Information on the Group's structure is provided in Note 31.

The consolidated financial statements were authorised for issue in accordance with the resolution of the directors on 17 May 2019

2 Accounting Policies

2.1 Basis of Preparation

The consolidated financial statements of the Group have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013 ("the Act") as amended thereafter and other relevant provision of the Act.

The consolidated financial statements have been prepared on an accrual basis and under the historical cost convention, except for the following assets and liabilities which have been measured at fair value:

- Derivative financial instruments,
- Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments),
- Consideration for business combination (including contigent consideration).
- Assets and Liabilities acquired in business combination.

The consolidated financial statements are presented in Indian Rupees ('INR') or ('Rs') which is also the Company's functional currency and all values are rounded to the nearest crores, except when otherwise indicated. Wherever an amount is represented as Rs. '0' (zero), it construes a value less than rupees fifty lakhs.

Significant accounting estimates, assumptions and judgements

The preparation of the Group's consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

Taxes

There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts initially recorded, such differences will impact the current and deferred tax provisions in the period in which the tax determination is made. Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Defined benefit plan (gratuity benefits)

A liability in respect of defined benefit plans is recognised in the balance sheet, and is measured as the present value of the defined benefit obligation at the reporting date less the fair value of the plan assets. The present value of the defined

benefit obligation is based on expected future payments at the reporting date, calculated annually by independent actuaries. Consideration is given to expected future salary levels, experience of employee departures and periods of service. Refer note 35 for details of the key assumptions used in determining the accounting for these plans.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See Note 45 and 46 for further disclosures.

Provision against obsolete and slow-moving inventories

The Group reviews the condition of its inventories and makes provision against obsolete and slow-moving inventory items which are identified as no longer suitable for sale or use. Group estimates the net realisable value for such inventories based primarily on the latest invoice prices and current market conditions. The Group carries out an inventory review at each balance sheet date and makes provision against obsolete and slow-moving items. The Group reassesses the estimation on each balance sheet date.

Impairment of financial assets

The Group assesses impairment based on expected credit losses (ECL) model on trade receivables.

The Group uses a provision matrix to determine impairment loss allowance on the portfolio of trade receivables. The provision matrix is based on its histroically observed default rates over the expected life of the trade receivable and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length, for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a DCF model. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the asset's performance of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognised by the Group.

2.2 Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries, associates and joint ventures as at 31 March 2019. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Subsidiaries are entities controlled by the Group. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed off during the year are included in the consolidated financial statements from the date the Group gains control and until the date the Group ceases to control the subsidiary.

Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing the consolidated financial statements to ensure conformity with the group's accounting policies.

The financial statements of each of the subsidiaries, associates and joint ventures, other than Sinagro Produtos Agropecuarios SA. Group, 3SB Produtos Agricolas SA and Serra Bonita Sementes SA used for the purpose of consolidation are drawn up to same reporting date as that of the Company, i.e., year ended on 31 March. The audited consolidated financial statements of Sinagro Produtos Agropecuarios SA. Group, audited financial statements of 3SB Produtos Agricolas SA and Serra Bonita Sementes SA for the year ended 31st December 2018 have been considered for

the purpose of consolidation after making necessary adjustments for the effects of significant transactions or events, if any that occur till the reporting date of the group i.e. March 31.

Consolidation procedure:

- (a) Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the consolidated financial statements at the acquisition date.
- (b) Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary. The Business combinations policy explains how the group accounts for any related goodwill.
- (c) Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognised in assets, such as inventory and fixed assets, are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements. Ind AS12 Income Taxes applies to temporary differences that arise from the elimination of profits and losses resulting from intragroup transactions.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any realted non controlling interest and other components of equity. Any interest retained in the form of subsidiary is measured at fair value at the date the control is lost. Any resulting gain or loss is recognised in the statement of profit and loss.

2.3 Summary of significant accounting policies

a Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any noncontrolling interests in the acquiree. For each business combination, the Group elects whether to measure the noncontrolling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their acquisition date fair values.

The consideration transferred does not include amount related to the settlement of pre-existing relationships with the acquiree. Such amounts are generally recognised in the statement of profit and loss.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of Ind AS 109 Financial Instruments, is measured at fair value with changes in fair value recognised in statement of profit and loss. If the contingent consideration is not within the scope of Ind AS 109, it is measured in accordance with the appropriate Ind AS. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and any difference subsequent its settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests, and any previous interest held, over the fair value of identifiable assets acquired net of fair value of liabilities assumed. Any gain on a bargain purchase is recognised in OCI and accumulated in equity as capital reserve if there exists clear evidence, of the underlying reasons for classifying the business combination as resulting in a bargain purchase; otherwise the gain is recognised directly in equity as capital reserve.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

A cash generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised in statement of profit and loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

Where goodwill has been allocated to a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed in these circumstances is measured based on the relative values of the disposed operation and the portion of the cash-generating unit retained.

b. Investment in associates and joint ventures

The group's interest in equity in investees comprise interests in associates and joint ventures.

An associate is an entity in which the group has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the group has joint control and has right to the net assets of the arrangement, rather than the right to its assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognised at cost which includes transaction costs. Subsequent to intial recognition the consolidated financial statements include the groups share of profit and loss and OCI of equity accounted investee until the date on which significant influence or joint control ceases."

c. Current versus non-current classification

The Group presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current.

Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Group has identified twelve months as its operating cycle for the purpose of current / non current classification of assets and liabilities.

d. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

Revenue is stated inclusive of excise duty and excludes sales tax/ value added tax (VAT)/Goods and Service Tax (GST).

The specific recognition criteria described below must also be met before revenue is recognised.

Sale of goods

Revenue is recognised upon transfer of control of promised goods to customers in an amount that reflects the consideration which the Company expects to receive in exchange for those goods.

Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer which is usually on shipment.

Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, rebates, scheme allowances, price concessions, incentives, and returns, if any, as specified in the contracts with the customers. Revenue excludes taxes collected from customers on behalf of the government. Accruals for discounts/incentives and returns are estimated (using the most likely method) based on accumulated experience and underlying schemes and agreements with customers. Due to the short nature of credit period given to customers, there is no financing component in the contract.

Rendering of services

Income from services are recognized as and when the services are rendered.

Interest income

For all debt instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in other income in the statement of profit and loss.

Export Incentive

Duty free imports of raw materials under Advance License for Imports as per the Export and Import Policy are matched with the exports made against the said licenses and the benefit / obligation is accounted by making suitable adjustments in raw material consumption.

The benefit accrued under the Duty Drawback scheme and other schemes as per the Export and Import Policy in respect of exports made under the said Schemes is included under the head "Revenue from Operations" as 'Export Incentive'

Dividends and Royalties

Dividend income is recognised when the Company's right to receive the payment is established, which is generally when shareholders approve the dividend. Royalty income is recognized on an accrual basis in accordance with the substance of the relevant agreement.

e. Non-current assets held for sale

The Group classifies non-current assets as held for sale if their carrying amounts will be recovered principally through a sale rather than through continuing use. Actions required to complete the sale should indicate that it is unlikely that significant changes to the sale will be made or that the decision to sell will be withdrawn. Management must be committed to the sale expected within one year from the date of classification.

For these purposes, sale transactions include exchanges of non-current assets for other non-current assets when the exchange has commercial substance. The criteria for held for sale is regarded met only when the assets are available for immediate sale in its present condition, subject only to terms that are usual and customary for sales of such assets, its sale is highly probable; and it will genuinely be sold, not abandoned. The Group treats sale of the asset or disposal of Company to be highly probable when:

- The appropriate level of management is committed to a plan to sell the asset,
- An active programme to locate a buyer and complete the plan has been initiated (if applicable),
- The asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value,
- The sale is expected to qualify for recognition as a completed sale within one year from the date of classification, and
- Actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.

Non-current assets held for sale to owners are measured at the lower of their carrying amount and the fair value less costs to sell. Assets and liabilities classified as held for sale are presented separately in the balance sheet.

Property, plant and equipment and intangible assets once classified as held for sale are not depreciated or amortised.

f. Property, plant and equipment

Items of Property, plant and equipment including capital work-in-progress are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Cost comprisess the purchase price and any attributable cost of bringing the asset to its working condition for its intended use. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. Subsequent expenditure related to an item of fixed asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. When significant parts of plant and equipment are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in statement of profit and loss as incurred. In respect of additions to /deletions from the property, plant and equipment, depreciation is provided on pro-rata basis with reference to the month of addition/deletion of the Assets.

Depreciation:

(i) Leasehold Land:

UPL Limited

No depreciation is provided for leasehold land since as per the lease agreements, the leases are renewable at the option of the Company for a further periods of 99 years at the end of the lease periods of 99 years, without /with marginal payment of further premium.

United Phosphorus Vietnam Limited:

Lease Rentals and other costs incurred in conjunction with securing the land use rights of leased land are recognised on a straight line basis over 37 years in accordance with the term of the lease.

(ii) Other Assets:

The Group depreciates on a straight line method based on following estimated useful life of assets.

SI. No	Nature of tangible Assets	Useful Life (years)
1	Aircraft	8 years
2	Building	18-60 years
3	Furniture, Fixtures & Equipments	3-15 years
4	Improvements-Leasehold	6-10 years
5	Laboratory Equipments	10 years
6	Land-Leasehold	50 years or term of lease if shorter
7	Office Equipment	3-33 years
8	Plant and Equipment	3-25 years
9	Vehicles	3-15 years

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

q. Intangible assets

i) Goodwill

- Goodwill is initially measured at cost, being the excess of the aggregate fair value of the consideration transferred over the net of fair value of identifiable assets acquired and liabilities assumed. (Refer 2.3(a) Accounting policy for Business Combination and Goodwill)
- Subsequent measurement is at cost less accumulated impairment losses.
- Goodwill is not amortised and is tested for impairment annually.

ii) Other intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets with finite life are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in statement of profit and loss in the period in which the expenditure is incurred.

The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at the end of each reporting period. Gains or losses arising from derecognition of an intangible asset are

measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is derecognised.

Research costs are expensed as incurred. Development expenditures on an individual project are recognised as an intangible asset when the Group can demonstrate the technical feasibility of completing the intangible asset so that the asset will be available for use or sale.

Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation expense is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

A summary of the policies applied to the Group's intangible assets is as follows

Intangible assets	Useful life	Amortisation method
Product Acquisitions	Fifteen years	Amortised on straight-line basis from the month of additions to match their future economic benefits
Germ plasm	Ten to fifteen years	Amortised on straight-line basis
Other Intangible assets	Three to Five years	Amortised on straight-line basis
Intellectual Property Rights/ technology	Fifteen years	Amortised on straight-line basis
Distribution Network/ Customer Relationships	Fifteen years	Amortised on straight-line basis
Non compete	Five Years	Amortised on straight-line basis
Brand	Infinite	To be tested for impairment

h. Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

Foreign currencies

The Group's consolidated financial statements are presented in Indian Rupee (INR), which is also the Group's functional currency. For each entity the Group determines the functional currency and items included in the financial statements of each entity are measured using that functional currency.

Transactions and balances

Transactions in foreign currencies are initially recorded by the Group's entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Transactions in foreign currency are recorded applying the exchange rate at the date of transaction. Monetary assets and liabilities denominated in foreign currency remaining unsettled at the end of the year, are translated at the closing rates prevailing on the Balance Sheet date. Non-monetary items which are carried in terms of historical cost denominated in foreign currency are reported using the exchange rate at the date of transaction. Exchange differences arising as a result of the above are recognized as income or expenses in the statement of profit and loss except for exchange differences arising on a monetary item which, in substance, forms part of the Group's net investment in a foreign operation which is accumulated in a Foreign Currency Translation Reserve until the disposal of the net investment. Exchange difference arising on the settlement of monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognised as income or expenses in the year in which they arise.

Exchange difference on such contracts are recognized in the statements of profit and loss in the year in which the exchange rate changes. Any profit and loss arising on cancellation or renewal of forward exchange contract is recognized as income or as expenses for the year.

Foreign exchange differences on foreign currency borrowings, loans given/taken, settlement gain/loss and fair value gain/losses on derivative contracts relating to borrowings are accounted and disclosed under 'finance cost'.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or statement of profit and loss, respectively).

Translation of financial statements of foreign entities

On consolidation, the assets and liabilities of foreign operations are translated into INR at the rate of exchange prevailing at the reporting date and their statements of profit and loss are translated at exchange rates prevailing at the dates of the transactions. For practical reasons, the group uses a monthly average rate to translate income and expense items, if the average rate approximates the exchange rates at the dates of the transactions. The exchange differences arising on translation for consolidation are recognised in OCI. On disposal of a foreign operation, the component of OCI relating to that particular foreign operation is reclassified to the statement of profit and loss.

Any goodwill arising in the acquisition/ business combination of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.

i. Fair value measurement

The Group measures financial instruments, such as, derivatives at fair value at each balance sheet date on a portfolio basis.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

This note summarises accounting policy for fair value. Other fair value related disclosures are given in the relevant notes

- Contingent consideration (note 42)
- Quantitative disclosures of fair value measurement hierarchy (note 46)
- Financial instruments (including those carried at amortised cost) (note 5, 6, 7, 10, 11, 11A, 15, 16, 19, 44, 45, 46, 47)

k. Leases

The determination of whether an arrangement is (or contains) a lease is based on the substance of the arrangement at the inception of the lease. The arrangement is, or contains, a lease if fulfilment of the arrangement is dependent on the use of a specific asset or assets and the arrangement conveys a right to use the asset or assets, even if that right is not explicitly specified in an arrangement.

For arrangements entered into prior to 1 April 2015, the Group has determined whether the arrangement contain lease on the basis of facts and circumstances existing on the date of transition.

Group as a lessee

A lease is classified at the inception date as a finance lease or an operating lease. A lease that transfers substantially all the risks and rewards incidental to ownership to the Group is classified as a finance lease.

Finance leases are capitalised at the commencement of the lease at the inception date fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in finance costs in the statement of profit and loss, unless they are directly attributable to qualifying assets, in which case they are capitalized in accordance with the Group's general policy on the borrowing costs (See note 2.1). Contingent rentals are recognised as expenses in the periods in which they are incurred.

A leased asset is depreciated over the useful life of the asset. However, if there is no reasonable certainty that the Group will obtain ownership by the end of the lease term, the asset is depreciated over the shorter of the estimated useful life of the asset and the lease term.

Operating lease payments are recognised as an expense in the statement of profit and loss on a straight-line basis over the lease term.

Group as a lessor

Leases in which the Group does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. Rental income from operating lease is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised over the lease term on the same basis as rental income. Contingent rents are recognised as revenue in the period in which they are earned.

Leases are classified as finance leases when substantially all of the risks and rewards of ownership transfer from the Group to the lessee. Amounts due from lessees under finance leases are recorded as receivables at the Group's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the net investment outstanding in respect of the lease.

Inventories

- (i) Stocks of stores and spares, packing materials and raw materials are valued at lower of cost or net realisable value. Cost is determined on moving weighted average basis. The aforesaid items are valued below cost if the finished products in which they are to be incorporated are expected to be sold at a loss.
- (ii) Semi-finished products, finished products and by-products are valued at lower of cost or net realisable value and for this purpose, cost is determined on standard cost basis which approximates the actual cost. Cost of finished goods includes excise duty, as applicable. Variances, exclusive of abnormally low volume and operating performance, are capitalized into inventory.
- (iii) Traded goods are valued at lower of cost and net realizable value. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on a weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

m. Impairment of non-financial assets

The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an

asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flows after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Group extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the longterm average growth rate for the products, industries, or country or countries in which the entity operates, or for the market in which the asset is used.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit and loss.

Goodwill is tested for impairment annually as at 31 March and when circumstances indicate that the carrying value may be impaired.

Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised. Impairment losses relating to goodwill are not reversed in future periods.

Intangible assets with indefinite useful lives are tested for impairment annually as at 31 March at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired.

n. Provisions

General

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost. Provisions are reviewed at each balance sheet and adjusted to reflect the current best estimates.

Contingent liabilities recognised in a business combination

A contingent liability recognised in a business combination is initially measured at its fair value. Subsequently, it is measured at the higher of the amount that would be recognised in accordance with the requirements for provisions above or the amount initially recognised less, when appropriate, cumulative amortisation recognised in accordance with the requirements for revenue recognition.

o. Taxes

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Group operates and generates taxable income.

Current income tax relating to items recognised outside statement of profit and loss is recognised outside profit or loss (either in other comprehensive income or in equity). Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of taxable temporary differences associated with investments in subsidiaries and interests in joint ventures, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is reasonably certain that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries and interests in joint ventures, deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become reasonable certainty that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit and loss is recognised outside the statement of profit and loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Tax benefits acquired as part of a business combination, but not satisfying the criteria for separate recognition at that date, are recognised subsequently if new information about facts and circumstances change. Acquired deferred tax benefits recognised within the measurement period reduce goodwill related to that acquisition if they result from new information obtained about facts and circumstances existing at the acquisition date. If the carrying amount of goodwill is zero, any remaining deferred tax benefits are recognised in OCI/ capital reserve depending on the principle explained for bargain purchase gains. All other acquired tax benefits realised are recognised in statement of profit and loss.

Minimum Alternate Tax (MAT)

Minimum Alternate Tax (MAT) is in the nature of unused tax credit which can be carried forward and utilised when the Group will pay normal income tax during the specified period. Deferred tax assets on such tax credit is recognised to the extent that it is probable that the unused tax credit can be utilised in the specified future period.

p. Retirement and other employee benefits

1. UPL Limited and SWAL Corporation Limited

- i) Provident Fund is a defined contribution scheme established under a State Plan. The contributions to the scheme are charged to the statement of profit and loss in the year when employee rendered related services.
- Superannuation Fund is a defined contribution scheme and contributions to the scheme are charged to the statement of profit and loss in the year when the contributions are due. The scheme is funded with an insurance company in the form of a qualifying insurance policy.
- iii) The companies have a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on post employment at 15 days salary (last drawn salary) for each completed year of service as per the rules of the company. The aforesaid liability is provided for on the basis of an actuarial valuation made on projected unit credit method at the end of the financial year. The scheme is funded with an insurance company in the form of a qualifying insurance policy.
- iv) The Group has other long term employee benefits in the nature of leave encashment. The liability in respect of leave encashment is provided for on the basis of actuarial valuation made on projected unit credit method at the end of the financial year. The aforesaid leave encashment is funded with an insurance company in the form of a qualifying insurance policy.
- v) Remeasurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to statement of profit and loss in subsequent periods.

The Companies contribute to a defined contribution plan which are charged to the statement of profit and loss as incurred.

q. Share-based payments

Measurement and disclosure of the employee share based payment plans is done in accordance with Ind AS 102, "Share based payments". The Group measures compensation cost relating to employee stock options using the fair value method. Compensation expense is amortised over the vesting period of the option on a straight line basis.

r. Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognised initially at cost and then measured at fair value at each reporting date, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Debt instruments at amortised cost

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the statement of profit and loss. The losses arising from impairment are recognised in the statement of profit and loss.

Debt instrument at FVTOCI

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- a) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- b) The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the other comprehensive income (OCI). However, the Group recognizes interest income, impairment losses and reversals and foreign exchange gain or loss in the statment of profit and loss. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of profit and loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the FIR method

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

In addition, the Group may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch').

Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Equity investments

All equity investments in the scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognised by the Company as an acquirer in a business combination to which Ind AS 103 applies are classified as at FVTPL. For all other equity instruments, the Group may make an irrevocable election to present in other comprehensive income subsequent changes in the fair value. The Group makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Group decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss, even on sale of investment. However, the Group may transfer the cumulative gain or loss within equity.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Group's consolidated balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a quarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Group applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- a) Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, trade receivables and bank balance
- b) Financial assets that are debt instruments and are measured as at FVTOCI

- c) Lease receivables under Ind AS 17
- d) Trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 18 (referred to as contractual revenue receivables' in these financial statements)
- e) Financial guarantee contracts which are not measured as at FVTPL

The Group follows 'simplified approach' for recognition of impairment loss allowance on:

- Trade receivables or contract revenue receivables; and
- All lease receivables resulting from transactions within the scope of Ind AS 17

The application of simplified approach does not require the Group to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Group determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- All contractual terms of the financial instrument (including prepayment, extension, call and similar options) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument
- Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms
- Financial assets measured as at amortised cost, contractual revenue receivables and lease receivables: ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the company does not reduce impairment allowance from the gross carrying amount.

s. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, or payables, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Group that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognised in the statement of profit and loss.

Loans and borrowings

This is the category most relevant to the Group. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in statement of profit and loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

This category generally applies to borrowings. For more information refer Note 15.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the standalone balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Derivative financial instruments

Initial recognition and subsequent measurement

The Group uses derivative financial instruments, such as forward currency contracts, full currency swaps and interest rate swaps, to hedge its foreign currency risks and interest rate risks, respectively. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently remeasured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Fair value changes are recongnised in the statement of profit and loss.

u. Convertible preference shares

Convertible preference shares are separated into liability and equity components based on the terms of the contract.

On issuance of the convertible preference shares, the fair value of the liability component is determined using a market interest rate for an equivalent non-convertible instrument. This amount is classified as a financial liability measured at amortised cost (net of transaction costs) until it is extinguished on conversion or redemption.

The remainder of the proceeds are allocated to the conversion option that is recognised and included in equity if the conversion option meets Ind AS 32 criteria for fixed to fixed classification. Transaction costs are deducted from equity, net of associated income tax. The carrying amount of the conversion option is not remeasured in subsequent years.

Transaction costs are apportioned between the liability and equity components of the convertible preference shares based on the allocation of proceeds to the liability and equity components when the instruments are initially recognised.

Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the consolidated statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Group's cash management.

w. Cash dividend

The Group recognises a liability to make cash distributions to equity holders of the parent when the distribution is authorised and the distribution is no longer at the discretion of the Group. As per the corporate laws in India, a distribution is authorised when it is approved by the shareholders. A corresponding amount is recognised directly in equity.

x. Government grants

"Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic

basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

y. Earnings Per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

z. Segment Reporting:

Based on "Management Approach" as defined in Ind AS 108-Operating Segments, the Chief Operating Decision Maker evaluates the Group's performance and allocates the resources based on an analysis of various performance indicators by business segments. Inter segment sales and transfers are reflected at market prices.

Unallocable items includes general corporate income and expense items which are not allocated to any business segment.

The Group prepares its segment information in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Group as a whole. Common allocable costs are allocated to each segment on an appropriate basis.

aa. Contingent Liability and Contingent Asset:

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Group does not recognize a contingent liability but discloses its existence in the consolidated financial statements.

ab. Biological Assets:

Sinagro Produtos Agropecua'rios S.A. and 3SB Produtos Agricolas S.A.

Biological assets of the group consists of harvest of soybean, corn, cotton and beans. Such biological assets are recognised at fair value, less cost to sell, when the Group controls the asset as a result of past events, it is probable that future economic benefits associated with the asset will flow to the enterprise, and the fair value or cost of the asset can be measured reliably. Any changes to fair value are recognised in the statement of profit and loss.

ac. Recent accounting pronouncements

Standards issued but not yet effective

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2019 has notified the following new Ind AS which the Group has not applied as they are effective for annual periods beginning on or after April 1, 2019:

IND AS 116-Leases:

The new standard on leases sets out the principles for the recognition, measurement, presentation and disclosure of the leases. The core objective of this standard is to ensure that lessees and lessors provide relevant information in a manner that faithfully represent those transactions.

The Group is required to adopt Ind AS 116, Leases from 1 April 2019. Ind AS 116 introduces a single, onbalance sheet lease accounting model for lessees. A lessee recognises a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. Lessor accounting remains similar to the current standard – i.e. lessors continue to classify leases as finance or operating leases. It replaces existing leases guidance, Ind AS 17, Leases.

The Group has completed an initial assessment of the potential impact on its consolidated financial statements but has not yet completed its detailed assessment. The quantitative impact of adoption of Ind AS 116 on the consolidated financial statements in the period of initial application is not reasonably estimable as at present.

the total assets and liabilities on the balance sheet will increase with a decrease in net total assets, due to the depreciation of right of use assets being on a straightline basis whilst the lease liability reduces by the principal amount of repayments;

- Interest expense will increase due to the unwinding of the effective interest rate implicit in the lease liability. Interest expense will be greater earlier in a lease's life, due to the higher principal value, causing profit variability over the term of lease. This effect may be partially mitigated due to the number of leases held by the Group at various stages of their terms; and
- operating cash flows will be higher and financing cash flows will be lower, as repayment of the principal portion of all lease liabilities will be classified as financing activities.

The Group plans to apply Ind AS 116 initially on 1 April 2019, using the modified retrospective approach. Therefore, the cumulative effect of adopting Ind AS 116 will be recognised as an adjustment to the opening balance of retained earnings at 1 April 2019, with no restatement of comparative information.

The Group plans to apply the practical expedient to grandfather the definition of a lease on transition. This means that it will apply Ind AS 116 to all contracts entered into before 1 April 2019 and identified as leases in accordance with Ind AS 17.

In addition to the above, the following amendments to existing standards have been issued, are not yet effective and are not expected to have a significant impact on the Group's consolidated financial statements:

- Amendments to Ind AS 103, Business Combinations, and Ind AS 111, Joint Arrangements: This interpretation clarifies how an entity accounts for increasing its interest in a joint operation that meets the definition of a business.
- Amendments to Ind AS 109, Financial Instruments: amendments relating to the classification of particular pre payable financial assets.
- Amendments to Ind AS 12, Income Taxes, clarify that all income tax consequences of dividends (including payments on financial instruments classified as equity) are recognized consistently with the transactions that generated the distributable profits - i.e. in profit or loss, other comprehensive income or equity. Further Appendix C, uncertainty over income tax treatments has been added to clarify how entities should reflect uncertainties over income tax treatments, in particular when assessing the outcome a tax authority might reach with full knowledge and information if it were to make an examination.
- Amendment to Ind AS 19, Employee Benefits The amendment to Ind AS 19 clarifies that on amendment, curtailment or settlement of a defined benefit plan, the current service cost and net interest for the remainder of the annual reporting period are calculated using updated actuarial assumptions – i.e. consistent with the calculation of a gain or loss on the plan amendment, curtailment or settlement. This amendment also clarifies that an entity first determines any past service cost, or a gain or loss on settlement, without considering the effect of the asset ceiling. This amount is recognized in profit or loss. The entity then determines the effect of the asset ceiling after plan amendment, curtailment or settlement. Any change in that effect is recognized in other comprehensive income (except for amounts included in net interest).
- Amendments to Ind AS 23, Borrowing Costs, clarify that the general borrowings pool used to calculate eligible borrowing costs excludes only borrowings that specifically finance qualifying assets that are still under development or construction.

Impact on adoption of above changes in standards is not material.

2.4 Changes in accounting policies

- The Company applied Ind AS 115 for the first time. The nature and effect of the changes as a result of adoption of the new accounting standard are described below.
- Several other amendments and interpretations apply for the first time in April 1, 2018, but do not have an impact on the financial statements of the Company. The Company has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective.
- The Company adopted Ind AS 115 as per the modified retrospective approach, which requires the cumulative effect on adoption of Ind AS 115 to retained earnings at April 1, 2018. The adoption of Ind AS 115 did not have any impact on the financial statements of the Company as at and for the year ended March 31, 2019.

3. Property, plant and equipment and Capital work-in-progress

3. Property, plant and equipment and Capital work-in-progress	and ed	uipmer	nt and	Capital	work-ir	-progre	SSS								E/	₹ In crores
	Land - Freehold	Leasehold	Building	Building	Plant and Equipment	Laboratory	Furniture, Fixtures and Equipment	Office Equipment	Vehicles	Assets Taken on Lease Furniture, Vehicles Fixtures and Equipments	vehicles	Land Improve- ments	Building Improve- ments	Aircraft	Capital Work-in- Progress	Total
Cost or valuation	727	162	471	23	3 511	19	٠ ٢	79	112	2	2	۲,	58	73	223	r r
Additions during the year	, 77	70 '	8	3 '	563	12	0 0	26	23	1 '	1 '	2 '	2 0	<u> </u>	991	1,708
Disposals during the year	'		(1)	'	(73)	•	(2)	(3)	(12)	1	(1)		'	1		(92)
Transfers/Capitalised	1														(541)	(541)
Reclassification		1 4	w ć	1 <	(31)	∞ L	(9)	15	(2)	•	1	' ((5)	1	' '	(15)
Exchange differences At 31 March 2018	727	163	572	27	4.089	2 88	- 67	119	120	- 2	-	m &	- 06	74	1.090	091
Additions during the year			250		1.018	10	22	21	31	'	(0)	'			1.155	2,515
Acquisition during the year	40	132	728	1 '	1,107) !	101	. '	102	1) '	1	08	2,290
(Note 40)																
Disposals during the year	(0)	(2)	(1)		(88)	(T)	(4)	(5)	(10)	(1)			(0)	1	1	(113)
Transfers/Capitalised	1	1	1	1	1	1	1	1	1	1	1	1	1	1	(1,219)	(1,219)
Reclassification	1 (0	0	' ;	5	1 (1 3	€	1 (1 (1 3	٠,	' '	44	4
Exchange differences	7	(6)	(32)	(1)	(81)	0	(5)	(1)	(8)	(0)	(0)	(1)		5	16	(114)
At 31 March 2019	272	284	1,516	28	6,046	95	210	134	234	2	_	17	93	79	1,166	10,177
Depreciation At 1 April 2017	'		201	17	1,947	75	63	000	95			14	39	19	ı	2 439
Depreciation charge for the		. 1	16	2	262	9	0	13	19	ı	. 1	- '	9	10		343
year (Note 25)			3	į			(9	ę							į
Disposals during the year	1	1	£;	(7)	(64)	' 1	(2)	(2)	6	1	1	1	1	1	1	(80)
Reclassification	'	1	(L)	' <	(77)	J (1	(G) F	= ~	(7)	۱ (1	' (1	1 (1	(18)
At 31 March 2018		-	232	21	2.214	39	- 62	82	67	2	_	17	45	28		2.811
Depreciation charge for the	1	_	27	_	335	_	12	17	24	0	0	0	_	10	1	441
year (Note 25) Depreciation charge on	,	000	391	1	730	1	29	1	54	1	1	1	1		1	1,281
acquired assets (Note 40)																
Disposals during the year	'	(0)	(1)	1	(71)	(1)	(3)	(5)	(8)	(0)	1	1	(0)	1	1	(88)
Reclassification		1	1	1	(1)	1	_	1	9	1	1	1	1	1	1	(1)
Exchange differences	1	(2)	(22)	(1)	(55)	(0)	(3)	(0)	(4)	(0)	(0)	(1)	0	2	1	(86)
At 31 March 2019	1	38	627	22	3,152	45	136	94	132	2	_	17	52	40	1	4,357
Net book value At 31 March 2019	272	246	889	9	2,894	50	74	4	102	(0)	(0)	(0)	42	39	1,166	5,820
At 31 March 2018	227	162	340	9	1,875	47	35	37	53	0		_	45	46	1,090	3,964
Net book value							₹ Ir	₹ In crores								

Net book value		₹ In crores
	As at March 31, 2019	As at March 31, 2019 As at March 31, 2018
Plant, property and equipment	4,654	2,874
Capital work-in-progress	1,166	1,090
Total	5,820	3,964

Capital Work in ProgressCapital work-in-progress as at 31 March 2019 comprises expenditure for the plant and building in the course of construction.

Security

For property, plant and equipment given as security (Refer Note 15)

Notes to Consolidated Financial Statements for the year ended March 31, 2019

Ļ		,	
ö	Ĺ)	
Ų	1)	
5	/ [7	
•	`		
9	Ļ)	
0		2	
7		7	
č			
ī	ζ	5	
ŧ			
7			
_		•	
	٠		

4. Illeangible assets	כו												₩	₹ In crores
	Goodwill*					Other Inta	Other Intangible Assets	Ş					Intangible	Total
		Data Access Fees	Product Registrations	Product Acquisitions	Task Force Expenses	Software/ License Fees	Customer	Brands/ Trade Marks	Non-compete	Trade	Right to Use	Germplasm	asset under development	(Excl. Goodwill)
Cost			+-	_)					
At 1 April 2017	419	116	2,709	742	22	62	436	301	22	18	'	256	159	4,843
Additions during the year	1	_	239	1	ı	∞	ı	1	1	1	\sim	1	187	438
Deductions during the year		1	(18)	1	1	1	ı	1	1		1	1	ı	(18)
Transfer/Capitalised		1	1	1	1	1	ı	1	1		1	1	(112)	(112)
Reclassification		1	20	1	1	(2)	1	(19)	1		1	6	ı	1
Foreign Exchange Adjustment	13	<u></u>	180	2	ı	4	(4)	ı	1	1	ı	ı	(2)	173
At 31 March 2018	432	110	3,130	747	22	72	432	282	22	18	3	265	229	5,324
Acquisitions during the	15,035	1	12,132	1	1	305	2,811	409	346	ı	ı	1	356	16,359
year (Note 4U)			L 17.1			1		C					161	378
Additions duffing the year	,					7- (7	1				5	070
Transfer/Canitalized	<u> </u>	1	(87)	1	ı	(7)	ı	1	1	'	1	1	- (09)	(84)
IIalisiel/Capitalised		-	' (1		' (1	' '	1		ı	1	(02)	(02)
Keclassification	1	1	(5)		1	0	1 6	Ω,	1 (. ,	1 (1 .	(44)	(44)
Foreign Exchange	(416)	ı	(291)	√	1	(15)	(30)		(3)	_	0	4	(25)	(352)
Adjustment A+31 March 2019	15.050	110	15 035	752	22	377	2 21/1	809	365	10	n	260	617	21.468
A mortingtion	0,0	-	200	107	77	310	1170		200	2	ו	004	5	7
At 1 April 2017	1	115	2,071	300	14	49	428	281	22	13	'	222	'	3,515
Amortisation for the vear		_	243	50	m	2	9	4		m	1	10	1	325
(Note 25)														
Amortisation on disposals		1	(13)	1	1	ı	1	1	1		1	1	1	(13)
Reclassification			14	(/	1	(2)	1	1	1	'	1	21	ı	19
Foreign Exchange	1	(1)	142	2	(1)	2	(3)	(19)	1	_	1	1	•	126
Adjustment														
At 31 March 2018	1	108	2,457	345	16	57	431	266	22	17	•	253	1	3,972
Amortisation on acquired intangibles (Note 40)		ı	3,809	1	ı	264	280	35	96	1	1	ı	ı	4,483
Amortisation for the year		_	395	49	C	10	30	9	00	_	_	5	1	208
(Note 25)														
Amortisation on disposals	1	1	(24)	1	1	(2)	ı	1	0		1	1	1	(81)
Reclassification		ı	(4)	1	1	0	(0)	2	(0)		1	1	ı	_
Foreign Exchange	1	ı	(190)	(0)	1	(12)	(21)	0	(2)	_	0	4	1	(221)
Adjustment														
At 31 March 2019	1	109	6,388	394	19	317	719	311	124	19	_	262	1	8,662
Net book value		,	1	(I	(1		((ı	1	(
At 31 March 2019	15,050	_	8,64/	358	m	99	2,495	38/	241	0	7	_	/19	12,814
At 31 March 2018	432	2	673	402	9	15	_	16	1	_	m	12	229	1,360

4. Intangible assets (contd.)

₹ In crores

Net book value	March 31, 2019	March 31, 2018
Goodwill	15,050	432
Other intangible assets	12,197	1,131
Intangible assets under development	617	229
Total	27,864	1,792

^{*}Goodwill is tested for impairment on an annual basis and whenever there is an indication that the recoverable amount is less than its carrying amount based on a number of factors including business plan, operating results, future cash flows and economic conditions.

The Group generally uses discounted cash flows method to determine the recoverable amount. These discounted cash flow calculations use five-year projections that are based on financial forecasts. Cash flow projections take into account past experience and represent managements's best estimate about future development.

5. Investments ₹ In crores

		\ III CI OI E3
	March 31, 2019	March 31, 2018
Non-current		
Investments accounted for using the equity method		
Investment stated at cost		
(A) Investments in equity instruments		
a. Investment in Associates (Unquoted)		
(i) 5,675 [March 2018: 5,675] Equity Shares fully paid-up in 3SB Produtos Agricolas SA [includes goodwill of Rs. 66 Crores [March 2018 Rs. 73 Crores]	89	102
(ii) 87,298,237 [March 2018: 87,298,237] Equity Shares fully paid-up in Sinagro Produtos Agropecuarios SA. [includes goodwill of Rs. 44 Crores, [March 2018: Rs. 48 Crores] (refer Note (a) below)	0	0
(iii) 921,000 [March 2018: 921,000] Equity Shares of Rs 10 each fully paid-up in Chemisynth [Vapi] Limited (refer Note (a) below)	0	0
(iv) 18,130 [March 2018: 18,130] Equity shares of Rs. 100 each of Universal Pestochem [Industries] Pvt. Ltd. (refer Note (a) below)	0	0
(v) 3,350,000 [March 2018: 3,350,000] Equity Shares of Rs.10 each fully paid-up in Kerala Enviro Infrastructure Limited	5	3
(vi) 37,681 [March 2018: 37,681] Equity shares of Rs. 10 each, fully paid-up in Weather Risk Management Services Pvt Ltd [includes goodwill of Rs. 4 Crores [March 2018 Rs. 3 Crores]	13	10
(vii) 103,016,215 [March 2018:103,016,215] Equity shares of Rs. 1 each, fully paid-up in Serra Bonita Sementes S.A.[includes goodwill of Rs. (12) Crores [March 2018 Rs. (14) crores]	190	208
(viii) 17,85,000 [March 2018: Nil] Equity shares of CNY 0.30 each, fully paid up in DAC (Dillian Advanced Chemical)	1	-
(ix) 260 [March 2018: Nil] Equity shares of Rs.1 each, fully paid-up in Agronamics [includes goodwill of Rs. 4 crores]	5	-
(x) 7,44,526 [March 2018: Nil] Equity shares of Rs. 1 each, fully paid-up in Novon Protecta [includes goodwill of Rs. (2) crores]	7	-
(xi) 2,510 [March 2018: Nil] Equity shares of Rs. 0.01 each, fully paid-up in Agrifokus [includes goodwill of Rs. (5) crores]	4	-
(xiii) 1,004 [March 2018: Nil] Equity shares of Rs. 1 each, fully paid-up in Novon Retail [includes goodwill of Rs. 4 crores]	7	-
(xiv) 251 [March 2018: Nil] Equity shares of Rs. 1 each, fully paid up in Silvix Forestry [includes goodwill of Rs. 1 lakh]	0	-
(xv) 1,920 [March 2018: Nil] Equity shares of Rs. 0.10 each, fully paid-up in Nexus AG [includes goodwill of Rs. 4 crores]	10	-
(xvi) 4,478 [March 2018: Nil] Equity shares of XOF 10,000 each, fully paid-up in Société des Produits Industriels et Agricoles	4	-

5. Investments (contd.)

₹ In crores

(ii) 1,627 [March 2018: 1,627] Equity Shares of TR.1,000 each fully paid-up in United Phosphorus [Bangladesth United (Feef Note (a) below) (iii) 200 [March 2018: 200] Equity shares of 1,000 each fully paid-up in United 23 21 21 21 22 23 21 21 20 21 21 21 21 22 21 21			March 31, 2019	March 31, 2018
Phosphorus (Bangladesh) Limited (refer Note (a) below)	b.	Investment in Joint Ventures (Unquoted)		
(ii) 200 [March 2018; 200] Equity shares fully paid up in Hodogaya UPL Co. Ltd (ii) 88,223 [March 2018; 88,223 [Fality shares of 1 AUD acth fully paid up in Longreach Plant Breeders Management Private Limited [includes goodwill of Rs.18 Crores, [March 2018; Rs.18 Crores] Total non-current investments accounted for using the Equity Method Investment stated at Amortised Cost Investments in Government or trust securities (Unquoted) (i) Indira Vikas Patra [Face Value; Current Year; Rs. 0.06 lac. [March 31, 2018; Rs. 0.06 lac.] (ii) National Saving Certificates [Face Value; Current Year; Rs. 0.09 lac. [March 31, 2018; Rs. 0.06 lac.] Investments in Equity Instruments Quoted) Investments atated at Fair Value through OCI Investments in Equity Instruments Quoted) Investment in Others (ii) 17,000,000 [March 2018; 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 [March 31, 2018; 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018; 50,000] Equity Shares of Rs.10 each fully paid-up in Inivi Trading Limited (iv) 41,150 [March 31, 2018; 50,000] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (iv) 43,307 [March 31, 2018; 53,007] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (iv) 1,3937 [March 31, 2018; 53,007] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited. (iv) 1,391,630 [March 31, 2018; 1,7990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (iv) 1,891,630 [March 21, 2018; Nil] Equity Shares of TWD 9.53 each, fully paid-up in ISAGRO S.FA. (B) (iv) 1,891,630 [March 21, 2018; Nil] Equity shares of FWD 9.53 each, fully paid-up in ISAGRO S.FA. (B) (iv) 1,264,427 [March 2018; Nil] Equity shares of FWD 9.53 each, fully paid-up in ISAGRO S.FA. (B) (iv) 1,264,427 [March 2018; Nil] Equity shares of FWD 9.53 each, fully paid-up in ISAGRO S.FA. (B) (iii) 5,24,427 [March 2018; Nil] Equity shares of PWD 9.53 each, fully paid-up in ISAGRO S.FA. (B) (iv) 1,264,427 [March 2018; Nil] Equit	(i)		0	0
(ii) 88,223 [March 2018: 88,223] Equity shares of 1 AUD each fully paid-up in Longreach Plant Breeders Management Private Limited (includes goodwill of Rs.18 Crores, [March 2018: Rs.18 Crores] Total non-current investments accounted for using the Equity Method Investment in Government or trust securities (Unquoted) (Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.[March 31, 2018: Rs. 0.06 lac.]) (Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.[March 31, 2018: Rs. 0.06 lac.]) (Investments in Government or trust securities (Unquoted) (Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) (Investments in Unity Instruments (Quoted) (Investment in Others (In 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Rs. 2 94 Kaisha Ltd. (I) 28, 100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (II) 50,000 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Inivi Trading Limited (IV) 41,150 [March 31, 2018: 14,150] Equity Shares of Rs.10 each fully paid-up in IDFC Interest (Industry Limited) (IV) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Interest (IV) 1,7990 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Interest (IV) 1,7990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (IV) 1,891,630 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (IV) 1,891,630 [March 31, 2018: Nil] Equity shares of PS.2 each fully paid-up in ISAGRO S.A. (IV) Investment in Others (IV) 1,891,630 [March 31, 2018: Nil] Equity shares of FS.2 each fully paid-up in Kyoyu Agri (IV) (IV) (IV) (IV) (IV) (IV) (IV) (IV)	(ii)		23	21
Plant Breeders Management Private Limited [includes goodwill of Rs.18 Crores, [March 2018: Rs.18 Crores] Total non-current investments accounted for using the Equity Method Investment stated at Amortised Cost Investments in Government or trust securities (Unquoted) (i) Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.[March 31, 2018: Rs. 0.06 lac] (ii) National Saving Certificates [Face Value: Current Year: Rs. 0.09 lac. [March 31, 2018: Rs. 0.06 lac]] Investments in Equity Instruments (Quoted) Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investments in Equity Instruments (Quoted) Investments in Equity Instruments (Quoted) Investments in Cohers (i) 11,700,000 [March 2018: 11,700,000 Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (ii) 28,100 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (ii) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in DFC Journal State Financial Corporation (iii) 7,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Journal State Financial Corporation (iii) 7,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Journal College Financial Corporation (iii) 7,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Journal College Financial College Financ				
[March 2018: Rs.18 Crores] Total non-current investments accounted for using the Equity Method Investments in Government or trust securities (Unquoted) [Investments stated at Alair Value through OCI Investments in Equity Instruments (Quoted) [Investments Instruments Investments Instruments Investments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments Instruments (Unquoted) [Investments in Equity Instruments (Unquoted) [Investments in Equity Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Stated at Fair Value through Profit and Loss [Instruments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments Instruments (Unquoted) [Investments Instruments (Unquoted) [Investments Instruments (Unquoted) [Investment Instruments (Unquoted) [Investment Instruments (Unquoted)	. ,			
Total non-current investments accounted for using the Equity Method Investment stated at Amortised Cost Investment sin Government or trust securities (Unquoted) () Indira Vikas Patra (Face Value: Current Year: Rs. 0.06 lac.) (ii) National Saving Certificates (Face Value: Current Year: Rs. 0.09 lac.) [March 31, 2018: Rs. 0.06 lac.) (iii) National Saving Certificates (Face Value: Current Year: Rs. 0.09 lac.) [March 31, 2018: Rs. 0.09 lac.] Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investment in Others (iii) 28,100 (March 2018: 11,700,000 Equity Shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 (March 31, 2018: 28,100) Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 (March 31, 2018: 50,000) Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 (March 31, 2018: 50,000) Equity Shares of Rs.10 each fully paid-up in DFC Limited (iv) 5,307 (March 31, 2018: 53,07) Equity Shares of Rs.10 each fully paid-up in IDFC Dank Limited. (vi) 5,307 (March 31, 2018: 53,07) Equity Shares of Rs.10 each fully paid-up in IDFC Dank Limited. (vii) 17,990 (March 31, 2018: 17,990) Equity Shares of Rs.2 each fully paid-up in DFC Dank Limited. (vii) 17,990 (March 31, 2018: Nil) Equity Shares of USD 3.35 each fully paid-up in DFC Dank Limited. (vii) 1,891,630 (March 2018: Nil) Equity Shares of USD 3.35 each fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 (March 2018: Nil) Equity shares of EUR 1.37 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 (March 2018: Nil) Equity shares of EUR 1.37 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 (March 2018: Nil) Equity shares of PLN 103.02 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 (March 2018: Nil) Equity shares of PLN 103.02 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 1,000 (March 2018: Nil) Equity shares of PLN 103.02 each, fully paid-up in Grand Biotechnology Co., Ltd. (iii) 1,000 (
Investment stated at Amortised Cost Investments in Government or trust securities (Unquoted) (i) Indira Vikias Patra [Face Value: Current Year: Rs. 0.06 lac.][March 31, 2018: Rs. 0.06 lac.]] (ii) National Saving Certificates [Face Value: Current Year: Rs. 0.09 lac. [March 31, 2018: Rs. 0.06 lac.]] Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC United (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited (vii) 1,891,630 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of EUR 1,37 each, fully paid-up in Kyoyu Agri (ii) 3,344,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in ISAGRO S.P.A. (B) (vi) 1,000 [March 2018: Nil] Equity shares of UND 9.53 each, fully paid-up in ISAGRO S.P.A. (B) (vi) 1,100 [March 2018: Nil] Equity shares of UND 9.53 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity sha			408	386
(i) Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.][March 31, 2018: Rs. 0.06 lac.]] (ii) National Saving Certificates [Face Value: Current Year: Rs. 0.09 lac.] [March 31, 2018: Rs. 0.09 lac.]] Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investments in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity Shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Dank Limited (iv) 17,390 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in Bank of Bancola Limited (iv) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (iv) 17,990 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of IWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A.(B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (ii) 5,244.27 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully pai	Inv			
Investments Stated at Fair Value through OCI		Investments in Government or trust securities (Unquoted)		
(ii) National Saving Certificates [Face Value: Current Year: Rs. 0.09 lac. [March 31, 2018: Rs. 0.09 lac] Investments in Equity Instruments (Quoted) Investment in Equity Instruments (Quoted) Investment in Comment in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity shares of Rs. 10 each fully paid-up in Gujarat State Financial Corporation (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs. 10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs. 10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 5,307] Equity Shares of Rs. 10 each fully paid-up in IDFC United (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs. 10 each fully paid-up in IDFC United (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs. 10 each fully paid-up in IDFC United (iv) 5,307 [March 31, 2018: 17,990] Equity Shares of Rs. 2 each fully paid-up in IDFC United (iv) 1,891,630 [March 31, 2018: 17,990] Equity Shares of Rs. 2 each fully paid-up in Bank of Baroda Limited (ivi) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investment in Others (iv) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Kyoyu Agri Shares of USD 9,53 each, fully paid-up in Kyoyu Agri Shares (United Collary Collar) Shares (United Collary Collar) Shares (United Collary Collar) Shares (United Collary Collar) Shares of EuR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (iv) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each in Taxa Global Environmen	(i)	Indira Vikas Patra [Face Value: Current Year: Rs. 0.06 lac.[March 31, 2018: Rs. 0.06	0	0
Rs. 0.09 Iac] Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in DFC Journal State Financial Corporation (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in DFC Journal State Financial Corporation (iv) 41,150 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in DFC Limited (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in DFC Journal State Financial Corporation (iv) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in DFC Journal State Financial Corporation (iv) 18,91630 [March 31, 2018: Nil] Equity Shares of Rs.2 each fully paid-up in Bank Journal Corporation (iv) 18,91630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (iv) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Eq		lac]]		
Investments stated at Fair Value through OCI Investments in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kalsha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) S0,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 5,307 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited (vi) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investment in Others (v) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of FWD 9.53 each, fully paid-up in Kyoyu Agri (vi) 1,500 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (v) 126 [March 2018: Nil] Equity shares of FWD 10,000 each, fully paid-up in ISAGRO S.P.A. (B) (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator	(ii)	National Saving Certificates [Face Value: Current Year: Rs. 0.09 lac. [March 31, 2018:	0	0
Investments in Equity Instruments (Quoted) Investment in Others (i) 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo (ii) 12,81,00 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat (iii) S0,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi (iii) S0,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi (iv) 41,150 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in DEC (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in IDEC (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDEC (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDEC (iv) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.20 each fully paid-up in IDEC (iv) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.20 each fully paid-up in Bank (iv) 18,91,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agroffresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) (iv) 18,91,630 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand (iv) 18,44,000 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO (iv) 18,44,27 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO (iv) 126 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator (iv)		Rs. 0.09 lac]]		
Investment in Others	Inv	estments stated at Fair Value through OCI		
(i) 11,700,000 [March 2018: 11,700,000 Equity shares fully paid up in Ishihara Sangyo Kaisha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in IDFC Using Imited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in IDFC Using March 31, 2018: 53,07] Equity Shares of Rs.10 each fully paid-up in IDFC Using Intel (vi) 5,307 [March 31, 2018: 53,07] Equity Shares of Rs.10 each fully paid-up in IDFC Using Intel (vi) 17,990 [March 31, 2018: 53,07] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 10,000 each, fully pa				
Kaisha Ltd. (ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited (vi) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (vi) 126 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in SAGRO S.P.A. (B) (vi) 126 [March 2018: Nii] Equity shares of PLN 10.00 each, fully paid-up in Elevator Sieradz (vii) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vii) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJ LUKANG PHARMACEUTICAL CO.,LTD Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
(ii) 28,100 [March 31, 2018: 28,100] Equity Shares of Rs.10 each fully paid-up in Gujarat State Financial Corporation (iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 19,000] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vi) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: Nii] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO 5.24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nii] Equity shares of PLN 10,000 each, fully paid-up in Elevator Sieradz (vii) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vii) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vi) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds (Unquoted) (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL 2 2 Investment Private Limited	(i)		82	94
State Financial Corporation (iii) S0,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vi) 17,990 [March 31, 2018: 5,307] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited. (vii) 17,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Bank of Baroda Limited. (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investment in Others (vii) 1,741,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (vii) 3,44,000 [March 2018: Nii] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (vii) 5,24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (vi) 126 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) (6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL 2 2 2 Investment Private Limited				
(iii) 50,000 [March 31, 2018: 50,000] Equity Shares of Rs.10 each fully paid-up in Nivi Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vi) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 17,991 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEI] LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) (6,855 [March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL 2 2 2 Investment Private Limited	(ii)		0	0
Trading Limited (iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited (vii) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 18,930 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO 5 - S.P.A. (B) (iv) 126 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJ LUKANG PHARMACEUTICAL CO.,LTD (Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) (6,855 [March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (2 40,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (2 10,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (2 2 1 Investment Private Limited				
(iv) 41,150 [March 31, 2018: 41,150] Equity Shares of Rs.10 each fully paid-up in Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vi) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,990 [March 31, 2018: Nii]] Equity Shares of USD 3.35 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 1,26 [March 2018: Nii] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vi) MEJJI LUKANG PHARMACEUTICAL CO.,LTD (vii) MEJJI LUKANG PHARMACEUTICAL CO,LTD (vii) MEJJI LUKANG PHARMACEUTICAL CO,LTD (vii) MEJJI LUKANG PHARMACEUTICAL CO,UTD (vii) Rostments in Optionally Convertible Bonds (Unquoted) (6,855 [March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (vii) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (vii) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (vii) 240,000 (March 21, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (vii) 240,000 (March 21, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL (vii) 240,000 (March 21, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL	(iii)		0	0
Transpek Industry Limited (v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vi) 1,7990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in IDFC Bank Limited. (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment Private Limited (B) Investment Private Limited		9		
(v) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(i∨)		6	5
Limited (vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
(vi) 5,307 [March 31, 2018: 5,307] Equity Shares of Rs.10 each fully paid-up in IDFC Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nii] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nii] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nii] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nii] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nii] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nii] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nii] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(\vee)		0	0
Bank Limited. (vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
(vii) 17,990 [March 31, 2018: 17,990] Equity Shares of Rs.2 each fully paid-up in Bank of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(∨i)		0	0
of Baroda Limited (vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL 2 2 2 Investment Private Limited				
(vii) 1,891,630 [March 31, 2018: Nil] Equity Shares of USD 3.35 each fully paid-up in Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(vii)		0	0
Agrofresh Solutions Inc. (Listed on the NASDAQ) Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	,			
Investments in Equity Instruments (Unquoted) Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(VII)		44	-
Investment in Others (i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEJJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
(i) 7,41,800 [March 2018: Nil] Equity shares of TWD 9.53 each, fully paid-up in Grand Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD 8 Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
Biotechnology Co., Ltd. (ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(:)		2	
(ii) 3,44,000 [March 2018: Nil] Equity shares of JPY 267.91 each, fully paid-up in Kyoyu Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(1)		2	_
Agri (iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEJJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(::)		_	
(iii) 5,24,427 [March 2018: Nil] Equity shares of EUR 1.37 each, fully paid-up in ISAGRO S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(11)		O	-
S.P.A. (B) (iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	/iii)		E	
(iv) 126 [March 2018: Nil] Equity shares of HUF 10,000 each, fully paid-up in Cseber (v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(111)		J	_
(v) 1,000 [March 2018: Nil] Equity shares of PLN 103.02 each, fully paid-up in Elevator Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(iv)		0	
Sieradz (vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				_
(vi) 1,000 [March 2018: Nil] Equity shares, fully paid-up in Rogatory letter (A) (vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(v)		O	
(vii) MEIJI LUKANG PHARMACEUTICAL CO.,LTD Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	(\vi)		10	
Investments stated at Fair Value through Profit and Loss (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				_
 (A) Investments in Optionally Convertible Bonds (Unquoted) 6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited 			O	
6,855 [March 31, 2018: 6,855] Optionally Convertible Bonds of Rs.1.00,000 each in Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				
Tatva Global Environment Private Limited (B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited	()		83	76
(B) Investment in Equity Instruments (Unquoted) (i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL Investment Private Limited				, 3
(i) 240,000 (March 31, 2018: 240,000) Equity shares of Rs. 10 each fully paid-up in UPL 2 Investment Private Limited 2	(B)			
Investment Private Limited			2	2
	` '			_
	(ii)	Equity shares in Amira Nature foods Limited	35	33

5. Investments (contd.)

₹ In crores

	March 31, 2019	March 31, 2018
(iii) 57 [March 31, 2018: 57] Ordinary Shares of 1 Rand each fully paid-up in Cropserve	0	0
[PTY] Limited		
(iv) 3,435,070 [March 31, 2018: 3,435,070] Equity Shares of Rs.10 each fully paid-up in	4	3
Narmada Clean Tech Limited		
(v) 10,000 [March 2018: 10,000] Equity Shares of Rs.10 each fully paid—up in	0	0
Janakalyan Sahakari Bank Limited		
(vi) 1,000,000 (March 31, 2018: 1,000,000) Equity Shares of Rs.10 each fully paid-up in	1	0
Uniphos International Limited		
(vii) 45,000 (March 31, 2018: 45,000) Equity Shares of Rs.10 each fully paid-up in Bloom	1	1
Packaging Private Limited		
(viii) 19,025 (March 31, 2018: 19,025) Equity Shares of Rs.10 each fully paid-up in Bench	1	1
Bio Private Limited		
(ix) 100 [March 31, 2018: 100] Equity Shares of Natural Art KK	0	0
(C) Investment in Others	2	2
415 [March 2018: 415] Optionally convertible Debentures of Rs. 50,000 each of	2	2
Bloom Packaging Pvt. Ltd. Nil [March 31, 2018: 201,834,849] Non-convertible Debentures of BRL 1 each of		424
IBI Brasil Empreendimentos E Participacoes S.A.	_	424
Investments in Others (Unquoted)	7	7
Total Other Non-Current Investments	298	648
Total Non-Current Investments	706	1,034
		.,
	March 31, 2019	March 31, 2018
Current		
Investments stated at Fair Value through profit and loss		
Investments in Others (Unquoted)	2	-
Total Current Investments	2	-
Total Investments	708	1,034
Aggregate amount and market value quoted investments	133	99
Aggregate amount of unquoted investments	575	935
Impairment of investments	-	_

Investments at fair value through Profit and loss (fully paid) reflect investment in debt instruments. Refer note 45 for determination of their fair values.

Investments at fair value through OCI (fully paid) reflect investment in quoted equity securities. Refer note 45 for determination of their fair values.

Note

a. Share of losses has been restricted to the carrying value of the investment

6. Loans ₹ In crores

	Non-cu	urrent	Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Security deposit				
a. Unsecured, Considered good	85	62	35	31
b. Unsecured, Considered doubtful	2	2	-	-
Less: Allowance for doubtful security deposit	(2)	(2)	-	-
	85	62	35	31
(B) Loans and Advances to related parties (refer note 38)				
a. Unsecured, Considered good	71	89	0	96
	71	89	0	96
(C) Loans to employees				
a. Unsecured, Considered good	-	0	1	8
	-	0	1	8

6. Loans (contd.)

	Non-cu	ırrent	Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(D) Sundry loans				
a. Unsecured, Considered good	-	-	15	12
b. Unsecured, Considered doubtful	2	2	-	-
Less: Allowance for doubtful sundry loans	(2)	(2)	-	-
	-	-	15	12
Total loans	156	151	51	147

Loans and receivables are non-derivative financial assets which generate a fixed or variable interest income for the Group.

7. Other financial assets

₹ In crores

	Non-cı	urrent	Curr	ent
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Interest receivable				
a. Unsecured, Considered good	-	-	10	49
b. Unsecured, Considered doubtful	-	-	-	0
Less: Allowance for doubtful Interest receivable	-	-	-	(0)
	-	-	10	49
(B) Derivative instruments at fair value through				
profit or loss				
Derivative contracts (net)	-	_	28	_
	-	-	28	-
(C) Export Benefits receivables				
Unsecured, Considered good	35	35	138	94
	35	35	138	94
(D) Others				
a. Unsecured, Considered good	132	_	134	24
b. Unsecured, Considered doubtful	2	2	-	_
Less: Allowance for doubtful other financial assets	(2)	(2)	-	_
	132	-	134	24
Total Other Financial Assets	167	35	310	167

8. Other assets ₹ In crores

	Non-cu	ırrent	Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(i) Capital advance	51	93	-	-
(ii) Statutory receivables	206	219	1,600	915
(iii) Other advances	24	7	584	260
Total Other Assets	281	319	2,184	1,175

9. Inventories

(Valued at lower of cost and net realisable value)

₹ In crores

	March 31, 2019	March 31, 2018
a. Raw materials and components	2,434	957
b. Work in progress	550	372
c. Finished goods	5,408	2,561
d. Traded goods	690	478
e. Store and spares [including fuel]	83	72
f. Packing material	99	93
g. By products	5	5
Total inventories	9,270	4,538

Amount of write down of inventories to net realisable value and other provisions / losses recognised in the statement of profit and loss as an expense is Rs. 9 Crores (31 March 2018: Rs 23 Crores)

10. Trade receivables ₹ In crores

	Non-cı	ırrent	Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Unsecured, Considered good				
- From related parties	-	-	141	220
- From others	4	1	11,671	5,836
Unsecured, Considered doubtful				
- From others	-	-	1,063	366
Less: Allowance for doubtful Trade receivables	-	-	(1,063)	(366)
Total Trade receivables	4	1	11,812	6,056

No trade or other receivable are due from directors or other officers of the company either severally or jointly with any other person. There are no trade or other receivable are due from firms or private companies respectively in which any director is a partner, a director or a member.

Trade receivables are non-interest bearing and are generally on terms of 45 to 270 days.

For explanations on Group's Credit risk management process. (Refer note 47)

The Group has entered into an agreement to sell and assign its receivables on a non recourse basis with various banks. This is treated as a "true sale" for both legal and financial reporting purposes. As such, the assets once transferred are not reflected on the balance sheet date. At 31st March, 2019, the Group sold receivables which have been recognised of Rs. 4925 Crores (Rs. 2,051 Crores at 31st March, 2018).

11. Cash and cash equivalents

₹ In crores

	March 31, 201	9 March 31, 2018
Balances with banks		
- Current accounts	198	141
- Foreign currency accounts		2
- Current accounts outside India	2,00	1,519
Fixed deposit accounts		
- Fixed deposits outside India	603	1,164
Cheques/drafts on hand	24	32
Cash on hand		1
	2,826	2,859

11A. Other bank balances

₹ In crores

	March 31, 2019	March 31, 2018
- Deposits with original maturity for more than 3 months but less than 12 months	2	14
- Margin money deposit *	14	14
- Unclaimed dividend accounts	8	7
	25	35

^{*} Margin money deposits given as security against bank guarantees.

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise the following: ₹ In crores

	March 31, 2019	March 31, 2018
Balances with banks:		
- Current accounts	198	141
- Foreign currency accounts	0	2
- Current accounts outside India	2,001	1,519
Fixed deposit accounts	603	1,164
Cheques/drafts on hand	24	32
Cash on hand	1	1
	2,826	2,859

12. Share Capital

Authorised share capital

	Equity shares of	Equity shares of INR 2 each	
	Nos.	₹ In crores	
As at April1, 2017	1,23,75,00,000	248	
Increase/(decrease) during the year	-	-	
At March 31, 2018	1,23,75,00,000	248	
Increase/(decrease) during the year	-	-	
At March 31, 2019	1,23,75,00,000	248	

Issued equity capital

Equity shares of Rs. 2 each issued, subscribed and fully paid

	Nos.	₹ In crores
At April 1, 2017	50,70,17,118	101
Increase during the year due to :		
Conversion of OCPS & CCPS	22,24,287	1
ESOP allotments	91,676	0
At March 31, 2018	50,93,33,081	102
Increase during the year	9,589	0
At March 31, 2019	50,93,42,670	102

Terms/ rights attached to equity shares

The Company has one class of equity shares having par value of Rs. 2 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

During the year ended March, 2019, the amount of per share dividend proposed as distributions to equity shareholders is Rs. 8 (March, 2018: Rs. 8)

The Board has recommended issue of bonus shares in the ratio 1:2 (one bonus equity share of Rs. 2 each for every two fully paid-up equity shares held), subject to the approval of the shareholders of the company.

Details of shareholders holding more than 5% shares in the company Name of the shareholder

Equity shares of INR 2 each fully paid	March 31, 2019		March 3	1, 2018
	No. in crores	% holding	No. in crores	% holding
		in the class		in the class
Nerka Chemicals Private Limited	10	19.94%	10	19.94%
Uniphos Enterprises Limited	3	5.01%	3	5.01%

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of

There are 42,353,062 shares (March 31, 2018: 42,353,062) underlying equity shares of the Company in respect of GDR's traded on Luxemburg Stock Exchange and against conversion of each GDR ten equity shares were issued.

12A. Preference Share Capital

Authorised share capital

	Compulsorily convertible preference (CCPS) shares of ₹ 10 each	
	No.	₹ In crores
As at April1, 2017	22,95,00,000	230
Increase/(decrease) during the year	-	-
At March 31, 2018	22,95,00,000	230
Increase/(decrease) during the year	-	-
At March 31, 2019	22,95,00,000	230

Issued preference share capital

Preference shares of INR 10 each issued, subscribed and fully paid		Optionally Convertible Preference Shares (OCPS)			
	No.	₹ In crores	No.	₹ In crores	
As at April1, 2017	2,46,42,786	25	8,19,40,125	82	
(Decrease) during the year	(2,46,42,786)	(25)	(8,19,40,125)	(82)	
At March 31, 2018	-	-	-	-	
(Decrease) during the year	-	-	-	-	
At March 31, 2019	-	-	-	-	

Terms/ rights attached to preference shares

Each Compulsory convertible preference share (CCPS) had a par value of INR 10 and was convertible at the option of the shareholders into Equity shares of the Company starting within 18 months from the date of allotment i.e. from August 08, 2016 into ten new equity shares of INR 2 each for every four hundred and seventy one CCPS held. CCPS not converted within 18 months from the date of allotment, would be automatically converted into equity shares of the Company at the end of 18 months from the date of allotment. The CCPS carried a dividend of 5% per annum, payable annually, subject to deduction of taxes at source, if applicable. The CCPS were non-cumulative and non-participating in nature. The holder of CCPS shall have right to vote in accordance with Section 47 of the Companies Act, 2013.

Each Optionally convertible preference share (OCPS) had a par value of INR 10 and was convertible at the option of the shareholders into Equity shares of the Company within 18 months from the date of allotment i.e. from August 08, 2016 into ten new equity shares of INR 2 for every four hundred and seventy one OCPS held. OCPS not converted within 18 months from the date of allotment, were to be automatically redeemed at par. The OCPS carried a dividend of 5% per annum, payable annually, subject to deduction of taxes at source, if applicable. The OCPS shall be non-cumulative and non-participating in nature. The holder of OCPS had right to vote in accordance with Section 47 of the Companies Act, 2013. The presentation of the liability and equity portions of these shares is explained in the summary of significant accounting policy.

13. Other equity

i) Securities Premium

	₹ In crores
At April 1, 2017	4,498
Increase/(Decrease) during the year due to conversion of OCPS,CCPS and ESOP allotments	109
At March 31, 2018	4,607
Additions during the year	-
At March 31, 2019	4,607

ii) Retained Earnings

	₹ In crores
Balance as at April 1, 2017	4,303
Add: Profit for the year	2,022
Less: Remeasurement gains/(losses) of defined benefit plans	(7)
Less: Appropriations:	
Dividend on equity shares paid during the year	(357)
Acquisition of non-controlling interests	(11)

13. Other equity (contd.)

	₹ In crores
Transfer to debenture redemption reserve, capital redemption reserve and share based payments	(23)
reserve	
Total appropriations	(391)
At March 31, 2018	5,927
Add: Profit for the year	1,447
Less: Remeasurement gains/(losses) of defined benefit plans	3
Less: Appropriations:	
Dividend on equity shares paid during the year	(407)
Transfer to debenture redemption reserve, capital redemption reserve and share based payments	1
reserve	
TPG ADIA share capital	5,335
Total appropriations	4,928
At March 31, 2019	12,306

iii) Other Reserves

Capital Redemption Reserve

	₹ In crores
At April 1, 2017	36
Increase/(Decrease) during the year due to conversion of OCPS and CCPS	9
At March 31, 2018	45
Changes during the year	-
At March 31, 2019	45

Capital Reserve

	₹ In crores
As at April1, 2017	171
Changes during the year	22
At March 31, 2018	193
Changes during the year	(16)
At March 31, 2019	177

Debenture Redemption Reserve

	₹ In crores
As at April1, 2017	127
Add: Amount transferred from retained earnings	14
At March 31, 2018	141
Less: Amount transferred to retained earnings	(1)
At March 31, 2019	140

General Reserve

	₹ In crores
As at April1, 2017	1,848
Changes during the year	-
At March 31, 2018	1,848
Changes during the year	-
At March 31, 2019	1,848

Share based payment reserve

	₹ In crores
As at April1, 2017	2
Changes during the year	(2)
At March 31, 2018	-
Changes during the year	-
At March 31, 2019	0

13. Other equity (contd.)

Non-controlling interest reserve

	INR Crores
As at April1, 2017	(3,693)
Changes during the year	-
At March 31, 2018	(3,693)
Changes during the year	-
At March 31, 2019	(3,693)

Cashflow hedge reserve for OCI

	INR Crores
As at April1, 2017	-
Changes during the year	-
At March 31, 2018	-
Changes during the year	(62)
At March 31, 2019	(62)

FVTOCI reserve

	INR Crores
As at April1, 2017	(54)
Changes during the year	10
At March 31, 2018	(44)
Changes during the year	(60)
At March 31, 2019	(104)

Foreign currency translation reserve

	INR Crores
As at April1, 2017	(24)
Changes during the year	67
At March 31, 2018	43
Changes during the year	(763)
At March 31, 2019	(720)

Securities Premium - Where the Holding Company issues shares at a premium, whether for cash or otherwise, a sum equal to the aggregate amount of the premium received on those shares shall be transferred to "Securities Premium". The Holding Company may issue fully paid-up bonus shares to its members out of the securities premium reserve and can use this reserve for buy-back of shares.

Capital redemption reserve - Capital redemption reserve was created for buy-back of shares and can be utilised for issuance of fully paid up bonus shares.

Capital reserve - The Group recognises profit or loss on purchase, sale, issue or cancellation of the Group's own equity instruments to capital reserve.

Debenture redemption reserve (DRR) - The Holding Company has issued redeemable non-convertible debentures. The Companies (Share capital and Debentures) Rules, 2014 (as amended), require the Company to create DRR out of profits of the Company available for payment of dividend. DRR is required to be created for an amount which is equal to 25% of the value of debentures issued.

Share based payment reserve - The Holding Company has an employee stock option scheme under which the option to subscribe for the companies share have been granted to the key employees and directors. The share-based payment reserve is used to recognize the value of equity-settled share-based payments provided to the key employees and directors as part of their remuneration. Refer to Note 36 for further details of the scheme.

General reserve - General reserve is created out of the profits earned by the Holding Company by way of transfer from surplus in the statement of profit and loss. The Holding Company can use this reserve for payment of dividend and issue of fully paid-up and not paid-up bonus shares.

13. Other equity (contd.)

Other reserves ₹ In crores

	March 31, 2019	March 31, 2018
Capital redemption reserve	45	45
Capital reserve	176	193
Debenture redemption reserve	140	141
General reserve	1,848	1,848
Non-controlling interest reserve	(3,693)	(3,693)
Cashflow hedge reserve for OCI	(62)	-
FVTOCI reserve	(104)	(44)
Foreign currency translation reserve	(720)	43
Total other reserves	(2,370)	(1,468)

The disaggregation of changes in OCI by each type of reserves in equity is disclosed in note 28.

14. Distribution made and proposed

₹ In crores

	March 31, 2019	March 31, 2018
Cash dividends on Equity shares declared and paid:		
Final dividend for the year 31 March 2018: Rs. 8 per share (31 March 2017: Rs. 7 per share)	407	357
	407	357
Proposed dividends on Equity shares:		
Proposed cash dividend for the year 31 March 2019: Rs. 8 per share (March 31, 2018:	407	407
Rs. 8 per share)		
	407	407

Note

Proposed dividend on equity shares is subject to approval at the annual general meeting and is not recognised as a liability as at 31 March.

14A. Shares reserved for issue under options

For details of shares reserved for issue under the Employee Stock Option Plan (ESOP) of the Holding Company (refer note 36)

15. Borrowings

Non-current Borrowings ₹ In crores

	Effective interest rate (%)	Maturity	March 31, 2019	March 31, 2018
Non-current borrowings	(10)			
Debentures				
Redeemable non-convertible debentures	10.53% to 10.85%	2019-2026	458	682
(NCDs) (Unsecured) (refer note a below)				
()			458	682
Bonds (Unsecured) (Refer Note b below)				
3.25% Senior Notes	3.25%	13th October	3,437	3,230
		2021	-, -	
4.50% Senior Notes	4.50%	8th March 2028	2,045	1,937
Term Loan			,	,
From Bank				
Foreign currency loan (Unsecured)	3M LIBOR + 1.60%	2019-2024	20,394	2
Foreign currency loan (Secured)	6.15% to 13.85%	2019-2022	1	3
(Refer Note c below)				
From others (Unsecured)	2.00%	2019-2023	17	19
Long term maturities of finance lease				
obligation				
Obligations under finance leases			30	_
			26,383	5,873

15. Borrowings (contd.)

	Effective interest rate (%)	Maturity	March 31, 2019	March 31, 2018
Current maturities of long term borrowings Debentures	interestrate (70)			
Redeemable non-convertible debentures (NCDs) (Unsecured) (refer note a below)			273	127
			273	127
Term loans Foreign currency loan (Secured) (Refer Note c below)	6.15% to 13.85%	2019-2022	1	4
Current maturities of finance lease obligation			1	4
Obligations under finance leases			4	_
			4	-
Total non-current borrowings			26,661	6,004
Less: Amount clubbed under "other current financial liabilities" (Refer Note 16)			(278)	(131)
Net non-current borrowings			26,383	5,873
Aggregate secured loans (non-current) Aggregate unsecured loans (non-current) Current borrowings Loan from banks			1 26,382	5,870
Secured (Refer Note d below)	MCLR+50bsp and 7.79% to 10.95%	on demand	169	65
Unsecured:	6 1 17000 10		4.507	
Working capital loan repayable on demand from banks:	6 months LIBOR+48 to 85bps,1month GSEC+5bps and 7.29% to 7.55%, 30 Days T Bill Rate + 0.05%, 5.11%, LIBOR + 0.5%, 10.38% to 10.52%, 3.00% to 7.85%, 3.45%, 9.18% to 10.50%, 24% to 28%, 3.40% to 3.60%	on demand	1,597	556
Commercial paper (refer note e below)	7.29%-7.55%	Within 90 days	400	-
			2,166	621
Discounted trade receivables (Unsecured)	7% - 14%, 3,75%	2018-2019	312	13
Total augment haveaugnes			312	13
Total current borrowings Aggregate secured loans (current)			2,478	634 65
Aggregate unsecured loans (current)			2,309	569

a. Unsecured redeemable non-convertible debentures (NCD's)

- The borrowings and current maturities of long term borrowings include Rs 48 crores (March 31, 2018: Rs. 49 crores) pertaining to interest accrued but not due on account of recognition of debentures at amortised cost as per EIR method.
- ii) NCDs of face value amounting to Rs. 300 crores (March 31, 2018: Rs. 300 crores) have been issued under two series and are redeemable at par at the end of 7th year Rs. 150 crores i.e June, 2019 and 10th year Rs. 150 crores i.e June, 2022 from the date of allotment. Out of the above, NCDs amounting to Rs. 90 crores have been bought back by the Company.
- iii) NCDs of face value amounting to Rs. 250 crores (March 31, 2018: Rs. 250 crores) are redeemable at par at the end of 15th year i.e July 2026 from the date of allotment. The NCDs carry a call option at the end of 10th year from the date of allotment.

15. Borrowings (contd.)

- iv) NCDs of face value aggregating to Rs. 225 crores (March 31, 2018: Rs. 300 crores) have been issued under three series and are redeemable at par of Rs 75 crores each at the end of 12th year, 11th year and 9th year i.e. October 2022, October 2021 and October 2019 respectively from the date of allotment.
- v) NCDs mentioned above carry a coupon rate ranging from 10.35% to 10.70%.

b. Bonds (Unsecured)

Bonds are listed on Singapore Stock exchange and are recorded at amortised cost.

c. Foreign currency loan from banks (secured)

The Group has accounts receivables pledged as collateral for credit assignments with recourse and has machinery, equipment and vehicles collateralized under financing and finance lease.

d. Loan repayable on demand from Banks (Secured)

Outstanding loan is secured by hypothecation of inventories, bills receivables, book debts and all movable assets of the Company both present and future, wherever situated.

e. Commercial Paper

Commercial papers mentioned above carry a coupon rate ranging from 7.29% to 7.55% which are maturing in May 2019. Out of above, ICICI bank and Axis Mutual Fund Trustee A/c holds Rs. 100 cr each and Rs. 200 crore is held by Invesco Trustee Private Limited A/c

16. Other financial liabilities

₹ In crores

	Non-current		Current	
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Financial liabilities at fair value through profit or loss				
Derivative contracts (net)	53	134	1	41
Other financial liabilities carried at amortised cost				
Current maturities of long term borrowings	-	-	275	131
(Refer Note 15)				
Payable towards acquisition of additional stake in	65	94	2	27
UPL Do Brasil (Refer note: 42)				
Creditors for capital goods	-	-	70	155
Interest accrued and not due on borrowings	-	-	181	59
Unpaid dividend	-	-	8	7
Trade deposits	-	-	61	73
Current maturities of long term finance lease	-	-	4	-
Others	18	4	897	262
Total other financial liabilities	136	232	1,499	755

17. Provisions

Long term provisions

	Jubilee	Leave	Environmental	Reorganisation	Labour	Total
		benefits			claim	
At 1 April 2017	1	-	12	-	3	16
Arising during the year	0	-	1	-	3	4
Utilised	(0)	_	(0)	-	-	(1)
Foreign currency translation effect	-	_	0	-	0	1
At 31 March 2018	1	-	13	-	6	20
Arising during the year	0	-	2	-	1	3
Utilised	(0)	_	-	-	(3)	(3)
Foreign currency translation effect	(0)	_	(0)	-	(0)	(1)
At 31 March 2019	1	-	15	-	4	20

17. Provisions (contd.)

Short term provisions ₹ In crores

	Leave	Dividend	Contingencies	Re	Contingent	Provision	Provision-	Total
	benefits	on CCPS		organisation	liabilities	Gratuity	Defined	
					provision for		Benefits	
					PPA			
At 1 April 2017	84	2	6	1	-	17	43	153
Arising during the year	8	-	-	_	-	5	2	15
Utilised	(5)	(2)	-	_	-	-		(7)
Foreign currency translation effect	(2)	-	-	(1)	-	1	5	3
At 31 March 2018	85	-	6	-	-	23	50	164
Arising during the year	88	-	9	36	408	8	2	551
Due to Acquisition of Arysta Life	-	-	-	_	_	59	89	148
Science & its subsidiaries								
Utilised	(2)	-	-	_	-	-	-	(2)
Foreign currency translation effect	(4)	-	(0)	(1)	(7)	(3)	(2)	(17)
At 31 March 2019	167	0	15	35	401	87	139	844

Jubilee Provision:

The amount of provision represents the future jubliee expenses which are expected to be paid to the Company's employees when they reach an employement of 25 and 40 years, based on acturial calculations.

ii) Environmental provision:

The Group's operations are subject to environmental laws and regulations in the jurisdictions in which group operates. Some of these laws restrict the amount and type of emissions that group's operations can release into the environment. Group has made necessary provision required by respective local laws. The out flow of these would depend on the cessation of the respective operations.

iii) Reorganization provision:

Due to a downward trend and a stronger competition, management has announced a cost reduction plan in some of the geographies which includes a decrease in headcounts and other costs. The Group made provision in respect of the same and outflow is expected on compeletion of the respective activities.

iv) Labour / employee claim provision:

Companies in the Group are parties to various lawsuits that are at administrative or judicial level or in their initial stages, involving labour, tax and civil matters. The Group contest in court all claims and based on the assessment of their legal counsel, record a provision when the risk of loss is considered probable. The outflow is expected on completion of the respective events.

v) Provision for contingencies:

The Group has considered provision for contingencies based on the best estimate of management of possible outflow relating to customs assessment on imports.

vi) Provision for gratuity:

Some entities of the Group have a defined benefit gratuity plan. Every employee who has completed five years or more of a service gets a gratuity on post employment at 15 days salary (last drawn salary) for each completed year of service as per the rules of the Company. The aforesaid liability is provided for on the basis of an actuarial valuation on projected unit credit method made at the end of the financial year. The scheme is funded with an insurance Company in the form of a qualifying insurance policy.

18. Income taxes

The major components of income tax expense for the years ended 31 March 2019 and 31 March 2018 are:

Consolidated statement of profit and loss:

Profit or loss section ₹ In crores

	March 31, 2019	March 31, 2018
Current income tax:		
Current income tax charge	442	311
Adjustments of tax relating to earlier years	(4)	(79)
Deferred tax:		
Relating to origination and reversal of temporary differences	(273)	43
Income tax expense reported in the statement of profit or loss	165	275

18. Income taxes (contd.)

OCI section

Deferred tax related to items recognised in OCI during the year:

₹ In crores

	March 31, 2019	March 31, 2018
Gain on FVTOCI financial assets and net gain/loss on remeasurement of defined	2	(5)
benefit plans.		
Income tax charged to OCI	2	(5)

Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for 31 March 2018 and 31 March 2019:

₹ In crores

	March 31, 2019	March 31, 2018
Accounting profit before tax	1,684	2,305
Accounting profit before income tax	1,684	2,305
At India's statutory income tax rate of 34.994% (31 March 2018: 34.608%)	589	798
Profit taxable at higher/lower/nil tax rates in certain jurisdictions	(619)	(451)
Additional deduction on expenditure on research and development	(18)	(7)
Adjustment of tax relating to previous years	(1)	(144)
Other tax credits and allowances	(12)	(38)
Income exempt for tax purpose	(84)	(22)
Impact of change in tax rates	2	41
Utilisation of previously unrecognised tax losses	2	1
Share of results of associates and joint ventures	(5)	32
Other non-deductible expenses	67	11
Profit/(Loss) on sale of subsidiary	(15)	-
Unrecognised deferred tax asset on carry forward losses	190	74
Others	68	(20)
At the effective income tax rate of 9.78% (31 March 2018: 11.93%)	165	275
Income tax expense reported in the statement of profit and loss	165	275
	9.78%	11.93%

c) Deferred tax

Deferred tax relates to the following:

	Balance	Sheet	Statement of p	rofit and loss
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Differences in carrying values of property,plant &	(335)	(267)	68	(3)
equipment.				
Fair value of derivatives	(10)	-	10	_
Unrealised profits on intercompany transactions	(21)	185	206	48
Financial assets impairment - expected credit loss	266	135	(131)	11
Carry forward of tax losses and unabsorbed	109	84	(25)	47
depreciation				
Leave encashment	28	25	(3)	(2)
Minimum alternative tax credit	81	69	(12)	(57)
Defined benefits obligation - Gratuity	28	14	(14)	(7)
Provisions and others	330	196	(134)	23
Adjustment to PV of Assets / Liabilities	(7)	-	7	_
Unrealized gain on securities	(8)	-	8	-
Exchange impact	3	-	(3)	(17)
Amortization of Goodwill	(53)	-	53	-
Deferred tax recognised on fair valued assets				
and liabilities on PPA accounting for Arysta Group				
acquisition -				
Tangible Assets	(40)	_	-	_
Intangible Assets	(2,580)	_	-	_

18. Income taxes (contd.)

	Balance	Balance Sheet		profit and loss
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
Inventory	(123)	-	-	-
Current Liabilities and Provisions	149	-	-	-
Tax benefits	39	-	(39)	-
Others	(67)	-	(263)	-
Deferred tax expense/(income)	-	-	(273)	43
Net deferred tax assets/(liabilities)	(2,210)	441	-	-

Reflected in the balance sheet as follows:

₹ In crores

	Balance Sheet		
	March 31, 2019 March 31, 2		
Deferred tax assets	731	529	
Deferred tax liabilities:	(2,942)	(88)	
Deferred tax Assets (net)	(2,210)	441	

Reconciliation of deferred tax liabilities (net):

₹ In crores

	March 31, 2019	March 31, 2018
Opening balance as of 1 April	441	501
Tax income/(expense) during the period recognised in profit or loss	273	(43)
Tax income/(expense) during the period recognised in OCI	2	(5)
Exchange impact	3	(12)
Deferred tax acquired in business combinations*	(2,929)	_
Closing balance as at 31 March	(2,210)	441

^{*} including deferred tax recognised for PPA for Arysta

The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

The Group has tax losses of Rs. 1,196 Crores (31 March 2018: Rs. 547 Crores) that are available for offsetting for period upto ten years against future taxable profits of the companies in which the losses arose.

Deferred tax assets have not been recognised in respect of these losses as they may not be used to offset taxable profits elsewhere in the Group, they have arisen in subsidiaries that have been loss-making for some time, and there are no other tax planning opportunities or other evidence of recoverability in the near future. If the Group were able to recognise all unrecognised deferred tax assets of current year, the profit would increase by Rs. 190 Crores.

The Group has not recognized deferred tax liability with respect to unremitted retained earnings and associated foreign currency translation reserve with respect to certain of its subsidiaries and joint ventures where the Group is in a position to control the timing of the distribution of profits and it is probable that the subsidiaries and joint ventures will not distribute the profits in the foreseeable future.

The temporary differences associated with investments in subsidiaries, associate and joint venture, for which a deferred tax liability has not been recognised.

In the previous year, pursuant to the completion of assessments for the past years, the Holding Company had written back an excess provision of tax and recognised minimum alternate tax credit entitlement relating to earlier periods aggregating to Rs 146 Crores. Further due to chnages in tax laws in the USA in previous year, tax rate in US reduced from 36% to 25%. Accordingly the Group has recognised appropriate effect on Defered Tax Assets.

19. Trade payables

₹ In crores

	Curr	ent
	March 31, 2019	March 31, 2018
Trade payables	9,423	5,675
	9,423	5,675

Terms and conditions of the above financial liabilities:

- Trade payables are non-interest bearing and are normally settled on 90-360 days terms
- For explanations on Group's Credit risk management process. Refer note 47

20. Other current liabilities

₹ In crores

	March 31, 2019	March 31, 2018
Advances against orders	338	214
Statutory liabilities	386	143
Total other current liabilities	724	357

21. Revenue from operations

₹ In crores

	March 31, 2019	March 31, 2018
Sale of products (including excise duty) (Refer note: 49)	21,594	17,244
Sale of services		
Job-Work /Service income	15	25
Other operating revenues		
Export incentives	105	102
Refund of statutory receivables	12	22
Royalty income	6	1
Excess provisions in respect of earlier years written back (net)	36	57
Miscellaneous receipts	67	55
Total Revenue from operation	21,837	17,506

The Government of India introduced the Goods and Services Tax (GST) with effect from 1st July 2017, consequently revenue from operations for the period from July 31, 2017 upto March 31, 2019 is net of GST. However revenue for the quarter ended 30th June 2017 included in the year ended March 31, 2018 is inclusive of excise duty. The Net Revenue from Operations (Net of GST/ Excise Duty) as applicable are stated below-

₹ In crores

	March 31, 2019	March 31, 2018
Revenue from operations	21,837	17,506
Less: Excise Duty	-	(128)
Net Revenue from operations	21,837	17,378

Dislosure under Ind AS 115 - Revenue from contracts with customers

The Company is engaged into manufacturing of agrochemicals, industrial chemicals and production and sale of vegetable and field crops. There is no impact on the Company's revenue on applying Ind AS 115 from the contract with customers.

Disaggregation of revenue from contracts with customers

- a. The management determines that the segment information reported under Note 39 Segment reporting is sufficient to meet the disclosure objective with respect to disaggregation of revenue under Ind AS 115 Revenue from contract with Customers. Hence, no seperate disclosures of disaggregated revenues are reported.
- b. The Company's performance obligation are satisfied upon shipment and payment is generally due by 45 to 270 days.

Contract balances ₹ In crores

	March 31, 2019	March 31, 2018
Trade receivables (refer note 10)	11,816	6,057
Contract liablities (refer note 20)	338	214

21. Revenue from operations (contd.)

d. Reconciliation of revenue from contract with customers with contracted price

₹ In crores

	March 31, 2019	March 31, 2018
Revenue from contract with customer as per the contract price	25,534	21,048
Adjustments made to contract price on account of :-		
a) Discounts / Rebates / Incentives (Refer note below)	2,497	2,364
b) Sales Returns (Refer note below)	1,443	1,440
Revenue from contract with customer	21,594	17,244
Sale of services	15	25
Other operating revenue	227	237
Revenue from operations	21,837	17,506

Discounts / Rebates / Incentives

The Group issues multiple discount schemes to its customers in order to capture market share. The Company makes a provision for the discount it expects to give to its customers based on the terms of the scheme as at 31 March 2019. Revenue is adjusted for the expected value of discount to be given

Sales returns

The Group recognizes a provision based on the previous history of sales return. Revenue is adjusted for the expected value of return.

22. Other income

Outstanding dues of micro and small enterprises

₹ In crores

	Curi	Current	
	March 31, 2019	March 31, 2018	
Interest income on			
Loans and others	137	132	
Unwinding of interest on trade receivable	82	282	
Other non-operating income			
Profit on sale of current and non current investments (net)	9	(7)	
Rent received	3	2	
Profit on sale of property, plant and equipment (net)	3	2	
Miscellaneous income	8	3	
Total	240	414	

23. Employee benefits expense

₹ In crores

	March 31, 2019	March 31, 2018
Salaries, wages and bonus	1,901	1,556
Contribution to provident and other funds (Refer note 35)	41	34
Gratuity and other retirement benefits (Refer note 35)	10	11
Staff welfare expenses	143	112
Total	2,095	1,713

24. Finance costs ₹ In crores

	March 31, 2019	March 31, 2018
Interest:		
- On Debentures	77	81
- On Term Loans	405	209
- On Cash Credit and Working Capital Demand Loan Accounts	157	126
- On Fixed Deposits and Fixed Loans	11	5
- On Others	120	55
Exchange difference (net)	(35)	145
Unwinding of interest on trade payables	126	113
Loss on derivatives Instruments	40	(8)
Other financial charges	62	57
Total	963	783

25. Depreciation and amortization expense

₹ In crores

	March 31, 2019	March 31, 2018
Depreciation of property, plant and equipment	451	343
Amortization of intangible assets	518	332
Total	969	675

26. Other expense

₹ In crores

	March 31, 2019	March 31, 2018
Power and fuel	402	291
Transport charges	683	661
Sub-contracting expenses	901	741
Travelling and conveyance	327	256
Exchange difference (net)	298	11
Advertising and sales promotion	341	229
Legal and professional fees	314	269
Sales commission	126	213
Rent (Refer note: 37)	200	153
Labour charges	174	138
Repairs and maintenance		
Plant and machinery	91	81
Buildings	20	12
Others	130	108
Effluent disposal charges	130	99
Consumption of stores and spares	109	83
Rates and taxes	69	76
Warehousing costs	111	119
Insurance	79	69
Registration charges	80	70
Allowances for doubtful debts and advances (net)	(41)	17
Communication costs	42	42
Royalty charges	79	43
Bad debts / advances written off	10	2
Charity and Donations [(includes Rs 18 crores (31 March 2018: Rs 22 crores) paid for	51	53
political purpose)]		
Assets written off	10	10
Sundry credit balances written off (net)	(12)	15
Research and development expenses	34	19
Other expenses	268	168
Total	5,025	4,048

27. Exceptional items

	March 31, 2019	March 31, 2018
Acquisition cost (Refer note a below)	332	_
Restructuring/reorganisation cost	-	29
Product contamination and counterfeiting	-	13
Towards Competition Comission of India	-	7
Integration cost (Refer note c below)	41	-
Litigation and other exceptional cost (Refer note b below)	76	-
Dilution impact	2	-
Others	-	14
Total	451	63

- a) During the year, the group has acquired Arysta group of companies and all expenses incurred for this acquisition viz Anti trust filling expenses, Due Diligence and other incidental expenses.
- b) Other exceptional cost includes certain litigation expenses which were incurred in certain regions.
- c) Integration cost consist of restructuring and severance pay pertaining to Arysta group acquisition.

28. Components of Other Comprehensive Income (OCI), net of tax

The disaggregation of changes to OCI by each type of reserve in equity is shown below:

₹ In crores

	, , ,					(111 010103
	Attributable to the owners of the parent Attributable			Total		
	Cash flow hedge reserve	FVTOCI reserve	Foreign currency translation reserve	Retained earnings	to non controlling interest	
Foreign exchange translation	-	-	(763)	-	-	(763)
differences						
Impact of hedging done	(62)	-	-	_	-	(62)
Gain/(loss) on FVTOCI financial assets	-	(60)	-	-	-	(60)
Re-measurement gains/(losses) on	-	-	-	3	-	3
defined benefit plans						
Total	(62)	(60)	(763)	3	-	(882)

₹ In crores

During the year ended 31 March 2018	Attributable	to the owners of	Attributable	Total	
	FVTOCI reserve	Foreign currency translation reserve	Retained earnings	to non controlling interest	
Foreign exchange translation differences	-	67	-	-	67
Gain/(loss) on FVTOCI financial assets	10	-	-	-	10
Re-measurement gains/(losses) on defined benefit	-	-	(7)	-	(7)
plans					
Total	10	67	(7)	-	70

Analysis of items of OCI, net of tax

Foreign exchange translation differences

These comprise of all exchange differences arising from translation of financial statements of foreign operations as well as translation of liabilities that hedge the company's net investment in a foreign subsidiary.

Gain/(loss) on FVTOCI financial assets

The group has elected to recognise changes in fair value of certain investments in equity securities in other comprehensive income. These changes are accumulated within the FVOCI equity investments within the equity. The group transfers amount therefrom to retained earnings when the relevant equity securities are derecognized.

Re-measurement gains/(losses) on defined benefit plans

Remeasurement of defined benefit plans comprises acturial gains and losses and return on plan assets (excluding interest income).

29. Earnings per share (EPS)

	March 31, 2019	March 31, 2018
Profit attributable to Equity holders of the parent:	1,447	2,022
Profit attributable to Equity holders of the parent for basic earnings per share	1,447	2,022
Interest on convertible preference shares	-	-
Profit attributable to Equity holders of the parent adjusted for the effect of dilution	1,447	2,022
Weighted average number of Equity shares for basic EPS*		
Effect of dilution:	50,93,41,987	50,82,06,912
Employee stock options	81,587	91,176
Convertible preference shares	-	-
Weighted average number of Equity shares adjusted for the effect of dilution *	50,94,23,574	50,82,98,088
Earnings per Equity share (in INR)		
Basic (face value of Rs 2 each)	28.42	39.79
Diluted (face value of Rs 2 each)	28.41	39.78

^{*} There have been no other transactions involving Equity shares or potential Equity shares between the reporting date and the date of authorisation of these financial statements.

30. Amalgamation with Advanta Limited

The Hon'ble High Court of Gujarat vide its order dated June 23, 2016 had sanctioned the Scheme of Amalgamation of Advanta Limited with the Company with an appointed date of April 01, 2015. In accordance with the provisions of the scheme and as approved by the High Court, the amalgamation was accounted for under the purchase method specified in Accounting Standard 14 - 'Accounting for Amalgamations' which is different from Ind AS 103 'Business Combinations'. As per the Court approval the goodwill arising on amalgamation is being amortised over a period of ten years from the appointed date, which is not amortised under Ind AS 103 but only tested for impairment.

31. Group information

Information about subsidiaries

The consolidated financial statements of the Group includes subsidiaries listed in the table below:

Sr	Name	Principal activities	Country of		% Controlli	ng Interest
No			incorporation/		March 31,	March 31,
			Principal place		2019	2018
			of business			
1	Shroffs United Chemicals Limited	Crop protection	India		100%	100%
2	SWAL Corporation Limited	Crop protection	India		100%	100%
3	United Phosphorus (India) LLP	Crop protection	India		100%	100%
4	United Phosphorus Global LLP	Crop protection	India		100%	100%
5	Optima Farm Solutions Limited	Crop protection	India		100%	100%
6	UPL Europe Limited	Crop protection	United		78%	100%
			Kingdom			
7	UPL Deutschland GmbH	Crop protection	Germany		78%	100%
8	UPL Polska Sp z.o.o.	Crop protection	Poland		78%	100%
9	UPL Benelux B.V.	Crop protection	Netherlands		78%	100%
10	Cerexagri B.V.	Crop protection	Netherlands		78%	100%
11	Blue Star B.V.	Crop protection	Netherlands	#4	-	100%
12	United Phosphorus Holdings	Crop protection	Netherlands		78%	100%
	Cooperatief U.A.					
13	United Phosphorus Holdings B.V.	Crop protection	Netherlands		78%	100%
14	Decco Worldwide Post-Harvest Holdings	Crop protection	Netherlands		78%	100%
	Cooperatief U.A.					
15	Decco Worldwide Post-Harvest Holdings	Crop protection	Netherlands		78%	100%
	B.V.					
16	United Phosphorus Holding, Brazil B.V.	Crop protection	Netherlands		78%	100%
17	UPL Italia S.R.L.	Crop protection	Italy		78%	100%
18	UPL Iberia, S.A.	Crop protection	Spain		78%	100%
19	Decco Iberica Postcosecha, S.A.U.	Crop protection	Spain		78%	100%
20	Transterra Invest, S. L. U.	Crop protection	Spain		78%	100%
21	Cerexagri S.A.S.	Crop protection	France		78%	100%
22	Neo-Fog S.A.	Crop protection	France		78%	100%
23	UPL France	Crop protection	France		78%	100%
24	United Phosphorus Switzerland Limited	Crop protection	Switzerland		78%	100%
25	Agrodan, ApS	Crop protection	Denmark		78%	100%
26	Decco Italia SRL	Crop protection	Italy		78%	100%
27	Limited Liability Company "UPL"	Crop protection	Russia		78%	100%
28	Decco Portugal Post Harvest, Unipessoal	Crop protection	Portugal		78%	100%
	LDA (formerly known as UPL Portugal					
	Unipessoal LDA)					
29	United Phosphorus Inc.	Crop protection	USA		78%	100%
30	UPI Finance LLC	Crop protection	USA		78%	100%
31	Cerexagri, Inc. (PA)	Crop protection	USA		78%	100%
32	UPL Delaware, Inc.	Crop protection	USA		78%	100%

Sr	Name	Principal activities	Country of		% Controllir	ng Interest
No			incorporation/		March 31,	March 31,
			Principal place		2019	2018
			of business			
33	Canegrass LLC	Crop protection	USA		55%	70%
34	Decco US Post-Harvest Inc	Crop protection	USA		78%	100%
35	RiceCo LLC	Crop protection	USA		78%	100%
36	Riceco International, Inc.	Crop protection	Bahamas		78%	100%
37	UPL Corporation Limited	Crop protection	Mauritius		78%	100%
38	UPL Limited	Crop protection	Mauritius	#	_	100%
39	UPL Management DMCC	Crop protection	United Arab		78%	100%
			Emirates			
40	UPL Limited	Crop protection	Gibraltar		78%	100%
41	UPL Agro S.A. de C.V.	Crop protection	Mexico		78%	100%
42	Decco Jifkins Mexico Sapi	Crop protection	Mexico		78%	100%
43	Uniphos Industria e Comercio de	Crop protection	Brazil		78%	100%
	Produtos Quimicos Ltda.					
44	Upl do Brasil Industria e Comércio de	Crop protection	Brazil		78%	100%
	Insumos Agropecuários S.A.					
45	UPL Costa Rica S.A.	Crop protection	Costa Rica		78%	100%
46	UPL Bolivia S.R.L	Crop protection	Bolivia		78%	100%
47	UPL Paraguay S.A.	Crop protection	Paraguay		78%	100%
48	Icona Sanluis S.A.	Crop protection	Argentina		78%	100%
49	DVA Technology Argentina S.A.	Crop protection	Argentina	#1	_	100%
50	UPL Argentina S A	Crop protection	Argentina		78%	100%
51	Decco Chile SpA	Crop protection	Chile		78%	100%
52	UPL Colombia SAS	Crop protection	Colombia		78%	100%
53	United Phosphorus Cayman Limited	Crop protection	Cayman		78%	100%
			Islands			
54	UP Aviation Limited	Crop protection	Cayman		78%	100%
			Islands			
55	UPL Australia Limited	Crop protection	Australia		78%	100%
56	UPL New Zealand Limited	Crop protection	New Zealand		78%	100%
57	UPL Shanghai Limited	Crop protection	China		78%	100%
58	UPL Limited (Korea)	Crop protection	Korea		78%	100%
59	PT.UPL Indonesia	Crop protection	Indonesia		78%	100%
60	PT Catur Agrodaya Mandiri	Crop protection	Indonesia		78%	100%
61	UPL Limited	Crop protection	Hong Kong		78%	100%
62	UPL Philippines Inc.	Crop protection	Philippines		78%	100%
63	UPL Vietnam Co. Limited	Crop protection	Vietnam		78%	100%
64	UPL Limited, Japan	Crop protection	Japan		78%	100%
65	Anning Decco Fine Chemical Co. Limited	Crop protection	China		43%	55%
66	UPL Ziraat Ve Kimya Sanayi Ve Ticaret	Crop protection	Turkey		78%	100%
	Limited Sirketi					
67	UPL Agromed Tarim Ilaclari ve	Crop protection	Turkey	#2	78%	100%
	Tohumculuk Sanayi ve Ticaret A.S.					
68	Safepack Products Limited	Crop protection	Israel		78%	100%
69	Citrashine (Pty) Ltd	Crop protection	South Africa		78%	100%
70	UPL Africa SARL	Crop protection	Senegal	#6	-	_
71	Prolong Limited	Crop protection	Israel	#3	78%	100%
72	Perrey Participações S.A	Crop protection	Brazil		78%	100%
73	Agrinet Solutions Limited	Crop protection	India		50%	50%
74	Advanta Netherlands Holding B.V.	Seed Business	Netherlands		78%	100%

Sr	Name	Principal activities	Country of		% Controlli	ng Interest
No			incorporation/		March 31,	March 31
			Principal place		2019	2018
			of business			
75	Advanta Semillas SAIC	Seed Business	Argentina		78%	1009
6	Advanta Holdings B.V.	Seed Business	Netherlands		78%	1000
7	Advanta Seeds International	Seed Business	Mauritius		78%	1009
78	Pacific Seeds Holdings (Thailand) Limited	Seed Business	Thailand		78%	1009
9	Pacific Seeds (Thai) Limited	Seed Business	Thailand		78%	1009
0	Advanta Seeds Pty Ltd	Seed Business	Australia		78%	100
1	Advanta US LLC (formerly known as Advanta U.S. Inc.)	Seed Business	USA		78%	100
2	Advanta Comercio De Sementes LTDA.	Seed Business	Brazil		78%	100
3	PT Advanta Seeds Indonesia	Seed Business	Indonesia		78%	100
4	Advanta Seeds DMCC	Seed Business	United Arab Emirates		78%	100
5	Essentiv LCC	Crop protection	USA		39%	50
5	UPL Limited Mauritius (Formely known as UPL Agro Limited Mauritius)	Crop protection	Mauritius	`@3	78%	100
7	UPL Jiangsu Limited	Crop protection	China	`@2	55%	70
3	Riceco International Bangladesh Ltd	Crop protection	Bangladesh	`@3	78%	100
)	Uniphos Malaysia Sdn Bhd	Crop protection	Malaysia	`@3	78%	100
)	Advanta Seeds Ukraine LLC	Seed Business	Ukraine		78%	100
	Decco Gıda Tarım ve Zirai Ürünler San. Tic A.S.	Crop protection	Turkey	@	78%	
)	Arysta LifeScience Investments LLC	Crop protection	USA	@1	78%	
}	Arysta LifeScience America Inc.	Crop protection	USA	@1	78%	
1	ANESA S.A.	Crop protection	Belgium	@1	78%	
5	Arysta LifeScience Management Company, LLC	Crop protection	USA	@1	78%	
5	Arysta LifeScience SPC, LLC	Crop protection	USA	@1	78%	
7	Arysta LifeScience India Limited	Crop protection	India	@1	78%	
3	Arysta LifeScience Agriservice Private	Crop protection	India	@1	78%	
	Limited		111010	<u> </u>	7.070	
)	Arysta LifeScience Togo SAU	Crop protection	Togo	@1	78%	
00	Arysta Agro Private Limited	Crop protection	India	@1	78%	
)1	Arysta LifeScience do Brasil Indústria Química e Agropecuária SA	Crop protection	Brazil	@1	68%	
)2	Volcano Agrociencia Industria e Comercio de Defensivos Agricolas Ltda	Crop protection	Brazil	@1	78%	
)3	GBM USA LLC	Crop protection	USA	@1	78%	
)4	Arysta LifeScience Canada, Inc.	Crop protection	Canada	@1	78%	
)5	Arysta LifeScience Canada BC Inc.	Crop protection	Canada	@1	78%	
)6	Arysta LifeScience North America, LLC	Crop protection	USA	@1	78%	
7	Arysta LifeScience NA Holding LLC	Crop protection	USA	@1	78%	
8(Arysta LifeScience Inc.	Crop protection	USA	@1	78%	
)9	Arysta LifeScience Services LLP	Crop protection	India	@1	78%	
10	Arysta LifeScience France SAS	Crop protection	France	@1	78%	
11	Arysta LifeScience Benelux SPRL	Crop protection	Belgium	@1	78%	
12	Arysta LifeScience (Mauritius) Ltd	Crop protection	Mauritius	@1	78%	
13	Arysta LifeScience South Africa (Pty) Ltd	Crop protection	South Africa	@1	78%	
14	Arysta Health and Nutrition Sciences Corporation	Health Nutrition Solution	Japan	@1	78%	

Sr	Name	Principal activities	Country of		% Controllin	ng Interest
No			incorporation/ Principal place		March 31, 2019	March 31, 2018
115	Anysta LifeCsianse Corporation	Crop protection	of business	<u></u>	78%	
115 116	Arysta LifeScience Corporation Arysta LifeScience S.A.S.	Crop protection	Japan France	@1 @1	78%	-
117	Arysta LifeScience Chile S.A.	Crop protection	Chile	@1 @1	78%	_
118		Crop protection	Mexico	@1 @1	78%	_
	Arysta LifeScience Mexico, S.A.de C.V	Crop protection	Mexico		78%	_
119	Grupo Bioquimico Mexicano, S.A. de C.V.	Crop protection		@1		_
120	MacDermid Agricultural Solutions Netherlands Cooperatief UA	Crop protection	Netherlands	@1	78%	-
121	Arysta LifeScience UK & Ireland Ltd	Crop protection	U.K.	@1	78%	-
122	Arysta LifeScience Europe Sarl	Crop protection	France	@1	78%	-
123	MacDermid Agricultural Solutions Italy Srl	Crop protection	Italy	@1	78%	-
124	Platform Sales Suisse GmbH	Crop protection	Switzerland	@1	78%	-
125	MacDermid Agricultural Solutions Holdings BV	Crop protection	Netherlands	@1	78%	-
126	Dutch Agricultural Investment Partners LLC	Crop protection	USA	@1	78%	-
127	Netherlands Agricultural Investment Partners LLC	Crop protection	USA	@1	78%	-
128	Arysta LifeScience Bulgaria EOOD	Crop protection	Bulgaria	@1	78%	_
129	Arysta LifeScience Romania SRL	Crop protection	Romania	@1	78%	_
130	Arysta LifeScience Kiev LLC	Crop protection	Ukraine	@1	78%	_
131	Arysta LifeScience Great Britain Ltd	Crop protection	U.K.	@1	78%	_
132	Arysta LifeScience Technology BV	Crop protection	Netherlands	@1	78%	_
133	Arysta LifeScience Netherlands BV	Crop protection	Netherlands	@1	78%	_
134	Arysta LifeScience RUS LLC	Crop protection	Russia	@1	78%	_
135	Netherlands Agricultural Technologies CV	Crop protection	Netherlands	@1	78%	_
136	Dutch Agricultural Formations CV	Crop protection	Netherlands	@1	78%	_
137	Arysta LifeScience Turkey Tarim Urunleri Limited Sirketi	Crop protection	Turkey	@1	78%	_
138	Arysta LifeScience Australia Pty Ltd.	Crop protection	Australia	@1	78%	_
139	Chemtura (Thailand) Ltd	Crop protection	Thailand	@1	78%	_
140	MacDermid (Shanghai) Chemical Ltd.	Crop protection	China	@1	78%	_
141	Arysta-LifeScience Ecuador S.A.	Crop protection	Ecuador	@1	78%	_
142	Arysta LifeScience Ougrée Production Sprl	Crop protection	Belgium	@1	78%	-
143	Arysta LifeScience Hellas S.A. Plant Protection, Nutrition and Other Related Products and Services	Crop protection	Greece	@1	78%	-
144	Arysta LifeScience Iberia SLU	Crop protection	Spain	@1	78%	_
145	Arysta Lifescience Italia SrL	Crop protection	Italy	@1	78%	_
146	Agriphar Poland Sp. Zoo	Crop protection	Poland	@1	78%	_
147	Arysta LifeScience Switzerland Sarl	Crop protection	Switzerland	@1	78%	_
148	Arysta Animal Health SAS	Animal Health	France	@1	78%	_
149	PPWJ Sci	Animal Health	France	@1	78%	_
150	Santamix Iberica SL	Animal Health	Spain	@1	78%	_
151	Arysta LifeScience Global Services Limited	Crop protection	Ireland	@1	78%	-
152	Arysta LifeScience European Investments Limited	Crop protection	U.K.	@1	78%	-
153	Arysta LifeScience U.K. Limited	Crop protection	U.K.	@1	78%	_
154	Arysta LifeScience U.K. CAD Limited	Crop protection	U.K.	@1	78%	-

Sr .	Name	Principal activities	Country of		% Controlli	ng Interes
10			incorporation/ Principal place of business		March 31, 2019	March 3° 2018
55	Arysta LifeScience U.K. EUR Limited	Crop protection	U.K.	@1	78%	
56	Arysta LifeScience U.K. JPY Limited	Crop protection	U.K.	@1	78%	
57	Arysta LifeScience U.K. USD Limited	Crop protection	U.K.	@1	78%	
58	Arysta Lifescience U.K. Holdings Limited	Crop protection	U.K.	@1	78%	
59	Arysta LifeScience Japan Holdings	Crop protection	Japan	@1	78%	
- 0	Goudou Kaisha	C	6	01	700/	
50	Arysta LifeScience Cameroun SA	Crop protection	Cameroon	@1	78%	
51	Callivoire SGFD S.A.	Crop protection	Cote D'Ivoire	@1	78%	
52	Arysta LifeScience Egypt Ltd	Crop protection	Egypt	@1	78%	
53	Calli Ghana Ltd.	Crop protection	Ghana	@1	78%	
54	Arysta LifeScience Kenya Ltd.	Crop protection	Kenya	@1	78%	-
55	Mali Protection Des Cultures (M.P.C.) SA	Crop protection	Mali	@1	66%	
6	Agrifocus Limitada	Crop protection	Mozambique	@1	78%	
7	Arysta LifeScience Holdings SA (Pty) Ltd	Crop protection	South Africa	@1	78%	
8	Anchorprops 39 (Pty) Ltd	Crop protection	South Africa	@1	78%	
59	Callietha Investments (Pty) Ltd	Crop protection	South Africa	@1	78%	
70	Sidewalk Trading (Pty) Ltd	Crop protection	South Africa	@1	78%	
71	Volcano Agroscience (Pty) Ltd	Crop protection	South Africa	@1	78%	
72	Volcano Chemicals (Pty) Ltd	Crop protection	South Africa	@1	78%	
73	Arysta LifeScience Tanzania Ltd	Crop protection	Tanzania	@1	78%	
4	Arysta LifeScience (Shanghai) Co., Ltd.	Crop protection	China	@1	78%	
75	Pt. Arysta LifeScience Tirta Indonesia	Crop protection	Indonesia	@1	39%	
76	Arysta LifeScience Korea Ltd.	Crop protection	Korea	@1	78%	
77	Arysta LifeScience Pakistan (Pvt.) LTD.	Crop protection	Pakistan	@1	78%	
78	Arysta LifeScience Philippines Inc.	Crop protection	Philippines	@1	78%	
79	Arysta LifeScience Asia Pte., Ltd.	Crop protection	Singapore	@1	78%	
30	Arysta LifeScience (Thailand) Co., Ltd.	Crop protection	Thailand	@1	78%	
31	Arysta LifeScience Vietnam Co., Ltd.	Crop protection	Vietnam	@1	78%	
32	Arysta LifeScience Holdings France SAS	Crop protection	France	@1	78%	
33	Goëmar Développement SAS	Crop protection	France	@1	78%	
34	Laboratoires Goëmar SAS	Crop protection	France	@1	78%	
35				_	78%	
	Natural Plant Protection S.A.S.	Crop protection	France	@1		
36	Arysta LifeScience Czech s.r.o.	Crop protection	Czech Rpb	@1	78%	
37	Arysta LifeScience Germany GmbH	Crop protection	Germany	@1	78%	
38	Arysta LifeScience Magyarorszag Kft.	Crop protection	Hungary	@1	78%	
39	Arysta LifeScience Polska Sp. z.o.o	Crop protection	Poland	@1	78%	
90	Betel Reunion S.A.	Crop protection	Reunion(Fr)	@1	51%	
91	Arysta LifeScience Vostok Ltd.	Crop protection	Russia	@1	78%	
92	Arysta LifeScience Slovakia S.R.O.	Crop protection	Slovakia	@1	78%	
93	Arysta LifeScience Ukraine LLC	Crop protection	Ukraine	@1	78%	
)4	Arysta LifeScience Global Limited	Crop protection	U.K.	@1	78%	
95	Arysta LifeScience Argentina S.A.	Crop protection	Argentina	@1	78%	
96	Arysta LifeScience Colombia S.A.S	Crop protection	Colombia	@1	78%	
97	Arysta LifeScience CentroAmerica, S.A.	Crop protection	Guatemala	@1	78%	
98	Arysta LifeScience Mexico Holding S.A.de C.V	Crop protection	Mexico	@1	78%	
99	Bioenzymas S.A. de C.V.	Crop protection	Mexico	@1	78%	
00	Desarrollos Inmobiliarios Alianza de	Crop protection	Mexico	@1	78%	
	Coahuila, S.A. de C.V.			<u> </u>	, 0, 10	

Sr	Name	Principal activities	Country of		% Controlli	ng Interest
No			incorporation/		March 31,	March 31,
			Principal place		2019	2018
			of business			
201	Omega Agroindustrial, S.A. de C.V.	Crop protection	Mexico	@1	78%	-
202	Agroquimicos y Semillas, S.A. de C.V.	Crop protection	Mexico	@1	78%	_
203	Servicios Agricolas Mundiales SA de CV	Crop protection	Mexico	@1	78%	-
204	Tecno Extractos Vegetales, S.A. de C.V.	Crop protection	Mexico	@1	78%	-
205	Tesaurus Mexico S.A. de C.V.	Crop protection	Mexico	@1	78%	-
206	Arysta LifeScience Paraguay S.R.L.	Crop protection	Paraguay	@1	78%	-
207	Arysta LifeScience Peru S.A.C	Crop protection	Peru	@1	78%	-
208	Arysta LifeScience Costa Rica SA.	Crop protection	Costa Rica	@1	78%	-
209	Arysta LifeScience de Guatemala, S.A.	Crop protection	Guatemala	@1	78%	-
210	Arysta LifeScience S.R.L.	Crop protection	Bolivia	@1	52%	-
211	Myanmar Arysta LifeScience Co., Ltd.	Crop protection	Myanmar	@1	78%	-
212	Arysta LifeScience U.K. BRL Limited	Crop protection	U.K.	@1	78%	-
213	Etec Crop Solutions Limited	Crop protection	New Zealand	@1	78%	-
214	MacDermid Agricultural Solutions	Crop protection	Australia	@1	78%	-
	Australia Pty Ltd					
215	Arvesta Corporation	Crop protection	USA	@1	78%	-
216	Arysta LifeScience Registrations Great	Crop protection	U.K.	@1	78%	-
	Britain Ltd					
217	Agriphar SDN BHD	Crop protection	Malaysia	@1	78%	-
218	Agriphar de Costa Rica SA	Crop protection	Costa Rica	@1	78%	-
219	Agriphar de Colombia SAS	Crop protection	Colombia	@1	78%	-
220	Industrias Agriphar SA	Crop protection	Guatemala	@1	78%	-
221	Kempton Chemicals (Pty) Ltd	Crop protection	South Africa	@1	78%	-
222	Agripraza Ltda.	Crop protection	Portugal	@1	78%	-
223	Arysta LifeScience Corporation	Crop protection	Dominican	@1	78%	_
	Republica Dominicana, SRL		Rpb			
224	Grupo Bioquimico Mexicano Republica	Crop protection	Dominican	@1	78%	-
	Dominicana SA		Rpb			
225	Arysta LifeScience Ecuador S.A.	Crop protection	Ecuador	@1	78%	_
226	Arvesta Paraguay S.A.	Crop protection	Paraguay	@1	78%	_
227	Arysta Agroquimicos y Fertilzantes	Crop protection	Uruguay	@1	78%	_
	Uruguay SA					
228	Arysta LifeScience U.K. USD-2 Limited	Crop protection	U.K.	@1	78%	-
229	Veto-Pharma SA	Animal Health	France	@1, #5	78%	-
230	Wyjolab S.A.	Animal Health	France	@1, #5	78%	-
231	MacDermid (Nanjing) Chemical Ltd.	Crop protection	China	@1,#1	0%	

- @ Subsidiary formed during the year
- @1 Subsidiary acquired during the year
- @2 Subsidiary formed during the previous year
- `@3 Subsidiary acquired during the previous year
- # During the previous year UPL Limited, Mauritius merged in UPL Corporation Limited, Mauritius.
- #1 Subsidiary divested during the year.
- #2 During the previous year, the Group through its step down wholly owned subsidiary, has increased its stake from 51% to 100%
- #3 During the previous year, the Group through its step down wholly owned subsidiary, has increased its stake from 50% to 100%
- #4 During the year, Blue Star B.V. was merged into United Phosphorus Holdings B.V.
- #5 During the year, Veto-Pharma SA and Wyjolab S.A. were merged into Arysta Animal Health SAS
- #6 Subsidiary divested during the previous year.

31. Group information (contd.)

Associates

The Group's interest in associates are summarised below

Sr	Name	Country of		% equity	interest
No		incorporation/ Principal place of business		March 31, 2019	March 31, 2018
1	Weather Risk Management Private Ltd	India	##	32%	27%
2	Ingen Technologies Private Limited	India		*	*
3	Kerala Enviro Infrastructure Limited	India		28%	28%
4	Polycoat Technologies 2010 Limited	Israel	###	-	20%
5	3SB Produtos Agricolas S.A.	Brazil	\$\$\$,#	45%	49%
6	Sinagro Produtos Agropecuarios S.A.	Brazil	\$\$\$,#	45%	49%
7	Seara Comercial Agricola Ltda.	Brazil		**	**
8	Serra Bonita Sementes S.A.	Brazil	\$\$	33%	33%
9	Bioplanta Nutricao Vegetal,Industria e Comercio S.A.	Brazil		***	***
10	Chemisynth (Vapi) Limited	India		30%	30%
11	Universal Pestochem (Industries) Limited	India		44%	44%
12	Agri Fokus (Pty) Ltd.	South Africa	\$	25%	-
13	Novon Retail Company (Pty) Ltd.	South Africa	\$	25%	-
14	Agronamic (Pty) Ltd.	South Africa	\$	28%	-
15	Novon Protecta (Pty) Ltd	South Africa	\$	25%	-
16	Silvix Forestry (Pty) Ltd.	South Africa	\$	25%	-
17	Nexus AG (Pty) Ltd	South Africa	\$	25%	-
18	Dalian Advanced Chemical Co.Ltd.	China	\$	21%	-
19	Société des Produits Industriels et Agricoles	Senegal	\$	32%	_
20	CGNS Limited	U.K.	\$	25%	-
21	Callitogo SA	Togo	\$	35%	

^{\$} Investment in Associates during the year.

\$\$\$ 5% stake divested during the year

Additional 5% stake acquired during the year

Additional 9% stake acquired during the previous year

Divested during the year

Joint arrangement in which the group is a venturer

The Group's interest in joint ventures is summarised below

Sr	Name	Country of	% equity interest	
No		incorporation/ Principal	March 31,	March 31,
		place of business	2019	2018
1	Hodagaya UPL Co. Limited	Japan	40%	40%
2	Longreach Plant Breeders Management Pty Limited	Australia	70%	70%
3	United Phosphorus (Bangladesh) Limited	Bangladesh	50%	50%

32. Material partly owned subsidiary

Financial information of subsidiary that have material non-controlling interests is provided below: Proportion of equity interest held by non-controlling interests(NCI):

	Country of	March 31,	March 31,
	incorporation/ Principal	2019	2018
	place of business		
UPL Corporation Limited	Mauritius	22%	0%

^{*} This is 100% step-down subsidiary of Weather Risk Management Private Ltd.

^{**} This is 51% step-down subsidiary of Sinagro Produtos Agropecuarios S.A.

^{***} These are 33.33% Joint ventures of Sinagro Produtos Agropecuarios S.A.

^{\$\$} Investment made during the previous year ended 2017-18

32. Material partly owned subsidiary (contd.)

Information regarding non-controlling interest

₹ In crores

	March 31, 2019	March 31, 2018
Accumulated balances of material non-controlling interest:		
UPL Corporation Limited	2,891	_

	March 31, 2019
Profit/(loss) allocated to material non-controlling interest:	
UPL Corporation Limited	61

Summarised statement of profit or loss for the year ended 31 March 2019:

₹ In crores

	March 31, 2019
Revenue	6,576
Profit for the year	277
Total comprehensive income	277
Attributable to non-controlling interests	61
Dividends paid to non-controlling interests	-

Summarised balance sheet as at 31 March 2019:

₹ In crores

	March 31, 2019
Current Assets	22,234
Non-current Assets	31,899
Current Liabilities	(11,533)
Non-current Liabilities	(29,585)
Total equity	13,015
Attributable to:	
Equity holders of parent	10,124
Non-controlling interest	2,891

33. Investment in Joint Ventures

a) The Group has a 40% (31 March 2018: 40%) interest in Hodogaya UPL Co. Limited, a joint venture incorporated in Japan. Hodogaya UPL Co. Limited is involved in the manufacturing, trading and distribution of crop protection chemicals. The Group's interest in Hodogaya UPL Co. Limited is accounted for using the equity method in the consolidated financial statements. Summarised financial information of the joint venture, based on its financial statements, and reconciliation with the carrying amount of the investment in consolidated financial statements are set out below:

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets, including cash and cash equivalents INR 21 Crores (31st March 2018:	143	136
INR 19 Crores)		
Non-current assets	1	0
Current liabilities, including tax payable INR 3 Crores (31 March 2018: INR 1 Crores)	(86)	(84)
Non-current liabilities	-	-
Equity	58	52
Proportion of the Group's ownership	40%	40%
Carrying amount of the investment(Note)	23	21

Note: The group does not have Goodwill

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	216	215
Profit for the year	6	3
Other Comprehensive Income(OCI)	-	-
Total comprehensive income for the year	6	3
Group's share of total comprehensive income(40%)	2	1

33. Investment in Joint Ventures (contd.)

The group had no contingent liabilities or capital commitments relating to its interest in Hodogaya UPL Co. Limited as at 31 March 2019 and 31 March 2018. The joint venture had no other contingent liabilities or capital commitments as at 31 March 2019 and 31 March 2018.

b) The Group has a 70 % (31 March 2018: 40%) interest in Longreach Plant Breeders Management Pty Limited, a joint venture incorporated in Australia. Longreach Plant Breeders Management Pty Limited is involved in the development of wheat seeds. The Group's interest in Longreach Plant Breeders Management Pty Limited is accounted for using the equity method in the consolidated financial statements. Summarised financial information of the joint venture, based on its financial statements, and reconciliation with the carrying amount of the investment in consolidated financial statements are set out below: ₹ In crores

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets including cash and cash equivalents INR 30 Crores. (31st March 2018:	75	68
INR 5 Crores).		
Non-current assets	49	46
Current liabilities	(79)	(80)
Non-current liabilities	(0)	(0)
Equity	46	34
Proportion of the Group's ownership	70%	70%
Carrying amount of the investment before Goodwill	32	24
Add: Goodwill	18	18
Carrying amount of the investment	50	42

₹ In crores

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	44	48
Profit for the year	13	15
Other Comprehensive Income(OCI)	-	-
Total comprehensive income for the year	13	15
Group's share of total comprehensive income(70%)	9	11

The group had no contingent liabilities or capital commitments relating to its interest in Longreach Plant Breeders Management Pty Limited as at 31 March 2019 and 31 March 2018. The joint venture had no other contingent liabilities or capital commitments as at 31 March 2019 and 31 March 2018.

In the year ended 31 March 2019 and 31 March 2018, the group did not receive dividends from any of its Joint Ventures.

The group also has interest in an immaterial Joint Venture United Phosphorous (Bangladesh) Limited.

34. Investment in Associates

a) The Group has a 27.52% (31 March 2018: 27.52%) interest in Kerala Enviro Infrastructure Limited, which is involved in the business of management of hazardous waste. Kerala Enviro Infrastructure Limited is a private entity that is not listed on any public exchange. The Group's interest in Kerala Enviro Infrastructure Limited is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of Kerala Enviro Infrastructure Limited as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in Kerala Enviro Infrastructure Limited: ₹ In crores

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets	18	15
Non-current assets	14	11
Current liabilities	(3)	(3)
Non-current liabilities	(12)	(11)
Equity	17	12
Proportion of the Group's ownership	28%	28%
Carrying amount of the investment	5	3

34. Investment in Associates (contd.)

₹ In crores

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	19	14
Profit for the year	5	2
Other Comprehensive Income(OCI)	0	-
Total comprehensive income for the year	5	2
Group's share of profit for the year	1	1

Contingent Liability not provided for Rs. 1.55 crores (Previous Year Rs. 1.55 crores) for the appeals pending with Income tax for the AY 2015-16.

b) The Group has a 45% (31 March 2018: 49%) interest in 3SB Produtos Agropecuarios S.A., which is involved in business of planting, cultivation and commericialization of agriculture products. 3SB Produtos Agropecuarios S.A. is a private entity that is not listed on any public exchange. The Group's interest in 3SB Produtos Agropecuarios S.A. is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of 3SB Produtos Agropecuarios S.A. as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in 3SB Produtos Agropecuarios S.A.:

₹ In crores

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets	234	244
Non-current assets	223	281
Current liabilities	(333)	(375)
Non-current liabilities	(68)	(91)
Equity	56	59
Proportion of the Group's ownership	45%	49%
Carrying amount of the investment excluding Goodwill	25	29
Goodwill	66	73
Impact of dilution of Equity holding	(2)	0
Carrying amount of the investment	89	102

₹ In crores

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	308	408
Profit for the year	(2)	(7)
Other Comprehensive Income(OCI)	-	-
Total comprehensive income for the year	(2)	(7)
Group's share of profit for the year	(1)	(3)

The associate had no contingent liabilities or capital commitments as at 31 March 2019 and 31 March 2018.

c) The Group has a 45% (31 March 2018: 49%) interest in Sinagro Produtos Agropecuarios S.A., which is involved in the business of retail sales and commercial representation of crop protection chemical and seeds. Sinagro Produtos Agropecuarios S.A. is a private entity that is not listed on any public exchange. The Group's interest in Sinagro Produtos Agropecuarios S.A. is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of Sinagro Produtos Agropecuarios S.A.as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in Sinagro Produtos Agropecuarios S.A.:

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets	1,052	966
Non-current assets	335	382
Current liabilities	(1,438)	(1,355)
Non-current liabilities	(64)	(153)

34. Investment in Associates (contd.)

₹ In crores

Summarised balance sheet	March 31, 2019	March 31, 2018
Non-controlling interest	(14)	(12)
Equity	(129)	(172)
Proportion of the Group's ownership	45%	49%
Carrying amount of the investment excluding Goodwill	(58)	(84)
Goodwill	44	48
Additional investment during the relevant period	15	36
Carrying amount, restricting loss from associate	-	-

₹ In crores

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	1,790	2,011
Profit for the year	(20)	(210)
Other Comprehensive Income(OCI)	-	-
Total comprehensive income for the year	(20)	(210)
Group's share of profit for the year	(9)	(103)
Group's share of profit for the year, restricting loss from associates to the extent of	-	
investment.		

Contingent Liability not provided for Rs. 11 crores (previous year: 14 crores) towards possible losses as assessed by legal advisors.

d) The Group has a 32.1% (31 March 2018: 27.37%) interest in Weather Risk Management Services Private Limited, which is grown into a comprehensive Climate Risk Management company. The company has its range of patented producs and services delivered in customized formats to clients ranging from large corporate houses to poor peasants in remotest of villages. In order to deliver these products where they are required, the company has developed its own retail network and handy technologies which have found applications in diverse sectors. Weather Risk Management Services Private Limited also provides environmental consulting services to governments, institutions and corporate houses. The Group's interest in Weather Risk Management Services Private Limited, is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of Weather Risk Management Services Private Limited as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in Weather Risk Management Services Private Limited.:

₹ In crores

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets	26	20
Non-current assets	11	21
Current liabilities	(10)	(8)
Non-current liabilities	(0)	(8)
Non-controlling interest	0	0
Equity	27	26
Proportion of the Group's ownership	32%	27%
Carrying amount of the investment excluding Goodwill	9	7
Goodwill	4	3
Carrying amount of the investment	13	10

₹ In crores

		(111 01 01 00
Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	28	29
Profit for the year	(3)	(0)
Other Comprehensive Income(OCI)	(0)	(0)
Total comprehensive income for the year	(3)	(0)
Group's share of profit for the year	(1)	(0)

The associate had no contingent liabilities or capital commitments as at 31 March 2019 and 31 March 2018.

34. Investment in Associates (contd.)

e) The Group has 33.33% (31 March 2018: 33.33%) interest in Serra Bonita Sementes S.A, which is mainly engaged in producing certified soy beans & crop seeds, producing soy beans, corn grains, sorghum grains, millet grains & beans. The Group's interest in Sinagro Produtos Agropecuarios S.A. is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of Serra Bonita Sementes S.A. as included in its own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in Serra Bonita Sementes S.A:

Summarised balance sheet	March 31, 2019	March 31, 2018
Current assets	184	119
Non-current assets	562	686
Current liabilities	(90)	(110)
Non-current liabilities	(48)	(31)
Non-controlling interest	-	-
Equity	608	664
Proportion of the Group's ownership	33%	33%
Carrying amount of the investment excluding Goodwill	202	221
Goodwill	(12)	(14)
Carrying amount of the investment	190	208

₹ In crores

Summarised statement of profit and loss	March 31, 2019	March 31, 2018
Revenue	207	174
Profit for the year	7	2
Other Comprehensive Income(OCI)	0	0
Total comprehensive income for the year	7	2
Group's share of profit for the year	2	1

The associate had no contingent liabilities or capital commitments as at 31 March 2019 and 31 March 2018.

f) The group has a 28.4% interest in Agronamic Proprietary Limited, which is involved in the buying and selling of agricultural chemicals. Agronamic Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in Agronamic Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of Agronamic Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in Agronamic Proprietary Limited:

Summarised balance sheet	March 31, 2019
Current assets	54
Non-current assets	0
Current liabilities	(52)
Non-current liabilities	-
Non-controlling interest	-
Equity	3
Proportion of the Group's ownership	28%
Carrying amount of the investment excluding Goodwill	1
Goodwill	4
Carrying amount of the investment	5

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	36
Profit for the year	1
Other Comprehensive Income(OCI)	-
Total comprehensive income for the year	1
Group's share of profit for the year	0

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

34. Investment in Associates (contd.)

g) The group has a 25.1% interest in Silvix Forestry Proprietary Limited, which is involved in the distribution of chemicals. Silvix Forestry Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in Silvix Forestry Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of Silvix Forestry Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in Silvix Forestry Proprietary Limited:

₹ In crores

Summarised balance sheet	March 31, 2019
Current assets	10
Non-current assets	0
Current liabilities	(8)
Non-current liabilities	-
Non-controlling interest	-
Equity	1
Proportion of the Group's ownership	25%
Carrying amount of the investment excluding Goodwill	0
Goodwill	0
Carrying amount of the investment	0

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	5
Profit for the year	0
Other Comprehensive Income(OCI)	0
Total comprehensive income for the year	0
Group's share of profit for the year	0

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

h) The group has a 25.1% interest in Agrifokus Proprietary Limited, which is involved in the trading chemicals, insecticides and herbicides. Agrifokus Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in Agrifokus Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of Agrifokus Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in Agrifokus Proprietary Limited:

₹ In crores

Summarised balance sheet	March 31, 2019
Current assets	93
Non-current assets	2
Current liabilities	(62)
Non-current liabilities	0
Non-controlling interest	-
Equity	33
Proportion of the Group's ownership	25%
Carrying amount of the investment excluding Goodwill	8
Goodwill	(5)
Carrying amount of the investment	4

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	9
Profit for the year	1
Other Comprehensive Income(OCI)	0
Total comprehensive income for the year	1
Group's share of profit for the year	0

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

34. Investment in Associates (contd.)

i) The group has a 25.1% interest in Novon Retail Company Proprietary Limited, which is involved in the selling of fertilizers and chemicals. Novon Retail Company Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in Novon Retail Company Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of Novon Retail Company Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in Novon Retail Company Proprietary Limited:

Summarised balance sheet	March 31, 2019
Current assets	62
Non-current assets	7
Current liabilities	(55)
Non-current liabilities	(1)
Non-controlling interest	-
Equity	13
Proportion of the Group's ownership	25%
Carrying amount of the investment excluding Goodwill	3
Goodwill	4
Carrying amount of the investment	7

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	21
Profit for the year	2
Other Comprehensive Income(OCI)	0
Total comprehensive income for the year	2
Group's share of profit for the year	0

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

j) The group has a 25.1% interest in Novon Protecta Proprietary Limited, which is involved in the distribution of agricultural chemicals. Novon Protecta Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in Novon Protecta Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of Novon Protecta Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in Novon Protecta Proprietary Limited:

₹ In crores

Summarised balance sheet	March 31, 2019
Current assets	160
Non-current assets	4
Current liabilities	(126)
Non-current liabilities	(1)
Non-controlling interest	-
Equity	36
Proportion of the Group's ownership	25%
Carrying amount of the investment excluding Goodwill	9
Goodwill	(2)
Carrying amount of the investment	7

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	35
Profit for the year	1
Other Comprehensive Income(OCI)	0
Total comprehensive income for the year	1
Group's share of profit for the year	0

Contingent liability consists of claims against the group not acknowledged as debt amounting to INR 2 crores as on 31 March 2019.

34. Investment in Associates (contd.)

k) The group has a 25.1% interest in NexusAG Proprietary Limited, which is involved in the wholesale of agricultural chemicals for crop protection and fertilizer products for plant nutrition. NexusAG Proprietary Limited is a private entity that is not listed on any public exchange. The groups interest in NexusAG Proprietary Limited is accounted for using the equity method in the consolidated financial statements. The following table summarizes the financial information of NexusAG Proprietary Limited as included in it's own financial statements, adjusted for fair value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarized financial information of the Group's investment in NexusAG Proprietary Limited:

Summarised balance sheet	March 31, 2019
Current assets	120
Non-current assets	18
Current liabilities	(110)
Non-current liabilities	(6)
Non-controlling interest	-
Equity	22
Proportion of the Group's ownership	25%
Carrying amount of the investment excluding Goodwill	6
Goodwill	4
Carrying amount of the investment	10

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	57
Profit for the year	1
Other Comprehensive Income(OCI)	0
Total comprehensive income for the year	1
Group's share of profit for the year	0

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

The group has a 21% interest in Dalian Advanced Chemical Co.Ltd.(DAC) which is involved in the formulation of Chloropicrin. DAC is private entity that is not listed on any public exchange. DAC is accounted for using the equity method in the consolidated financial statements. The following table summarises the financial information of DAC as included in its own financials statements, adjusted for faire value adjustments at acquisition and differences in accounting policies. The following table illustrates the summarised financial information of the Group's investment in DAC. ₹ In crores

Summarised balance sheet	March 31, 2019
Current assets	0
Non-current assets	2
Current liabilities	(0)
Non-current liabilities	-
Non-controlling interest	-
Equity	3
Proportion of the Group's ownership	21%
Carrying amount of the investment excluding Goodwill	1
Goodwill	-
Carrying amount of the investment	1

₹ In crores

Summarised statement of profit and loss	March 31, 2019
Revenue	0
Profit for the year	(0)
Other Comprehensive Income(OCI)	-
Total comprehensive income for the year	(0)
Group's share of profit for the year	(0)

The associate had no contingent liabilities or capital commitments as at 31 March 2019.

35. Net employee defined benefit liabilities

₹ In crores

	March 31, 2019	March 31, 2018
Net employee defined benefit liabilities	226	73
- Gratuity Plan (Note 35 (b) to (g))	87	44
- Defined benefit pension scheme (Note 35(h))	139	29

The following tables summarise the components of net benefit expense recognised in the statement of profit or loss and the funded status and amounts recognised in the balance sheet for the respective plans:

The amounts recognised in the statement of Profit and Loss are as follows:

₹ In crores

(i) Defined Benefit Plan	Gratuity	
	March 31, 2019	March 31, 2018
Current service cost	9	8
Past Service Cost	4	4
Interest cost on benefit obligation	5	4
Expenses recognised in Profit and Loss(under the head Employee Benefit	18	16
Expenses in Note23)		
Return on plan assets	(3)	(2)
Net actuarial (gain)/loss recognised during the year	(6)	(3)
Remeasurements recognised in Other Comprehensive Income(OCI)	(8)	(5)
Total Expenses recognised in the statement of Profit & Loss	10	11
Actual return on plan assets	3	2

₹ In crores

(ii) Defined Contribution Plan	Provident Fund	
	March 31, 2019	March 31, 2018
Current service cost included under the head Employee Benefit Expense in Note 23	19	16

₹ In crores

(iii) Defined Contribution Plan	Superannual Fund	
	March 31, 2019	March 31, 2018
Current service cost included under the head Employee Benefit Expense in Note 23	10	10

₹ In crores

(iv) Defined Contribution Plan	Pension Fund	
	March 31, 2019	March 31, 2018
Current service cost included under the head Employee Benefit Expense in Note 23	1	-

b) The amounts recognised in the Balance Sheet are as follows:

	Defined Benefit Plan - Gratuity	
	March 31, 2019 March 31, 2018	
Present value of funded obligation	172	73
Less: Fair value of plan assets	85	29
Net Liability	87	44

35. Net employee defined benefit liabilities (contd.)

c) Changes in the present value of the defined benefit obligation representing reconciliation of opening and closing balance thereof are as follows: ₹ In crores

	Gratuity	
	March 31, 2019	March 31, 2018
Opening defined benefit obligation	73	63
Defined benefit obligation on account of acquisition of Arysta Life Science and its	127	-
subsidiaries		
Interest cost	5	5
Current service cost	9	9
Benefits paid	(7)	(4)
Actuarial changes arising from changes in financial assumption	(6)	(3)
Past service cost	(6)	0
Exchange difference	(23)	3
Closing defined benefit obligation	172	73

Changes in the fair value of plan assets are as follows:

₹ In crores

	Gratuity	
	March 31, 2019	March 31, 2018
Opening fair value of plan assets	29	28
Fair Value of plan assets on account of acquisition of Arysta Life Science and its	54	-
subsidiaries		
Return on plan assets	2	2
Actuarial changes arising from changes in financial assumption	(1)	(1)
Closing fair value of plan assets	85	29

Expected contribution to defined benefit plan for the year

₹ In crores

Gratuity	
March 31, 2019	March 31, 2018
27	23

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

	Gratuity	
	March 31, 2019	March 31, 2018
	%	%
Investments with insurer under: Funds managed by insurer	100	100

g) The principal actuarial assumptions at the Balance Sheet date.

₹ In crores

	March 31, 2019	March 31, 2018	
Discount rate	2.80%-7.70%	2.75 - 7.29%	
Return on plan assets	2.80%-7.70%	6.85 - 7.29%	
Mortality Rate	Indian Assured Lives Mortality	Indian Assured Lives Mortality	
	(2006-08) Ult. and Indonesia - III	(2006-08) Ult. and Indonesia - III	
	(2011)	(2011)	
Annual increase in salary costs	7%	8%	
Attriation rate	8%	8%	

A quantitative sensitivity analysis for significant assumption as at 31 March 2018 is as shown below:

Assumptions ₹ In crores

Sensitivity Level	1% increase	1% decrease
Impact on defined benefit obligation		
Discount rate	(2)	4
Future salary increases	4	(2)
Withdrawal rate	1	1

35. Net employee defined benefit liabilities (contd.)

The sensitivity analysis above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

h) Defined benefit pension scheme

The Group operates unfunded defined benefit pension scheme in its entities located in France which are limited to retirement indemnities as applicable in France. The cost of providing benefits is calculated using project unit credit method. The amount recognised as liability for the year ended 31 March 2019 amounts to Rs. 139 Crores (31 March 2018: Rs. 29 Crores)

36. Share based payments

During the year ended March 31, 2019, the following employee stock option plan (ESOPs) were in existence. The relevant details of the scheme and the grant are as follows:

1 Employees stock option and share plan 2006

1a The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on September 20, 2006 which provides for a grant of 840,000 options (each option convertible into share) to employees.

Particulars	March 31, 2019	March 31, 2018	
Number of options granted	5,08,390	5,08,390	
(net of options lapsed)			
Method of settlement (Cash/Equity)	Equity	Equity	
Vesting period	Spread over 4 years and 6	Spread over 4 years and 6	
	months	months	
Exercise period	10 years	10 years	

1b The details of the activity have been summarized below

Particulars	As at March 31, 2019 (No. of equity shares)	As at March 31, 2018 (No. of equity shares)
Outstanding at the beginning of the year	16,500	52,250
Exercisable at the beginning of the year	16,500	52,250
Forfeited during the year	-	-
Exercised during the year	-	35,750
Vested during the year	-	-
Expired during the year	-	-
Outstanding at the end of the year	16,500	16,500
Exercisable at the end of the year*	16,500	16,500
Weighted average remaining contractual life (in	2.91	3.91
years)		

For options excercised during the current period, the weighted average share price at the exercise date was Rs. Nil (Mar 31, 2018: Rs. 833).

1c Stock options granted

The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

Particulars	As at March 31, 2019	As at March 31, 2018	
Weighted average share price/market price	68.75	68.75	
Exercise price (Rs. per share)	57.00	57.00	
Expected volatility	64.49%	64.49%	
Life of the options granted (vesting and exercise	Vesting period + 18 months i.e.	Vesting period + 18 months i.e.	
period) in years	3 years, 4 years, 5 years, and 6	3 years, 4 years, 5 years, and 6	
	years, for each Vesting tranche	years, for each Vesting tranche	
	of 25%	of 25%	
Expected dividends	0.30% per annum	0.30% per annum	
Average risk-free interest rate	8.04% per annum	8.04% per annum	

36. Share based payments (contd.)

2 Employees stock option plan (ESOP) 2013

2a The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on December 03, 2013 which provides for a grant of 1,300,000 options (each option convertible into shares) to employees.

Particulars	March 31, 2019 and March 31, 2018		
Dates of grant	30-Jan-14	27-May-14	27-May-14
Dates of board approval	30-Jan-14	27-May-14	27-May-14
Date of shareholders approval	3-Dec-13	3-Dec-13	3-Dec-13
Number of options granted	7,11,752	35,000	35,000
Method of settlement (Cash / Equity)	Equity	Equity	Equity
Vesting period	Spread over 4 years		
Exercise period	60 months from the date of grant		

2b The details of the activity have been summarized below

Particulars	As at March 31, 2019	As at March 31, 2018
	(No. of equity	(No. of equity
	shares)	shares)
Outstanding at the beginning of the year	14,676	23,723
Exercisable at the beginning of the year	13,269	2,814
Granted during the year	-	-
Forfeited during the year	-	-
Exercised during the year	9,047	9,047
Vested during the year	-	19,502
Expired during the year	-	-
Outstanding at the end of the year	5,629	14,676
Exercisable at the end of the year*	4,222	13,269
Weighted average remaining contractual life (in years)	0.32	1.02

For options excercised during the current period, the weighted average share price at the exercise date was Rs. 756.33 (Mar 31, 2018: Rs. 703.80).

2c Stock options granted

The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

Particulars	As at	As at
	March 31, 2019	March 31, 2018
Weighted average share price/market price (Rs. per share)	112.81	112.81
Exercise price (Rs. per share)	Grant 1 Rs	Grant 1 Rs
	103.80	103.80
	Grant 2 Rs	Grant 2 Rs
	262.75	262.75
	Grant 3 Rs	Grant 3 Rs
	319.70	319.70
Expected volatility	49.17%	49.17%
Life of the options granted (vesting and exercise period) in years	Vesting period	Vesting period
	+ 6 months	+ 6 months
Expected dividends	0%	0%
Average risk-free interest rate	8.71% per	8.71% per
	annum	annum

^{*}Eligible Employees holding 1 Option shall be entitled to purchase 1.06 new equity shares as per the scheme of Amalgamation.

36. Share based payments (contd.)

3 Employees stock option plan (ESOP) 2017

3a The Company instituted an Employees Stock Option Scheme ("ESOPs") for certain employees as approved by the shareholders on July 08, 2017 which provides for a grant of 2,500,000 options (each option convertible into share) to employees.

Particulars	March 31, 2019 and March 31, 2018
Dates of grant	25-Jan-18
Dates of board approval	25-Jan-17
Number of options granted	60,000
Method of settlement (Cash / Equity)	Equity
Vesting period	Spread over 2 years
Contractual life of Option	5 years

Vesting Conditions	Grant Date	Number of Options	Contractual life of Options
1 year from grant date	25-Jan-18	20,000	4 years
2 years from grant date	25-Jan-18	40,000	5 years

3b The details of the activity have been summarized below

₹ In crores

Particulars	March 31, 2019	March 31, 2018
Outstanding at the beginning of the year	60,000	-
Exercisable at the beginning of the year	-	-
Granted during the year	-	60,000
Forfeited during the year	-	-
Exercised during the year	-	-
Vested during the year	20,000	-
Expired during the year	-	-
Outstanding at the end of the year	60,000	60,000
Exercisable at the end of the year*	40,000	-
Weighted average remaining contractual life (in years)	3.49	4.49

3c The Black Scholes valuation model has been used for computing the weighted average fair value considering the following inputs:

Particulars	March 31, 2019	March 31, 2018
Weighted average share price/market price (Rs. per share)	824	824
Exercise price (Rs. per share)	784	784
Expected volatility	21.49%	21.49%
Life of the options granted (vesting and exercise period) in years	2 to 3.25 years	2 to 3.25 years
Expected dividends	-	_
Average risk-free interest rate	7.22% per	7.22% per
	annum	annum

3d Effect of the employee option plan on the Statement of Profit and Loss and on its financial position

Particulars	March 31, 2019	March 31, 2018
Total employee compensation cost pertaining to stock option plan	1	0
Liability for employee stock option plan outstanding as at the year end	1	2

^{*}Eligible employees holding 1 Option shall be entitled to purchase 1.06 new equity shares as per the scheme of Amalgamation.

37. Commitments and contingencies

A. Commitments:

a. Leases

Operating lease commitments — Company as lessee

The Group has entered into operating lease arrangements for its office premises (including utilities).

Future minimum rentals payable under non-cancellable operating leases as at 31 March are, as follows: ₹ In crores

Particulars	March 31, 2019	March 31, 2018
Within one year	62	52
After one year but not more than five years	124	125
More than five years	6	17
	191	195

There is no contingent rent recognised in the consolidated statement of profit and loss.

Finance lease

The Group has entered into finance lease arrangements for some of its vehicles and certain equipments. These leasing agreements provide for purchase option after 2 to 3 years. The Group's obligations under finance leases are secured by the lessor's title to the leased assets. Future minimum lease payments under finance leases with the present value of the net minimum lease payments are as follows:

	March 31, 2019		March 31, 2018	
	Minimum lease	Present value of MLP	Minimum lease	Present value of MLP
	payments		payments	
Within one year	2	1	1	1
After one year but not more than five years	17	14	0	0
More than five years	-	-	-	-
Total minimum lease payments	19	15	1	1
Less: amounts representing finance	(4)	-	(0)	0
charges				
Present value of minimum lease payments	15	15	1	1

b) Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances) ₹ In crores

March 31, 2019	March 31, 2018
255	157

c) One of the Subsidiaries has entered into an agreement with Syngenta Seeds, Inc. for the resale and distribution of Syngenta branded Seed Corn. It is a Ten Year agreement expiring on 31st August, 2024, in which they must exclusively sell Syngenta brands during the first five years and are committed to minimum sales percentages during the remainder of the contract. As at the balance sheet date, the effects of this commitment is unknown.

B. Contingent liabilities

The Group is involved in a number of appellate, judicial and arbitration proceedings (including those described below) concerning matters arising in the course of conduct of the Group's businesses. Some of these proceedings in respect of matters under litigation are in early stages, and in some other cases, the claims are indeterminate. A summary of claims asserted on the Group in respect of these cases have been summarised below.

a. Guarantees ₹ In crores

	March 31, 2019	March 31, 2018
Guarantees given by the Group on behalf of third parties	5	9

37. Commitments and contingencies (contd.)

b. Tax Contigencies

Amounts in respect of claims asserted by various revenue authorities on the Group, in respect of taxes, which are in dispute, have been tabulated below: ₹ In crores

Nature of Tax	March 31, 2019	March 31, 2018
Disputed Excise Duty / Service Tax Liability (excluding interest)	196	203
Disputed Income-tax Liability (excluding interest)	26	26
Disputed Sales-tax Liability	31	75
Disputed Custom duty Liability	34	34
Disputed Fiscal Penalty for cancellation of licenses	33	33

The management believes that the claims made are untenable and is contesting them. As of the reporting date, the management is unable to determine the ultimate outcome of above matters. However, in the event the revenue authorities succeed with enforcement of their assessments, the Group may be required to pay some or all of the asserted claims and the consequential interest and penalties, which would reduce net income and could have a material adverse effect on net income in the respective reported period.

c. Amount in respect of other claims

₹ In crores

Nature of Claim	March 31, 2019	March 31, 2018
Claims payable to growers.	22	13
Other Claims (claims related to contractual and other disputes)	31	20
Group's share of contingent liabilities of associates:-		
Claims against the Associates not acknowledged as debts.	5	23

Agrofresh Inc (USA) had filed a litigation against one subsidiary of the Group and the other shareholders of the subsidiary inter alia for infringement of patents owned by Agrofresh in respect of a product, for loss of profits and for breach of contract. During the previous year the Group had provided Rs. 1.29 crores towards amounts expected to be paid in this regard being the estimated profits earned from the product till December 2016. During the year, the Group's has obtained a favorable ruling resulting in invalidation of Agrofresh's patent.

The Group had filed for dissolution of the subsidary and a counter claim of Rs.16.29 crores has been filed for the proposed dissolution. The Group understands that this claim, if any, should be against the non controlling interest shareholder and is likely to be rejected in its present form. The Group plea for dissolution of subsidiary has been upheld. Agrofresh has appealed this outcome. The litigation for the loss of profits, damages and breach of contract for the main claim is in progress. While effect of all the above is not ascertainable, the Group does not expect this to materially affect its financial statements.

Management is generally unable to reasonably estimate a range of possible loss for proceedings or disputes other than those included in the estimate above, including where:

- plaintiffs / parties have not claimed an amount of money damages, unless management can otherwise determine an appropriate amount;
- ii. the proceedings are in early stages;
- iii. there is uncertainty as to the outcome of pending appeals or motions or negotiations;
- iv. there are significant factual issues to be resolved; and/or
- v. there are novel legal issues presented.

However, in respect of the above matters, management does not believe, based on currently available information, that the outcomes of the litigation, will have a material adverse effect on the Group's financial condition, though the outcomes could be material to the Group's operating results for any particular period, depending, in part, upon the operating results for such period.

d. Pursuant to the judgment of the Supreme Court of India on 28 February 2019 regarding the allowances to be considered for computing Provident Fund liability, certain components of compensation hitherto excluded from PF need to be included. There are interpretative challenges in application of the judgment retrospectively and the Company has been legally advised that the judgment would be applicable prospectively. The financial statements disclose a contingent liability in this regard. No provision has been made for the period from 28 February to 31 March 2019 as the same is not material.

37. Commitments and contingencies (contd.)

C. Contingent Assets

During the previous year the company settled its claim of Rs 13.74 Crs against agrochemicals trader regarding illegal parallel-trading of unauthorised copies of UPL's product. No gain had been recognised during the previous financial year because the receipt of the additional consideration was not virtually certain as it was dependent on the ability of the party to pay the compensation

38. Related Party Disclosures:

a) Name of other related parties with whom transactions have taken place during the year.

Joint Venture Companies:

United Phosphorus (Bangladesh) Limited Hodogaya UPL Co. Limited Longreach Plant Breeders Management Pty Limited

ii) Associate Companies:

Kerala Enviro Infrastructure Limited Weather Risk Management Services Private Limited 3SB Produtos Agrícolas S.A. Sinagro Produtos Agropecuários S.A. Seara Bonita Sementes S.A. Chemisynth (Vapi) Limited Universal Pestochem Industries Limited

Agri Fokus (Pty) Ltd. Novon Retail Company (Pty) Ltd. Agronamic (Pty) Ltd. Novon Protecta (Pty) Ltd Silvix Forestry (Pty) Ltd. Nexus AG (Pty) Ltd

Dalian Advanced Chemical Co.Ltd. Société des Produits Industriels et Agricoles

CGNS Limited Callitogo SA

iii) Enterprises over which key management personnel and their relatives have significant influence (Other Related Parties):

Bharuch Enviro Infrastructure Limited Tatva Global Environment Private Limited Bloom Packaging Private Limited Tatva Global Environment (Deonar) Limited Bloom Seal Containers Private Limited Ultima Search Daman Ganga Pulp and Papers Private Limited Uniphos International Limited Demuric Holdings Private Limited Uniphos Enterprises Limited

Enviro Technology Limited Uniphos Envirotronic Private Limited Gharpure Engineering and Construction Private Limited UPL Environmental Engineers Limited

Uniphos Envirotronic Private Limited

JRF International GC Laboratories lai Trust

Nerka Chemicals Private Limited

Pot Plants

Sanguine Holdings Private Limited

Vikram Farm Ubania Realty LLP VIS Investments Limited Bench Bio Private Limited Agraja Properties Limited

Crop Care Federation of India Vankala Krishi Care Pvt Ltd

iv) Key Management Personnel and their relatives:

Whole Time Directors and their relatives

Mr. Rajnikant D. Shroff Mr. Jaidev R. Shroff * Mr. Vikram R. Shroff * Mrs. Sandra R. Shroff *

Mr. Kalyan Banerjee (Upto: 31st July 2018)

Mr. Arun C. Ashar Mrs. Asha Ashar * Mr. Navin Ashar *

* Relative of key management personnel.

Mr. Hardeep Singh Mr. Vasant Gandhi Mr. Pradeep Goyal Mr. Vinod Sethi

Dr. Reena Ramchandran

Mr. Pradip Madhavji (Upto: 26th April 2018) Mr. Anand Vora - Chief Financial Officer Mr. M.B Trivedi - Company Secretary

38. Related Party Disclosures: (contd.)

₹ In crores (b) The following transactions were carried out with related parties in the ordinary course of business as disclosed in the audited accounts of the individual companies in the Group, associate companies and joint ventures.

0000 . 32 13 0 **61** 61 **FOTAL** 0000 32 13 0 related parties Other 31 March 2018 29 Associates | 20 | 81 50 **20** 20 **61** Ventures oint -1000000 22 8 8 8 8 20 80 43 TOTAL ------443 related Other 31 March 2019 1 1 1 0 1 1 Associates . . 0 0 - -1 1 1 0 **20** 20 **48** Ventures Joint ongreach Plant Breeders Management Services Pty ongreach Plant Breeders Management Services Pty Sharpure Engineering & Construction Private Tatva Global Environment Private Limited atva Global Environment Private Limited **Sloom Seal Containers Private Limited** Bharuch Enviro Infrastructure Limited Sinagro Produtos Agropecuários S.A. Uniphos Envirotronic Private Limited Uniphos Envirotronic Private Limited Sinagro Produtos Agropecuários S.A. Bloom Packaging Private Limited **Jniphos Enterprises Limited** 3SB Productos Agricolas S.A. Hodogaya UPL Co. Limited Hodogaya UPL Co. Limited NATURE OF TRANSACTIONS: ingen Technologies P.Ltd PURCHASES OF GOODS MANAGEMENT FEES INTEREST RECEIVED GROUP RECHARGE SALE OF GOODS RENT RECEIVED **FIXED ASSETS EXPENSES** ROYALTY INCOME _imited _imited _imited Others Others 9 6 9 (e 2. a) (e \bigcirc (

Notes to Consolidated Financial Statements for the year ended March 31, 2019

_	
_	:
\overline{C}	3
Ċ	-
\overline{c}	5
C)
_	_
i	'n
ă	í
2	1
Ξ	5
77	1
<u>v</u>	9
C)
τ	5
ŭ	í
٠.	í
\subset	١
▔	
>	•
÷	,
=	į
π,)
Δ	
~	5
2	!
Ų.	ļ
Ξ	:
η	2
a	5
$\tilde{\sim}$	è
+	i
~	ì
\approx	
r.)

Source and best of the second								₹ In crores
NATURE OF TRANSACTIONS:		31 Ma	31 March 2019			31 March 2018	h 2018	
	Joint	Associates	Other	TOTAL	Joint	Associates	Other	TOTAL
	Ventures		related parties		Ventures		related parties	
Chemie Synth (Vapi) Limited.		1	1	1	1	0	1	0
c) OTHERS		0	_	_	1	0	0	0
Vikram Farm		1	0	0	ı	0	ı	0
Pot Plants		1	0	0	ı	1	1	1
Crop Care Federation of India		1	0	0	I	ı	0	0
Uniphos Envirotronic Private Limited		1	0	I	ı	ı	ı	ı
others		0	0	0	1	ı	ı	ı
d) SERVICES		0	94	95	1	1	79	79
Bharuch Enviro Infrastructure Limited		1	93	93	1	ı	77	77
Others		0	2	2	ı	ı	2	2
e) RENT		1	_	_	İ	1	_	_
Sanguine Holdings Private Limited		1	0	0	ı	ı	0	0
Ultima Search		1	0	0	I	ı	0	0
Bloom Packaging Private Limited		1	0	0	ı	ı	0	0
Jai Trust		1	0	0	ı	1	ı	ı
		1	0	0	I	ı	ı	ı
f) ROYALTY		1	1	ī	ı	1	ı	•
Longreach Plant Breeders Management Services Pty	ses Pty	1	ı	I		ı	ı	ı
g) COMMISSION EXPENSE		1	ı	1	1	1	1	1
		1	ı	ı	ı	ı	ı	ı
h) PROVISION FOR DOUBTFUL ADVANCES		1	ı	1	ı	1	ı	1
		1	I	ı	I	I	I	ı
i) CONTRIBUTION TO CSR		1	ı	1	ı	1	1	1
Vikram Farm		1	ı	ı	ı	ı		1
j) GROUP RECHARGE		0	1	0	0	1	1	0
Longreach Plant Breeders Management Services Pty Limited	ces Pty	0	I	0	0	I	I	0
3. FINANCE		1	1	1	ı	1	1	1
a) INTEREST INCOME			1	5	5	42	1	47
Longreach Plant Breeders Management Services Pty Limited	ces Pty	-	1	Ŋ	5	ı	ı	Ŋ
Bharuch Enviro Infrastructure Limited		1	1	ı	1	ı	ı	I
Sinagro Produtos Agropecuários S.A.		1	ı	ı	I	20	ı	20
Tatva Global Environment Private Limited		1	ı	1	I	ı	ı	ı
3SB Productos Agricolas S.A.		1	1	ı	I	22	ı	22
others		1	1	1	I	1	1	I

Notes to Consolidated Financial Statements for the year ended March 31, 2019 38. Related Party Disclosures: (contd.)

38. Related Party Disclosures: (contd.)								₹In crores
NATURE OF TRANSACTIONS:		31 March 2019	n 2019			31 March 2018	th 2018	
	Joint	Associates	Other	TOTAL	Joint	Associates	Other	TOTAL
	אפוומושא		parties		א שוונחו ש		parties	
b) LOAN /INTER CORPORATE DEPOSITS GIVEN	1	1	ı	1		ı	ı	ı
Tatva Global Environment Private Limited	1	1	1	I	ı	I	1	ı
Sinagro Produtos Agropecuários S.A.	ı	1	ı	ı	I	ı	1	1
Gharpure Engineering and Constructions	1	1	1	ı	ı	ı	ı	ı
Others	ı	1	1	ı	ı	ı	ı	ı
c) PURCHASE/ALLOTMENT OF BONDS	ı	1	1	1	ı	1	1	
Weather Risk Management Services Private Limited	ı	1	ı	1	ı	1	1	1
Tatva Global Environment Private Limited	ı	ı	I	ı	I	ı	ı	ı
d) REPAYMENT OF LOAN / INTER CORPORATE DEPOSITS GIVEN	1	1	ı	_	I	1	ı	_
Tatva Global Environment Private Limited	1	1	1	ı	ı	ı	1	1
Gharpure Engineering and Constructions	ı	1	1	I	I	ı	1	ı
Bharuch Enviro Infrastructure Limited	ı	1	ı	I	I	1	ı	ı
Others	ı	1	ı	I	ı	ı	1	ı
e) ADVANCES GIVEN	ı	1	2	2	ı	1	17	17
Urbania Realty LLP	ı	1	2	2	I	ı	17	17
f) SALE/REDEMPTION OF SHARES/NCD	ı	1	ı	1	ı	1	1	1
UPL Investment India Pvt. Ltd.	ı	1	1	ı	I	ı	ı	ı
g) RECEIPT AGAINST LOAN GIVEN	ı	1	ı	ı	1	1	<u></u>	—
	ı	1	ı	I	ı	ı	<u></u>	<u></u>
4. REIMBURSEMENTS	ı	1	ı	ı	1	1	1	1
a) RECEIVED	ı	1	_	_	ı	1	0	0
Uniphos Envirotronic Private Limited	ı	1	0	0	I	ı	0	0
Ultima Search	ı	1	0	0	ı	ı	0	0
Others	1	1	0	0	ı	ı	0	0
b) MADE	1	1	0	0	ı	1	1	1
UPL Enviromental Engineering Limited	I	1	0	0	I	ı	ı	ı
Urbania Realty LLP	ı	1	0	0	ı	ı	ı	ı
Others	1	1	0	0	I	ı	1	1
5. OUTSTANDINGS AS AT BALANCE SHEET DATE	ı	1	ı	ı	ı	1	1	1
a) PAYABLES	14	0	4	18	25	c	3	31
Longreach Plant Breeders Management Services Pty	ı	1	I	I	12	I	ı	12
Limited								
Sinagro Produtos Agropecuários S.A.	1 4	1	ı	1 4	1 (I	ı	1 (
Hodogaya UPL Co. Limited	4	1 (l «	4.	<u>, </u>	1 (1 (<u>, , , , , , , , , , , , , , , , , , , </u>
Others	ı	O	4	4	I	Υ)	Υ	0

Notes to Consolidated Financial Statements for the year ended March 31, 2019

38. Related Party Disclosures: (contd.)								₹ In crores
NATURE OF TRANSACTIONS:		31 March 2019	h 2019			31 March 2018	h 2018	
	Joint	Associates	Other	TOTAL	Joint	Associates	Other	TOTAL
	Ventures		related		Ventures		related parties	
b) RECEIVABLES	24	86	19	141	29	187	4	220
Hodogaya UPL Co. Limited	24	ı	ı	24	28	ı	ı	28
Bharuch Enviro Infrastructure Limited	1	I	M	M	ı	ı	1	ı
3SB Produtos Agrícolas S.A.	1	4	1	4	ı	51	1	51
Sinagro Produtos Agropecuários S.A.	ı	85	ı	85	ı	129	ı	129
Longreach Plant Breeders Management Services Pty	0	ı	ı	T	ı	ı	1	1
Others	1	6	16	25			4	12
C) LOANS / INTER CORPORATE DEPOSITS GIVEN	200) 1	2 (1	71	29	127	- 1	186
) [1). ¹	. 1	1	54	1	54
Longreach Plant Breeders Management Services Pty	58	I	I	58	29	ı	ı	59
Cinadro Agropecijários A	ı	1	1	,	ı	73	1	73
Bharirth Enviro Infrastructura Limitad		ı	ي ا	' (ı)		<u> </u>
Dijalucij Elivijo IIII asti ucture Elimited Bloom Dazkazina Drivato Limitad	I	I	0 0	2 C	ı	I	ı	ı
DIOUIII Fackayiiiy Fiivate Eiiiiited Otbors	I	I	V <	V <	ı	I	ı	
d) MANAGEMENT EFES RECEIVABLE			† '	† '			10	10
							2 ~	<u> </u>
Gharnire Engineering and Construction Private	1 1	1 1	1 1		1 1	1 1	- 00	- 00
))
Bharuch Enviro Infrastructure Limited	ı	1	ı	1	ı	I	I	ı
Others				1			<u></u>	<u></u>
e) INTEREST RECEIVABLES	0	ı	0	_	0	ı	0	_
Gharpure Engineering and Construction Private	I	1	I	Ī	1	1	I	ı
, U =								
Sinagro Produtos Agropecuarios s.A.	1 (1	ı	1 (1 (I	ı	1 (
Longreach Plant Breeders Management Services Pty Limitod)	1	ı	O)	I	ı	0
Tatva Clobal Epvironmont Drivato Limitod				C				
Jacka Giobal Elivil Office Fillyace Elifica		1	>			ı	' (' (
	1	1	I	I	ı	1	0	0
f) DEPOSITS GIVEN	1	1	ı	ı	1	1	14	14
Bharuch Enviro Infrastructure Limited	1	1	ı	1	ı	I	∞	∞
Daman Ganga Pulp and Papers Private Limited	ı	1	1	1	ı	ı	4	4
Bloom Packaging Private Limited	1	1	1	ı	ı	1	1	ı
Others	ı	1	1	1	1	ı	2	2
g) ADVANCES GIVEN	ı	ı	29	29	ı	ı	27	27
Urbania reality LLP	ı	1	29	29	ı	ı	27	27

38. Related Party Disclosures: (contd.)

c) Transactions with key management personnel of the Holding Company and their relatives

₹ In crores

Nature of Transactions	Year ended	Year ended
	March 31, 2019	March 31, 2018
Remuneration		
- Mr. Rajnikant D. Shroff	13	10
- Mr. Jaidev R. Shroff	38	13
- Mr. Vikram R. Shroff	12	8
- Mrs. Sandra R. Shroff	8	8
- Mr. Arun C. Ashar	1	3
- Mr. Kalyan Banerjee	3	1
- Others	1	4
Total	76	47
Rent paid		
- Mr. Rajnikant D. Shroff	0	0
- Mr. Jaidev R. Shroff	1	1
- Mr. Vikram R. Shroff	7	6
- Mrs. Sandra R. Shroff	0	0
Total	9	8
Professional fees		
Mr. Navin Ashar	1	0
Loan given during the year		
Mr. Anand Vora	-	0
Sundry Deposits Given		
Mr. Kalyan Banarjee	0	-
Mr. R.D.Shroff	0	-
Outstandings as at the Balance Sheet Date		
Sundry deposits given	-	2
Loan outstanding	-	0

Note

This includes short term employee benefits and key management personnel who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognied as per Ind AS19-Employee Benefits in the consolidated financial statements. As these employee benefits are lumpsum such amounts provided on the basis of actuarial valuation, the same is not included above.

2 Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

39. Segment information

(A) Primary Segment Reporting (by Business Segment)

	Portionary Segment Reporting (L	y business		-b 2010			21 1/10/6	-b 2010	- In crores
Sr.	Particulars	Λ		ch 2019	T-4-1	Λ		ch 2018	T-4-1
No.		Agro Activity	Non Agro Activity	Unallo- cated	Total	Agro Activity	Non Agro Activity	Unallo- cated	Total
1	Revenue from operations (net)								
а	External	21,147	681	9	21,837	16,917	574	15	17,506
C	Intersegment	(285)	285	-	-	(183)	183	-	_
	Total	20,862	966	9	21,837	16,734	757	15	17,506
2	Segment Results								
а	Contribution	3,564	147		3,711	3,722	66		3,788
	Intersegment profits	(53)	53			(37)	37		-
	Total Segment Results	3,511	200	-	3,711	3,685	103	-	3,788
	Less:								
	(i) Finance Costs				963				783
	(ii) Unallocable Expenditure/ Income (net)				627				544
	(iii) Share of profit/(loss) of associates and joint ventures				14				(93)
	(iv) Exceptional items (refer note no. 27)				451				63
	Total Profit before Tax				1,684				2,305
	Provision for tax								
	Current tax				442				311
	Adjustments of tax relating to earlier years				(4)				(79)
	Deferred tax				(273)				43
	Profit for the year attributable to				1,519				2,030
	Owners of the parent				1,447				2,022
	Non-controlling interest				72				8
	Other Information								
	Segment Assets	56,128	1,356	5,564	63,048	17,209	738	5,096	23,043
	Segment Liabilities	11,034	353	33,658	45,045	6,320	176	7,359	13,855
	Capital Expenditure	1,447	139	7	1,594	1,325	69	19	1,413
	Depreciation	389	37	25	451	291	27	25	343
	Amortization	441	-	77	518	267	_	65	332
	Non cash expenses other than depreciation	(38)	4	-	(34)	39	5	-	44

39. Segment information (contd.)

(B) Secondary Segment Reporting (by Geographical location of the customers)

₹ In crores

Particulars			31 Mar	ch 2019		
	India	Europe	North	Latin	ROW	Total
			America	America		
Revenue by Geographical Market	3,314	3,532	3,697	7,457	3,837	21,837
Carrying amount of Non Current Operating Assets						
(Non Current Assets for this purpose consists of	3,801	2,004	25,450	1,568	1,141	33,964
property, plant and equipment, Capital work-in-						
progress, Intangible assets, Intangible assets under						
development and other non current assets)						

₹ In crores

Particulars			31 Mar	ch 2018		
	India	Europe	North	Latin	ROW	Total
			America	America		
Revenue by Geographical Market	3,317	2,305	3,083	5,692	3,109	17,506
Carrying amount of Non Current Operating Assets						
(Non Current Assets for this purpose consists of	3,138	997	371	1,084	485	6,075
property, plant and equipment, Capital work-in-						
progress, Intangible assets, Intangible assets under						
development and other non current assets)						

- (1) The business of the Group is divided into two business segments. These segments are the basis for management control and hence form the basis for reporting. The business of each segment comprises of:
 - a) Agro Activity This is the main area of the Group's operation and includes the manufacture and marketing of conventional agrochemical products, seeds and other agricultural related products.
 - b) Non-agro Activity Non agro activities includes manufacture and marketing of industrial chemical and other non agricultural related products.
- (2) Capital expenditure consist of additions of property, plant and equipment and intangible assets.
- (3) Segment Revenue in the above segments includes sales of products net of taxes.
- (4) Inter Segment Revenue is taken as comparable third party average selling price for the year.
- (5) Segment Revenue in the geographical segments considered for disclosure are as follows:
 - a) Revenue in India includes sales to customers located within India.
 - b) Revenue in Europe includes sales to customers located within Europe.
 - c) Revenue in North America includes sales to customers located within North America.
 - d) Revenue in Latin America includes sales to customers located within Latin America.
 - e) Revenue in Rest of world includes sales to customers located other than above Geographic segments.
- (6) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.
- (7) Based on "management approach" defined under Ind AS 108 Operating Segments, the Chief Operating Decision Maker evaluates the company's performance and allocates resources based on an analysis of various performance indicators by business segments. Accordingly information has been presented along these segments

40. Acquisition of a subsidiary

On 31st January 2019, the Group acquired the entire share capital of Arysta Lifescience Inc, a global provider of innovative crop protection solutions including BioSolutions and Seed Treatment. As a result the Group obtained control of Arysta and it's subsidiaries.

For the two months ended 31st March 2019, the Group's result include a revenue of INR 1,968 crores and a profit of INR 131 crores without fair valuation adjustments pertaining to business combination of Arysta Lifescience Inc and its subsidiaries. Acquisition occurred towards the end of year and considering size and spread of business and different GAAP followed by Arysta Group, it was impracticable to calculate estimated Full year revenue and profit if it would have occurred on 1st April 2018.

A. Consideration

	₹ In crores
Consideration	31,459
Total	31,459

The consideration is subject to further adjustments as per the stock purchase agreements signed between the parties based on the level of working capital of the acquired business at the closing date. The maximum additional consideration would be INR 160 crores as required by Ind AS 103- Business Combinations.

The acquisition fulfills UPL's objective of creating an integrated patent and post patent agricultural solutions business with a global footprint. It will enable the group to offer a complete basket of solutions comprising of crop protection chemicals, bio solutions and seeds covering the entire crop value chain from planting to harvest.

B. Acquisition - related costs

The Group incurred acquisition related costs of INR 332 crore related to the acquisition of Arysta Group. These costs have been included under "Exceptional items."

C. Identifiable assets acquired and liabilities assumed

The following table summarises the recognised amounts of assets acquired and liabilities assumed at the date of acquisition.

	₹ In crores
Property,Plant and Equipment	141
Inventories	869
Intellectual Property Rights/ technology	6,045
Distribution Network/ Customer Relationships	2,289
Non compete	239
Brand	367
Current liabilities	(100)
Deferred Tax Liability	(2,831)
Contingent Liabilities on PPA	(412)
Total identifiable net assets acquired	6,606

Measurement of fair values

The valuation techniques used for measuring the fair values of material assets acquired were as follows

Assets	Valuation technique used
Acquired	
Property, Plant and Equipment	The Cost Approach relies upon the principle of substitution and recognizes that a prudent investor will pay no more for an asset than the cost to replace it anew with an identical or similar unit of
	equal utility. Replacement Cost New (RCN) is the current cost of producing or constructing a similar new item having the nearest equivalent utility as the property being valued. Under this approach, the value is determined by adjusting the replacement / reproduction cost new by the loss in value
	due to physical deterioration and obsolescence for asset (by passage of time and use of the asset), where applicable.

40. Acquisition of a subsidiary (contd.)

Assets Acquired	Valuation technique used
	Market Approach: The Market Approach, commonly referred to as the Sales Comparison Approach, measures value based on what other purchasers in the market have paid for assets that can be considered reasonably similar to those being valued. When the Market Approach is utilized, data are collected on the prices paid for reasonable comparable assets. Adjustments are made to the comparable assets to compensate for differences between those assets and the asset being valued. The application of the Market Approach results in an estimate of the price reasonably expected to be realized from the sale of the asset.
Intangible Assets	Relief-from-royalty method and multi-period excess earnings method: The relief-from-royalty method considers the discounted estimated royalty payments that are expected to be avoided as a result of the patents being owned. The multi-period excess earnings method considers the present value of net cash flows expected to be generated by the customer relationships, by excluding any cash flows related to contributory assets
Inventories	Market comparison technique: The fair value is determined based on the estimated selling price in the ordinary course of business less the estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories.

Fair values measured on a provisional basis

The Group is in process to finalise purchase price accounting for Arysta Group acquisiton. As it was occurred towards the end of year and considering size of acquisition and spread of Arysta Group business, fair valuation is provisional. It will be finalised within one year from the date of acquisiton as per Ind AS 103.

If any new information is obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, or any additional provisions that existed at the date of acquisition, then the accounting for the acquisition will be revised.

D. Goodwill

Goodwill arising from the acquisition has been recognised as follows

	Note	₹ In crores
Consideration transferred	(A)	31,459
NCI, based on their proportionate interest in the recognised amounts of the		496
assets and liabilitites of Arysta		
Net worth on date of acquisition		(10,313)
Fair value of identifiable net assets	(C)	(6,606)
		15,035

Goodwill primarily relates to revenue synergies expected from complementary product portfolio and cross selling opportunities across key markets from the business combination

41. Research and development costs

₹ In crores

Re	search and Development costs, as certified by the Management.	March 31, 2019	March 31, 2018
a)	Revenue expenses debited to appropriate heads in statement of Profit & Loss	417	334
b)	Capital Expenditure	64	69

42. Payable towards acquisition of additional stake in UPL Do Brasil

Out of the consideration payable to previous shareholders of UPL Do Brasil Industria E Comercio de insumos Agropecurios SA amounting to Rs. 121 Crores as on March 31, 2018 (Rs. 246 Crores as on 31st March'17), UPL group has settled Rs.54 Crores during the year (Rs. 125 Crores in the year ended March 31, 2018) with previous shareholders. Out of the amount payable, the amount payable within one year from the balance sheet date amounting to Rs. 2 Crores (Rs. 27 Crores in March 31, 2018) has been disclosed as current and balance amount of Rs.65 Crores (Rs. 94 Crores as on March 31, 2018) has been disclosed as non current.

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013:

New York	S Particulars	ars Name of the Entity in the Groun			31ct	31st March 2019	2019						31st Mar	31st March 2018			
Net/Assert is Share in profit Share in the charter Charter is Share in profit Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter is Share in the charter Charter Share in the charter Charter is Share in the charter Charter Share in the charter Charter is Share in the charter C	raincai				1510	≟ ⊦	6102						J ISC IVIAL	0107110			
Standard Chemical Limited 196 2596 2476 2466 2476 2			Net As total minu liab	sets i.e. assets is total ilities	Share in pro or loss		hare in other income	Share compre inco	in total ehensive ome	Net Ass total a minus liabil	ets i.e. Issets total ities	Share in	n profit oss	Share i compre inco	in other thensive ome	Share ii comprek inco	n total nensive me
UPL Unitided, Indiaed 29% 4,299 52% 746 52% 4,756 48% 96.3 46% 9 Swalf Corporation Limited 10% 10 0			%	Amount		ount		%	Amount	%	Amount	%	Amount	%	Amount		Amount
Syndfa United Chemicals Limited 196	Parent		29%	4,299		746		132%	746	52%	4,726	48%	963			46%	963
Swal Corporation United Prosphorus (circal Lippe) Where Prosphorus (circal Lippe) Oya	Indian		%0		%0			%0		%0		%00	<u> </u>			%0	
United Prosportus (India) Up	וומומו		2 6		2 6) (2 6	٥ ر	2 6		2 6				2 5	
United Phosphorus Global Lipp Opping a part of the par		Swal Corporation Limited	<u> </u>	X (X		77		8 5	77	8 3	ر ا	8 8	30			S :	20
United Prosphorus Global Lip		United Phosphorus (India) Llp	%0	36		<u></u>		7%	0	%	15	7%	33			7%	33
Apysta Lifescience Benefut Springer (Anysta Lifescience Ut Chemany) Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Ut Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany Anysta Lifescience Chemany		United Phosphorus Global Llp	%0	0	%0	ı		%0	1	%0	0	%0	ı			%0	ı
Agriert Solutions Limited Aysta alfacerience And Limited Aysta discretices India Limited Aysta discretices Endea Limited Aysta discretices Endea Limited Aysta discretices Endea Limited Aysta discretice Benefux SprI OW COW COW COW COW COW COW COW COW COW		Optima Farm Solutions Ltd	%0	40	1%	10		7%	10	%0	29	7%	20			1%	20
Arysta Lifescience India Limited Arysta Lifescience Registervice Private Limited Arysta Lifescience Registervice Private Limited Arysta Lifescience Services Limited Arysta Lifescience Services Limited Arysta Lifescience Services Limited Arysta Lifescience Services Limited Arysta Lifescience Registervice Private Limited Arysta Lifescience Life Limited Arysta Lifescience Life Limited Arysta Lifescience Life Richard Limited Arysta Lifescience Life Life Richard Limited Arysta Lifescience Life Life Richard Limited Arysta Lifescience Life Life Richard Limited Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Life Life Richard Life Arysta Lifescience Services Limited Arysta Lifescience Contact Richard Life Arysta Lifescience Contact Richard Life Arysta Lifescience Contact Richard Life Arysta Lifescience Contact Richard Life Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Limited Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Richard Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Contact Arysta Lifescience Registrations Great Britain Arysta Lifescience Registrations Great Britain Arysta Lifescience Registrations Great Britain Arysta Lifescience Registrations Great Britain Arysta Lifescience Registrations Great Britain Arysta Lifesci		Agrinet Solutions Limited	%0	M	%0	1		%0	1	%0	M	%0	1			%0	1
Arysta Lirescience Agrisen/ce Private Limited 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0		Arysta Lifescience India Limited	1%	108	%0	7		%0	2	1		1	1			1	1
Arysta Agro Private Limited Arysta Agro Private Limited Arysta Lifescience Services LIP Arysta Lifescience Courier Breelux Spril Arysta Lifescience Ougle Breelux Spril Arysta Lifescience Ougle Breelux Spril Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Br. Limited Arysta Lifescience U.K. Limited Arysta Lifescience U.K. Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Holdings Limited Arysta Lifescience U.K. Contineed Arysta Lifescience U.K. Limited Arysta Lifescience U.K. Limited Arysta Lifescience U.K. Limited Arysta Lifescience U.K. Limited Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience Contineed Arysta Lifescience U.K. Limited Arysta Lifescience Contineed Arysta Lifescie		Arvsta Lifescience Agriservice Private Limited	%0	0	%0	1		%0	ı	1		1	1			1	1
Arysta Lifescience Benelux SprI 096 0		Arvsta Aaro Private Limited	%0	0	%0	1		%0	1	1		1	1			1	1
Aysta Lifescience Benefux Spril Aysta Lifescience Benefux Spril 1967, 670 670 670 670 670 670 670 670 670 670		Arvsta Lifescience Services Llo	%0	· C	%0	- 1		%0		1		-	1			1	1
Aysta Lifescience Benelux SprI 5% 670 6% 82 15% 82 -	-oreian		%0	2	%0	0		%0	0	1		1	1			1	1
1.36% 5.25% 5.9% 5.9% 7.0%)		2%	670	%9	82		15%	82	1		ı	ı			1	ı
36% 5,258 -5% 70% 70% -12% 70% 2% 203 6% 114 5% 114 114 112 2% 3.04 4,371 5% 80 114 80 114 80 114 112 1.0		Arysta Lifescience Ougrée Production Sprl	%0	51	%0	m		1%	\mathbb{C}	1		1	1			1	1
30% 4,371 5% 80 114% 80		Upl Europe Ltd.(Formerly Known As United	-36%	(5,258)		(0/)		-12%	(70)	7%	203	%9	114			2%	114
30% 4,371 5% 80 80 14% 80		Phosphorus Limited, U.K.)				`			,								
No. 6 6 0% 1 0 0% (3) 0% (3) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Arysta Lifescience U.K. Brl Limited	30%	4,371	2%	80		14%	80	1		1	1			1	1
LS		Arysta Lifescience Uk & Ireland Ltd	%0	9	%0	<u></u>		%0	_	1		1	1			1	1
As 0% 37 2% 26 26 0% 14 0% 09 0 0% 0 0 0% 0 0 0 0% 0 0 0 0 0 0		Arysta Lifescience Global Services Limited	-3%	(446)	%0	(3)		%0	(3)	ı		ı	ı			1	ı
and 0% (0) 0% (0		Upl Deutschland Gmbh(Formerly Known As	%0	37	7%	26		2%	26	%0	14	%0	0			%0	6
9% - 0% -		United Phosphorus Gmbh - Germany)															
11 % (1) 0% (0) 0% 0		Arysta Lifescience U.K. Usd-2 Limited	%0	1	%0	1		%0	1	1		1	1			1	1
0% (1) 0% (0) 0% (0)		United Phosphorus Polska Sp.Z O.O - Poland	%0	(0)	%0	0		%0	0	%0	(0)	%0	0)			%0	0
15% (2,156) 0% (1) 0% (1)		Arysta Lifescience U.K. Jpy Limited	%0	(1)	%0	(0)		%0	0	ı		1	ı			1	1
-15% (2,156) 0% (1) 0% (1) 6 0% 36 6 0% 36 6 0% 0% 11 0 0 0 0		Arysta Lifescience U.K. Limited	%0		%0	0		%0	0	1		1	1			1	1
10% 6 0 0% 7 36 6% 36		Arysta Lifescience U.K. Holdings Limited	-15%	(2,156)	%0	(1)		%0	(1)	ı		1	1			ı	ı
20% 2,956 2% 36		Arysta Lifescience Romania Srl	%0	9	%0	_		1%	_	ı		1	ı			ı	1
0% (1) 0% (0) 0% (0) 0% (0) 0% (1) 0%		Arysta Lifescience Global Limited	20%	2,956	7%	36		%9	36	1		1	1			1	1
19% (1) 0% (0) 0% (0) - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Arysta Lifescience Switzerland Sarl	%0	1	%0	1		%0	1	1		1	1			1	1
11% 122 2% 23 1% 136 14% 23 11% 103 11% 15 19 19 19 19 19 19 19 19 19 19 19 19 19		Arysta Lifescience U.K. Cad Limited	%0	(1)	%0	0		%0	0	ı		ı	ı			1	1
-10% (1,398) -1% (9) -2% (9) - 2		Upl Benelux B.V.(Formerly Known As	1%	122	7%	23		4%	23	%	103	7%	15			%	15
-4% (588) 0% 0 0 0		Arysta Lifescience European Investments	-10%	(1,398)	-1%	(6)		-2%	(6)	ı		1	ı			ı	1
-4% (588) 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		Limited															
-21% (3,092) -6% (82) -14% (82)		Arysta Lifescience Great Britain Ltd	-4%	(288)		0		%0	0	1		1	1			1	1
%0 - %0 - %0		Arysta Lifescience U.K. Usd Limited	-21%	(3,092)		(82)		-14%	(82)	1		1	1			1	ı
		Arysta Lifescience Registrations Great Britain	%	ı	%0	1		%0	I	1		1	1			1	1

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)

New Assets i.e. to thick state in particles and seeks and seeks are in particles to the income and seeks and seeks are incomed as income and seeks are incomed as income and seeks are incomed as inc	Particulars Name of 1	Name of the Entity in the Group			33	31st March 2019	h 2019							31st Mar	31st March 2018			
total assets minus tasses and ta			Net Asse	ts i.e.	Share in p	·	Share in	-	Share in	n total	Net Ass	ets i.e.	Share ir	profit ר	Share	in other	Share	Share in total
% Amount %<			total as minus 1 liabilit	sets total ies	orlos		compreh incor		comprel inco	hensive me	total a minus liabili	sssets total ities	or le	0.55	compre	ehensive ome	compre	comprehensive income
0% (5) 0% 1 0% 1				mount		mount		Amount		Amount		Amount	%	Amount	%	Amount	%	Amount
2% 1054 0% 3 2% 220 0% - 2% 1554 0% 43 - - - - 1% 199 0% (4) - - - - 1% 199 0% (4) - - - - 7% 957 0% (6) - - - - 0% (5) 0% (0) 0% (20) 0% (1) 0% (7) 0% (0) 0% (20) 0% (1) 0% (1) 0% (0) 0% (0) 0% (1) 0% (1) 0% (0) 0% (0) 0% (1) 0% (1) 0% (0) 0% (0) 0% (1) 0% (1) 0% (0) 0% (0) 0% (1) 0% (1)	Arysta Lifescience Germany Gmbh	h	%0	(5)	%0	_			%0	_	ı		I	I			ı	'
15.6 15.9 2.6 4.1 -1.9 4.4 -2.0 0.0	Arysta Lifescience U.K. Eur Limited	p	%%	1,054	%0	7 70			% %	7	' %0	000	- %00	' Ц			' %0	' '
9%	Arvsta Lifescience Netherlands Bv		7 / %	199	%0	3 4			- 2 %	3 4	\ \ \	0 1 1	2 1) '			> '	י ר
7% 957 0% (6) -1% (6) -1% (7) -1% (7) -1% (7) -1% (7) -1%	Blue Star B.V.		%0	1	%0	0			%0	() ()	%0	0	%0	(1)			%0	<u> </u>
46% (6,734) -8% (119) -21% (119) 0% (20) 0% (1) 2% 290 6% 89 16% 89 -3% (279) 0% (1) 0% (0) 0% (0) 0% (0) 0% (0) 0% (1) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0% (0) 0% (0) 0% (27) 0% (0) 0%	Macdermid Agricultural Solutions Holdings Bv	Holdings Bv	7%	957		(9)			-1%	(9)	ı		1	. 1			1	'
2% 52 0% (0) 0% (0) -	United Phosphorus Holdings Cooperatief U.A.	peratief U.A	-46%	6,734)		(119)			-21%	(119)	%0	(20)	%0	(1)			%0	<u></u>
2% 290 6% 89 16% 89 -3% (279) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 12% 1,785 1% 11 -2% (1) -1% (0) 0% (0) 0% (27) -1% (15) -1% (14) -1% (29) -1% (17) -2% (297) -1% (15) -3% (14) -1% (17) -1 -2% (297) -3% (296) -1% (17) -1 -2% (297) -3% (24) -4% (24) -4% (24) -4% (24) -4% (24) -6% 588 0% (3) 0% 55 -1% (14) -1 -2% (24) -4% (24) -6% 588 0% (3) 0% 55 -1% 13 -2 -2 <t< td=""><td>Macdermid Agricultural Solutions Netherlands Cooperatief Ua</td><td></td><td>%0</td><td>52</td><td>%0</td><td>(0)</td><td></td><td></td><td>%0</td><td>(0)</td><td>1</td><td></td><td>1</td><td>1</td><td></td><td></td><td>1</td><td>'</td></t<>	Macdermid Agricultural Solutions Netherlands Cooperatief Ua		%0	52	%0	(0)			%0	(0)	1		1	1			1	'
0% (1) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0% (0) 0%	United Phosphorus Holdings B.V., Netherlands		2%	290	%9	88			16%	89	-3%	(279)	%0	(0)			%0	0
12% (0) 0% (0) 0% (0) 0% (0) 0% (0) 12% 1,785 1% 11 2% 11 -<	Arysta Lifescience Technology Bv		%0	_	%0	(0)			%0	(0)	ı		ı	ı			ı	'
12% 1,785 1% 11 2% 11 -3% 10 -3% 11 -3% 11 -3% 11 -3% 11 -3% 11 -3% 11 -3% 14 -1%	Decco Worldwide Post-Harvest Holdings Cooperatief U.A.	Idings	%0	(0)	%0	(0)			%0	(0)	%0	(0)	%0	(0)			%0	9
0% (57) 0% (4) -1% (4) -1% (62) 0% 2 -2% (297) -1% (15) -3% (15) -3% (296) -1% (17) -7% (991) -2% (24) -4% (24) -6% (561) 2% 43 4% 552 -1% (14) -3% (14) 6% 58 0% (3) 0% 55 1% 13 2% 13 1% 48 0% (3) 0% 6 0% 3 0% 3 0% 6 - </td <td>Dutch Agricultural Formations Cv</td> <td></td> <td>12%</td> <td>1,785</td> <td>1%</td> <td></td> <td></td> <td></td> <td>7%</td> <td></td> <td>ı</td> <td></td> <td>1</td> <td>1</td> <td></td> <td></td> <td>1</td> <td>'</td>	Dutch Agricultural Formations Cv		12%	1,785	1%				7%		ı		1	1			1	'
0% - 0% -	Decco Worldwide Post-Harvest Holdings B.V.	Idings B.V.	%0	(57)	%0	(4)			-1%	(4)	-1%	(62)	%0	2			%0	2
-2% (297) -1% (15) -3% (15) -3% (17) -7% (991) -2% (24) -4% (24) -6% (561) 2% 43 0% 552 -1% (14) -3% (14) -6% (561) 2% 43 0% 552 -1% (14) -3% (14) -6% 588 0% 43 0% 65 0% 3 0% 13 1% 48 0% 6 0% 0 0 0% 0 0 0 - - - - 0% 0 0 0 0 0 -	Netherlands Agricultural Technologies Cv	gies Cv	%0	1	%0	1			%0	ı	1		1	1			'	
-7% (991) -2% (24) -4% (24) -6% (561) 2% 4% 552 -1% (14) -3% (14) 6% 588 0% 0% 55 1% 13 2% 13 6 0% 0% 0% 6 0% 3 0% 0 - - - 0% 7 0% 3 1% 3 - - - 0% 7 0% 3 0% 0 0 - - - 0% 7 0% 2 0% 0 -	United Phosphorus Holding, Brazil B.V.	B.V.	-5%	(297)	-1%	(15)			-3%	(15)	-3%	(562)	-1%	(17)			-1%	-17
4% 552 -1% (14) -3% (14) 6% 588 0% 0% 59 1% 13 2% 13 1% 48 0% 0% 65 0% 3 0% 0 0 - - 0% 7 0% 3 1% 3 - - - 0% 7 0% 3 1% 3 - - - 0% 7 0% 2 0% 0 0 - - - 0% 6 0% 2 0% 0 0 - <td>Advanta Holdings Bv, Netherland</td> <td></td> <td>-2%</td> <td>(166)</td> <td>-2%</td> <td>(24)</td> <td></td> <td></td> <td>-4%</td> <td>(24)</td> <td>%9-</td> <td>(261)</td> <td>7%</td> <td>43</td> <td></td> <td></td> <td>2%</td> <td>43</td>	Advanta Holdings Bv, Netherland		-2%	(166)	-2%	(24)			-4%	(24)	%9-	(261)	7%	43			2%	43
0% 59 1% 13 2% 13 1% 48 0% 0% 65 0% 3 0% 0 -	Advanta Netherlands Holdings Bv,Netherlands		84	252	-1%	(14)			-3%	(14)	%9	200	%0	(3)			%0	ή
0% 65 0% 3 -	Upl Italia S.R.L.(Formerly Known As Cerexagri	Cerexagri	%0	59	7%	13			2%	13	7%	48	%0	9			%0	9
0% 13 0% 0 0 0 0 0 0 0% 13 0% 3 1% 3 - - - 0% 6 0% 2 0% 2 - - 1% 81 0% 4 1% 4 - - 0% (5) 0% (0) 0 0 - - 0% 38 0% 4 1% 4 - - 1% 105 1% 17 3% 17 1% 2% 308 1% 12 2% 12 3% 307 2% 0% 37 0% 1 0% 1 0% 1 0% 37 0% 1 0% 1 0% 0% 1 0% 1 0% 1 0% 0% 1 0% 0 0 0 - -	Italia S.K.L.) Anvsta I ifescience Italia Srl		%0	7.7	%0	~			%0	(°	1		'	-			1	'
0% 7 0% 3 1% 3 -	Macdermid Adricultural Solutions Italy Srl	taly Srl	%0	, (%) C			2 %) (
1% 81 0% (4) -1% (4) 1% 88 0% 0% (5) 0% (0) -1% (4) 1% 88 0% 0% 38 0% 4 1% 4 - - - 1% 105 1% 17 3% 17 1% 92 1% -1% (76) 2% 24 4% 24 -1% (104) 0% 2% 37 0% 7 1% 7 0% 307 2% 0% 37 0% 7 1% 7 0% 31 0% 0% - 0% 0 0 0 - - -	Arvsta Lifescience Bulgaria Eood		%0	2	%0	m			% %	m	ı		I	ı			ı	, i
1% 81 0% (4) -1% (4) 1% 88 0% 0% (5) 0% (0) -	Arysta Lifescience Hellas S.A. Plant Protection,	Protection		9	%0	7			%0	2	1		ı	1			1	'
1% 81 0% (4) -1% (4) 1% 88 0% 0% (5) 0% (0) -	Nutrition And Other Related Products And Services	ıcts And																
0% (5) 0% (0) 0% (0) -	Upl Iberia, Sociedad Anonima		1%	8	%0	(4)			-1%	(4)	1%	∞ ∞	%0	0			%0	0
0% 38 0% 4 1% 4 - - - - - 1% 17 1% 92 1% -1% (76) 2% 24 4% 24 -1% (104) 0% 2% 308 1% 12 2% 12 3% 307 2% 0% 37 0% 7 1% 7 0% 31 0% 0% - 0% 0 0% 0 - -	Santamix Iberica SI		%0	(5)	%0	0			%0	0	1		1	1				
1% 105 1% 17 3% 17 1% 92 1% -1% (76) 2% 24 4% 24 -1% (104) 0% 0% 37 0% 7 1% 7 0% 31 0% 0% - 0% 1 0% 1 - - 0% - 0% 0 0% 0 - -	Arysta Lifescience Iberia Slu		%0	38	%0	4			1%	4	1		1	1			1	'
(76) 2% 24 4% 24 -1% (104) 0% 308 1% 12 2% 12 3% 307 2% 37 0% 7 0% 31 0% - 0% 1 0% 31 0% - 0% 0 0% 0 -	Decco Iberica Postcosecha, S.A.U., Spain (Formerly Cerexagni Iberica)	, Spain	1%	105	7%	17			3%	17	1%	92	1%	13			1%	13
308 1% 12 2% 12 3% 307 2% 31 0% 31 0% 1 - 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Transterra Invest, S. L. U., Spain		-1%	(76)	2%	24			4%	24	-1%	(104)	%0	4			%0	4
37 0% 7 1% 7 0% 31 0% - 0% 1 - - - - 0% 0 - -	Cerexagri S.A.S.		7%	308	1%	12			7%	12	3%	307	7%	45			2%	45
- 0% 1 - 0% 1 0.0% 1 0.0% 1 0.0% 1 0.0% 1	Neo-Fog S.A.		%0	37	%0	_			1%	7	%0	31	%0	M			%0	M
- 0 %0 0 960 -	Veto-Pharma Sa		%0	I	%0	_			%0	_	ı		1	1			1	
	Wyjolab S.A.		%0	1	%0	0			%0	0	1		1	1			1	

Notes to Consolidated Financial Statements for the year ended March 31, 2019

	H
<u></u>	
ltd	
0	
9	
$\tilde{\omega}$	
9	
7	
T,	
ď	
S	
nies	
ā	
은	
n	
ŭ	
Φ	
드	
4	
I 0	
目	
Φ	
3	
ed	
ج	
S	
0	
ant t	
sua	
y,	
jū	
7	١
Ī	
ne	
e	
at	
St	
-	
:5	
Ē	
L	
ted financia	
D	
Ħ	
d	
=	
S	
0	
Ü	
5	
-	
ė	
÷	
9	
ē	
ō	
ati	
Ĕ	
Z	
¥	
Ï	

Mark Assets Lange Transfer	U	nach naitace	Nome of the Entity is the			1010	, dozela	0100						70 V V V V	0100 42			
Marchelle Marc	_	Particulars	Name of the Entity In the Group			315	c March .	2019				-		s ist iviar	cn 2018			
10 10 10 10 10 10 10 10	<u> </u>				ets i.e. issets total ities	Share in proor loss		nare in other mprehensive income	Share i comprel inco	n total nensive me	Net Asse total as minus	ets i.e. ssets total ties	Share in or lo	profit ss	Share in other comprehensive income		Share in total comprehensive income	n total nensive me
1.6 1.04 2.96 2.3 2.9 2.				%	Amount					Amount		Amount		Amount		Amount	%	Amount
10% 1,455 2% 35			Upl France(Formerly Known As As Pen Sas)	1%	104	2%	23		4%	23	1%	98	%0	(5)			%0	-5
1.1 (76) 096 (3) -146 (3) -146 (3) -176			Arysta Lifescience S.A.S.	10%	1,455	7%	35		%9	35	ı		ı	ı			1	1
1. 0% 4 1 0% 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			Arysta Lifescience France Sas	-1%	(2/2)	%0	(3)		-1%	(3)	1		1	1			1	1
1,000 1,00			United Phosphorus Switzerland Limited.	%0	_	%0	0		%0	0	%0	_	%0	0			%0	0
1-36 (375) (386) (487) (488)			Agrodan, Aps	%0	C	%0	0		%0	0	%0	M	%0	4			%0	4-
1,0% 4,8 0,9% 4, 1,9% 1,9			Platform Sales Suisse Gmbh	-3%	(375)	_	(38)		-7%	(38)	1		1	1			1	1
1.9% 4.8% -1.9%			Decco Italia Srl,Italy	%0	48		4		1%	4	1%	48	%0	4			%0	4
1-3% (485) -19% (8)			Natural Plant Protection S.A.S.	%0	50	%0	<u></u>		%0	_	ı		ı	ı			ı	1
196 (66) 096 (1) 096			Arysta Lifescience Holdings France Sas	-3%	(485)	-1%	(8)		-1%	(8)	1		1	1			1	1
146 130 146 15 15 15 15 15 15 15 1			Goëmar Développement Sas	%0	(99)	%0	(1)		%0	(E)	1		1	1			1	1
Fig. 148 096 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			Laboratoires Goëmar Sas	1%	130	1%	15		3%	15	1		ı	ı			ı	1
1			Arysta Animal Health Sas	1%	148	%0	_		%0	_	1		1	1			1	1
19			Betel Reunion S.A.	%0	4	%0	(0)		%0	0	1		1	1			1	1
Incrive the control of the control o			Arysta Lifescience Europe Sarl	%0	0	%0	(0)		%0	0	1		1	1			1	1
ssia) 0% 12 0% 3 1 1% 3 0% 10			Ppwj Sci	%0	<u></u>	%0	0		%0	0	1		ı	ı			ı	1
seia) 6			Limited Liability Company "Upl" (Formerly	%0	12	%0	m		1%	\sim	%0	10	%0	_			%0	<u></u>
0% 22 0% 4 1% 4 - <td></td> <td></td> <td> Cisc United Phosphorus Limited, Russia)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>			Cisc United Phosphorus Limited, Russia)															
0% 42 0% 7 1% 7 - - 0% 00 - 0% 00 0			Arysta Lifescience Czech S.R.O.		22	%0	4		1%	4	ı		ı	1			ı	ı
0% (2) 0% (2) 0% (2) 0% (2) 0% (2) 0% 0 0% 0			Arysta Lifescience Magyarorszag Kft.	%0	42	%0	7		1%	7	ı		1	1			1	1
0% (20) 0% (1) 0% (1) - <td< td=""><td></td><td></td><td>Advanta Seeds Ukraine Llc</td><td>%0</td><td>4</td><td>%0</td><td>(2)</td><td></td><td>%0</td><td>(2)</td><td>%0</td><td>0</td><td>%0</td><td>1</td><td></td><td></td><td>%0</td><td>1</td></td<>			Advanta Seeds Ukraine Llc	%0	4	%0	(2)		%0	(2)	%0	0	%0	1			%0	1
1% 74 0% 5 1% 5 - <td></td> <td></td> <td>Arysta Lifescience Vostok Ltd.</td> <td></td> <td>(20)</td> <td>%0</td> <td>(1)</td> <td></td> <td>%0</td> <td>(1)</td> <td>1</td> <td></td> <td>1</td> <td>1</td> <td></td> <td></td> <td>1</td> <td>1</td>			Arysta Lifescience Vostok Ltd.		(20)	%0	(1)		%0	(1)	1		1	1			1	1
1% 116 1% 17 3% 17 -<			Arysta Lifescience Polska Sp. Z.O.O	1%	74	%0	2		1%	2	1		ı	ı			ı	ı
0% (0) 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0 0% 0 0 0% 0 <			Arysta Lifescience Rus Llc	1%	116	1%	17		3%	17	1		1	1			1	1
0% - 0% -			Decco Portugal Post Harvest Lda		0	%0	0		%0	0	%0	0	%0	0			%0	0
0% - 0% -			Agripraza Ltda.	%0	ı	%0	I		%0	I	1		ı	ı			ı	1
0% 4 0% 2 0% 2 -			Agriphar Poland Sp. Zoo	%0	1	%0	1		%0	I	ı		ı	1			ı	1
0% 28 1% 18 3% 18 - </td <td></td> <td></td> <td>Arysta Lifescience Slovakia S.R.O.</td> <td>%0</td> <td>4</td> <td>%0</td> <td>7</td> <td></td> <td>%0</td> <td>2</td> <td>ı</td> <td></td> <td>ı</td> <td>ı</td> <td></td> <td></td> <td>ı</td> <td>ı</td>			Arysta Lifescience Slovakia S.R.O.	%0	4	%0	7		%0	2	ı		ı	ı			ı	ı
0% 0% 0 0% - 0 0% 0 0 0 0 0 0 0 0 0 0 0			Arysta Lifescience Ukraine Llc	%0	28	1%	<u>∞</u>		3%	18	1		1	1			1	1
15% (2,225) 4% 60 11% 60 -9% (857) 3% (857) 60 60 60 60 60 60 60 60 60 60 60 60 60			Arysta Lifescience Kiev Llc	%0	0	%0	1		%0	I	ı		ı	1			ı	1
100 (Us) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			United Phosphorus Inc., U.S.A.	-15%	(2,225)	4%	09		11%	09	%6-	(857)	3%	57			3%	57
3% 369 0% 2 0 0% 2 19 19 19 19 19 19 19 19 19 19 19 19 19			Upi Finance Llc	%0	0	%0	0		%0	0	%0	0	%0	0			%0	0
t Inc (Us) 0% (26) -1% (16) -3% (16) 0% (10) -1% (10) 0% (10) 0% 45 1% 8 1% 8 1% 8 1% 54 1% 54 1% 0% (24) 0% (27) 0% (27) 1% 87 2% (27) 1% 84 0% 157% 230 2% 266 11% 21 82% (462) -82% (462) -82% (462) -3			Cerexagri, Inc. (Pa),Usa	3%	369		2		%0	2	4%	358	1%	12			1%	12
The (Us) 0% 45 1% 8 1% 8 1% 54 1% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%			Upl Delaware, Inc.,Usa	%0	(56)		(16)		-3%	(16)	%0	(10)	-1%	(14)			-1%	-14
t. Inc (Us) 0% 70 -2% (36) -6% (36) 1% 99 1% 0 0% (2.4) 0% (2.4) 0% (0) 0% (2.2) -1% (3.6) 1% 0.0% (3.5) 1% 0.0% (Canegrass Llc, Usa	%0	45		∞		1%	∞	1%	54	1%	21			%	21
nc.Bhamas			Decco Us Post-Harvest Inc (Us)	%0	70		(36)		%9-	(36)	7%	66	1%	16			%	16
nc.Bhamas 19% 23,036 -32% (462) -5% (27) 1% 84 0% 24 24 24 24 24 24 24 25 24 24 24 25 24 24 24 25 24 25 24 25 24 25 25 25 25 25 25 25 25 25 25 25 25 25			Essentiv Lcc (50%)	%0	(24)	_	(0)		%0	0)	%0	(22)	-1%	(14)			-1%	41-
nc.Bhamas 2% 266 1% 21 4% 21 3% 230 2% 26. 157% 23,036 -32% (462) -82% (462) -92% (300) -92% -92% (300) -92% (Riceco Llc,Usa	7%	87	_	(27)		-2%	(27)		84		(3)			%0	φ.
157% 23,036 -32% (462) -82%			Riceco International, Inc.Bhamas	7%	266		21		4%	21	3%	230	7%	42			7%	42
	_		Arysta Lifescience Inc.	157%	23,036		(62)		-82%	(462)	ı		ı	ı			1	ı

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)

- 1-		N			Č	4	0						-	0.00			ווו כוסועמ
	Particulars	Name of the Entity in the Group			31	31St March 2019	2019						3 IST March 20 IS	cn 2018			
2			Net Assets i.e. total assets minus total liabilities	ets i.e. ssets total ties	Share in profit or loss		Share in other comprehensive income	Share	Share in total comprehensive income	Net Assets i.e. total assets minus total liabilities	sets i.e. assets total ities	Share in profit or loss	n profit	Share in other comprehensive income	Share in other comprehensive income	Share in total comprehensive income	n total nensive me
			%	Amount	% An	Amount	% Amount	%	Amount	%	Amount	%	Amount	%	Amount	%	Amount
		Arysta Lifescience Management Company, Llc	-1%	(163)	-3%	(41)		-7%	(41)	ı		1	1			1	1
		Arysta Lifescience Spc, Llc	%0	ı	%0	ı		%0	ı	ı		ı	ı			ı	1
		Arysta Lifescience America Inc.	%0	29	%0	_		%0	_	1		1	1			ı	1
		Arvesta Corporation	%0	1	%0	1		%0	1	1		1	1			1	1
		Advanta Us, Llc (Foremerly Known As	%0	(6)	-3%	(48)		%6-	(48)	%0	37	-4%	(83)			-4%	-83
		Advanta Us Inc,Usa)															
		Arysta Lifescience Canada, Inc.	%6	1,359	1%			7%		1		1	1			1	1
		Arysta Lifescience Canada Bc Inc.	7%	972	%0	7		%0	2	ı		ı	ı			ı	1
		Arysta Lifescience North America, Llc	-10%	(1,397)	-1%	(12)		-2%	(12)	1		ı	ı			1	1
		Arysta Lifescience Na Holding Llc	3%	410	%0	M		1%	\mathbb{C}	1		ı	ı			1	1
		Gbm Usa Llc	%0	(8)	%0	1		%0	1	1		1	1			1	1
		Dutch Agricultural Investment Partners Llc	%0	ı	%0	1		%0	ı	1		ı	ı			1	1
		Netherlands Agricultural Investment	%0	10	%0	_		%0	_	1		1	1			1	1
		Partners Llc															
		Arysta Lifescience Investments Llc	%0	2	%0	0		%0	(0)	ı		1	1			ı	1
		Upl Corporation Limited, Mauritius	-41%	(6,015)	12%	177		31%	177	-23%	(2,118)	%8-	(164)			%8-	-164
		Upl Limited	%0	1	%0	1		%0	1	%0	1	20%	403			19%	403
		Upl Management Dmcc	1%	157	7%	27		2%	27	1%	123	1%	26			1%	26
		Upl Limited Mauritius	3%	475	13%	186		33%	186	3%	255	%6	187			%6	187
		Advanta Seeds International, Mauritius	2%	758	%9	89		16%	89	%9	585	4%	75			4%	75
		Advanta Seeds Dmcc [Formerly Advanta	1%	155	%0	(5)		-1%	(5)	7%	151	%0	(6)			%0	6-
		Seeds Jlt], Uae															
		Upl Limited, Gibraltor (Formerly Known As	20%	2,953	37%	537		95%	537	25%	2,340	14%	290			14%	290
		Uniphos Limited, Gibraltor)															
		Arysta Lifescience (Mauritius) Ltd	7%	238	%	<u></u>		7%	73	1		1	1			1	1
		Upl Agro Sa De Cv.(Formerly Known As United	%0	(23)	%0	<u> </u>		-1%		%0	(12)	%0	(3)			%0	ή
		Phosphorus De Mexico, S.A. De C.V.)	ò	1	Š	Ś		5	Ć								
		Arysta Lirescience Mexico, s.A. De C.V	% ; % ;	9/7	<u></u>	(X)		<u> </u>	(X)	1		1	1			1	1
		Arysta Litescience Mexico Holding S.A.De C.V	 % O	(3)	 % 0	0		% 0	0	1		ı	ı			1	1
		Decco Postharvest Mexico (Formerly Known As Decro lifkins Mexico Sani)	% 0	(12)	% 0	<u>4</u>		-1%	(4)	%0	8	%0	(2)			%0	-5
		Bioenzymas S.A. De C.V.	%0	1)	%0			%0	C	1		1	'			1	1
		Decarrollos Inmohiliarios Alianza De Coahiila	2 %	7 0	2 %) (8 6	9 (ı		1	1			1	1
		S.A. De C.V.	2)	2	2		5	9			ı					
		Grupo Bioquimico Mexicano, S.A. De C.V.	7%	313	1%	10		2%	10	1		1	1			ı	1
		Agroquimicos Y Semillas, S.A. De C.V.	%0	16	%0	0		%0	0	1		1	ı			1	1
		Omega Agroindustrial, S.A. De C.V.	%0	0	%0	(3)		%0	(3)	1		1	1			1	•
		Servicios Agricolas Mundiales Sa De Cv	%0	00	%0	, 7		%0	, , , , ,	1		1	1			1	1
		Tecno Extractos Vegetales, S.A. De C.V.	1%	66	%0	_		%0	_	ı		ı	ı			ı	ı

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)

Particulars Name of the Entity in the Group				0	3 I St March 20 I 9	או 100 נ						7	SISCIMALCII ZUIB	20712			
	Net /	Net Assets i.e. total assets		Share in profit or loss		Share in other comprehensive		Share in total comprehensive		Net Assets i.e. total assets		Share in profit or loss	profit ss	Share i	Share in other comprehensive	Share in total comprehensive	n total hensive
	ail la	minus total liabilities	a			Income	ข	Income	o l	minus total liabilities	otal es			IDCI	Income	псоте	ше
	%	Am	Amount	% An	Amount	% Am	Amount		Amount	% A	Amount	d %	Amount	%	Amount	%	Amount
Tesaurus Mexico S.A. De C.V.	%0	%	0	%0	1			%0	1	ı		1	1			1	1
Advanta Commercio De Sementes Ltda,Brazil		%	(95)	-3%	(46)			%8-	(46)	-2%	(217)	-4%	(83)			-4%	-83
Perrey Participações S.A	%0		_	%0	0			%0	(0)	%0	∞	%0	1			%0	1
Uniphos Industria E Comercio De Produtos	odutos 0%	%	12	%	19			3%	19	7%	140	1%	_			1%	
Quimicos Ltda.																	
United Phosphorus Indústria E Comércio de	0	%	1	%0	1		-	%0	1	%0	(13)	%0	ı			%0	1
Produtos Químicos Ltda.																	
Upl Do Brasil - Industria E Comércio De	φ	(1),	(1,100)	13%	194			34%	194	13%	1,159	3%	52			2%	52
Insumos Agropecuários S.A.																	
Volcano Agrociencia Industria E Comercio De	0	%	7	%0	(0)			%0	(0)	1		1	1			1	1
Defensivos Agricolas Ltda																	
Arysta Lifescience Centroamerica, S.A.	A. 0%		1	%0	1			%0	ı	ı		1	ı			ı	ı
Arysta Lifescience De Guatemala, S.A.	%0	%	0	%0	0			%0	(0)	1		1	1			1	1
Industrias Agriphar Sa	%0	%	1	%0	1			%0	ı	ı		ı	1			ı	ı
Arysta Lifescience Corporation Republica	blica 0%	%	ı	%0	1		-	%0	ı	ı		1	1			1	1
Dominicana, Srl																	
Grupo Bioquimico Mexicano Republica Dominicana Sa	0	%	1	%0	1			%0	1	1		1	1			ı	1
Upl Costa Rica S.A.	%0		(20)	%0	(1)			%0	(1)	%0	(56)	-1%	(12)			-1%	-12
Arysta Lifescience S.R.L.	%0	%	40	%0	(E)			%0	Ξ	1	,	1	, 1			1	1
Upl Bolivia S.A	%0		(13)	%0	(-1%		%0	(1)	%0	(1)			%0	
Upl Paraguay S.A.	%0		(9)	%0	4			1%	4	%0	(9)	%0	4			%0	4
Arysta Lifescience Paraguay S.R.L.	%0	%	20	%0	_			%0	_	1		1	1			1	1
Arvesta Paraguay S.A.	%0	%	1	%0	1			%0	1	1		1	ı			1	1
Dva Technology Argentina S.A.	%0	%	1	%0	0			%0	0	%0	0	%0	ı			%0	ı
Icona Sanluis S A - Argentina	%0		(24)	%0	(9)			-1%	(9)	%0	(18)	%0	(5)			%0	<u>-</u> 5
Advanta Semillas Saic, Argentina	%0	%	(22)	-2%	(22)			-4%	(22)	%0	~	-1%	(53)			-1%	-29
Arysta Lifescience Costa Rica Sa.	%0		(1)	%0	0			%0	0	ı		1	1			ı	1
Agriphar De Costa Rica Sa	_	<u>~</u>	1	%0	1			%0	ı	1		1	ı			ı	1
Arysta Agroquimicos Y Fertilzantes Uruguay	ruguay 0%	%	1	%0	1			%0	1	1		ı	ı			ı	1
Sa																	
Arysta Lifescience Ecuador S.A.	%0	%	ı	%0	ı			%0	ı	ı		ı	ı			ı	ı
Arysta-Lifescience Ecuador S.A.	0		10		(1)			%0	(1)	1		ı	ı			ı	1
Upl Argentina S A (Formerly Known As Icona S A - Argentina)	vs Icona -2%		(235)	15%	(220)		``i'	39%	(220)	%	(45)	-4%	(80)			-4%	-80
Arysta Lifescience Argentina S.A.	7%	%	178	-1%	(13)			-2%	(13)	1		1	1			1	1
Decco Chile Spa	%0	%	10	%				1%		%0	12	%0	9			%0	9
Arysta Lifescience Chile S.A.	2%		300	%0	m			1%	m	ı		ı	1			ı	1
((((((((((((((((((((200	700	C	700				700	C								

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)

	4 9	Share in total comprehensive income	Amount	ı	<u>о</u> -	1	1	14	M	10				0		1	4	0	ı	16	1	1	<u></u>		ı	1	80	ı	o o	1	1	4	C) <u>{</u>	0	1 (97
	30	Share in total comprehensiv income	%	I	%0	I	1	1%	%0	%0				%0		1	%0	%0	-	1%	ı	1	%0		I	1	4%	ı	%0	1	ı	%0	200	% 6	8	1 0	<u>\$</u>
	40	Share in other comprehensive income	Amount																																		
31st March 2018	010210	Share I compre inc	%																																		
31st Ma	ייים ייים	Share in profit or loss	Amount	1	(6)	1	1	14		10		' '		0		1	4	0		16	1	1	$\overline{}$		ı	1	80	ı	0	1	1	4	(9 5	0	1 (97
	3	snare in pr or loss	%	I	%0	ı	1	1%	%0	%0		1 1		%0		1	%0	%0		1%	ı	1	%0		I	1	4%	ı	%0	1	1	%0	700	% ~	8	1 0	8
		ets I.e. ssets total ities	Amount		12			29	15	25				∞			17	2		207			M				334		4			\sim		(4)		(96
	10 V +0 IV	Net Assets I.e. total assets minus total liabilities	%	I	%0	I	1	1%	%0	%0		1 1		%0		1	%0	%0	1	7%	I	1	%0		I	ı	4%	ı	%0	1	ı	%0	700	% % O O	% >	1 0	%7
		are in total prehensive income	Amount	29	(12)	(1)	. 1	(12)	2	7	V) '		_		_	(5)	0	(3)	47	0	0	(2)		_	(1)	108	0	10	(2)	1	(4)	ر	7 ⊔	n ((1)	77
		Share in total comprehensive income	%	2%	-2%	%0	%0	-2%	%0	7%	10%	8 %)	%0		%0	-1%	%0	-1%	%	%0	%0	%0		%0	%0	19%	%0	7%	%0	%0	-1%	700	% %		% ?	4 %
	, d+0	Share in other comprehensive income	Amount																																		
31st March 2019	2021	share compre inc	%																																		
S1st Ma	ייים איז	Share in profit or loss	Amount	29	(12)	(1)	,	(12)	2		9) '		_		_	(5)	0	(3)	47	0	0	(2)		_	=======================================	108	0	10	(2)	1	4		7 1		(E)	77
	40	share	%	7%	-1%	%0	%0	-1%	%0	%0	700	%		%0		%0	%0	%0	%0	3%	%0	%0	%0		%0	%	7%	%0	1%	%0	%0	%0	700	% 6	8 6	% 6	% 7
		r Assets I.e. tal assets inus total iabilities	Amount	006	_	116	1	51	~	32	70	0 '		\mathbb{C}		47	10	5	30	248	2	7	_		(1)	24	458	67	4	51	4	0	(7)	(7)	(9)	78	730
		Net Assets I.e total assets minus total liabilities	%	%9	%0	1%	%0	%0	%0	%0	10%	%-0)	%0		%0	%0	%0	%0	7%	%0	%0	%0		%0	%0	3%	%0	%0	%0	%0	%0	700	% % O O	% ? 6 0	% %	%7
Name of the Entity in the Groun				Arysta Lifescience Do Brasil Indústria Química E Agropecuária Sa	Upl Colombia Sas(Foremerly Known As Evofarms Colombia Sa)	Arysta Lifescience Colombia S.A.S	Agriphar De Colombia Sas	United Phosphorus Cayman Limited	Up Aviation Limited, Cayman Island	Upl Australia Limited (Formerly Known As	Arveta Liferciano Australia Day 140	Macdermid Adricultural Solutions Australia	Pty Ltd	Upl New Zealand Limited (Formerly Known As	United Phosphorus Limited, New Zealand)	Etec Crop Solutions Limited	Upl Shanghai Ltd (Formerly Known As United Phosphorus (Shanghai) (Ompany Limited)	Upl liagnsu Limited	Arvsta Lifescience (Shandhai) Co. Ltd	Advanta Seeds Ptv Ltd,Australia	Macdermid (Nanjing) Chemical Ltd.	Macdermid (Shanghai) Chemical Ltd.	Upl Limited Korea Co.Ltd. (Formerly Known	As United Phosphorus (Korea) Limited)	Arysta Lifescience Korea Ltd.	Arysta Lifescience Pakistan (Pvt.) Ltd.	Pacific Seeds (Thai) Ltd, Thailand	Myanmar Arysta Lifescience Co., Ltd.	Pacific Seeds Holdings (Thai) Ltd, Thailand	Arysta Lifescience (Thailand) Co., Ltd.	Chemtura (Thailand) Ltd	Pt.Upl Indonesia (Formerly Known As Pt.	United Phosphorus Indonesia)	Pt Catur Agrodaya Mahuni, Indonesia D+ Advanta Condo Indonesia	Pt. Advanta Seeds Indonesia	Pt. Arysta Litescience Tirta Indonesia	Upi Limited, Hong Kong(Formerly Known As United Phosphorus Limited, Hongkong)
S Particulars		0 Z																																			

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Inform	43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)	nancial sta	temen	t purs	uant	to Sch	edule	III of	The C	ompar	ies Act	, 2013: (contd.)	₹ In crores	ores
S. Particulars	S. Particulars Name of the Entity in the Group			31st March 2019	:h 2019						31st Ma	31st March 2018			
° N		Net Assets i.e. Share in profit Share in other Share in total stresses or loss comprehensive comprehensive nincome liabilities	Share in or le	oss	Share in oth comprehens income	Share in other comprehensive income	Share in tor comprehens income		let Assets i.e total assets minus total liabilities	e. Sha	are in profit or loss	Net Assets i.e. Share in profit Share in other total assets or loss comprehensive comprehensive minus total liabilities	other ensive c	Share in other Share in total comprehensive income income	otal Sive
		% Amount		% Amount % Amount % Amount	%	Amount	% Ar		% Am	unt %	Amount	% Amount % Amount % Amount % Amount	mount	% Am	ount
	Upl Philippines Inc. (Formerly Known As	0%	1%	10			7%	10 0%	%0	(1)	(2) %0			%0	
	United Phosphorus Corp. Philippines)														

31st March 2019 Share in profit Share in other Share in total Net Assets i.e. Share in profit Share in other Share in total Share in other Sha	comprehensive comprehensive total assets or loss comprehensive comprehensive income income income income	Amount % Amount % Amount % Amount %	2% 10 0% (1) 0% (7) 0%		4% 24 1% 79 1% 21		- 0% 2 0% (0) 0%					1% 103 0% (1) 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	D '		2 -1% (15)		9 0% (1) 0%	1	1	%0 (3) 0%	1	0% (1) 0%		1	1	1 1	1	1	1
31st March 2019 Share in profit Share in other Share in total Net Assets i.e. Share in profit Comprehensive Compr	comprehensive total assets or loss income minus total liabilities	% Amount % Amount % Amount %	10 0% (1) 0%	- 20	6/ 1/0/ 1/2	- 14	2 0%			1 1	()	103 0%	%O 07	1 0%	-1%		%0	1	1	_				1			1	1	1
31st March 2019 Share in profit Share in other Share in total Net Assets i.e. Share in profit Comprehensive Compr	comprehensive total assets or loss income minus total liabilities	% Amount % Amount	10 0% (1) 0%	- 20	6/ 1/0/ 1/2	- 14	2 0%			1 1	()	103 0%	%O 07	1 0%	-1%		%0	1	1	_				ı			1	1	1
Share in profit Share in other Share in total Net Assets i.e. Share in or lose comprehensive compr	comprehensive total assets income minus total liabilities	% Amount % Amount %	10 0% (1) 0%	- 20	6/ 1/0/ 1/2	- 14	2 0%			1 1	()	103 0%	%O 07	1 0%	-1%		%0	1	ı	_				1			1	1	1
Share in profit Share in other Share in total Net Assets i.e. Share in or lose comprehensive compr	comprehensive total assets income minus total liabilities	% Amount % Amount %	(1) 0% (1)	- 20	6/ 0%	14	7	1 1		1 1	(103	07					1	ı	%0	1	%0		ı	ı	1 1	1	ı	1
31st March 2019 Share in profit Share in other Share in total Net Assets i.e. or loss comprehensive comprehensive total assets	comprehensive income	% Amount %	10 0%	(1)	74	- 14		1 7		1 1					7		0												
31st March 2019 Share in profit Share in other Share in total controller comprehensive	comprehensive income	% Amount %	10	£ 6	47	4	%0 -	12		1 1	Č	 %	% '	,,,			19			40		(9)							
31st March 2019 Share in profit Share in other Share in total controller comprehensive		%					ı	12	(2)			_	_	%0	%0		%0	1	ı	%0	1	%0		ı	1	1 1	1	ı	1
31st March 2019 Share in profit Share in other comprehensive		%	2%	%0	\$ \$	%)	(0)	((43)	0 (2	(24)		(32)	\sim	0	(12)	4			0	(0)	. 4		1	1
31st March 2019 Share in profit Share in other comprehensive		Amount				(1)	% 8	% % %	%2-	%0	ò	% ?	% - %	%0	-4%		%9-	7%	%	-2%	7%	%		%0	% %	% % -7 C	-1%	%0	% %
31st Marc Share in profit	inco																												
31st Marc Share in profit	0	%																											
Share in		Amount	10	£ 5	77	4	1	- 1	(7)	(0)	((43)	n (7	(24)		(32)	\sim	0	(12)	4	_		0	0	- (4)		1	ı
	or lo	W %	1%	%6	% 7	1%	% 6	% % C	%%	%6	ò	%5,	% % 0 0	%0	-5%		-2%	%0	%0	-1%	%0	%		%0	% 8	% % 0 0	%0	%0	% %
ets i.e	ssets total ties	Amount	2	(50)	90	73	7	- 418	(780 8)	(0)	1	(2,793)	547	. 2	69		(12)		0	28	94	(4)		(2)	(79)	107	86	0	' (
Net Assets i.e.	total assets minus total liabilities	%	%0	%0	<u>\$</u>	%0	% 8	% % %	27.0%	? %		-19% -19%	 % % 5 C	%0	%0		%0	%0	%0	%0	1%	%0		%0	-1%	 % % 5 ~	1%	%0	% %
Particulars Name of the Entity in the Group			Upl Philippines Inc.(Formerly Known As United Phosphorus Corp. Philippines)	Arysta Lifescience Philippines Inc.	Upi Vietnam Co. Ltd (Formerly Known As United Phosphorus Vietnam Co., Limited)	Arysta Lifescience Vietnam Co., Ltd.	Uniphos Malaysia Sdn Bhd	Agripnar San Bnd Arysta Health And Nutrition Sciences	Corporation Anyera Lifascianna Communation	nopno5 sbi			Anning Decco Fille Cheffical Co. Liftineu, China Arvsta Lifescience Asia Pte . I td	Riceco International Bangladesh Limited	Upl Ziraat Ve Kimya Sanayi Ve Ticaret Limited Sirketi (Formerly Known As Cerexagri Ziraat	Ve Kimya Sanayi Ve Ticaret Limited Sirketi, Turkev)	Upl Agromed Tohumculuk Sa,Turkey	Decco Gida Tarım Ve Zirai Ürünler San. Tic A.S.	Anysta Lifescience Turkey Tarim Urunleri Limited Sirketi	Safepack Products Limited, Isreal	Agrifocus Limitada	Citrashine (Pty) Ltd, South Africa(Foremrly Known As Friedshelf 1114 (Pty) Ltd, South	Africa)	Anchorprops 39 (Pty) Ltd	Anysta Lifescience Holdings Sa (Pty) Ltd	Callietha investments (Pty) Ltd Volcano Agroscience (Pty) Ltd	Arysta Lifescience South Africa (Pty) Ltd	Volcano Chemicals (Pty) Ltd	Kempton Chemicals (Pty) Ltd

Notes to Consolidated Financial Statements for the year ended March 31, 2019

43. Information required for consolidated financial statement pursuant to Schedule III of The Companies Act, 2013: (contd.)

(:	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			Ċ		0.00						Ċ		0.00			
'n	Particulars	Name of the Entity in the Group		-	3	31st March 2019	61.07						3	31st March 2018	N 2018			
No No			Net Assets i.e. total assets minus total liabilities	ets i.e. ssets total ities	Share in profit or loss		Share in other comprehensive income		Share in total comprehensive income		Net Assets i.e. total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income	other ensive ne	Share in total comprehensive income	n total nensive me
			%	Amount	W %	Amount	% Ar	Amount	% Ar	Amount	% Ar	Amount	% Aı	Amount	' %	Amount	%	Amount
		Arysta Lifescience Tanzania Ltd	%0	(3)	%0	(1)			%0	(1)	1		1	1			ı	1
		Arysta Lifescience Cameroun Sa	%0	(8)	%0	M			1%	\sim	ı		ı	ı			ı	1
		Upl Africa Sarl	%0	I	%0	ı			%0	ı	%0	1	%0	0			%0	0
		Prolong Limited	%0	(0)	%0	(2)			%0	(2)	%0	7	%0	(1)			%0	
		Arysta Lifescience Egypt Ltd	%0	2	%0	(0)			%0	(0)	ı		ı	ı			I	ı
		Arysta Lifescience Togo Sau	%0	2	%0	0			%0	(0)	1		1	ı			1	ı
		Calli Ghana Ltd.	%0	(10)	%0	(1)			%0	(1)	1		1	1			1	1
		Callivoire Sgfd S.A.	%0	43	%0	(0)			%0	(0)	1		1	1			1	1
		Mali Protection Des Cultures (M.P.C.) Sa	%0	2	%0	M			1%	\sim	ı		ı	ı			ı	ı
									%0	1							%0	ı
ω -	Non-controlling interest	ling interest	-23%	(3,358)	-5%	(72)			13%	(72)	%0	(19)	%0	(8)			%0	∞
4	Associates Indian																	
		Kerala Enviro Infrastructure Limited	%0	2	%0	_			%0	_	%0	M	%0	_			%0	_
		Weather Risk Management Private Ltd	%0	13	%0	(1)			%0	(1)	%0	10	%0	(0)			%0	0
		Universal Pestochem (Industries) Limited	%0	I	%0	ı			%0	1	ı		1	1	ı	ı	1	ı
		Chemisynth (Vapi) Limited	%0	I	%0	1			%0	1	%0		%0	(0)			%0	0
	Foreign	3Sb Produtos Agrícolas S.A. (45%)	1%	88	%0	(1)			%0	(1)	1%	102	%0	(4)			%0	4-
		Sinagro Produtos Agropecuários S.A. (45%)	%0	I	%0	ı			%0	1	%0		-5%	(103)			-5%	-103
		Seara Bonita Sementes S.A. (33.33%)	1%	190	%0	2			%0	2	7%	208	%0	_			%0	_
		Agri Fokus (Pty) Ltd.	%0	4	%0	0			%0	0								
		Novon Retail Company (Pty) Ltd.	%0		%0	0			%0	0								
		Agronamic (Pty) Ltd.	%0	2	%0	0			%0	0								
		Novon Protecta (Pty) Ltd	%0		%0	0			%0	0								
		Silvix Forestry (Pty) Ltd.	%0	0	%0	0			%	0								
		Nexus Ag (Pty) Ltd	%0	10	%0	0			%0	0								
		Dalian Advanced Chemical Co.Ltd.	%0	_	%0	0			%0	(0)								
		Société Des Produits Industriels Et Agricoles	%0	4	%0	1			%0	ı								
2	Joint Venture																	
	Foreign	Hodagaya UPL Co. Limited	%0	23	%0	7			%0	2	%0	21	%0	_			%0	_
		Longreach Plant Breeders Management Pty	% 0	20	7%	0			7%	0	%	42	%				7%	
		רבו																
9	Other Comp	Other Comprehensive Income					100%	(882) -1	-156%	(882)					100%	70	3%	70
		Total	100%	14,645	100%	1,447 100%		(882) 1	100%	565 1	100% 9	9,169 1	100%	2,022	100%	70	100%	2,092

44. Hedging activities and derivatives

Derivatives not designated as hedging instruments

The Group uses full currency interest rate swaps and foreign exchange forward contracts to manage some of its transaction exposures. The foreign exchange forward contracts are not designated as cash flow hedges and are entered into for periods consistent with foreign currency exposure of the underlying transactions.

The Group enters into foreign exchange forward contracts with the intention to reduce the foreign exchange risk of expected sales and purchases, these contracts are not designated in hedge relationships and are measured at fair value through profit or loss. ₹ In crores

Na	ture of Instrument	Currency	31 March 2019	31 March 2019	31 March 2018	31 March 2018	Purpose - Hedging/
			(In '000) Amount outstanding	Amount outstanding	(In '000) Amount outstanding	Amount outstanding	Speculation
(a)	Forward contracts - Sell	USD	1,25,564	868	3,874	25	Hedging
	Forward contracts - Sell	AUD	10,650	53	-	-	Hedging
	Forward contracts - Sell	EUR	39,552	307	2,893	23	Hedging
	Forward contracts - Sell	CAD	3,200	16	-	-	Hedging
	Forward contracts - Sell	NZD	814	4	-	-	Hedging
	Forward contracts - Buy	USD	5,24,261	3,626	74,571	486	Hedging
	Forward contracts - Buy	EUR	33,687	262	_	_	Hedging
	Forward contracts - Buy	JPY	4,40,167	27	_	_	Hedging
(b)							
(i)	(a) Option Receivable	USD	10,000	69	_	_	Hedging
(ii)	Full Currency Interest Rate Swap contracts - Buy	USD	_	_	1,11,179	725	Hedging
,							(refer note 1 below)
	Full Currency Interest Rate Swap contracts - Buy						
(111)	Cross Currency Interest Rate Swaps on Loans Payable	EUR	-	-	25,667	207	Hedging (refer note 1 below)
	Cross Currency Interest Rate Swaps on Loans Payable						
		EUR	13,28,872	10,321	-	-	Hedging (refer note 2 below)
	Note 1:- Hedging against the underlying INR borrowings by which: - Group will receive principal in INR and pay in	JPY	4,43,00,000	2,766	-	-	Hedging (refer note 2 below)
	foreign currency Group will receive fixed interest in INR and pay fixed / floating interest in foreign currency.						,
	Note 2:- Hedging against the underlying USD						
	borrowings by which: - Group will receive principal in USD and pay						
	in EUR and JPY - Group will receive floating interest in USD						
	and pay fixed interest in EUR and JPY.						
(C)	Un-hedged Foreign Currency Exposure on:						
	1 Payables	USD	21,16,797	14,639	3,50,549	2,285	
	(including Foreign Currency payable	EUR	1,77,453	1,378	3,102	25	
	in respect of derivative contracts as	GBP	20,047	182	6,937	64	
	mentioned in (b) (ii & iii) above)	JPY	4,46,41,717	2,746	-	-	
		CHF	461	3	5	0	
		DKK	3,643	4	878	1	
		CLP	8,78,658	9	-	-	
		AED	136	0	1,076	2	
		INR	2,697	0	-	-	

44. Hedging activities and derivatives (contd.)

₹ In crores

Nature of Instrument	Currency	31 March 2019	31 March 2019	31 March 2018	31 March 2018	Purpose - Hedging/
						Speculation
		(In '000)	Amount	(In '000)	Amount	Speculation
		Amount	outstanding	Amount	outstanding	
		outstanding		outstanding		
	PLN	11	0	11	0	
	CAD	11,595	60	146	1	
	BRL	677	1	-	-	
	MUR	776	0	-	-	
	AUD	1,800	9	-	-	
	COP	1,48,61,709	32	73,61,730	17	
	ARS	1,77,319	28	-	-	
	CZK	24,105	7	0	0	
	HUF	93,837	2	163	0	
	CFA/XOF	1,70,633	2	-	-	
	TRY	59	0	-	-	
	ZAR	4,660	2	_	-	
	PYG	8,23,512	1	_	_	
	THB	-	_	421	0	
Receivable	USD	12,40,402	8,578	3,78,725	2,468	
	EUR	1,77,158	1,376	6,805	55	
	GBP	29,235	265	5,085	47	
	JPY	4,46,59,602	2,747	1,06,713	7	
	CHF	181	1	864	6	
	DKK	932	1	834	1	
	CLP	25,45,931	26	_	_	
	AED	946	2	8	0	
	NZD	24	0	_	_	
	PLN	4,092	7	3,431	7	
	CAD	85,528	441	7,978	40	
	AUD	6,806	33	1,450	7	
	COP	2,54,15,945	55	34,56,462	8	
	ARS	6,10,999	97	3 1,30, 102	_	
	CFA/XOF	2,948	0	_	_	
	ZAR	5,77,495	275	_	_	
	PYG	25,030	0	_	_	
	RON	5,841	10	_	_	
	RUB	2,38,602	25	_	_	

45. Catergory-wise classification of Financial Instruments

	Refer	Non-Ci	urrent	Curr	rent
	note	As at	As at	As at	As at
		March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
(A) Accounting, classification and Fair					
Value:					
Investments accounted for using the	5	408	386	-	-
equity method					
Financial assets measured at fair value					
through profit or loss (FVTPL)					
Investments in others (unsecured)	5	9	433	2	-
Investments in unquoted equity shares	5	42	40	-	-
Investments in unquoted optionally	5	83	76	-	-
convertible bonds					
Derivative contracts (net)	7	-	_	28	_
		135	549	30	-

45. Catergory-wise classification of Financial Instruments (contd.)

	Refer	Non-C	urrent	Curi	rent
	note	As at	As at	As at	As at
				March 31, 2019	
Financial assets measured at fair value					
through other comprehensive income					
(FVTOCI)					
Investments in quoted equity shares	5	133	99	-	-
Investments in unquoted equity shares	5	30	-	-	-
		163	99	-	_
Financial assets measured at amortised cost					
Sundry deposits	6	85	62	35	31
Loans and advances to related party	6	71	89	0	96
Loans to employees	6	0	0	1	8
Sundry loans	6	-	-	15	12
Trade receivables	10	4	1	11,812	6,056
Interest Receivable	7	-	-	10	49
Export benefit receivables	7	35	35	138	94
Cash and Cash Equivalents	11	-	-	2,826	2,859
Other Bank Balances	11A 7	122	-	25 134	35
Other advances	/	132 327	187	14,996	9,264
Financial liabilities measured at fair value		527	107	14,990	9,204
through profit or loss (FVTPL)					
Derivative contracts	16	53	134	1	41
Derivative contracts	10	53	134	1	41
Financial liabilities measured at			134	1	71
amortised cost					
Redeemable Non convertible Debentures	15	458	682	_	_
(Unsecured)	15	130	002		
Bonds (Unsecured)					
- 3.25% Senior Notes	15	3,437	3,230	_	_
- 4.50% Senior Notes	15	2,045	1,937	_	_
From Bank		_, _,	,,,,,,		
- Foreign currency loan (Unsecured)	15	20,394	2	-	_
- Foreign currency loan (Secured)	15	1	3	169	65
- Others borrowings	15	17	19	1,597	556
Long term maturities of finance lease					
obligation					
- Obligations under finance leases	15	30	-	-	-
Commercial Papers	15	-	-	400	-
Discounted Trade receivables (Unsecured)	15	-	-	312	13
- Factoring with recourse					
Current maturities of long term	16	-	-	275	131
borrowings					
Payable towards acquisition of additional	16	65	94	2	27
stake in UPL Do Brasil					
Capital goods creditors	16	-	-	70	155
Interest accrued and not due on	16	-	-	181	59
borrowings					
Trade Deposits	16	-	-	61	73
Trade payables (including Acceptances)	19	-	-	9,423	5,675
Unpaid dividend	16	-	-	8	7
Current maturities of long term lease	16	-	-	4	-
obligation					
Others	16	18	4	897	262
		26,466	5,971	13,399	7,023

45. Catergory-wise classification of Financial Instruments (contd.)

(B) Measurement of fair value:

Valuation techniques and significant unobservable inputs:

(i) Financial instruments measured at fair value

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

- The fair value of unquoted instruments, loans from banks and other financial liabilities, as well as other non-current financial liabilities is estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities. In addition to being sensitive to a reasonably possible change in the forecast cash flows or the discount rate, the fair value of the equity instruments is also sensitive to a reasonably possible change in the growth rates. Management regularly assesses a range of reasonably possible alternatives for those significant unobservable inputs and determines their impact on the total fair value.
- The fair values of the unquoted equity shares have been estimated using a DCF model. The valuation requires management to make certain assumptions about the model inputs, including forecast cash flows, discount rate, credit risk and volatility. The probabilities of the various estimates within the range can be reasonably assessed and are used in management's estimate of fair value for these unquoted equity investments.
- The fair values of the remaining FVTOCI financial assets are derived from quoted market prices in active markets.
- The fair values of the Company's interest-bearing borrowings and loans are determined by using DCF method using discount rate that reflects the issuer's borrowing rate as at the end of the reporting period. The own nonperformance risk as at 31 March 2018 was assessed to be insignificant.

The discount for lack of marketability represents the amounts that the Company has determined that market participants would take into account when pricing the investments.

(ii) Financial instrument measured at amortized cost:

The carrying amount of financial assets and financial liability measured at amortized cost in the financial statements are a resonable approximation of their fair value since the Company does not anticipate that the carrying amounts would be significantly different from the value that would eventually be received or settled.

46. Fair value hierarchy

The following table provides the fair value measurement hierarchy of the Group's assets and liabilities.

Quantitative disclosures fair value measurement hierarchy for assets as at 31 March 2019:

Particulars	Date of Fair value measurement using]
	valuation	Total	Quoted	Significant	Significant
			prices in	observable	unobservable
			active markets	inputs	inputs
			(Level 1)	(Level 2)	(Level 3)
Assets measured at fair value:					
FVTOCI financial investments (Note 5):					
Investments in equity instruments (Quoted)	31-Mar-19	133	133	-	-
Others (Unquoted)	31-Mar-19	30	-	-	30
FVTPL financial investments (Note 5):					
Investments in equity instruments	31-Mar-19	42	-	-	42
(Unquoted)					
Investments in Optionally Convertible Bonds	31-Mar-19	83	-	-	83
(Unquoted)					
Investments in Others (Unquoted)	31-Mar-19	11	-	-	11
FVTPL Derivative Contracts (Note 7):					
Derivative contracts	31-Mar-19	28	28	-	_

46. Fair value hierarchy (contd.)

Quantitative disclosures fair value measurement hierarchy for liabilities as at 31 March 2019:

₹ In crores

Particulars	Date of	Fair value measurement using				
	valuation	Total	Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
Liabilities measured at fair value: Derivative financial liabilities (Note 16):						
Derivative contracts	31-Mar-19	54	54	-	_	

Quantitative disclosures fair value measurement hierarchy for assets as at 31 March 2018:

₹ In crores

Qualiticative disclosures fall value illeasuren	ierre riierai erry	101 455615 45	ac 5 : War cri 20		
Particulars	Date of		Fair value measurement using		
	valuation	Total	Quoted prices	Significant	Significant
			in	observable	unobservable
			active markets	inputs	inputs
			(Level 1)	(Level 2)	(Level 3)
Assets measured at fair value:					
FVTOCI financial investments (Note 5):					
Investments in Equity Instruments (Quoted)	31-Mar-18	99	99	-	_
Others (Unquoted)	31-Mar-18	-	-	-	-
FVTPL financial investments (Note 5):					
Investment in Equity Instruments (Unquoted)	31-Mar-18	40	-	-	40
Investments in Optionally Convertible Bonds	31-Mar-18	76	-	-	76
(Unquoted)					
Investment in Others (Unquoted)	31-Mar-18	433	-	-	433

Quantitative disclosures fair value measurement hierarchy for liabilities as at 31 March 2018:

₹ In crores

Particulars	Date of	Fair value measurement using			
	valuation	Total	Quoted prices in active markets (Level 1)	observable	Significant unobservable inputs (Level 3)
Liabilities measured at fair value: Derivative financial liabilities (Note 16):					
Derivative contracts	31-Mar-18	175	175	-	_

47. Financial risk management objectives and policies

The Group's principal financial liabilities, other than derivatives, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Group's operations. The Groups principal financial assets include loans, trade and other receivables, and cash and cash equivalents that derive directly from its operations. The Group also holds FVTOCI investments and enters into derivative transactions.

The Group is exposed to market risk, credit risk and liquidity risk. The Group's senior management oversees the management of these risks. All derivative activities for risk management purposes are carried out by specialist teams that have the appropriate skills, experience and supervision. It is the Group's policy that no trading in derivatives for speculative purposes may be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below.

Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk. Financial instruments affected by market risk include loans and borrowings, deposits, FVTOCI investments and derivative financial instruments.

47. Financial risk management objectives and policies (contd.)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's long-term debt obligations with floating interest rates.

The Group manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings and by using interest rate swaps.

Interest rate sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings affected. With all other variables held constant, the Group's profit before tax is affected through the impact on floating rate borrowings, as follows:

	Increase/ decrease	Effect on profit or loss	Effect on equity
	in basis points		
	(Level 1)	(Level 2)	(Level 3)
31-Mar-19			
USD	+50	(39)	(26)
	-50	39	26
Others	+100	(4)	(3)
	-100	4	3
31-Mar-18			
USD	+50	(1)	(1)
	-50	1	1
Others	+100	(3)	(2)
	-100	3	2

The assumed movement in basis points for the interest rate sensitivity analysis is based on the currently observable market environment, showing a significantly higher volatility than in prior years.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (when revenue or expense is denominated in a foreign currency).

The Group manages its foreign currency risk by hedging transactions that are expected to occur within a maximum 12-month period for hedges of actual sales and purchases and 12-month period for foreign currency loans.

When a derivative is entered into for the purpose of being a hedge, the Group negotiates the terms of those derivatives to match the terms of the hedged exposure. For hedges of forecast transactions the derivatives cover the period of exposure from the point the cash flows of the transactions are forecasted up to the point of settlement of the resulting receivable or payable that is denominated in the foreign currency.

The Group hedges its exposure to fluctuations on the foreign currency loan by using foreign currency swaps and forwards.

At 31 March 2019, the Group hedge position is stated in Note 44. This foreign currency risk is hedged by using foreign currency forward contracts and full currency interest rate swaps.

Foreign currency sensitivity

The following tables demonstrate the sensitivity to a reasonably possible change in USD and EUR exchange rates, with all other variables held constant. The impact on the Group's profit before tax is due to changes in the fair value of monetary assets and liabilities. The Group's exposure to foreign currency changes for all other currencies is not material.

	Change in USD rate	Effect on profit or loss	Effect on equity
31-Mar-19	1%	(61)	(40)
	-1%	61	40
31-Mar-18	1%	2	1
	-1%	(2)	(1)

47. Financial risk management objectives and policies (contd.)

	Change in	Effect on	Effect on
	Euro rate	profit or loss	equity
31-Mar-19	1%	(0)	(0)
	-1%	0	0
31-Mar-18	1%	0	0
	-1%	(0)	(0)

The movement in the pre-tax effect is a result of a change in the fair value of monetary assets and liabilities denominated in US dollars, where the functional currency of the entity is a currency other than US dollars. Although the derivatives have not been designated in a hedge relationship, they act as an economic hedge and will offset the underlying transactions when they occur.

Equity price risk

The Group's listed and non-listed equity securities are susceptible to market price risk arising from uncertainties about future values of the investment securities. The investment in listed and unlisted equity securities are not significant.

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.

Financial instruments and cash deposits

Credit risk from balances with banks and financial institutions is managed by the Group's treasury department. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through counterparty's potential failure to make payments.

The Group's maximum exposure to credit risk for the components of the balance sheet at 31 March 2019 and 31 March 2018 is the carrying amounts as illustrated in Note 10 except for derivative financial instruments.

Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Group's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The Group manages liquidity risk by maintaining adequate reserves, by continuously monitoring forecast and actual cash flows and matching the maturity profiles of the financial assets and liabilities.

The table below summarises the maturity profile of the Group's financial liabilities based on contractual undiscounted payments.

	Less than 1 year	1 to 5 years	> 5 years	Total
Year ended				
31-Mar-19				
Borrowings (Refer Note 15)	2,878	23,966	2,295	29,139
Other financial liabilities (Refer Note 16)	1,499	83	-	1,582
Trade and other payables (Refer Note 19)	9,423	-	-	9,423
Derivative contracts (Refer Note 16)	1	53	-	54
	13,800	24,102	2,295	40,197
Year ended				
31-Mar-18				
Borrowings (Refer Note 15)	634	3,798	2,206	6,637
Other financial liabilities (Refer Note 16)	715	98	-	812
Trade and other payables (Refer Note 19)	5,675	-	-	5,675
Derivative contracts (Refer Note 16)	41	134	-	175
	7,064	3,900	2,206	13,170

48. Capital management

Capital includes equity attributable to the equity holders of the Parent. Capital management is to ensure that Group maintains an efficient capital structure and healthy capital ratios in order to support its business and maximise shareholder value. The Group manages its capital structure and makes adjustments to it, in light of changes in economic conditions or its business requirements. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes during the year ended March 31, 2019 and March 31, 2018.

The Group monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. Net debt is calculated as loans and borrowings less cash and cash equivalents. ₹ In crores

	March 31, 2019	March 31, 2018
Borrowings (Note 15)	29,139	6,637
Less: cash and cash equivalents (Note 11)	(2,826)	(2,859)
Net debt	26,313	3,778
Equity	18,003	9,188
Total capital	18,003	9,188
Capital and net debt	44,316	12,966
Gearing ratio	59%	29%

In order to achieve this overall objective, the Group's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

As per our report of even date attached.

For BSR&Co.LLP **Chartered Accountants**

Firm registration number: 101248W/W-100022

For and on behalf of the Board of Directors of UPL Limited CIN No.-L24219GJ1985PLC025132

Bhavesh Dhupelia

Partner

Membership no.: 042070

Place: Mumbai Date: May 17, 2019 R.D. Shroff

Chairman & Managing Director

Din No.-00180810 Place: Mumbai

Anand Vora

Chief Financial Officer

Place: Mumbai Date: May 17, 2019 A.C. Ashar

Whole-time Director Din No.- 00192088 Place: Mumbai

M.B.Trivedi

Company Secretary Membership no.: ACS4250 Place: San Francisco

